U.S. patent application number 14/112859 was filed with the patent office on 2014-06-19 for bispecific antibodies against her2 and cd3.
This patent application is currently assigned to GENMAB A/S. The applicant listed for this patent is Bart De Goeij, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Paul Parren, Janine Schuurman. Invention is credited to Bart De Goeij, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Paul Parren, Janine Schuurman.
Application Number | 20140170149 14/112859 |
Document ID | / |
Family ID | 47041975 |
Filed Date | 2014-06-19 |
United States Patent
Application |
20140170149 |
Kind Code |
A1 |
Neijssen; Joost J. ; et
al. |
June 19, 2014 |
BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3
Abstract
Bispecific antibodies which comprise one antigen-binding region
binding to an epitope of human epidermal growth factor receptor 2
(HER2) and one antigen-binding region binding to human CD3, and
related antibody-based compositions and molecules, are disclosed.
Pharmaceutical compositions comprising the antibodies and methods
for preparing and using the antibodies are also disclosed.
Inventors: |
Neijssen; Joost J.;
(Werkhoven, NL) ; Meesters; Joyce I.; (Utrecht,
NL) ; De Goeij; Bart; (Ultrecht, NL) ;
Labrijn; Aran Frank; (Nigtevecht, NL) ; Parren;
Paul; (Odijk, NL) ; Schuurman; Janine;
(Diemen, NL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Neijssen; Joost J.
Meesters; Joyce I.
De Goeij; Bart
Labrijn; Aran Frank
Parren; Paul
Schuurman; Janine |
Werkhoven
Utrecht
Ultrecht
Nigtevecht
Odijk
Diemen |
|
NL
NL
NL
NL
NL
NL |
|
|
Assignee: |
GENMAB A/S
Copenhagen K
DK
|
Family ID: |
47041975 |
Appl. No.: |
14/112859 |
Filed: |
April 20, 2012 |
PCT Filed: |
April 20, 2012 |
PCT NO: |
PCT/EP2012/057307 |
371 Date: |
February 12, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61552286 |
Oct 27, 2011 |
|
|
|
Current U.S.
Class: |
424/136.1 ;
435/252.3; 435/254.2; 435/328; 435/69.6; 530/351; 530/387.3;
530/391.7 |
Current CPC
Class: |
A61K 47/6803 20170801;
C07K 2317/41 20130101; C07K 16/1063 20130101; C07K 2317/74
20130101; C07K 2317/77 20130101; C07K 2317/732 20130101; C07K
2317/21 20130101; C07K 2317/76 20130101; A61K 47/6851 20170801;
C07K 2317/526 20130101; A61K 39/3955 20130101; A61K 47/6829
20170801; C07K 16/2803 20130101; C07K 2317/92 20130101; A61K
47/6849 20170801; A61P 43/00 20180101; A61K 47/6855 20170801; C07K
16/32 20130101; A61K 47/6813 20170801; A61P 35/00 20180101; C07K
1/113 20130101; C07K 2317/52 20130101; C07K 2317/75 20130101; C07K
16/468 20130101; A61K 47/6879 20170801; C07K 16/2809 20130101; C07K
2317/73 20130101; C07K 2317/31 20130101; A61K 2039/505
20130101 |
Class at
Publication: |
424/136.1 ;
530/387.3; 530/351; 530/391.7; 435/328; 435/69.6; 435/254.2;
435/252.3 |
International
Class: |
C07K 16/46 20060101
C07K016/46; A61K 39/395 20060101 A61K039/395; A61K 47/48 20060101
A61K047/48; C07K 1/113 20060101 C07K001/113; C07K 16/32 20060101
C07K016/32; C07K 16/28 20060101 C07K016/28 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 20, 2011 |
DK |
PA 2011 00312 |
Apr 20, 2011 |
EP |
PCT/EP2011/056388 |
May 27, 2011 |
EP |
PCT/EP2011/058772 |
May 27, 2011 |
EP |
PCT/EP2011/058779 |
Oct 27, 2011 |
DK |
PA 2011 00824 |
Claims
1. A bispecific antibody comprising a first antigen-binding region
and a second antigen-binding region, which second antigen-binding
region binds an epitope on human CD3 and the first antigen-binding
region binds an epitope on human epidermal growth factor receptor 2
(HER2) and blocks the binding to HER2, optionally soluble HER2, of
a reference antibody selected from the group consisting of: a) an
antibody comprising a VH region comprising the sequence of SEQ ID
NO:63 and a VL region comprising the sequence of SEQ ID NO:67, b)
an antibody comprising a variable heavy (VH) region comprising the
sequence of SEQ ID NO:1 and a variable light (VL) region comprising
the sequence of SEQ ID NO:5, c) an antibody comprising a VH region
comprising the sequence of SEQ ID NO:165 and a VL region comprising
the sequence of SEQ ID NO:169, and d) an antibody comprising a VH
region comprising the sequence of SEQ ID NO:22 and a VL region
comprising the sequence of SEQ ID NO:26.
2. The bispecific antibody of claim 1, wherein the first
antigen-binding region blocks the binding to soluble HER2 of an
antibody of (a).
3. The bispecific antibody of claim 1, wherein the first
antigen-binding region blocks the binding to soluble HER2 of an
antibody of (b), (c), or (d).
4-5. (canceled)
6. The bispecific antibody of claim 1, wherein the first
antigen-binding region comprises VH CDR1, CDR2, and CDR3 sequences
selected from the group consisting of a) SEQ ID NOs: 2, 3 and 4,
respectively; b) SEQ ID NOS: 9, 10 and 11, respectively; c) SEQ ID
NOs:16, 17 and 18, respectively; d) SEQ ID NOs: 23, 24 and 25,
respectively; e) SEQ ID NOs:30, 163, and 31, respectively; f) SEQ
ID NOs: 36, 37 and 38, respectively: g) SEQ ID NOs: 43, 44 and 45,
respectively; h) SEQ ID NOs:50, 51 and 52, respectively; i) SEQ ID
NOs: 57, 58 and 59, respectively; j) SEQ ID NOs:64, 65 and 66,
respectively; k) SEQ ID NOs: 71, 72 and 73, respectively; l) SEQ ID
NOs: 166, 167 and 168, respectively; m) SEQ OD NOs: 173, 174, and
175, respectively; n) SEQ ID NOs: 180, 181, and 182, respectively;
o) SEQ ID NOs:187, 188, and 189, respectively; p) SEQ ID NOs:194,
195, and 196, respectively; and q) SEQ ID NOs:201, 202, and 203,
respectively.
7. A bispecific antibody comprising a first antigen-binding region
and a second antigen-binding region, which second antigen-binding
region binds an epitope on human CD3 and the first antigen-binding
region binds an epitope on HER2, wherein the first antigen-binding
region comprises a VH region and a VL region selected from the
group consisting of a) a VH region comprising the CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs:2, 3 and 4, respectively; and a VL
region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID
NOs:6, DAS, and SEQ ID NO:7, respectively; b) a VH region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:9, 10
and 11, respectively; and a VL region comprising the CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs:13, AAS, and SEQ ID NO:14,
respectively; c) a VH region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:16, 17 and 18, respectively; and a VL
region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID
NOs:20, VAS, and SEQ ID NO:21, respectively; d) a VH region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:23, 24
and 25, respectively; and a VL region comprising the CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs:27, AAS, and SEQ ID NO:28,
respectively; e) a VH region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:30, 163 and 31, respectively; and a VL
region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID
NOs:33, AAS, and SEQ ID NO:34, respectively; f) a VH region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:36, 37
and 38, respectively; and a VL region comprising the CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs:40, DAS, and SEQ ID NO:41,
respectively; g) a VH region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:43, 44 and 45, respectively; and a VL
region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID
NOs:47, AAS, and SEQ ID NO:48, respectively; h) a VH region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:50, 51
and 52, respectively; and a VL region comprising the CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs:54, AAS, and SEQ ID NO:55,
respectively; i) a VH region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:57, 58 and 59, respectively; and a VL
region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID
NOs:60, AAS, and SEQ ID NO:61, respectively; j) a VH region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:64, 65
and 66, respectively; and a VL region comprising the CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs:68, DAS, and SEQ ID NO:69,
respectively; k) a VH region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:71, 72 and 73, respectively; and a VL
region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID
NOs:75, DAS, and SEQ ID NO:76, respectively; l) a VH region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:166, 167
and 168, respectively; and a VL region comprising the CDR1, CDR2
and CDR3 sequences of SEQ ID NO: 170, GAS and SEQ ID NO:171,
respectively; m) a VH region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs: 173, 174 and 175, respectively; and a VL
region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID
NOs:177, DAS, and SEQ ID NO:178, respectively; n) a VH region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:180, 181
and 182, respectively; and a VL region comprising the CDR1, CDR2
and CDR3 sequences of SEQ ID NOs:184, GAS, and SEQ ID NO:185,
respectively; o) a VH region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:187, 188 and 189, respectively; and a VL
region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:
191, GAS, and SEQ ID NO:192, respectively; p) a VH region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:194, 195
and 196, respectively; and a VL region comprising the CDR1, CDR2
and CDR3 sequences of SEQ ID NOs:198, GAS, and SEQ ID NO:199,
respectively; q) a VH region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:201, 202 and 203, respectively; and a VL
region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID
NOs:205, GAS, and SEQ ID NO:206, respectively.
8. The bispecific antibody of claim 5, wherein the first
antigen-binding region comprises a VH region and a VL region
selected from the group consisting of a) a VH region comprising the
CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:2, 3 and 4,
respectively; and a VL region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:6, DAS, and SEQ ID NO:7, respectively; b) a
VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID
NOs:23, 24 and 25, respectively; and a VL region comprising the
CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:27, AAS, and SEQ ID
NO:28, respectively; c) a VH region comprising the CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs:64, 65 and 66, respectively; and a VL
region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID
NOs:68, DAS, and SEQ ID NO:69, respectively, and d) a VH region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:166, 167
and 168, respectively; and a VL region comprising the CDR1, CDR2
and CDR3 sequences of SEQ ID NOs: 170, GAS, and SEQ ID NO:171,
respectively.
9. A bispecific antibody of claim 1 comprising a first
antigen-binding region and a second antigen-binding region, which
second antigen-binding region binds an epitope on human CD3 and the
first antigen-binding region binds HER2 and comprises a) a VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:
2, 3 and 4, respectively, and, optionally a VL region comprising
the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:6, DAS, and SEQ ID
NO:7, respectively; b) a VH region comprising the CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs:64, 65 and 66, respectively; and,
optionally, a VL region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:68, DAS, and SEQ ID NO:69, respectively; c)
a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID
NOs:166, 167 and 168, respectively; and, optionally, a VL region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:170,
GAS, and SEQ ID NO:171, respectively; or d) a VH region comprising
the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:23, 24 and 25,
respectively; and, optionally, a VL region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:27, AAS, and SEQ ID NO:28,
respectively.
10-12. (canceled)
13. A bispecific antibody of claim 1 comprising a first
antigen-binding region and a second antigen-binding region, which
second antigen-binding region binds an epitope on human CD3 and the
first antigen-binding region binds HER2 and comprises: a) a VH
region comprising the sequence of SEQ ID NO:1 and, optionally a VL
region comprising SEQ ID NOs:5; b) a VH region comprising the
sequence of SEQ ID NO:63 and, optionally a VL region comprising SEQ
ID NOs:67; c) a VH region comprising the sequence of SEQ ID NO:165,
and, optionally, a VL region comprising the sequence of SEQ ID
NO:169; or d) a VH region comprising SEQ ID NO:22, and, optionally,
a VL region comprising the sequence of SEQ ID NO:26.
14-16. (canceled)
17. A bispecific antibody of claim 1, wherein the second
antigen-binding region blocks the binding to CD3 of a reference
antibody selected from the group consisting of a) an antibody
comprising a VH region comprising the sequence of SEQ ID NO:240 and
a VL region comprising the sequence of SEQ ID NO:241; b) an
antibody comprising a VH region comprising the sequence of SEQ ID
NO:234 and a VL region comprising the sequence of SEQ ID NO:235; c)
an antibody comprising a VH region comprising the sequence of SEQ
ID NO:238 and VL region comprising the sequence of SEQ ID NO:239;
and d) an antibody comprising a VH region comprising the sequence
of SEQ ID NO:236 and a VL region comprising the sequence of SEQ ID
NO:237.
18. A bispecific antibody of claim 1, wherein the second
antigen-binding region blocks the binding to CD3 of a reference
antibody comprising a VH region comprising the sequence of SEQ ID
NO:240 and a VL region comprising the sequence of SEQ ID
NO:241.
19. A bispecific antibody of claim 1, wherein the second
antigen-binding region comprises a VH region selected from the
group consisting of: a) a VH region comprising the CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs:242, 243 and 244, respectively; b) a
VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID
NO:234; c) a VH region comprising the CDR1, CDR2 and CDR3 sequences
of SEQ ID NO:238; and d) a VH region comprising the CDR1, CDR2 and
CDR3 sequences of SEQ ID NO:236.
20. A bispecific antibody of claim 1, wherein the second
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NO:242, 243 and 244,
respectively.
21. A bispecific antibody of claim 1 comprising a second
antigen-binding region comprising the VH CDR3 sequence of SEQ ID
NO:244 and a second antigen-binding region comprising the VH CDR3
sequence of SEQ ID NO:4.
22. The bispecific antibody of claim 21, wherein the second
antigen-binding region comprises the VL CDR3 sequence of SEQ ID
NO:246 and the second antigen-binding region comprises the VL CDR3
sequence of SEQ ID NO:7.
23. The bispecific antibody of claim 1, wherein the second
antigen-binding region comprises the VH CDR1, CDR2, and CDR3
sequences of SEQ ID NOs:242, 243 and 244, respectively; and,
optionally, the VL CDR1, CDR2 and CDR3 sequences of 245, DTS and
246, respectively.
24. The bispecific antibody of claim 1, wherein the second
antigen-binding region comprises a VH region comprising the
sequence of SEQ ID NO: 240 and, optionally, a VL region comprising
the sequence of SEQ ID NO:241.
25. The bispecific antibody of claim 1, wherein said bispecific
antibody further comprises a first Fc region and a second Fc
region.
26. The bispecific antibody of claim 1, comprising a first Fab-arm
comprising the first antigen-binding region and a first Fc-region,
and a second Fab-arm comprising the second antigen-binding region
and a second Fc-region.
27. The bispecific antibody of claim 1, comprising a first Fab-arm
comprising the second antigen-binding region and a first Fc-region,
and a second Fab-arm comprising the first antigen-binding region
and a second Fc-region.
28. The bispecific antibody of claim 26, wherein the isotypes of
the first and second Fc-regions are independently selected from
IgG1, IgG2, IgG3, and IgG4.
29. The bispecific antibody of claim 28, wherein the isotypes of
the first and second Fc-regions are independently selected from
IgG1 and IgG4.
30. The bispecific antibody of claim 29, wherein one of the first
and second Fc-regions is of an IgG1 isotype and one is of an IgG4
isotype; or wherein the isotypes of the first and second Fc regions
are IgG1.
31. (canceled)
32. The bispecific antibody of claim 1, which is effector-function
deficient.
33. The bispecific antibody of claim 26, wherein the first
Fc-region has an amino acid substitution at a position selected
from the group consisting of 409, 366, 368, 370, 399, 405 and 407,
and said second Fc-region has an amino acid substitution at a
position selected from the group consisting of 405, 366, 368, 370,
399, 407, and 409, and wherein said first Fc-region and said second
Fc-region are not substituted in the same positions.
34. The bispecific antibody of claim 26, wherein a) the first
Fc-region has an amino acid other than Lys, Leu or Met at position
409 and the second Fc-region has an amino acid substitution at a
position selected from the group consisting of 405, 366, 368, 370,
399 and 407; b) the first Fc-region has an amino acid other than
Lys, Leu or Met at position 409 and the second Fc-region has an
amino acid other than Phe at position 405; c) the first Fc-region
has an amino acid other than Lys, Leu or Met at position 409 and
the second Fc-region has an amino acid other than Phe, Arg or Gly
at position 405; d) the first Fc-region comprises a Phe at position
405 and an amino acid other than Lys, Leu or Met at position 409
and said second Fc-region comprises an amino acid other than Phe at
position 405 and a Lys at position 409; e) the first Fc-region
comprises a Phe at position 405 and an amino acid other than Lys,
Leu or Met at position 409 and the second Fc-region comprises an
amino acid other than Phe, Arg or Gly at position 405 and a Lys at
position 409; f) the first Fc-region comprises a Phe at position
405 and an amino acid other than Lys, Leu or Met at position 409
and the second Fc-region comprises a Leu at position 405 and a Lys
at position 409; g) the first Fc-region comprises a Phe at position
405 and an Arg at position 409 and said second Fc-region comprises
an amino acid other than Phe, Arg or Gly at position 405 and a Lys
at position 409; h) the first Fc-region comprises Phe at position
405 and an Arg at position 409 and the second Fc-region comprises a
Leu at position 405 and a Lys at position 409; i) the first
Fc-region comprises an amino acid other than Lys, Leu or Met at
position 409 and the second Fc-region comprises a Lys at position
409, a Thr at position 370 and a Leu at position 405; j) the first
Fc-region comprises an Arg at position 409 and the second Fc-region
comprises a Lys at position 409, a Thr at position 370 and a Leu at
position 405; k) the first Fc-region comprises a Lys at position
370, a Phe at position 405 and an Arg at position 409 and the
second Fc-region comprises a Lys at position 409, a Thr at position
370 and a Leu at position 405; l) the first Fc-region has an amino
acid other than Lys, Leu or Met at position 409 and the second
Fc-region has an amino acid other than Tyr, Asp, Glu, Phe, Lys,
Gln, Arg, Ser or Thr at position 407; m) the first Fc-region has an
amino acid other than Lys, Leu or Met at position 409 and the
second Fc-region has an Ala, Gly, His, Ile, Leu, Met, Asn, Val or
Tip at position 407; n) the first Fc-region has an amino acid other
than Lys, Leu or Met at position 409 and the second Fc-region has a
Gly, Leu, Met, Asn or Trp at position 407; o) the first Fc-region
has a Tyr at position 407 and an amino acid other than Lys, Leu or
Met at position 409 and the second Fc-region has an amino acid
other than Tyr, Asp, Glu, Phe, Lys, Gln, Arg, Ser or Thr at
position 407 and a Lys at position 409; p) the first Fc-region has
a Tyr at position 407 and an amino acid other than Lys, Leu or Met
at position 409 and the second Fc-region has an Ala, Gly, His, Ile,
Leu, Met, Asn, Val or Trp at position 407 and a Lys at position
409; q) the first Fc-region has a Tyr at position 407 and an amino
acid other than Lys, Leu or Met at position 409 and the second
Fc-region has a Gly, Leu, Met, Asn or Tip at position 407 and a Lys
at position 409; r) the first Fc-region has a Tyr at position 407
and an Arg at position 409 and the second Fc-region has an amino
acid other than Tyr, Asp, Glu, Phe, Lys, Gln, Arg, Ser or Thr at
position 407 and a Lys at position 409; s) the first Fc-region has
a Tyr at position 407 and an Arg at position 409 and the second
Fc-region has an Ala, Gly, His, Ile, Leu, Met, Asn, Val or Trp at
position 407 and a Lys at position 409; or t) the first Fc-region
has a Tyr at position 407 and an Arg at position 409 and the second
Fc-region has a Gly, Leu, Met, Asn or Trp at position 407 and a Lys
at position 409.
35-53. (canceled)
54. The bispecific antibody of claim 26, wherein the first
Fc-region has an amino acid other than Lys, Leu or Met at position
409, and the second Fc-region has (i) an amino acid other than Phe,
Leu and Met at position 368, (ii) a Trp at position 370, or (iii)
an amino acid other than Asp, Cys, Pro, Glu or Gln at position 399,
or (iv) an amino acid other than Lys, Arg, Ser, Thr, or Trp at
position 366.
55. The bispecific antibody of claim 26, wherein the first
Fc-region has an Arg, Ala, His or Gly at position 409, and the
second homodimeric protein has (i) a Lys, Gln, Ala, Asp, Glu, Gly,
His, Ile, Asn, Arg, Ser, Thr, Val, or Trp at position 368, or (ii)
a Trp at position 370, (iii) an Ala, Gly, Ile, Leu, Met, Asn, Ser,
Thr, Trp, Phe, His, Lys, Arg or Tyr at position 399, or (iv) an
Ala, Asp, Glu, His, Asn, Val, Gln, Phe, Gly, Ile, Leu, Met, or Tyr
at position 366.
56. The bispecific antibody of claim 26, wherein the first
Fc-region has an Arg at position 409, and the second Fc-region has
(i) an Asp, Glu, Gly, Asn, Arg, Ser, Thr, Val, or Trp at position
368, or (ii) a Trp at position 370, or (iii) a Phe, His, Lys, Arg
or Tyr at position 399, or (iv) an Ala, Asp, Glu, His, Asn, Val,
Gln at position 366.
57. The bispecific antibody of claim 26, wherein said first and
second CH3 regions, except for the specified mutations, comprise
the sequence of SEQ ID NO:256.
58. The bispecific antibody of claim 26, wherein neither said first
nor said second Fc-region comprises a Cys-Pro-Ser-Cys sequence in
the hinge region.
59. The bispecific antibody of claim 26, wherein both of said first
and said second Fc-region comprise a Cys-Pro-Pro-Cys sequence in
the hinge region.
60. (canceled)
61. The bispecific antibody of claim 26, wherein said first and
second Fc region, except for the specified mutations, comprise a
sequence independently selected from the group consisting of SEQ ID
NOs: 247, 248, 249, 250, 251, 252, 253, 254, and 255.
62. The bispecific antibody of claim 1, wherein the first and
second antigen-binding regions comprise human antibody VH sequences
and, optionally, human antibody VL sequences.
63. The bispecific antibody of claim 1, wherein the first and
second antigen-binding regions are from heavy-chain antibodies.
64. The bispecific antibody of claim 1, wherein the first and
second antigen-binding regions comprise a first and second light
chain.
65. The bispecific antibody of claim 64, wherein said first and
second light chains are different.
66. The bispecific antibody of claim 26, wherein the first and/or
the second Fc-region comprises a mutation removing the acceptor
site for Asn-linked glycosylation.
67. The bispecific antibody of claim 1, which is conjugated to one
or more other moieties, or contains one or more acceptor group for
the same.
68. The bispecific antibody of claim 67, which is conjugated to a
cytokine selected from the group consisting of IL-2, IL-4, IL-6,
IL-7, IL-10, IL-12, IL-13, IL-15, IL-18, IL-23, IL-24, IL-27,
IL-28a, IL-28b, IL-29, KGF, IFN.alpha., IFN.beta., IFN.gamma.,
GM-CSF, CD40L, Flt3 ligand, stem cell factor, ancestim, and
TNF.alpha..
69. An in vitro method for generating a bispecific antibody, said
method comprising the steps of: a) providing a first antibody
binding to an epitope on HER2 and comprising a first Fc region,
said Fc region comprising a first CH3 region, b) providing a second
antibody binding to an epitope on human CD3 and comprising a second
Fc region, said Fc region comprising a second CH3 region, c)
incubating said first antibody together with said second antibody
under reducing conditions, and d) obtaining said bispecific
antibody, wherein the sequences of said first and second CH3
regions are different and are such that the heterodimeric
interaction between said first and second CH3 regions is stronger
than each of the homodimeric interactions of said first and second
CH3 regions.
70. The method of claim 69, wherein the first antibody blocks the
binding to soluble human epidermal growth factor receptor 2 (HER2)
of an antibody comprising: a) a VH region comprising the sequence
of SEQ ID NO:1 and a VL region comprising the sequence of SEQ ID
NO:5, b) a VH region comprising the sequence of SEQ ID NO:63 and a
VL region comprising the sequence of SEQ ID NO:67, c) a VH region
comprising the sequence of SEQ ID NO:165 and a VL region comprising
the sequence of SEQ ID NO:169, and d) a VH region comprising the
sequence of SEQ ID NO:22 and a VL region comprising the sequence of
SEQ ID NO:26.
71. The method of claim 69, wherein the first Fc-region has an
amino acid substitution at a position selected from the group
consisting of 409, 366, 368, 370, 399, 405 and 407, and said second
Fc-region has an amino acid substitution at a position selected
from the group consisting of 405, 366, 368, 370, 399, 407, and 409,
and wherein said first Fc-region and said second Fc-region are not
substituted in the same positions.
72. A bispecific antibody obtainable by the method of claim 69.
73. A recombinant eukaryotic or prokaryotic host cell which
produces a bispecific antibody as defined in claim 1.
74. A pharmaceutical composition comprising a bispecific antibody
as defined in claim 1 and a pharmaceutically acceptable
carrier.
75. (canceled)
76. A method of treating cancer comprising administering to a
subject in need thereof a therapeutically effective amount of the
bispecific antibody of claim 1.
77. The method of claim 76, wherein the cancer is selected from the
group consisting of breast cancer, prostate cancer, non-small cell
lung cancer, bladder cancer, ovarian cancer, gastric cancer,
colorectal cancer, esophageal cancer, squamous cell carcinoma of
the head and neck, cervical cancer, pancreatic cancer, testis
cancer, malignant melanoma and soft-tissue cancer.
78. The method of claim 76, further comprising administering one or
more additional therapeutic agents.
79. (canceled)
80. A method for inhibiting growth and/or proliferation of one or
more tumor cells expressing HER2, comprising administering to a
subject in need thereof the bispecific antibody according to claim
1.
81. A method for treating cancer, comprising a) selecting a subject
suffering from a cancer comprising tumor cells co-expressing HER2,
and b) administering to the subject the bispecific antibody
according to claim 1.
82. The method of claim 81, wherein the cancer is selected from the
group consisting of breast cancer, colorectal cancer,
endometrial/cervical cancer, lung cancer, malignant melanoma,
ovarian cancer, pancreatic cancer, prostate cancer, testis cancer,
a soft-tissue tumor such as synovial sarcoma, and bladder
cancer.
83. A method for producing a bispecific antibody of claim 68, said
method comprising the steps of a) culturing a host cell of claim
73, and b) purifying the bispecific antibody from the culture
media.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to bispecific antibodies
directed to human epidermal growth factor receptor 2 (HER2) and
cluster determinant 3 (CD3) and to uses of such antibodies, in
particular their use in the treatment of cancer.
BACKGROUND OF THE INVENTION
[0002] HER2 is a 185-kDa cell surface receptor tyrosine kinase and
member of the epidermal growth factor receptor (EGFR) family that
comprises four distinct receptors: EGFR/ErbB-1, HER2/ErbB-2,
HER3/ErbB-3, and HER4/ErbB-4. Both homo- and heterodimers are
formed by the four members of the EGFR family, with HER2 being the
preferred and most potent dimerization partner for other ErbB
receptors (Graus-Porta et al., Embo J 1997; 16:1647-1655; Tao et
al., J Cell Sci 2008; 121:3207-3217). HER2 can be activated by
overexpression or by heterodimerization with other ErbBs that can
be activated by ligand binding (Riese and Stern, Bioessays 1998;
20:41-48). For HER2, no ligand has been identified. HER2 activation
leads to receptor phosphorylation, which triggers a cascade of
downstream signals through multiple signaling pathways, such as
MAPK, phosphoinositol 3-kinase/AKT, JAK/STAT and PKC, which
ultimately results in the regulation of multiple cellular
functions, such as growth, survival and differentiation (Huang et
al., Expert Opin Biol Ther 2009; 9:97-110).
[0003] Much of the attention on HER2 in tumors has been focused on
its role in breast cancer, in which HER2 overexpression is reported
in approximately 20% of the cases and is correlated with poor
prognosis (Reese et al., Stem Cells 1997; 15:1-8; Andrechek et al.,
Proc Natl Acad Sci USA 2000; 97:3444-3449; and Slamon et al.,
Science 1987; 235:177-182). Besides breast cancer, HER2 expression
has also been associated with other human carcinoma types,
including prostate cancer, non-small cell lung cancer, bladder
cancer, ovarian cancer, gastric cancer, colon cancer, esophageal
cancer and squamous cell carcinoma of the head & neck (Garcia
de Palazzo et al., Int J Biol Markers 1993; 8:233-239; Ross et al.,
Oncologist 2003; 8:307-325; Osman et al., J Urol 2005;
174:2174-2177; Kapitanovic et al., Gastroenterology 1997;
112:1103-1113; Turken et al., Neoplasma 2003; 50:257-261; and
Oshima et al., Int J Biol Markers 2001; 16:250-254).
[0004] Trastuzumab (Herceptin.RTM.) is a recombinant, humanized
monoclonal antibody directed against domain IV of the HER2 protein,
thereby blocking ligand-independent HER2 homodimerization, and to a
lesser extend heterodimerization of HER2 with other family members
in cells with high HER2 overexpression (Cho et al., Nature 2003;
421:756-760 and Wehrman et al., Proc Natl Acad Sci USA 2006;
103:19063-19068). In cells with modest HER2 expressing levels,
trastuzumab was found to inhibit the formation of HER2/EGFR
heterodimers (Wehrman et al., (2006), supra; Schmitz et al., Exp
Cell Res 2009; 315:659-670). Trastuzumab mediates
antibody-dependent cellular cytotoxicity (ADCC) and prevents
ectodomain shedding, which would otherwise result in the formation
of a truncated constitutively active protein in HER2 overexpressing
cells. Also inhibition of both in vitro and in vivo proliferation
of tumor cells expressing high levels of HER2 has been reported for
trastuzumab (reviewed in Nahta and Esteva, Oncogene 2007;
26:3637-3643). Herceptin.RTM. has been approved both for first-line
and adjuvant treatment of HER2 overexpressing metastatic breast
cancer, either in combination with chemotherapy, or as a single
agent following one or more chemotherapy regimens. Trastuzumab has
been found to be effective only in 20-50% of HER2 overexpressing
breast tumor patients and many of the initial responders show
relapse after a few months (Dinh et al., Clin Adv Hematol Oncol
2007; 5:707-717).
[0005] Pertuzumab (Omnitarg.TM.) is another humanized monoclonal
antibody. It is directed against domain II of the HER2 protein,
resulting in inhibition of ligand-induced heterodimerization (i.e.,
HER2 dimerizing with another member of the ErbB family to which a
ligand has bound); a mechanism reported to not strictly require
high HER2 expression levels (Franklin et al., Cancer Cell 2004;
5:317-328.). Although pertuzumab also mediates ADCC, the main
mechanism of action of pertuzumab relies on its dimerization
blockade (Hughes et al., Mol Cancer Ther 2009; 8:1885-1892).
Moreover, pertuzumab was found to enhance EGFR internalization and
downregulation by inhibiting the formation of EGFR/HER2
heterodimers, which otherwise tethers EGFR at the plasma membrane
(Hughes et al., 2009, supra). This correlates with the observation
that EGFR homodimers internalize more efficient than EGFR/HER2
dimers (Pedersen et al., Mol Cancer Res 2009; 7:275-284. The
complementary mechanisms of action of pertuzumab and trastuzumab
reportedly results in enhanced anti-tumor effects and efficacy when
combined in patients who progressed during prior trastuzumab
therapy (Baselga et al., J Clin Oncol 2010; 28:1138-1144), and a
phase III trial to evaluate this antibody combination together with
Docetaxel in previously untreated HER2-positive metastatic breast
cancer is underway.
[0006] An alternative approach to improve targeted antibody therapy
is by delivering cytotoxic cells or drugs specifically to the
antigen-expressing cancer cells. This concept of using T-cell for
efficient killing of tumor cells has been described already in 1985
(Stearz at al. Nature 1985, 314:628-631). For example, the
so-called trifunctional antibodies are bispecific antibodies,
targeting with one arm the antigen on the tumor cell and with the
other arm for instance CD3 on T cells, and provide Fc receptor
binding by the Fc region. Upon binding, a complex of T cells, tumor
cells and effector cells that bind the antibody Fc domain is
formed, leading to killing of the tumor cells (Muller and
Kontermann, BioDrugs 2010; 24:89-98.). Ertumaxomab is one such
trifunctional antibody against HER2 and CD3, which induces
cytotoxicity in cell lines with low HER2 expression and which is in
Phase II clinical development in metastatic breast cancer (Jones et
al., Lancet Oncol 2009; 10:1179-1187 and Kiewe et al., Clin Cancer
Res 2006; 12:3085-3091).
[0007] Alternatively, a complex of T cells and tumor cells are
formed, leading to killing of the tumor cells (Muller and
Kontermann, BioDrugs 2010; 24:89-98, Baeuerle and Reinhardt 2009,
Cancer Research 96: 4941) by an dual targeting antibody fragment
(e.g. dual targeting single chain antibodies). Blinatumomab (Bargou
et al, Science 2008, 321:974-976) is a single chain antibody
construct named BITE which induces cytotoxicity by targeting CD19
and CD3. Other antibody fragment based T-cell engaging bispecifics
have been described (Moore et al. 2011, Blood 117:4542-4551,
Baeuerle et el. Current opinion in Molecular Therapeutics 2009,
11:22-30).
[0008] The complex mechanisms regulating the function of HER2
warrant further research on new and optimized therapeutic
strategies against this proto-oncogene. Accordingly, there remains
a need for effective and safe products for treating HER2-related
diseases, such as cancer.
SUMMARY OF THE INVENTION
[0009] It is an object of the present invention to provide novel
effective bispecific antibodies comprising a first antigen-binding
region derived from a HER2 antibody and a second region having a
binding specificity for CD3, for medical use. Typically, the second
region is an antigen-binding region derived from a CD3 antibody,
optionally a known CD3 antibody.
[0010] As shown herein, the novel bispecific HER2.times.CD3
antibodies are capable of dose-dependent killing of HER2-expressing
cells in in vitro cytoxicity assays, effectively prevent tumor
growth in vivo, and/or have other advantages over monospecific HER2
or CD3 antibodies. In one aspect, the monospecific HER2 antibodies
from which the HER2-binding region is derived exhibit HER2 binding
characteristics or variable region sequences that differ from HER2
antibodies described in the art.
[0011] In preferred embodiments, the bispecific HER2.times.CD3
antibodies of the invention are prepared from HER2 antibodies that
are fully human or humanized, bind to novel epitopes, and/or have
favorable properties for therapeutic use in human patients. Each
Fab-arm of the bispecific antibodies may further include an
Fc-region, optionally comprising modifications promoting the
formation of the bispecific antibody, modifications affecting
Fc-mediated effector functions, and/or other features described
herein.
[0012] These and other aspects of the invention are described in
further detail below.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1: Alignment of HER2 HuMab heavy chain variable region
(VH) sequences with germline (reference) sequences (A-O). In each
VH sequence, the amino acids that differ from those of the germline
(reference) at specific positions are highlighted. Consensus VH
sequences are shown, where "X" indicates positions at which
alternative amino acids (selected from those aligned at each
position) are possible. The CDR1, CDR2, and CDR3 sequences are
underlined in each VH sequence. The consensus CDR sequences are
further defined in Table 4.
[0014] FIG. 2: Alignment of HuMab light chain variable region (VL)
sequences with germline (reference) sequences (panels A-H). In each
VL sequence, the amino acids that differ from those of the germline
(reference) at specific positions are highlighted. In, e.g., FIG.
2A, all VL sequences derived from the same V-segment (IgKV1-12-01),
but the closest J-segment differed between antibodies. Consensus VL
sequences are shown, where "X" indicates positions at which
alternative amino acids (selected from those aligned at the
indicated position) are possible. The CDR1, CDR2, and CDR3
sequences are underlined in each VL sequence. The consensus CDR
sequences are further defined in Table 4.
[0015] FIG. 3: Binding curves of HER2 antibodies to (A, B, E) high
(AU565) and (C, D, F) low (A431) HER2 expressing cell lines,
determined as described in Example 12. Data shown are mean
fluorescence intensities (MFI) of one representative experiment for
each cell line. The EC.sub.50 values indicate the apparent
affinities.
[0016] FIG. 4: Binding of HER2 antibodies to HER2 expressed on
monkey Rhesus epithelial cells. Data shown are mean fluorescence
intensities (MFI) of one experiment, described in Example 13.
[0017] FIG. 5: Chromium-release (ADCC) assay of HER2 antibodies,
showing PBMC-mediated lysis of .sup.51Cr-labeled SK-BR-3 cells
after incubation with HER2 antibody. Values depicted are the mean
maximum percentages .sup.51Cr-release.+-.the standard deviation
from one representative in vitro ADCC experiment with SK-BR-3
cells. See Example 15 for details.
[0018] FIG. 6: Effect of HER2 antibodies on the proliferation of
AU565 cells, as compared to untreated cells (set to 100%). Data
shown are percentages proliferation of AU565 cells compared to
untreated cells measured in three independent experiments.+-.the
standard deviation. * Significant (P<0.05). See Example 16 for
details.
[0019] FIG. 7: Percentage of viable MCF7 cells stimulated with
Heregulin-.beta.1 and treated with the indicated HER2 antibodies,
relative to cells stimulated with Heregulin-.beta.1 only. As a
control, the percentage proliferation of unstimulated cells is
shown (none). Data was obtained from three independent
experiments.+-.the stdev. * Significant inhibition of
Heregulin-.beta.1-induced proliferation (P<0.05). See Example 17
for details.
[0020] FIG. 8: ADC assay, showing killing of AU565 cells (A, B) or
A431 cells (C, D) via anti-kappa-ETA'-conjugated HER2 antibodies.
(A, B) Data shown are fluorescence intensities (FI) of one
representative experiment with AU565 cells treated with
non-conjugated and anti-kappa-ETA'-conjugated HER2 antibodies. (C,
D) Data shown are mean fluorescence intensities (MFI) of one
representative experiment with A431 cells treated with
non-conjugated and anti-kappa-ETA'-conjugated HER2 antibodies. See
Example 18 for details.
[0021] FIG. 9: Binding of bispecific HER2.times.CD3 antibodies to
Jurkat cells. All generated bispecific antibodies show binding to
Jurkat, albeit with a lower apparent affinity than the monospecific
parental antibodies (nomenclature=CD3 clone.times.HER2 clone).
[0022] FIG. 10: (A) Dose-dependent simultaneous binding of
HER2.times.CD3 antibodies (HER2 169.times.huCLB-T3/4) to labeled
AU565 cells (CFSE-Y-axis) and Jurkat cells (PKH26-X-asis), thereby
creating doublets of interconnected cells as shown by the
double-positive cells in FACS dot plot (Q2). (B) Representative
examples of FACS experiments showing the double positive events in
Q2 (dotted line) representing the cells simultanously bound via the
bispecific HER2.times.CD antibody.
[0023] FIG. 11: Dose dependent killing of AU565 cells by bispecific
HER2.times.CD3 antibodies. Bispecific antibodies were generated
from 4 different CD3 antibodies combined with two different HER2
antibodies (169 and 153) or control antibody IgG1 b12. (A) huOKT3,
(B) HUM291, (C) YTH12.5 and (D) huCLB-T3/4. See Example 21 for
details.
[0024] FIG. 12: Antibody induced downmodulation of HER2. Relative
percentage of HER2 expressed in AU565 cell lysate after 3 days
incubation with 10 .mu.g/mL antibody. The amount of HER2 was
quantified using a HER2-specific capture ELISA and plotted as a
percentage relative to untreated cells. Data shown are mean of
three experiments.+-.standard deviation.
[0025] FIG. 13: Colocalization analysis of HER2 antibodies (FITC)
with lysosomal marker LAMP1 (Cy5). FITC pixel intensity overlapping
with Cy5 for various monospecific HER2 antibodies. FITC pixel
intensity in LAMP1/Cy5 positive pixels of three different images is
plotted for each antibody. Group 3 antibodies 098 and 153 show
higher FITC pixel intensities in the LAMP1/Cy5 positive
compartments compared to antibodies 025 and pertuzumab from Group 2
and 169 and Herceptin.RTM. from Group 1.
[0026] FIG. 14: HER2 antibody binding to CHO-S cells transfected
with different HER2 ECD construct analyzed by means of flow
cytometry. Hu-HER2=fully human HER2, Hu-HER2-ch(I) CR1=hu-HER2 with
chicken domain I, Hu-HER2-ch(II)=hu-HER2 with chicken domain II,
hu-HER2-ch(III)=hu-HER2 with chicken domain III and
Hu-HER2-ch(IV)=hu-HER2 with chicken domain IV. Data shown are mean
fluorescence intensities (MFI) of one representative antibody,
TH1014-153. See Example 24 for details.
[0027] FIG. 15: In vivo effect of HER2-HuMabs in the NCI-N87 human
gastric carcinoma xenograft model in female CB.17 severe combined
immunodeficiency (SCID) mice. Data shown are mean
tumorsize.+-.S.E.M. per group (n=10 mice per group) (A, C) and
survival (B, D). See Example 25 for details.
[0028] FIG. 16: In vivo effect of HER2 HuMabs in BT-474 breast
tumor xenografts in Balb/C nude mice. Data shown are mean
tumorsize.+-.S.E.M. per group (n=8 mice per group) (A) and survival
(B). See Example 26 for details.
[0029] FIG. 17: Non-specific Fc-mediated killing in a cytotoxic
assay with PBMCs can be further reduced using antibodies with a
modified Fc region (LFLEDANQPS), whereas non-glycosylation via
N297Q alone does not completely remove this activity. These
mutations do no compromise the specific killing activity of
bispecific HER2.times.CD3 antibody. See Example 27 for details.
[0030] FIG. 18: Location of HER2 epitope has a strong effect on the
efficacy of the HER2.times.CD3 antibodies as shown by comparison
studies of three mAbs combined with the same anti-CD3 antibody
(huCLB-T3/4) in cytoxicity assays with either T-cells (A) or PBMCs
(B) as effector cells.
[0031] FIG. 19: T cell cytotoxicity assay using target cell lines
with various HER2 expression levels. Shown is the percentage of
viable cells after three days incubation with T cells in the
presence of HER2.times.CD3 bispecific antibody. The efficacy
positively correlated with the expression levels, as the cells with
the highest expression were killed at the lowest antibody
concentrations.
[0032] FIG. 20: CD69 expression of T cells co-cultured with AU565
tumor cells in the presence of bispecific HER2.times.CD3 antibody
and monospecific controls.
[0033] FIG. 21: CD69 expression of T cells in PBMC pool treated
with different Fc variants of DuoBody HER2 169.times.huCLBT3/4 in
the absence of tumor cells.
[0034] FIG. 22: Cytokine profile resulting from incubation of PBMCs
or T-cells with DuoBody huCLB T3/4-Q.times.HER2-169-Q (CD3-Q/169Q)
antibodies and HER2 positive tumor cells.
[0035] FIG. 23: GM-CSF production as a measure for T cell
activation by bispecific HER2.times.CD3 antibodies and the
contribution of non-specific Fc mediated activation.
[0036] FIG. 24: Evaluation of the in vivo efficacy of
HER2.times.CD3 bispecific mAb in a subcutaneous xenograft model
with HER2 expressing tumor cell line and human PBMCs. In (A), tumor
development (mean & SEM) in mice with NCI-N87 S.C. xenografts
and S.C. human PBMCs treated with bispecific HER2.times.CD3
antibodies is shown. Three dosing schedules were being compared,
and the lowest dose appeared to be most effective. In (B) the
percentage surviving mice (with tumor sizes smaller then 500
mm.sup.3) is shown in a Kaplan-Meier plot.
[0037] FIG. 25: Comparison between triple mutant (ITL), double
mutants (IT, IL, TL) and single mutant (L) human IgG1-2F8 in the
generation of bispecific antibodies by Fab-arm exchange with human
IgG4-7D8. The generation of bispecific antibodies after
2-MEA-induced in vitro Fab-arm exchange between the human IgG1-2F8
triple and double mutants and wild type IgG4-7D8 with a CPSC hinge
(A) or mutant IgG4-7D8-CPPC with a stabilized hinge (B), or the
single mutant IgG1-2F8-F405L and IgG4-7D8 with a wild type CPSC or
stabilized CPPC hinge (C), was determined by an ELISA. A
concentration series (total antibody) of 0-20 .mu.g/mL or 0-10
.mu.g/mL was analyzed in the ELISA for the experiments including
the double and single mutants, respectively. Combinations with the
double mutants IgG1-2F8-IL and -TL result in bispecific EGFR/CD20
binding similar as the triple mutant IgG1-ITL. Combinations with
the IgG1-2F8-IT do not result in a bispecific product. Combinations
with the single mutant IgG1-2F8-F405L result in bispecific
EGFR/CD20 binding.
[0038] FIG. 26: 2-MEA-induced Fab-arm exchange between IgG1-2F8-ITL
and IgG1-7D8-K409X mutants. The generation of bispecific antibodies
after 2-MEA-induced in vitro Fab-arm exchange between IgG1-2F8-ITL
and the indicated IgG1-7D8-K409X mutants was determined by an
ELISA. (A) A concentration series (total antibody) of 0-20 .mu.g/mL
was analyzed. The positive control is a purified batch of
bispecific antibody, derived from IgG1-2F8-ITL.times.IgG4-7D8-CPPC.
(B) The exchange is presented as bispecific binding at 20 .mu.g/mL
relative to the positive control (black bar). Dark grey bars
represents the bispecific binding between the IgG4 control
(IgG4-7D8.times.IgG4-2F8), the negative control
(IgG1-2F8.times.IgG1-7D8-K409R) and between IgG1-2F8-ITL and
IgG4-7D8-CPPC. Light grey bars represent results from
simultaneously performed Fab-arm-exchange reactions between the
indicated IgG1-7D8-K409X mutants and IgG1-2F8-ITL.
[0039] FIG. 27: 2-MEA-induced Fab-arm-exchange between
IgG1-2F8-F405X mutants and IgG1-7D8-K409R. The generation of
bispecific antibodies after 2-MEA-induced in vitro Fab-arm-exchange
between the indicated IgG1-2F8-F405X mutants and IgG1-7D8-K409R was
determined by an ELISA. (A) A concentration series (total antibody)
of 0-20 .mu.g/mL was analyzed in the ELISA. The positive control is
a purified batch of bispecific antibody, derived from
IgG1-2F8-F405L.times.IgG1-7D8-K409R. (B) The exchange is presented
as bispecific binding at 20 .mu.g/mL antibody concentration
relative to the positive control (black bar). Dark grey bars
represents the bispecific binding between the IgG4 control
(IgG4-7D8.times.IgG4-2F8) and the negative control
(IgG1-2F8.times.IgG1-7D8-K409R). Light grey bars represent results
from simultaneously performed Fab-arm-exchange reactions between
the indicated IgG1-2F8-F405X mutants and IgG1-7D8-K409R or
controls.
[0040] FIG. 28: 2-MEA-induced Fab-arm-exchange between
IgG1-2F8-Y407X mutants and IgG1-7D8-K409R. The generation of
bispecific antibodies after 2-MEA-induced in vitro Fab-arm-exchange
between the indicated IgG1-2F8-Y407X mutants and IgG1-7D8-K409R was
determined by an ELISA. (A) A concentration series (total antibody)
of 0-20 .mu.g/mL was analyzed in the ELISA. The positive control is
a purified batch of bispecific antibody, derived from
IgG1-2F8-F405L.times.IgG1-7D8-K409R. (B) The exchange is presented
as bispecific binding at 20 .mu.g/mL antibody concentration
relative to the positive control (black bar). Dark grey bars
represents the bispecific binding between the IgG4 control
(IgG4-7D8.times.IgG4-2F8) and the negative control
(IgG1-2F8.times.IgG1-7D8-K409R). Light grey bars represent results
from simultaneously performed Fab-arm-exchange reactions between
the indicated IgG1-2F8-Y407X mutants and IgG1-7D8-K409R or
controls.
[0041] FIG. 29: Generation of bispecific antibodies after
2-MEA-induced in vitro Fab-arm exchange between the indicated
IgG1-2F8-L368X mutants and IgG1-7D8-K409R was determined by an
ELISA using a concentration series (total antibody) of 0-20
.mu.g/mL (A). The positive control is a purified batch of
bispecific antibody, derived from
IgG1-2F8-F405L.times.IgG1-7D8-K409R. (B) Bispecific binding at 20
.mu.g/mL relative to the positive control (black bar). Dark grey
bars represents the bispecific binding between the IgG4 control
(IgG4-7D8.times.IgG4-2F8) and the negative control
(IgG1-2F8.times.IgG1-7D8-K409R). Light grey bars represent results
from simultaneously performed Fab-arm-exchange reactions between
the indicated IgG1-2F8-L368X mutants and IgG1-7D8-K409R.
[0042] FIG. 30: Generation of bispecific antibodies after
2-MEA-induced in vitro Fab-arm exchange between the indicated
IgG1-2F8-K370X mutants and IgG1-7D8-K409R was determined by an
ELISA using a concentration series (total antibody) of 0-20
.mu.g/mL (A). The positive control is a purified batch of
bispecific antibody, derived from
IgG1-2F8-F405L.times.IgG1-7D8-K409R. (B) Bispecific binding at 20
.mu.g/mL relative to the positive control (black bar). Dark grey
bars represents the bispecific binding between the IgG4 control
(IgG4-7D8.times.IgG4-2F8) and the negative control
(IgG1-2F8.times.IgG1-7D8-K409R). Light grey bars represent results
from simultaneously performed Fab-arm-exchange reactions between
the indicated IgG1-2F8-D370X mutants and IgG1-7D8-K409R.
[0043] FIG. 31: Generation of bispecific antibodies after
2-MEA-induced in vitro Fab-arm exchange between the indicated
IgG1-2F8-D399X mutants and IgG1-7D8-K409R was determined by an
ELISA using a concentration series (total antibody) of 0-20
.mu.g/mL (A). (B) Bispecific binding at 20 .mu.g/mL antibody
concentration relative to the positive control (black bar). Dark
grey bars represents the bispecific binding between the IgG4
control (IgG4-7D8.times.IgG4-2F8) and the negative control
(IgG1-2F8.times.IgG1-7D8-K409R). Light grey bars represent results
from simultaneously performed Fab-arm-exchange reactions between
the indicated IgG1-2F8-D399X mutants and IgG1-7D8-K409R.
[0044] FIG. 32: Generation of bispecific antibodies after
2-MEA-induced in vitro Fab-arm exchange between the indicated
IgG1-2F8-T366X mutants and IgG1-7D8-K409R was determined by an
ELISA using a concentration series (total antibody) of 0-20
.mu.g/mL (A). (B) The bispecific binding at 20 fag/mL antibody
concentration relative to the positive control (black bar). Dark
grey bars represents the bispecific binding between the IgG4
control (IgG4-7D8.times.IgG4-2F8) and the negative control
(IgG1-2F8.times.IgG1-7D8-K409R). Light grey bars represent results
from simultaneously performed Fab-arm-exchange reactions between
the indicated IgG1-2F8-T366X mutants and IgG1-7D8-K409R.
[0045] FIG. 33: Evaluation of the in vivo efficacy of
HER2.times.CD3 bispecific mAb in a subcutaneous xenograft model
with an HER2 expressing tumor cell line and human PBMCs. In (A),
tumor development (mean & SEM) in mice with NCI-N87 s.c.
xenografts and s.c. human PBMCs treated with bispecific
HER2.times.CD3 antibodies is shown. Different dosing schedules were
being compared, and 0.05 mg/kg and 0.5 mg/kg appeared to be
effective. In (B), the percentage mice with tumor sizes smaller
then 500 mm.sup.3 is shown in a Kaplan-Meier plot.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0046] The term "HER2" (also known as ErbB-2, NEU, HER-2, and
CD340), when used herein, refers to human epidermal growth factor
receptor 2 (SwissProt P04626) and includes any variants, isoforms
and species homologs of HER2 which are naturally expressed by
cells, including tumor cells, or are expressed on cells transfected
with the HER2 gene or cDNA. Species homologs include rhesus monkey
HER2 (macaca mulatta; Genbank accession No. GI:109114897).
[0047] The term "CD3" refers to the human CD3 protein complex,
which is composed of six distinct chains (a CD3.gamma. chain
(SwissProt P09693), a CD3.delta. chain (SwissProt P04234), two
CD3.epsilon. chains (SwissProt P07766), and one CD3 zeta chain
homodimer (SwissProt P20963) (.epsilon. .gamma.: .epsilon.
.delta.:.zeta..zeta.), and which is associated with the T cell
receptor .alpha. and .beta. chain. The term includes any CD3
variants, isoforms and species homologs which are naturally
expressed by cells, including T cells, or are expressed on cells
transfected with genes or cDNA encoding the aforementioned
chains.
[0048] The term "immunoglobulin" refers to a class of structurally
related glycoproteins consisting of two pairs of polypeptide
chains, one pair of light (L) low molecular weight chains and one
pair of heavy (H) chains, all four inter-connected by disulfide
bonds. The structure of immunoglobulins has been well
characterized. See for instance Fundamental Immunology Ch. 7 (Paul,
W., ed., 2nd ed. Raven Press, N.Y. (1989)). Briefly, each heavy
chain typically is comprised of a heavy chain variable region
(abbreviated herein as V.sub.H or VH) and a heavy chain constant
region. The heavy chain constant region typically is comprised of
three domains, C.sub.H1, C.sub.H2, and C.sub.H3. Each light chain
typically is comprised of a light chain variable region
(abbreviated herein as V.sub.L or VL) and a light chain constant
region. The light chain constant region typically is comprised of
one domain, C.sub.L. The V.sub.H and V.sub.L regions may be further
subdivided into regions of hypervariability (or hypervariable
regions which may be hypervariable in sequence and/or form of
structurally defined loops), also termed complementarity
determining regions (CDRs), interspersed with regions that are more
conserved, termed framework regions (FRs). Each V.sub.H and V.sub.L
is typically composed of three CDRs and four FRs, arranged from
amino-terminus to carboxy-terminus in the following order: FR1,
CDR1, FR2, CDR2, FR3, CDR3, FR4 (see also Chothia and Lesk J. Mol.
Biol. 196, 901-917 (1987)). Unless otherwise stated or contradicted
by context, CDR sequences herein are identified according to IMGT
rules (Brochet X., Nucl Acids Res. 2008; 36:W503-508 and Lefranc M
P., Nucleic Acids Research 1999; 27:209-212; see also internet http
address
imgt.cines.fr/IMGT_vquest/vquest?livret=0&Option=humanIg.
However, the numbering of amino acid residues in an antibody
sequence can also be performed by the method described in Kabat et
al., Sequences of Proteins of Immunological Interest, 5th Ed.
Public Health Service, National Institutes of Health, Bethesda, Md.
(1991) (phrases such as "variable domain residue numbering as in
Kabat", "Kabat position" or "according to Kabat" herein refer to
this numbering system). Particularly, for numbering of amino acids
in the constant region, the EU index numbering system (Kabat et al,
supra), can be used. The Kabat numbering of residues may be
determined for a given antibody as described in Kabat et al.,
supra.
[0049] In the present invention reference to amino acid positions
is, unless contradicted by the context, according to the EU-index
as described in Kabat et al., Sequences of Proteins of
Immunological Interest, 5th Ed. Public Health Service, National
Institutes of Health, Bethesda, Md. (1991).
[0050] The term "antibody" (Ab) in the context of the present
invention refers to an immunoglobulin molecule, a fragment of an
immunoglobulin molecule, or a derivative of either thereof, which
has the ability to specifically bind to an antigen under typical
physiological conditions with a half life of significant periods of
time, such as at least about 30 minutes, at least about 45 minutes,
at least about one hour, at least about two hours, at least about
four hours, at least about 8 hours, at least about 12 hours, about
24 hours or more, about 48 hours or more, about 3, 4, 5, 6, 7 or
more days, etc., or any other relevant functionally-defined period
(such as a time sufficient to induce, promote, enhance, and/or
modulate a physiological response associated with antibody binding
to the antigen and/or time sufficient for the antibody to recruit
an effector activity). The variable regions of the heavy and light
chains of the immunoglobulin molecule contain a binding domain that
interacts with an antigen. The constant regions of the antibodies
(Abs) may mediate the binding of the immunoglobulin to host tissues
or factors, including various cells of the immune system (such as
effector cells) and components of the complement system such as
C1q, the first component in the classical pathway of complement
activation. A HER2 antibody may also be a multispecific antibody,
such as a bispecific antibody, diabody, or similar molecule (see
for instance PNAS USA 90(14), 6444-8 (1993) for a description of
diabodies). Indeed, bispecific antibodies, diabodies, and the like,
provided by the present invention may bind any suitable target in
addition to a portion of HER2. As indicated above, the term
antibody herein, unless otherwise stated or clearly contradicted by
context, includes fragments of an antibody that are antigen-binding
fragments, i.e., retain the ability to specifically bind to the
antigen. It has been shown that the antigen-binding function of an
antibody may be performed by fragments of a full-length antibody.
Examples of antigen-binding fragments encompassed within the term
"antibody" include (i) a Fab' or Fab fragment, a monovalent
fragment consisting of the V.sub.L, V.sub.H, C.sub.L and C.sub.H1
domains, or a monovalent antibody as described in WO2007059782
(Genmab); (ii) F(ab').sub.2 fragments, bivalent fragments
comprising two Fab fragments linked by a disulfide bridge at the
hinge region; (iii) a Fd fragment consisting essentially of the
V.sub.H and C.sub.H1 domains; (iv) a Fv fragment consisting
essentially of the V.sub.L and V.sub.H domains of a single arm of
an antibody, (v) a dAb fragment (Ward et al., Nature 341, 544-546
(1989)), which consists essentially of a V.sub.H domain and also
called domain antibodies (Holt et al; Trends Biotechnol. 2003 Nov.;
21(11):484-90); (vi) camelid or nanobodies (Revets et al; Expert
Opin Biol Ther. 2005 Jan.; 5(1):111-24) and (vii) an isolated
complementarity determining region (CDR). Furthermore, although the
two domains of the Fv fragment, V.sub.L and V.sub.H, are coded for
by separate genes, they may be joined, using recombinant methods,
by a synthetic linker that enables them to be made as a single
protein chain in which the V.sub.L and V.sub.H regions pair to form
monovalent molecules (known as single chain antibodies or single
chain Fv (scFv), see for instance Bird et al., Science 242, 423-426
(1988) and Huston et al., PNAS USA 85, 5879-5883 (1988)). Such
single chain antibodies are encompassed within the term antibody
unless otherwise noted or clearly indicated by context. Although
such fragments are generally included within the meaning of
antibody, they collectively and each independently are unique
features of the present invention, exhibiting different biological
properties and utility. These and other useful antibody fragments
in the context of the present invention, as well as bispecific
formats of such fragments, are discussed further herein. It also
should be understood that the term antibody, unless specified
otherwise, also includes polyclonal antibodies, monoclonal
antibodies (mAbs), antibody-like polypeptides, such as chimeric
antibodies and humanized antibodies, and antibody fragments
retaining the ability to specifically bind to the antigen
(antigen-binding fragments) provided by any known technique, such
as enzymatic cleavage, peptide synthesis, and recombinant
techniques. An antibody as generated can possess any isotype.
[0051] The term "bispecific antibody" is in the context of the
present invention to be understood as an antibody having two
different antigen-binding regions defined by different antibody
sequences. This can be understood as different target binding but
includes as well binding to different epitopes in one target.
[0052] The term "bispecific antibody" is in the context of the
present invention to be understood as an antibody with two
different antigen-binding regions (based on sequence information).
This can mean different target binding but includes as well binding
to different epitopes in one target.
[0053] When used herein, unless contradicted by context, the term
"Fab-arm" or "arm" refers to one heavy chain-light chain pair.
[0054] When used herein, unless contradicted by context, the term
"Fc region" refers to an antibody region comprising at least a
hinge region, a CH2 domain, and a CH3 domain.
[0055] As used herein, "isotype" refers to the immunoglobulin class
(for instance IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM) that
is encoded by heavy chain constant region genes.
[0056] The term "monovalent antibody" means in the context of the
present invention that an antibody molecule is capable of binding a
single molecule of the antigen, and thus is not able of antigen
crosslinking.
[0057] An "antibody deficient in effector function" or an
"effector-function-deficient antibody" refers to an antibody which
has a significantly reduced or no ability to activate one or more
effector mechanisms, such as complement activation or Fc receptor
binding. Thus, effector-function deficient antibodies have
significantly reduced or no ability to mediate antibody-dependent
cell-mediated cytotoxicity (ADCC) and/or complement-dependent
cytotoxicity (CDC). An example of such an antibody is IgG4. Another
example is the introduction of mutations in Fc-region which can
strongly reduce the interaction with complement proteins and
Fc-receptors. See, for example, Bolt S et al., Eur J Immunol 1993,
23:403-411; Oganesyan, Acta Crys. 2008, D64, 700-704; and Shields
et al., JBC 2001, 276: 6591-6604.
[0058] A "HER2 antibody" or "anti-HER2 antibody" is an antibody as
described above, which binds specifically to the antigen HER2.
[0059] A "HER2.times.CD3 antibody" or "anti-HER2.times.CD3
antibody" is a multispecific antibody, optionally a bispecific
antibody, which comprises two different antigen-binding regions,
one of which binds specifically to the antigen HER2 and one of
which binds specifically to CD3.
[0060] The term "human antibody", as used herein, is intended to
include antibodies having variable and constant regions derived
from human germline immunoglobulin sequences. The human antibodies
of the invention may include amino acid residues not encoded by
human germline immunoglobulin sequences (e.g., mutations introduced
by random or site-specific mutagenesis in vitro or by somatic
mutation in vivo). However, the term "human antibody", as used
herein, is not intended to include antibodies in which CDR
sequences derived from the germline of another mammalian species,
such as a mouse, have been grafted onto human framework
sequences.
[0061] As used herein, a human antibody is "derived from" a
particular germline sequence if the antibody is obtained from a
system using human immunoglobulin sequences, for instance by
immunizing a transgenic mouse carrying human immunoglobulin genes
or by screening a human immunoglobulin gene library, and wherein
the selected human antibody is at least 90%, such as at least 95%,
for instance at least 96%, such as at least 97%, for instance at
least 98%, or such as at least 99% identical in amino acid sequence
to the amino acid sequence encoded by the germline immunoglobulin
gene. Typically, outside the heavy chain CDR3, a human antibody
derived from a particular human germline sequence will display no
more than 20 amino acid differences, e.g. no more than 10 amino
acid differences, such as no more than 9, 8, 7, 6 or 5, for
instance no more than 4, 3, 2, or 1 amino acid difference from the
amino acid sequence encoded by the germline immunoglobulin
gene.
[0062] When used herein, the term "heavy chain antibody" or
"heavy-chain antibody" refers to an antibody which consists only of
two heavy chains and lacks the two light chains usually found in
antibodies. Heavy chain antibodies, which naturally occur in e.g.
camelids, can bind antigens despite their lack of VL domains.
[0063] In a preferred embodiment, the antibody of the invention is
isolated. An "isolated antibody," as used herein, is intended to
refer to an antibody which is substantially free of other
antibodies having different antigenic specificities (for instance
an isolated antibody that specifically binds to HER2 is
substantially free of antibodies that specifically bind antigens
other than HER2). An isolated antibody that specifically binds to
an epitope, isoform or variant of HER2 may, however, have
cross-reactivity to other related antigens, for instance from other
species (such as HER2 species homologs). Moreover, an isolated
antibody may be substantially free of other cellular material
and/or chemicals. In one embodiment of the present invention, two
or more "isolated" monoclonal antibodies having different
antigen-binding specificities are combined in a well-defined
composition.
[0064] When used herein in the context of two or more antibodies,
the term "competes with" or "cross-competes with" indicates that
the two or more antibodies compete for binding to HER2, e.g.
compete for HER2 binding in the assay described in Example 14. An
antibody "blocks" or "cross-blocks" one or more other antibodies
from binding to HER2 if the antibody competes with the one or more
other antibodies 25% or more, with 25%-74% representing "partial
block" and 75%-100% representing "full block", preferably as
determined using the assay of Example 14. For some pairs of
antibodies, competition or blocking in the assay of the Examples is
only observed when one antibody is coated on the plate and the
other is used to compete, and not vice versa. Unless otherwise
defined or negated by context, the terms "competes with",
"cross-competes with", "blocks" or "cross-blocks" when used herein
is also intended to cover such pairs of antibodies.
[0065] The term "epitope" means a protein determinant capable of
specific binding to an antibody. Epitopes usually consist of
surface groupings of molecules such as amino acids or sugar side
chains and usually have specific three dimensional structural
characteristics, as well as specific charge characteristics.
Conformational and nonconformational epitopes are distinguished in
that the binding to the former but not the latter is lost in the
presence of denaturing solvents. The epitope may comprise amino
acid residues directly involved in the binding and other amino acid
residues, which are not directly involved in the binding, such as
amino acid residues which are effectively blocked or covered by the
specifically antigen binding peptide (in other words, the amino
acid residue is within the footprint of the specifically antigen
binding peptide).
[0066] The term "monoclonal antibody" as used herein refers to a
preparation of antibody molecules of single molecular composition.
A monoclonal antibody composition displays a single binding
specificity and affinity for a particular epitope. Accordingly, the
term "human monoclonal antibody" refers to antibodies displaying a
single binding specificity which have variable and constant regions
derived from human germline immunoglobulin sequences. The human
monoclonal antibodies may be generated by a hybridoma which
includes a B cell obtained from a transgenic or transchromosomal
nonhuman animal, such as a transgenic mouse, having a genome
comprising a human heavy chain transgene and a light chain
transgene, fused to an immortalized cell.
[0067] As used herein, the term "binding" in the context of the
binding of an antibody to a predetermined antigen or epitope
typically is a binding with an affinity corresponding to a K.sub.D
of about 10.sup.-7 M or less, such as about 10.sup.--8 M or less,
such as about 10.sup.-9 M or less, about 10.sup.-10 M or less, or
about 10.sup.-11 M or even less when determined by for instance
surface plasmon resonance (SPR) technology in a BIAcore 3000
instrument using the antigen as the ligand and the antibody as the
analyte, and binds to the predetermined antigen with an affinity
corresponding to a K.sub.D that is at least ten-fold lower, such as
at least 100 fold lower, for instance at least 1,000 fold lower,
such as at least 10,000 fold lower, for instance at least 100,000
fold lower than its affinity for binding to a non-specific antigen
(e.g., BSA, casein) other than the predetermined antigen or a
closely-related antigen. The amount with which the affinity is
lower is dependent on the K.sub.D of the antibody, so that when the
K.sub.D of the antibody is very low (that is, the antibody is
highly specific), then the amount with which the affinity for the
antigen is lower than the affinity for a non-specific antigen may
be at least 10,000 fold.
[0068] The term "k.sub.d" (sec.sup.-1), as used herein, refers to
the dissociation rate constant of a particular antibody-antigen
interaction. Said value is also referred to as the k.sub.off
value.
[0069] The term "k.sub.a" (M.sup.-1.times.sec.sup.-1), as used
herein, refers to the association rate constant of a particular
antibody-antigen interaction.
[0070] The term "K.sub.D" (M), as used herein, refers to the
dissociation equilibrium constant of a particular antibody-antigen
interaction.
[0071] The term "K.sub.A" (M.sup.-1), as used herein, refers to the
association equilibrium constant of a particular antibody-antigen
interaction and is obtained by dividing the k.sub.a by the
k.sub.d.
[0072] When used herein the term "heterodimeric interaction between
the first and second CH3 regions" refers to the interaction between
the first CH3 region and the second CH3 region in a
first-CH3/second-CH3 heterodimeric protein.
[0073] When used herein the term "homodimeric interactions of the
first and second CH3 regions" refers to the interaction between a
first CH3 region and another first CH3 region in a
first-CH3/first-CH3 homodimeric protein and the interaction between
a second CH3 region and another second CH3 region in a
second-CH3/second-CH3 homodimeric protein.
[0074] The term "reducing conditions" or "reducing environment"
refers to a condition or an environment in which a substrate, here
a cysteine residue in the hinge region of an antibody, is more
likely to become reduced than oxidized.
[0075] As used herein, the term "inhibits proliferation" (e.g.
referring to cells, such as tumor cells) is intended to include any
substantial decrease in the cell proliferation when contacted with
a HER2 antibody as compared to the proliferation of the same cells
not in contact with a HER2 antibody, e.g., the inhibition of
proliferation of a cell culture by at least about 10%, at least
about 20% or at least about 30%, or at least as much as a reference
antibody such as trastuzumab, e.g., as determined by an assay in
the Examples, e.g. Example 16.
[0076] As used herein, the term "promotes proliferation" (e.g.
referring to cells, such as tumor cells) is intended to include any
substantial increase in the cell proliferation when contacted with
a HER2 antibody as compared to the proliferation of the same cells
not in contact with a HER2 antibody, e.g., the promotion of
proliferation of a cell culture by at least about 10%, at least
about 20% or at least about 30%, or at least as much as a reference
antibody as F5, e.g., as determined by an assay in the
Examples.
[0077] As used herein, the term "internalization", when used in the
context of a HER2 antibody includes any mechanism by which the
antibody is internalized into a HER2-expressing cell from the
cell-surface and/or from surrounding medium, e.g., via endocytosis.
The internalization of an antibody can be evaluated using a direct
assay measuring the amount of internalized antibody (such as, e.g.,
the fab-CypHer5E assay described in Example 19), or an indirect
assay where the effect of an internalized antibody-toxin conjugate
is measured (such as, e.g., the anti-kappa-ETA assay of Example
18).
[0078] The present invention also provides antibodies comprising
functional variants of the V.sub.L region, V.sub.H region, or one
or more CDRs of the antibodies of the examples. A functional
variant of a V.sub.L, V.sub.H, or CDR used in the context of a HER2
antibody still allows the antibody to retain at least a substantial
proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of
the affinity/avidity and/or the specificity/selectivity of the
parent antibody and in some cases such a HER2 antibody may be
associated with greater affinity, selectivity and/or specificity
than the parent antibody.
[0079] Such functional variants typically retain significant
sequence identity to the parent antibody. The percent identity
between two sequences is a function of the number of identical
positions shared by the sequences (i.e., % homology=# of identical
positions/total # of positions .times.100), taking into account the
number of gaps, and the length of each gap, which need to be
introduced for optimal alignment of the two sequences. The percent
identity between two nucleotide or amino acid sequences may e.g. be
determined using the algorithm of E. Meyers and W. Miller, Comput.
Appl. Biosci 4, 11-17 (1988) which has been incorporated into the
ALIGN program (version 2.0), using a PAM120 weight residue table, a
gap length penalty of 12 and a gap penalty of 4. In addition, the
percent identity between two amino acid sequences may be determined
using the Needleman and Wunsch, J. Mol. Biol. 48, 444-453 (1970)
algorithm.
[0080] Exemplary variants include those which differ from a parent
antibody VH and/or VL sequence shown in FIGS. 1 and 2 at one or
more "variant" amino acid positions, denoted "X" in the
corresponding consensus sequence. Preferred variants are those in
which the new amino acid is selected from those at the
corresponding position in one of the aligned sequences in FIG. 1 or
2 (for details on CDR sequence variants, see Table 4).
Alternatively or additionally, the sequence of VH, VL or CDR
variants may differ from the sequence of the VH, VL or CDR of the
parent antibody sequences mainly by conservative substitutions; for
instance at least 10, such as at least 9, 8, 7, 6, 5, 4, 3, 2 or 1
of the substitutions in the variant are conservative amino acid
residue replacements.
[0081] In the context of the present invention, conservative
substitutions may be defined by substitutions within the classes of
amino acids reflected in the following table:
TABLE-US-00001 Amino acid residue classes for conservative
substitutions Acidic Residues Asp (D) and Glu (E) Basic Residues
Lys (K), Arg (R), and His (H) Hydrophilic Uncharged Residues Ser
(S), Thr (T), Asn (N), and Gln (Q) Aliphatic Uncharged Residues Gly
(G), Ala (A), Val (V), Leu (L), and Ile (I) Non-polar Uncharged
Residues Cys (C), Met (M), and Pro (P) Aromatic Residues Phe (F),
Tyr (Y), and Trp (W)
[0082] In the context of the present invention the following
notations are, unless otherwise indicated, used to describe a
mutation; i) substitution of an amino acid in a given position is
written as e.g. K405R which means a substitution of a Lysine in
position 405 with an Arginine; and ii) for specific variants the
specific three or one letter codes are used, including the codes
Xaa and X to indicate any amino acid residue. Thus, the
substitution of Arginine for Lysine in position 405 is designated
as: K405R, or the substitution of any amino acid residue for Lysine
in position 405 is designated as K405X. In case of deletion of
Lysine in position 405 it is indicated by K405*.
[0083] The term "recombinant host cell" (or simply "host cell"), as
used herein, is intended to refer to a cell into which an
expression vector has been introduced, e.g. an expression vector
encoding an antibody of the invention. Recombinant host cells
include, for example, transfectomas, such as CHO cells, HEK293
cells, NS/0 cells, and lymphocytic cells.
[0084] The term "transgenic non-human animal" refers to a non-human
animal having a genome comprising one or more human heavy and/or
light chain transgenes or transchromosomes (either integrated or
non-integrated into the animal's natural genomic DNA) and which is
capable of expressing fully human antibodies. For example, a
transgenic mouse can have a human light chain transgene and either
a human heavy chain transgene or human heavy chain transchromosome,
such that the mouse produces human HER2 antibodies when immunized
with HER2 antigen and/or cells expressing HER2. The human heavy
chain transgene may be integrated into the chromosomal DNA of the
mouse, as is the case for transgenic mice, for instance HuMAb.RTM.
mice, such as HCo7, HCo12, or HCo17 mice, or the human heavy chain
transgene may be maintained extrachromosomally, as is the case for
transchromosomal KM mice as described in WO02/43478. Similar mice,
having a larger human Ab gene repertoire, include HCo7 and HCo20
(see e.g. WO2009097006). Such transgenic and transchromosomal mice
(collectively referred to herein as "transgenic mice") are capable
of producing multiple isotypes of human monoclonal antibodies to a
given antigen (such as IgG, IgA, IgM, IgD and/or IgE) by undergoing
V-D-J recombination and isotype switching. Transgenic, nonhuman
animal can also be used for production of antibodies against a
specific antigen by introducing genes encoding such specific
antibody, for example by operatively linking the genes to a gene
which is expressed in the milk of the animal.
[0085] "Treatment" refers to the administration of an effective
amount of a therapeutically active compound of the present
invention with the purpose of easing, ameliorating, arresting or
eradicating (curing) symptoms or disease states.
[0086] An "effective amount" or "therapeutically effective amount"
refers to an amount effective, at dosages and for periods of time
necessary, to achieve a desired therapeutic result. A
therapeutically effective amount of a HER2 antibody may vary
according to factors such as the disease state, age, sex, and
weight of the individual, and the ability of the HER2 antibody to
elicit a desired response in the individual. A therapeutically
effective amount is also one in which any toxic or detrimental
effects of the antibody or antibody portion are outweighed by the
therapeutically beneficial effects.
[0087] An "anti-idiotypic" antibody is an antibody which recognizes
unique determinants generally associated with the antigen-binding
site of an antibody.
Further Aspects and Embodiments of the Invention
[0088] As described above, the invention relates to a bispecific
antibody comprising two different antigen-binding regions, one
which has a binding specificity for HER2 and one which has a
binding specificity for CD3.
[0089] In one aspect, the invention relates to a bispecific
molecule comprising a first antigen binding region from a HER2
antibody described herein and a second antigen binding region from
a CD3 antibody described herein.
[0090] In one embodiment, the HER2 antigen-binding region is from a
HER2 antibody which cross-blocks or binds to the same epitope as a
reference antibody from cross-block group 1, described herein. In a
specific embodiment, the bispecific antibody comprises an
antigen-binding region from an antibody of cross-block group 1, as
described herein.
[0091] In one embodiment, the HER2 antigen-binding region is from a
HER2 antibody which cross-blocks or binds to the same epitope as a
reference antibody from cross-block group 2, described herein. In a
specific embodiment, the bispecific antibody comprises an
antigen-binding region from an antibody of cross-block group 2, as
described herein.
[0092] In one embodiment, the HER2 antigen-binding region is from a
HER2 antibody which cross-blocks or binds to the same epitope as a
reference antibody from cross-block group 3, described herein. In a
specific embodiment, the bispecific antibody comprises an
antigen-binding region from an antibody of cross-block group 3, as
described herein.
[0093] In one embodiment, the HER2 antigen-binding region is from a
HER2 antibody which cross-blocks or binds to the same epitope as a
reference antibody from cross-block group 4, described herein. In a
specific embodiment, the bispecific antibody comprises an
antigen-binding region from an antibody of cross-block group 4, as
described herein.
[0094] In a particular embodiment, the bispecific antibody of any
one of the preceding embodiments comprises an antigen-binding
region which cross-blocks or binds to the same epitope as a
reference CD3 antibody comprising the VH and VL regions of CD3
antibody YTH12.5, HUM291 (also known as visilizumab),
huOKT3-C114S-gLC (related to teplizumab), all known in the art, or
comprising the VH and VL regions of CD3 antibody huCLB-T3/4, which
represents a humanized variant of CLB-T3/4. Further details on
these CD3 antibodies are provided in Example 21. In another
particular embodiment, the bispecific antibody of any one of the
preceding embodiments comprises an antigen-binding region from an
antibody selected from YTH12.5, HUM291 huOKT3-C114S-gLC and
huCLB-T3/4.
[0095] Thus, the bispecifc antibody of the present invention may
comprise a first antigen-binding region and a second
antigen-binding region, which first antigen-binding region binds an
epitope on human epidermal growth factor receptor 2 (HER2) and
which second antigen-binding region binds an epitope on human
CD3.
Antibodies and Antigen-Binding Regions
[0096] The bispecific antibody of the present invention comprises
two different antigen-binding regions which bind HER2 and CD3,
respectively. Furthermore, as described below one method of
producing a bispecific antibody of the present invention is based
on incubating a first HER2 antibody and a second CD3 antibody under
reducing conditions.
[0097] Antigen-binding regions binding to HER2 antibodies of the
present invention may belong to any of cross-block groups 1, 2, 3
and 4. In the following examples of such antigen-binding regions
bind to HER2 belonging to cross-block groups 1, 2, 3, and 4 are
given, and reference to "antigen-binding region" in this context is
intended to include both an antigen-binding region of a bispecific
antibody of the present invention, e.g. a first antigen-binding
region, and first HER2 antibody.
[0098] In a further or alternative embodiment of the present
invention, the bispecific antibody comprises an antigen-binding
region of one or more of the human antibodies of cross-blocks 1, 2,
3, or 4, which blocks the binding to HER2.
[0099] In a further or alternative embodiment of the present
invention, the bispecific antibody comprises an antigen-binding
region which blocks the binding to the same epitope on soluble HER2
as one or more of the human antibodies of cross-blocks 1, 2, 3, or
4.
[0100] In a further or alternative embodiment of the present
invention, the bispecific antibody comprises an antigen-binding
region which binds to the same epitope on HER2 as one or more of
the human antibodies of cross-blocks 1, 2, 3, or 4.
[0101] Thus, the bispecific antibody of the present invention may
comprise a first antigen-binding region and a second
antigen-binding region, which first and second antigen-binding
regions bind different epitopes, and wherein the first
antigen-binding region binds an epitope on human epidermal growth
factor receptor 2 (HER2).
[0102] The first antigen-binding region of the bispecific antibody
of the present invention may be an antigen-binding region from any
of cross-block groups 1, 2, 3, and 4.
Cross-Block Group 1
[0103] In one aspect, the bispecific antibody of the invention
comprises an antigen-binding region which blocks the binding to
HER2, e.g. soluble HER2, or binds to the same epitope on HER2 as
one or more of the human antibodies of cross-block group 1
described herein.
[0104] In one embodiment, the antigen-binding region cross-blocks
the binding to soluble HER2 of trastuzumab, when determined as
described in Example 14.
[0105] In one embodiment, the antigen-binding region blocks the
binding to HER2, e.g. soluble HER2, or binds to the same epitope as
a reference antibody comprising a VH region comprising the sequence
of SEQ ID NO:1 and a VL region comprising the sequence of SEQ ID
NO:5 (169).
[0106] In one embodiment, the antigen-binding region blocks the
binding to HER2, e.g. soluble HER2, or binds to the same epitope as
a reference antibody comprising a VH region comprising the sequence
of SEQ ID NO:8 and a VL region comprising the sequence of SEQ ID
NO:12 (050).
[0107] In one embodiment, the antigen-binding region blocks the
binding to HER2, e.g. soluble HER2, or binds to the same epitope as
a reference antibody comprising a VH region comprising the sequence
of SEQ ID NO:15 and a VL region comprising the sequence of SEQ ID
NO:19 (084).
[0108] In one embodiment, the antigen-binding region blocks the
binding to HER2, e.g. soluble HER2, or binds to the same epitope as
a reference antibody comprising VH and VL regions selected from the
group consisting of: [0109] a) a VH region comprising the sequence
of SEQ ID NO:77 and a VL region comprising the sequence of SEQ ID
NO:78 (049); [0110] b) a VH region comprising the sequence of SEQ
ID NO:79 and a VL region comprising the sequence of SEQ ID NO:80
(051); [0111] c) a VH region comprising the sequence of SEQ ID
NO:81 and a VL region comprising the sequence of SEQ ID NO:82
(055); [0112] d) a VH region comprising the sequence of SEQ ID
NO:83 and a VL region comprising the sequence of SEQ ID NO:84
(123); [0113] e) a VH region comprising the sequence of SEQ ID
NO:85 and a VL region comprising the sequence of SEQ ID NO:86
(161); and [0114] f) a VH region comprising the sequence of SEQ ID
NO:87 and a VL region comprising the sequence of SEQ ID NO:88
(124).
[0115] In another additional or alternative aspect of the
bispecific antibody of the invention, one antigen-binding region
binds to HER2 and comprises a VH CDR3, VH region and/or VL region
sequence similar or identical to such a sequence of an antibody
described herein.
[0116] In one embodiment, the antigen-binding region comprises a VH
CDR3 region having a sequence selected from the group consisting
of
[0117] SEQ ID NO:11 (050, 049, 051, 055), optionally wherein the VH
region is derived from the IgHV3-21-1 germline sequence;
[0118] SEQ ID No:130, such as the sequence of SEQ ID NO:18 (084),
optionally wherein the VH region is derived from the IgHV1-69-04
germline sequence;
[0119] SEQ ID NO:133 (169, 123, 161, 124), such as the sequence of
SEQ ID NO:4 (169), optionally wherein the VH region is derived from
the IgHV1-18-1 germline sequence; or
[0120] In one embodiment, the antigen-binding region comprises a VH
CDR3 region of one of antibodies 123, 161, or 124, as shown in FIG.
1, optionally wherein the VH region is derived from an IgHV1-18-1
germline.
[0121] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region selected from the
group consisting of [0122] a) a VH region comprising the CDR1, CDR2
and CDR3 sequences of SEQ ID NOs:9, 127 and 11, such as the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOS: 9, 10 and 11 (050);
optionally where the VH region is derived from an IgHV3-23-1
germline; [0123] b) a VH region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:128, 129 and 130, such the CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs:16, 17 and 18, respectively (084),
optionally where the VH region is derived from an IgHV1-69-04
germline; and [0124] c) a VH region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID NOs:131, 132, and 133, such as the CDR1,
CDR2, and CDR3 sequences of SEQ ID NOs: 2, 3 and 4 (169),
respectively, optionally where the VH region is derived from an
IgHV1-18-1 germline.
[0125] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region selected from the
preceding embodiments (a) or (b) and a VL region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID NO:13, XAS (wherein X is A
or V), and SEQ ID No:155, respectively, such as a CDR1 sequence
selected from SEQ ID Nos: 13 or 20, a CDR2 which is AAS or VAS, and
a CDR3 sequence selected from SEQ ID NOs:14 and 21 (050, 084);
respectively, optionally where the VL region is derived from an
IgKV1-12-01 germline.
[0126] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region which is the preceding
embodiment (c) and a VL region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID NO:6, DXS (wherein X=A or T), and SEQ ID NO:156
(169), respectively, optionally wherein the VL region is derived
from IgKV3-11-01.
[0127] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:2, 3 and 4, respectively;
and, optionally, a VL region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:6, DAS, and SEQ ID NO:7, respectively
(169).
[0128] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:9, 10 and 11, respectively;
and a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ
ID NOs:13, AAS, and SEQ ID NO:14, respectively (050).
[0129] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:16, 17 and 18, respectively;
and a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ
ID NOs:20, VAS, and SEQ ID NO:21, respectively (084).
[0130] In separate embodiments, the bispecific antibody or the
first antigen-binding region comprises: [0131] a) a VH region
comprising the sequence of SEQ ID NO:1 and, optionally, a VL region
comprising the sequence of SEQ ID NO:5 (169); [0132] b) a VH region
comprising the sequence of SEQ ID NO:8 and, preferably, a VL region
comprising the sequence of SEQ ID NO:12 (050); [0133] c) a VH
region comprising the sequence of SEQ ID NO:15 and, preferably, a
VL region comprising the sequence of SEQ ID NO:19 (084); [0134] d)
a VH region comprising the sequence of SEQ ID NO:77 and,
preferably, a VL region comprising the sequence of SEQ ID NO:78
(049); [0135] e) a VH region comprising the sequence of SEQ ID
NO:79 and, preferably, a VL region comprising the sequence of SEQ
ID NO:80 (051); [0136] f) a VH region comprising the sequence of
SEQ ID NO:81 and, preferably, a VL region comprising the sequence
of SEQ ID NO:82 (055); [0137] g) a VH region comprising the
sequence of SEQ ID NO:83 and, preferably, a VL region comprising
the sequence of SEQ ID NO:84 (123); [0138] h) a VH region
comprising the sequence of SEQ ID NO:85 and, preferably, a VL
region comprising the sequence of SEQ ID NO:86 (161); [0139] i) a
VH region comprising the sequence of SEQ ID NO:87 and, preferably,
a VL region comprising the sequence of SEQ ID NO:88 (124); and/or
[0140] j) a variant of any of said antibodies, wherein said variant
preferably has at most 1, 2 or 3 amino-acid modifications, more
preferably amino-acid substitutions, such as conservative amino
acid substitutions and substitutions where the new amino acid is
one at the same position in an aligned sequence in FIG. 1 or 2,
particularly at positions indicated by "X" in the corresponding
consensus sequence.
Cross-Block Group 2
[0141] In one aspect of the antibody of the invention, the
bispecific antibody comprises an antigen-binding region which
blocks the binding to HER2, e.g. soluble HER2, or binds to the same
epitope on HER2 as one or more of the human antibodies of
cross-block group 2 described herein.
[0142] In one embodiment, the antigen-binding region cross-blocks
the binding to soluble HER2 of pertuzumab, when determined as
described in Example 14.
[0143] In one embodiment, the antigen-binding region blocks the
binding to HER2, e.g. soluble HER2, or binds to the same epitope as
a reference antibody comprising a VH region comprising the sequence
of SEQ ID NO:22 and a VL region comprising the sequence of SEQ ID
NO:26 (025).
[0144] In one embodiment, the antigen-binding region blocks the
binding to HER2, e.g. soluble HER2, or binds to the same epitope as
a reference antibody comprising a VH region comprising the sequence
of SEQ ID NO:29 and a VL region comprising the sequence of SEQ ID
NO:32 (091).
[0145] In one embodiment, the antigen-binding region blocks the
binding to HER2, e.g. soluble HER2, or binds to the same epitope as
a reference antibody comprising a VH region comprising the sequence
of SEQ ID NO:35 and a VL region comprising the sequence of SEQ ID
NO:39 (129).
[0146] In one embodiment, the antigen-binding region blocks the
binding to HER2, e.g. soluble HER2, or binds to the same epitope as
a reference antibody comprising VH and VL regions selected from the
group consisting of: [0147] a) a VH region comprising the sequence
of SEQ ID NO:89 and a VL region comprising the sequence of SEQ ID
NO:90 (001); [0148] b) a VH region comprising the sequence of SEQ
ID NO:91 and a VL region comprising the sequence of SEQ ID NO:92
(143); [0149] c) a VH region comprising the sequence of SEQ ID
NO:93 and a VL region comprising the sequence of SEQ ID NO:94
(019); [0150] d) a VH region comprising the sequence of SEQ ID
NO:95 and a VL region comprising the sequence of SEQ ID NO:96
(021); [0151] e) a VH region comprising the sequence of SEQ ID
NO:97 and a VL region comprising the sequence of SEQ ID NO:98
(027); [0152] f) a VH region comprising the sequence of SEQ ID
NO:99 and a VL region comprising the sequence of SEQ ID NO:100
(032) [0153] g) a VH region comprising the sequence of SEQ ID
NO:101 and a VL region comprising the sequence of SEQ ID NO:102
(035); [0154] h) a VH region comprising the sequence of SEQ ID
NO:103 and a VL region comprising the sequence of SEQ ID NO:104
(036); [0155] i) a VH region comprising the sequence of SEQ ID
NO:105 and a VL region comprising the sequence of SEQ ID NO:106
(054); and [0156] j) a VH region comprising the sequence of SEQ ID
NO:107 and a VL region comprising the sequence of SEQ ID NO:108
(094).
[0157] In another additional or alternative aspect of the
bispecific antibody of the invention, the bispecific antibody or
the first antigen-binding region comprises a VH CDR3, VH region
and/or VL region sequence similar or identical to a sequence of the
novel antibodies described herein.
[0158] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH CDR3 region having a sequence
selected from the group consisting of
[0159] SEQ ID NO:136, such as the sequence of SEQ ID NO:25 (025),
optionally wherein the VH region is derived from the IgHV4-34-1
germline sequence;
[0160] SEQ ID NO:139, such as the sequence of SEQ ID NO:31 (091),
optionally wherein the VH region is derived from the IgHV4-34-01
germline sequence; and
[0161] SEQ ID NO:142, such as the sequence of SEQ ID NO:38 (129),
optionally wherein the VH region is derived from the IgHV3-30-01
germline sequence.
[0162] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH CDR3 region of one of
antibodies 001, 143, 019, 021, 027, 032, 035, 036, 054 or 094 as
shown in FIG. 1, optionally wherein the VH region is derived from
an IgHV4-34-1 germline.
[0163] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region selected from the
group consisting of [0164] a) a VH region comprising the CDR1, CDR2
and CDR3 sequences of SEQ ID NOs:134, 135 and 136, such as the
CDR1, CDR2 and CDR3 sequences of SEQ ID NOS: 23, 24 and 25 (025);
optionally where the VH region is derived from an IgHV4-34-1
germline; [0165] b) a VH region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:137, 138 and 139, such the CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs:30, 163, and 31, respectively (091),
optionally where the VH region is derived from an IgHV4-34-01
germline; and [0166] c) a VH region comprising the CDR1, CDR2, and
CDR3 sequences of SEQ ID NOs:140, 141 and 142, such as the CDR1,
CDR2, and CDR3 sequences of SEQ ID NOs: 36, 37 and 38 (129),
respectively, optionally where the VH region is derived from an
IgHV3-30-01 germline.
[0167] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region selected from the
preceding embodiment (a) and a VL region comprising the CDR1, CDR2,
and CDR3 sequences of SEQ ID NO:157, AAS, and SEQ ID No:164,
respectively, such as the CDR1, CDR2, and CDR3 sequences of SEQ ID
Nos:27, AAS, and SEQ ID NO:28 (025); respectively, optionally where
the VL region is derived from an IgKV1D-16-01 germline.
[0168] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region selected from the
preceding embodiment (b) and a VL region comprising the CDR1, CDR2,
and CDR3 sequences of SEQ ID NO:33, AX.sub.1X.sub.2 (wherein
X.sub.1 is A or T, preferably A; and X.sub.2 is S or F, preferably
S), and SEQ ID No:158, respectively, such as the CDR1, CDR2 and
CDR3 sequences of SEQ ID Nos:33, AAS, and SEQ ID NO:34 (091);
respectively, optionally where the VL region is derived from an
IgKV1D-16-01 germline.
[0169] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region which is the preceding
embodiment (c) and a VL region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID NO:40, DAS and SEQ ID NO:41 (129),
respectively, optionally wherein the VL region is derived from
IgKV3-11-01.
[0170] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:23, 24 and 25, respectively;
and, optionally, a VL region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:27, AAS, and SEQ ID NO:28, respectively
(025).
[0171] In one embodiment, the bispecific antibody comprises a VH
region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID
NOs:30, 163 and 31, respectively; and a VL region comprising the
CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:33, AAS, and SEQ ID
NO:34, respectively (091).
[0172] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:36, 37 and 38, respectively;
and a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ
ID NOs:40, DAS, and SEQ ID NO:41, respectively (129).
[0173] In separate embodiments, the bispecific antibody or the
first antigen-binding region comprises: [0174] a) a VH region
comprising the sequence of SEQ ID NO:22 and, optionally, a VL
region comprising the sequence of SEQ ID NO:26 (025); [0175] b) a
VH region comprising the sequence of SEQ ID NO:29 and, preferably,
a VL region comprising the sequence of SEQ ID NO:32 (091); [0176]
c) a VH region comprising the sequence of SEQ ID NO:35 and,
preferably, a VL region comprising the sequence of SEQ ID NO:39
(129); [0177] d) a VH region comprising the sequence of SEQ ID
NO:89 and, preferably, a VL region comprising the sequence of SEQ
ID NO:90 (001); [0178] e) a VH region comprising the sequence of
SEQ ID NO:91 and, preferably, a VL region comprising the sequence
of SEQ ID NO:92 (143); [0179] f) a VH region comprising the
sequence of SEQ ID NO:93 and, preferably, a VL region comprising
the sequence of SEQ ID NO:94 (019); [0180] g) a VH region
comprising the sequence of SEQ ID NO:95 and, preferably, a VL
region comprising the sequence of SEQ ID NO:96 (021); [0181] h) a
VH region comprising the sequence of SEQ ID NO:97 and, preferably,
a VL region comprising the sequence of SEQ ID NO:98 (027); [0182]
i) a VH region comprising the sequence of SEQ ID NO:99 and,
preferably, a VL region comprising the sequence of SEQ ID NO:100
(032); [0183] j) a VH region comprising the sequence of SEQ ID
NO:101 and, preferably, a VL region comprising the sequence of SEQ
ID NO:102 (035); [0184] k) a VH region comprising the sequence of
SEQ ID NO:103 and, preferably, a VL region comprising the sequence
of SEQ ID NO:104 (036); [0185] l) a VH region comprising the
sequence of SEQ ID NO:105 and, preferably, a VL region comprising
the sequence of SEQ ID NO:106 (054); [0186] m) a VH region
comprising the sequence of SEQ ID NO:106 and, preferably, a VL
region comprising the sequence of SEQ ID NO:108 (094); and/or
[0187] n) a variant of any of said antibodies, wherein said variant
preferably has at most 1, 2 or 3 amino-acid modifications, more
preferably amino-acid substitutions, such as conservative amino
acid substitutions and substitutions where the new amino acid is
one at the same position in an aligned sequence in FIG. 1 or 2,
particularly at positions indicated by "X" in the corresponding
consensus sequence.
Cross-Block Group 3
[0188] In one aspect of the bispecific antibody of the invention,
the bispecific antibody comprises an antigen-binding region which
blocks the binding to HER2, e.g. soluble HER2, or binds to the same
epitope on HER2 as one or more of the human antibodies of
cross-block group 3 described herein.
[0189] In one embodiment, the antigen-binding region cross-blocks
the binding to soluble HER2 of F5 and/or C1, when determined as
described in Example 14.
[0190] In one embodiment, the antigen-binding region blocks the
binding to HER2, e.g. soluble HER2, or binds to the same epitope as
a reference antibody comprising a VH region comprising the sequence
of SEQ ID NO:46 and a VL region comprising the sequence of SEQ ID
NO:49 (127).
[0191] In one embodiment, the antigen-binding region blocks the
binding to HER2, e.g. soluble HER2, or binds to the same epitope as
a reference antibody comprising a VH region comprising the sequence
of SEQ ID NO:49 and a VL region comprising the sequence of SEQ ID
NO:53 (159).
[0192] In one embodiment, the antigen-binding region blocks the
binding to HER2, e.g. soluble HER2, or binds to the same epitope as
a reference antibody comprising a VH region comprising the sequence
of SEQ ID NO:56 and a VL region comprising the sequence of SEQ ID
NO:60 (098).
[0193] In one embodiment, the antigen-binding region blocks the
binding to HER2, e.g. soluble HER2, or binds to the same epitope as
a reference antibody comprising a VH region comprising the sequence
of SEQ ID NO:63 and a VL region comprising the sequence of SEQ ID
NO:67 (153).
[0194] In one embodiment, the antigen-binding region blocks the
binding to HER2, e.g. soluble HER2, or binds to the same epitope as
a reference antibody comprising a VH region comprising the sequence
of SEQ ID NO:70 and a VL region comprising the sequence of SEQ ID
NO:74 (132).
[0195] In one embodiment, the antigen-binding region blocks the
binding to HER2, e.g. soluble HER2, or binds to the same epitope as
a reference antibody comprising VH and VL regions selected from the
group consisting of: [0196] a) a VH region comprising the sequence
of SEQ ID NO:109 and a VL region comprising the sequence of SEQ ID
NO:110 (105); [0197] b) a VH region comprising the sequence of SEQ
ID NO:111 and a VL region comprising the sequence of SEQ ID NO:112
(100); [0198] c) a VH region comprising the sequence of SEQ ID
NO:113 and a VL region comprising the sequence of SEQ ID NO:114
(125); [0199] d) a VH region comprising the sequence of SEQ ID
NO:115 and a VL region comprising the sequence of SEQ ID NO:116
(162); [0200] e) a VH region comprising the sequence of SEQ ID
NO:117 and a VL region comprising the sequence of SEQ ID NO:118
(033); [0201] f) a VH region comprising the sequence of SEQ ID
NO:119 and a VL region comprising the sequence of SEQ ID NO:120
(160) [0202] g) a VH region comprising the sequence of SEQ ID
NO:121 and a VL region comprising the sequence of SEQ ID NO:122
(166); [0203] h) a VH region comprising the sequence of SEQ ID
NO:123 and a VL region comprising the sequence of SEQ ID NO:124
(152); and [0204] i) a VH region comprising the sequence of SEQ ID
NO:125 and a VL region comprising the sequence of SEQ ID NO:126
(167).
[0205] In another additional or alternative aspect of the
bispecific antibody of the invention, the bispecific antibody or
the first antigen-binding region comprises a VH CDR3, VH region
and/or VL region sequence similar or identical to a sequence of the
novel antibodies described herein.
[0206] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH CDR3 region having a sequence
selected from the group consisting of
[0207] SEQ ID NO:148, such as the sequence of SEQ ID NO:48 (127),
optionally wherein the VH region is derived from the IgHV5-51-01
germline sequence;
[0208] SEQ ID NO:52 (159), optionally wherein the VH region is
derived from the IgHV5-51-01 germline sequence;
[0209] SEQ ID NO:145, such as the sequence of SEQ ID NO:59 (098),
optionally wherein the VH region is derived from the IgHV3-23-01
germline sequence;
[0210] SEQ ID NO:154, such as the sequence of SEQ ID NO:66 (153),
optionally wherein the VH region is derived from the IgHV3-30-03-01
germline sequence; and
[0211] SEQ ID NO:151, such as the sequence of SEQ ID NO:73 (132),
optionally wherein the VH region is derived from the IgHV1-18-01
germline sequence.
[0212] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH CDR3 region of one of
antibodies 105, 100, 125 or 162 as shown in FIG. 1, optionally
wherein the VH region is derived from an IgHV3-23-1 germline.
[0213] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH CDR3 region of one of
antibodies 033, 160, 166, 152 or 167 as shown in FIG. 1, optionally
wherein the VH region is derived from an IgHV3-30-3-01
germline.
[0214] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region selected from the
group consisting of [0215] a) a VH region comprising the CDR1, CDR2
and CDR3 sequences of SEQ ID NOs:146, 147 and 148, such as the
CDR1, CDR2 and CDR3 sequences of SEQ ID NOS: 43, 44 and 45 (127);
optionally where the VH region is derived from an IgHV5-51-01
germline; [0216] b) a VH region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:149, 51 and 52, such as the CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs:50, 51 and 52, respectively (159),
optionally where the VH region is derived from an IgHV5-51-01
germline; [0217] c) a VH region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID NOs:143, 144 and 145, such as the CDR1, CDR2,
and CDR3 sequences of SEQ ID NOs: 57, 58 and 59 (098),
respectively, optionally where the VH region is derived from an
IgHV3-23-01 germline; [0218] d) a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:152, 153 and 154, such as the
CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:64, 65 and 66,
respectively (153), optionally where the VH region is derived from
an IgHV3-30-03-01 germline; and [0219] e) a VH region comprising
the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:71, 150 and 151,
such as the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 71, 72
and 73 (132), respectively, optionally where the VH region is
derived from an IgHV1-18-01 germline.
[0220] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region selected from the
preceding embodiment (a) and a VL region comprising the CDR1, CDR2,
and CDR3 sequences of SEQ ID NO:47, AAS and SEQ ID NO:48,
respectively (127); respectively, optionally where the VL region is
derived from an IgKV1D-8-01 germline.
[0221] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region selected from the
preceding embodiment (b) and a VL region comprising the CDR1, CDR2,
and CDR3 sequences of SEQ ID NO:54, AAS, and SEQ ID No:55 (159);
respectively, optionally where the VL region is derived from an
IgKV1D-16-01 germline.
[0222] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region which is the preceding
embodiment (c) and a VL region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID NO:159, AAS and SEQ ID NO:160, respectively,
such as the VL CDR1, CDR2 and CDR3 sequences of SEQ ID NOS: 61, AAS
and SEQ ID NO:62 (098), optionally wherein the VL region is derived
from IgKV1D-16-01.
[0223] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region which is the preceding
embodiment (d) and a VL region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID NO:161, XAS (wherein X=D or A, preferably D),
and SEQ ID NO:162 (153), respectively, such as the VL CDR sequences
of SEQ ID NO:68, DAS, and 69, optionally wherein the VL region is
derived from IgKV1D-16-01.
[0224] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region which is the preceding
embodiment (e) and a VL region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID NO:75, DAS and SEQ ID NO:76 (132),
respectively, optionally wherein the VL region is derived from
IgKV3-11-01.
[0225] In one embodiment, the bisspecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:43, 44 and 45, respectively;
and a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ
ID NOs:47, AAS, and SEQ ID NO:48, respectively (127).
[0226] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:50, 51 and 52, respectively;
and a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ
ID NOs:54, AAS, and SEQ ID NO:55, respectively (159).
[0227] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:57, 58 and 59, respectively;
and a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ
ID NOs:60, AAS, and SEQ ID NO:61, respectively (098).
[0228] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:64, 65 and 66, respectively;
and, optionally, a VL region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:68, DAS, and SEQ ID NO:69, respectively
(153).
[0229] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:71, 72 and 73, respectively;
and a VL region comprising the CDR1, CDR2 and CDR3 sequences of SEQ
ID NOs:75, DAS, and SEQ ID NO:76, respectively (132).
[0230] In separate embodiments, the bispecific antibody or the
first antigen-binding region comprises: [0231] a) a VH region
comprising the sequence of SEQ ID NO:46 and, preferably, a VL
region comprising the sequence of SEQ ID NO:49 (127); [0232] b) a
VH region comprising the sequence of SEQ ID NO:49 and, preferably,
a VL region comprising the sequence of SEQ ID NO:53 (159); [0233]
c) a VH region comprising the sequence of SEQ ID NO:56 and,
preferably, a VL region comprising the sequence of SEQ ID NO:60
(098); [0234] d) a VH region comprising the sequence of SEQ ID
NO:63 an, optionally, a VL region comprising the sequence of SEQ ID
NO:67 (153); [0235] e) a VH region comprising the sequence of SEQ
ID NO:70 and, preferably, a VL region comprising the sequence of
SEQ ID NO:74 (132); [0236] f) a VH region comprising the sequence
of SEQ ID NO:109 and, preferably, a VL region comprising the
sequence of SEQ ID NO:110 (105); [0237] g) a VH region comprising
the sequence of SEQ ID NO:111 and, preferably, a VL region
comprising the sequence of SEQ ID NO:112 (100); [0238] h) a VH
region comprising the sequence of SEQ ID NO:113 and, preferably, a
VL region comprising the sequence of SEQ ID NO:114 (125); [0239] i)
a VH region comprising the sequence of SEQ ID NO:115 and,
preferably, a VL region comprising the sequence of SEQ ID NO:116
(162); [0240] j) a VH region comprising the sequence of SEQ ID
NO:117 and, preferably, a VL region comprising the sequence of SEQ
ID NO:118 (033); [0241] k) a VH region comprising the sequence of
SEQ ID NO:119 and, preferably, a VL region comprising the sequence
of SEQ ID NO:120 (160) [0242] l) a VH region comprising the
sequence of SEQ ID NO:121 and, preferably, a VL region comprising
the sequence of SEQ ID NO:122 (166); [0243] m) a VH region
comprising the sequence of SEQ ID NO:123 and, preferably, a VL
region comprising the sequence of SEQ ID NO:124 (152); [0244] o) a
VH region comprising the sequence of SEQ ID NO:125 and, preferably,
a VL region comprising the sequence of SEQ ID NO:126 (167); and/or
[0245] p) a variant of any of said antibodies, wherein said variant
preferably has at most 1, 2 or 3 amino-acid modifications, more
preferably amino-acid substitutions, such as conservative amino
acid substitutions and substitutions where the new amino acid is
one at the same position in an aligned sequence in FIG. 1 or 2,
particularly at positions indicated by "X" in the corresponding
consensus sequence.
Cross-Block Group 4
[0246] In one aspect of the bispecific antibody of the invention,
the bispecific antibody comprises an antigen-binding region which
binds HER2 but which does not block the binding to soluble HER2 of
a second antibody, optionally in immobilized form, comprising the
VH and VL sequences of any of trastuzumab, pertuzumab, F5, and C1,
when determined as described in Example 14.
[0247] In an additional or alternative aspect of the antibody of
the invention, the antigen-binding region blocks or cross-blocks
the binding to HER2 of one or more of the human antibodies of
cross-block group 4.
[0248] In one embodiment, the antigen-binding region blocks the
binding to HER2 of a reference antibody, optionally immobilized,
wherein the reference antibody comprises a VH region comprising the
sequence of SEQ ID NO:165 and a VL region comprising the sequence
of SEQ ID NO:169 (005), preferably wherein the antibody is fully
blocking when determined as described in Example 14.
[0249] In one embodiment, the antigen-binding region blocks the
binding to HER2 of a reference antibody, optionally immobilized,
wherein the reference antibody comprises a VH region comprising the
sequence of SEQ ID NO:172 and a VL region comprising the sequence
of SEQ ID NO:176 (006), preferably wherein the antibody is
fully-blocking when determined as described in Example 14.
[0250] In one embodiment, the antigen-binding region blocks the
binding to HER2 of a reference antibody, optionally immobilized,
wherein the reference antibody comprises a VH region comprising the
sequence of SEQ ID NO:179 and a VL region comprising the sequence
of SEQ ID NO:183 (059), preferably wherein the antibody is
fully-blocking when determined as described in Example 14.
[0251] In one embodiment, the antigen-binding region blocks the
binding to HER2 of a reference antibody, optionally immobilized,
wherein the reference antibody comprises a VH region comprising the
sequence of SEQ ID NO:186 and a VL region comprising the sequence
of SEQ ID NO:190 (060), preferably wherein the antibody is
fully-blocking when determined as described in Example 14.
[0252] In one embodiment, the antigen-binding region blocks the
binding to HER2 of a reference antibody, optionally immobilized,
wherein the reference antibody comprises a VH region comprising the
sequence of SEQ ID NO:193 and a VL region comprising the sequence
of SEQ ID NO:197 (106), preferably wherein the antibody is
fully-blocking when determined as described in Example 14.
[0253] In one embodiment, the antigen-binding region blocks the
binding to HER2 of a reference antibody, optionally immobilized,
wherein the reference antibody comprises a VH region comprising the
sequence of SEQ ID NO:200 and a VL region comprising the sequence
of SEQ ID NO:204 (111), preferably wherein the antibody is
fully-blocking when determined as described in Example 14.
[0254] In separate and specific embodiments, the antigen-binding
region blocks the binding of two, three, four, five, or six
reference antibodies of the preceding embodiment, such as, e.g.,
antibodies 005 and 111, antibodies 005 and 006; antibodies 059 and
106; antibodies 006 and 059; antibodies 059, 106, 005 and 060;
antibodies 006, 59, 060, and 111; or antibodies 059, 106, 005, 060,
111 and 006.
[0255] In one embodiment, the antibody, when immobilized, competes
for binding to soluble HER2 with all antibodies defined in the
preceding embodiment for 25% or more, preferably 50% or more, when
determined as described in Example 14.
[0256] In one aspect of the antibody of the invention, the antibody
binds the same epitope on HER2 as one or more of the novel human
antibodies described herein.
[0257] In one embodiment, the antigen-binding region binds the same
epitope as an antibody comprising a VH region comprising the
sequence of SEQ ID NO:165 and, optionally, a VL region comprising
the sequence of SEQ ID NO:169 (005).
[0258] In one embodiment, the antigen-binding region binds the same
epitope as an antibody comprising a VH region comprising the
sequence of SEQ ID NO:172 and a VL region comprising the sequence
of SEQ ID NO:176 (006).
[0259] In one embodiment, the antigen-binding region binds the same
epitope as an antibody comprising a VH region comprising the
sequence of SEQ ID NO:179 and a VL region comprising the sequence
of SEQ ID NO:183 (059).
[0260] In one embodiment, the antigen-binding region binds the same
epitope as an antibody comprising a VH region comprising the
sequence of SEQ ID NO:186 and a VL region comprising the sequence
of SEQ ID NO:190 (060).
[0261] In one embodiment, the antigen-binding region binds the same
epitope as an antibody comprising a VH region comprising the
sequence of SEQ ID NO:193 and a VL region comprising the sequence
of SEQ ID NO:197 (106).
[0262] In one embodiment, the antigen-binding region binds the same
epitope as an antibody comprising a VH region comprising the
sequence of SEQ ID NO:200 and a VL region comprising the sequence
of SEQ ID NO:204 (111).
[0263] In one embodiment, the antigen-binding region binds to the
same epitope as at least one antibody selected from the group
consisting of:
[0264] a) an antibody comprising a VH region comprising the
sequence of SEQ ID NO:207 and a VL region comprising the sequence
of SEQ ID NO:208 (041)
[0265] b) an antibody comprising a VH region comprising the
sequence of SEQ ID NO:209 and a VL region comprising the sequence
of SEQ ID NO:210 (150), and
[0266] c) an antibody comprising a VH region comprising the
sequence of SEQ ID NO:211 and a VL region comprising the sequence
of SEQ ID NO:212 (067);
[0267] d) an antibody comprising a VH region comprising the
sequence of SEQ ID NO:213 and a VL region comprising the sequence
of SEQ ID NO:214 (072);
[0268] e) an antibody comprising a VH region comprising the
sequence of SEQ ID NO:215 and a VL region comprising the sequence
of SEQ ID NO:216 (163);
[0269] f) an antibody comprising a VH region comprising the
sequence of SEQ ID NO:217 and a VL region comprising the sequence
of SEQ ID NO:218 (093);
[0270] g) an antibody comprising a VH region comprising the
sequence of SEQ ID NO:219 and a VL region comprising the sequence
of SEQ ID NO:220 (044).
[0271] In another additional or alternative aspect of the
bispecific antibody of the invention, the bispecific antibody or
the first antigen-binding region comprises a VH CDR3, VH region
and/or VL region sequence similar or identical to a sequence of the
HER2 antibodies described herein.
[0272] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH CDR3 region having an amino
acid sequence selected from the group consisting of
[0273] SEQ ID No:223, such as the sequence of SEQ ID No:168, 189,
196 (005, 060, 106), optionally wherein the VH region is derived
from the IgHV5-51-1 germline;
[0274] SEQ ID No:226, such as the sequence of SEQ ID NO:175 (006),
optionally wherein the VH region is derived from the IgHV3-23-1
germline sequence;
[0275] SEQ ID NO:229, such as the sequence of SEQ ID NO:182 (059),
optionally wherein the VH region is derived from the IgHV1-18-1
germline sequence; or
[0276] SEQ ID NO:231, such as the sequence of SEQ ID NO:203 (111),
optionally wherein the VH region is derived from the IgHV1-69-4
germline sequence.
[0277] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH CDR3 region comprising the
amino acid sequence of SEQ ID NO: 223, wherein X1=Q, H, or L; X2=R,
A, T, or K; X3=G; X4=D; X5=R or none; X6=G or none; X7=Y or F; X8=Y
or D; X9=Y, F, or H; X10=Y, D, S, F, or N; X11=M or L; and X12=V or
I; preferably, wherein X1=Q, X2=R or A; X5=X6=none; X7=Y or F;
X8=Y; X9=F; X10=Y; and X12=V. In a particular embodiment the
antibody comprises a VH CDR3 region comprising the amino acid
sequence of SEQ ID NO: 223, wherein X1=Q, X2=R or A; X3=G; X4=D,
X5=X6=none; X7=Y or F; X8=Y; X9=F; X10=Y; and X12=V.
[0278] In one embodiment the antibody or the first antigen-binding
region comprises a VH CDR3 region comprising the amino acid
sequence of SEQ ID NO:223, wherein X1=Q, X2=K; X3=G; X4=D,
X5=X6=none; X7=F; X8=Y; X9=X10=F; X11=L; and X12=V; or wherein
X1=Q, X2=A; X3=G; X4=D, X5=X6=none; X7=X8=Y; X9=Y; X10=N; X11=M;
and X12=V; or wherein X1=Q, X2=K; X3=G; X4=D, X5=X6=none; X7=X8=Y;
X9=H; X10=Y; X11=L; and X12=V; or wherein X1=Q, X2=K; X3=G; X4=D,
X5=X6=none; X7=Y; X8=Y; X9=F; X10=N; X11=L; and X12=V; or wherein
X1=Q, X2=R; X3=G; X4=D, X5=X6=none; X7=Y; X8=Y; X9=F; X10=N; X11=L;
and X12=V; or wherein X1=Q, X2=R; X3=G; X4=D, X5=X6=none; X7=Y;
X8=Y; X9=X10=F; X11=L; and X12=I; or wherein X1=Q, X2=A; X3=G;
X4=D, X5=X6=none; X7=X8=Y; X9=Y; X10=N; X11=M; and X12=V.
[0279] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH CDR3 region of one of
antibodies 041, 150, 067, 072, 163, or 093, as shown in FIG. 1,
optionally wherein the VH region is derived from an IgHV5-51-1
germline.
[0280] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region selected from the
group consisting of [0281] a) a VH region comprising the CDR1, CDR2
and CDR3 sequences of SEQ ID NOs:221, 222 and 223, such as [0282]
a. a CDR1 sequence selected from SEQ ID NOs:166, 187, and 194; a
CDR2 sequence selected from 167, 188, and 195; and a CDR3 sequence
selected from 168, 189, and 196 (005, 060, 106), [0283] b. the
CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:166, 167 and 168,
respectively (005), [0284] c. the CDR1, CDR2, and CDR3 sequences of
SEQ ID NOs:187, 188 and 189, respectively (060), [0285] d. the
CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:196, 197 and 198,
respectively (106), [0286] optionally where the VH region is
derived from an IgHV5-51-1 germline; [0287] b) a VH region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:224, 225
and 226, such the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:173,
174, and 175, respectively (006), optionally where the VH region is
derived from an IgHV3-23-1 germline; and [0288] c) a VH region
comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:227,
228, and 229, such as the CDR1, CDR2, and CDR3 sequences of SEQ ID
NOs: 180, 181 and 182 (059), respectively, optionally where the VH
region is derived from an IgHV1-18-1 germline; and [0289] d) a VH
region comprising the CDR1, CDR2, and CDR3 sequences of SEQ ID
NOs:230, 202 and 231, such as the CDR1, CDR2, and CDR3 sequences of
SEQ ID NOs: 201, 202 and 203 (111), respectively, optionally where
the VH region is derived from an IgHV1-69-4 germline.
[0290] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region selected from the
preceding embodiments (a), (c) or (d) and a VL region comprising
the CDR1, CDR2, and CDR3 sequences of SEQ ID NO:232, GAS, and SEQ
ID No:233, respectively, such as a CDR1 sequence selected from SEQ
ID Nos: 170, 184, 191, 198 and 205, a CDR2 which is GAS, and a CDR3
sequence selected from 171, 85, 192, 199 and 206 (005, 059, 060,
106, 111); respectively, optionally where the VL region is derived
from an IgKV3-20-01 germline.
[0291] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region which is the preceding
embodiment (b) and a VL region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID NO:177, DAS, and SEQ ID NO:178 (006),
respectively, optionally where the VL region is derived from
IgKV3-11-01.
[0292] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:166, 167 and 168,
respectively; and, optionally, a VL region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:170, GAS, and SEQ ID NO:171,
respectively (005).
[0293] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:173, 174 and 175,
respectively; and a VL region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:177, DAS, and SEQ ID NO:178, respectively
(006).
[0294] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:180, 181 and 182,
respectively; and a VL region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:184, GAS, and SEQ ID NO:185, respectively
(059).
[0295] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:187, 188 and 189,
respectively; and a VL region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:191, GAS, and SEQ ID NO:192, respectively
(060).
[0296] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:194, 195 and 196,
respectively; and a VL region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:198, GAS, and SEQ ID NO:199, respectively
(106).
[0297] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:201, 202 and 203,
respectively; and a VL region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:205, GAS, and SEQ ID NO:206, respectively
(111).
[0298] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1
sequence of SEQ ID NO:221, wherein X1=S; X2=T and X3=S; the CDR2
sequence of SEQ ID NO:226, wherein X1=Y and X2=H and the CDR3
sequence of SEQ ID NO:227, wherein X1=Q, X2=K; X3=G; X4=D,
X5=X6=none; X7=F; X8=Y; X9=X10=F; X11=L; and X12=V; and a VL region
comprising the CDR1 sequence of SEQ ID NO:232, wherein X1=X2=S; the
CDR2 sequence GAS; and the CDR3 sequence of SEQ ID NO: 233, wherein
X1=Q, X2=S, X3=X4=none and X5=L (041).
[0299] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1
sequence of SEQ ID NO:221, wherein X1=S; X2=T and X3=S; the CDR2
sequence of SEQ ID NO:222, wherein X1=Y and X2=H, and the CDR3
sequence of SEQ ID NO:223, wherein X1=Q, X2=A; X3=G; X4=D,
X5=X6=none; X7=X8=Y; X9=Y; X10=N; X11=M; and X12=V; and a VL region
comprising the CDR1 sequence of SEQ ID NO:232, wherein X1=X2=S; the
CDR2 sequence GAS; and the CDR3 sequence of SEQ ID NO: 233, wherein
X1=Q, X2=S, X3=X4=none and X5=L (150).
[0300] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1
sequence of SEQ ID NO:221, wherein X1=S; X2=T and X3=S; the CDR2
sequence of SEQ ID NO:222, wherein X1=Y and X2=D, and the CDR3
sequence of SEQ ID NO:223, X1=Q, X2=K; X3=G; X4=D, X5=X6=none;
X7=X8=Y; X9=H; X10=Y; X11=L; and X12=V; and a VL region comprising
the CDR1 sequence of SEQ ID NO:232, wherein X1=X2=S; the CDR2
sequence GAS; and the CDR3 sequence of SEQ ID NO: 233, wherein
X1=Q, X2=S, X3=P, X4=R and X5=L (067).
[0301] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1
sequence of SEQ ID NO:221, wherein X1=S; X2=T and X3=S; the CDR2
sequence of SEQ ID NO:222, wherein X1=Y and X2=D, and the CDR3
sequence of SEQ ID NO:223, wherein X1=Q, X2=K; X3=G; X4=D,
X5=X6=none; X7=Y; X8=Y; X9=F; X10=N; X11=L; and X12=V; and a VL
region comprising the CDR1 sequence of SEQ ID NO:232, wherein
X1=X2=S; the CDR2 sequence GAS; and the CDR3 sequence of SEQ ID NO:
233, wherein X1=Q, X2=S, X3=P, X4=R and X5=L (072).
[0302] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1
sequence of SEQ ID NO:221, wherein X1=R; X2=I and X3=S; the CDR2
sequence of SEQ ID NO:222, wherein X1=Y and X2=D, and the CDR3
sequence of SEQ ID NO:223, wherein X1=Q, X2=R; X3=G; X4=D,
X5=X6=none; X7=Y; X8=Y; X9=F; X10=N; X11=L; and X12=V; and a VL
region comprising the CDR1 sequence of SEQ ID NO:232, wherein
X1=X2=S; the CDR2 sequence GAS; and the CDR3 sequence of SEQ ID NO:
233, wherein X1=Q, X2=S, X3=X4=none and X5=L (163).
[0303] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1
sequence of SEQ ID NO:221, wherein X1=S; X2=T and X3=S; the CDR2
sequence of SEQ ID NO:222, wherein X1=Y and X2=D, and the CDR3
sequence of SEQ ID NO:223, wherein X1=Q, X2=R; X3=G; X4=D,
X5=X6=none; X7=Y; X8=Y; X9=X10=F; X11=L; and X12=I; and a VL region
comprising the CDR1 sequence of SEQ ID NO:232, wherein X1=X2=S; the
CDR2 sequence GAS; and the CDR3 sequence of SEQ ID NO: 233, wherein
X1=Q, X2=S, X3=X4=none and X5=L (093).
[0304] In one embodiment, the bispecific antibody or the first
antigen-binding region comprises a VH region comprising the CDR1
sequence of SEQ ID NO:221, wherein X1=R; X2=S and X3=S; the CDR2
sequence of SEQ ID NO:222, wherein X1=F and X2=D, and the CDR3
sequence of SEQ ID NO:223, wherein X1=Q, X2=A; X3=G; X4=D,
X5=X6=none; X7=X8=Y; X9=Y; X10=N; X11=M; and X12=V; and a VL region
comprising the CDR1 sequence of SEQ ID NO:232, wherein X1=X2=S; the
CDR2 sequence GAS; and the CDR3 sequence of SEQ ID NO: 233, wherein
X1=Q, X2=S, X3=X4=none and X5=L (044).
[0305] In separate embodiments, the bispecific antibody or the
first antigen-binding region comprises: [0306] a) a VH region
comprising the sequence of SEQ ID NO:165 and, optionally, a VL
region comprising the sequence of SEQ ID NO:169 (005) [0307] b) a
VH region comprising the sequence of SEQ ID NO:172 and, preferably,
a VL region comprising the sequence of SEQ ID NO:176 (006) [0308]
c) a VH region comprising the sequence of SEQ ID NO:179 and,
preferably, a VL region comprising the sequence of SEQ ID NO:183
(059) [0309] d) a VH region comprising the sequence of SEQ ID
NO:186 and, preferably, a VL region comprising the sequence of SEQ
ID NO:190 (060) [0310] e) a VH region comprising the sequence of
SEQ ID NO:193 and, preferably, a VL region comprising the sequence
of SEQ ID NO:197 (106) [0311] f) a VH region comprising the
sequence of SEQ ID NO:200 and, preferably, a VL region comprising
the sequence of SEQ ID NO:204 (111) [0312] g) a VH region
comprising the sequence of SEQ ID NO:297 and, preferably, a VL
region comprising the sequence of SEQ ID NO:208 (041) [0313] h) a
VH region comprising the sequence of SEQ ID NO:209 and, preferably,
a VL region comprising the sequence of SEQ ID NO:210 (150), [0314]
i) a VH region comprising the sequence of SEQ ID NO:211 and,
preferably, a VL region comprising the sequence of SEQ ID NO:212
(067), [0315] j) a VH region comprising the sequence of SEQ ID
NO:213 and, preferably, a VL region comprising the sequence of SEQ
ID NO:214 (072), [0316] k) a VH region comprising the sequence of
SEQ ID NO:215 and, preferably, a VL region comprising the sequence
of SEQ ID NO:216 (163), [0317] l) a VH region comprising the
sequence of SEQ ID NO:217 and, preferably, a VL region comprising
the sequence of SEQ ID NO:218 (093), [0318] m) a VH region
comprising the sequence of SEQ ID NO:219 and, preferably, a VL
region comprising the sequence of SEQ ID NO:220 (044), and/or
[0319] n) a variant of any of said antibodies, wherein said variant
preferably has at most 1, 2 or 3 amino-acid modifications, more
preferably amino-acid substitutions, such as conservative amino
acid substitutions and substitutions where the new amino acid is
one at the same position in an aligned sequence in FIG. 1 or 2,
particularly at positions indicated by "X" in the corresponding
consensus sequence.
Functional Properties of Antigen-Binding Regions or HER2 Antibodies
of Cross-Block Groups 1, 2, 3, and 4
[0320] In another aspect of the antibody of the invention, the
bispecific antibody comprises an antigen-binding region from a HER2
antibody which binds to the same HER2 epitope as one or more of the
novel Group 1, 2, 3 or 4 antibodies described herein, preferably
when determined as described in Example 14; and is further
characterized by one or more properties determined as described in
Examples 12, 13, 15, 16, 17, 18 and 19.
[0321] Thus the first antigen-binding region of the bispecific
antibody of the present invention may be same as one of the
following HER2 antibodies. The first HER2 antibody of the present
invention may have one or more of the following
characteristics.
[0322] In one embodiment, the HER2 antibody has a lower EC.sub.50
value (half maximal effective concentration) than trastuzumab in
binding to A431 cells, preferably an EC.sub.50 value lower than
0.80 .mu.g/ml, 0.50 .mu.g/ml, or 0.30 .mu.g/ml, when determined as
described in Example 12, and preferably binds the same epitope as
at least one reference antibody comprising the VH and VL regions
selected from the group consisting of [0323] a) a VH region
comprising the sequence of SEQ ID NO:1 and a VL region comprising
the sequence of SEQ ID NO:5 (169); [0324] b) a VH region comprising
the sequence of SEQ ID NO:15 and a VL region comprising the
sequence of SEQ ID NO:19 (084); [0325] c) a VH region comprising
the sequence of SEQ ID NO:22 and a VL region comprising the
sequence of SEQ ID NO:26 (025); [0326] d) a VH region comprising
the sequence of SEQ ID NO:29 and a VL region comprising the
sequence of SEQ ID NO:32 (091); [0327] e) a VH region comprising
the sequence of SEQ ID NO:46 and a VL region comprising the
sequence of SEQ ID NO:49 (127); [0328] f) a VH region comprising
the sequence of SEQ ID NO:49 and a VL region comprising the
sequence of SEQ ID NO:53 (159); [0329] g) a VH region comprising
the sequence of SEQ ID NO:56 and a VL region comprising the
sequence of SEQ ID NO:60 (098); [0330] h) a VH region comprising
the sequence of SEQ ID NO:63 and a VL region comprising the
sequence of SEQ ID NO:67 (153); [0331] i) a VH region comprising
the sequence of SEQ ID NO:70 and a VL region comprising the
sequence of SEQ ID NO:74 (132) [0332] j) a VH region comprising the
sequence of SEQ ID NO:1 and a VL region comprising the sequence of
SEQ ID NO:5 (005); [0333] k) a VH region comprising the sequence of
SEQ ID NO:8 and a VL region comprising the sequence of SEQ ID NO:11
(006); and [0334] l) a VH region comprising the sequence of SEQ ID
NO:15 and a VL region comprising the sequence of SEQ ID NO:19
(059).
[0335] In an additional or alternative embodiment, the HER2
antibody or the first antigen-binding region specifically binds
HER2-positive Rhesus monkey epithelial cells, when determined as
described in Example 13, and preferably binds the same epitope as
at least one reference antibody comprising the VH and VL regions
selected from the group consisting of the VH and VL regions of any
of antibodies 169, 050, 084, 025, 091, 129, 127, 159, 098, 153 132,
005, 006, 059, 060, 106 and 111.
[0336] In an additional or alternative embodiment, the anti-HER2
antibody or the first antigen-binding region efficiently induces
ADCC (antibody-dependent cell-mediated cytotoxicity), preferably
achieving a specific .sup.51Cr-release of at least 30%, more
preferably at least 40%, when determined as described in Example
15, and preferably binds the same epitope as at least one reference
antibody comprising the VH and VL regions selected from the group
consisting of: [0337] a) a VH region comprising the sequence of SEQ
ID NO:1 and a VL region comprising the sequence of SEQ ID NO:5
(169); [0338] b) a VH region comprising the sequence of SEQ ID NO:8
and a VL region comprising the sequence of SEQ ID NO:12 (050);
[0339] c) a VH region comprising the sequence of SEQ ID NO:15 and a
VL region comprising the sequence of SEQ ID NO:19 (084); [0340] d)
a VH region comprising the sequence of SEQ ID NO:22 and a VL region
comprising the sequence of SEQ ID NO:26 (025); [0341] e) a VH
region comprising the sequence of SEQ ID NO:29 and a VL region
comprising the sequence of SEQ ID NO:32 (091); [0342] f) a VH
region comprising the sequence of SEQ ID NO:35 and a VL region
comprising the sequence of SEQ ID NO:39 (129); and [0343] g) a VH
region comprising the sequence of SEQ ID NO:63 an, preferably, a VL
region comprising the sequence of SEQ ID NO:67 (153).
[0344] In an additional or alternative embodiment, the anti-HER2
antibody or the first antigen-binding region specifically binds
HER2-expressing AU565 cells but promotes ligand-independent
proliferation of the cells less than any of F5 and C1 when
determined as described in Example 16, and preferably binds the
same epitope as at least one reference antibody comprising the VH
and VL regions selected from the group consisting of [0345] a) a VH
region comprising the sequence of SEQ ID NO:1 and a VL region
comprising the sequence of SEQ ID NO:5 (169); [0346] b) a VH region
comprising the sequence of SEQ ID NO:8 and a VL region comprising
the sequence of SEQ ID NO:12 (050); [0347] c) a VH region
comprising the sequence of SEQ ID NO:15 and a VL region comprising
the sequence of SEQ ID NO:19 (084); [0348] d) a VH region
comprising the sequence of SEQ ID NO:22 and a VL region comprising
the sequence of SEQ ID NO:26 (025); [0349] e) a VH region
comprising the sequence of SEQ ID NO:29 and a VL region comprising
the sequence of SEQ ID NO:32 (091); [0350] f) a VH region
comprising the sequence of SEQ ID NO:35 and a VL region comprising
the sequence of SEQ ID NO:39 (129); [0351] g) a VH region
comprising the sequence of SEQ ID NO:46 and a VL region comprising
the sequence of SEQ ID NO:49 (127); [0352] h) a VH region
comprising the sequence of SEQ ID NO:49 and a VL region comprising
the sequence of SEQ ID NO:53 (159); [0353] i) a VH region
comprising the sequence of SEQ ID NO:56 and a VL region comprising
the sequence of SEQ ID NO:60 (098); [0354] j) a VH region
comprising the sequence of SEQ ID NO:63 and a VL region comprising
the sequence of SEQ ID NO:67 (153); [0355] k) a VH region
comprising the sequence of SEQ ID NO:70 and a VL region comprising
the sequence of SEQ ID NO:74 (132) [0356] l) a VH region comprising
the sequence of SEQ ID NO:1 and a VL region comprising the sequence
of SEQ ID NO:5 (005); and [0357] m) a VH region comprising the
sequence of SEQ ID NO:22 and a VL region comprising the sequence of
SEQ ID NO:26 (060).
[0358] In an additional or alternative embodiment, the anti-HER2
antibody or the/first antigen-binding region specifically binds
HER2-expressing AU565 cells and inhibits ligand-independent
proliferation of the cells, preferably inhibiting proliferation by
at least 20%, more preferably at least 25%, when determined as
described in Example 16, and preferably binds the same epitope as
at least one reference antibody comprising the VH and VL regions
selected from the group consisting of: [0359] a) a VH region
comprising the sequence of SEQ ID NO:1 and a VL region comprising
the sequence of SEQ ID NO:5 (169); and [0360] b) a VH region
comprising the sequence of SEQ ID NO:8 and a VL region comprising
the sequence of SEQ ID NO:12 (050).
[0361] In an additional or alternative embodiment, the anti-HER2
antibody specifically binds HER2-expressing AU565 cells but has no
significant effect on, or does not promote, ligand-induced
proliferation of the cells, preferably inhibiting proliferation by
no more than 25%, more preferably by no more than 15%, when
determined as described in Example 17, and binds the same epitope
as at least one reference antibody comprising the VH and VL regions
selected from the group consisting of: [0362] a) a VH region
comprising the sequence of SEQ ID NO:1 and a VL region comprising
the sequence of SEQ ID NO:5 (169); [0363] b) a VH region comprising
the sequence of SEQ ID NO:8 and a VL region comprising the sequence
of SEQ ID NO:12 (050); [0364] c) a VH region comprising the
sequence of SEQ ID NO:15 and a VL region comprising the sequence of
SEQ ID NO:19 (084); and [0365] d) a VH region comprising the
sequence of SEQ ID NO:56 and a VL region comprising the sequence of
SEQ ID NO:60 (098).
[0366] In an additional or alternative embodiment, the anti-HER2
antibody specifically binds HER2-expressing MCF-7 cells and
inhibits ligand-induced proliferation, e.g. it may completely
inhibit the ligand-induced effect or inhibit the total
proliferation by 50%, e.g. 60% or 70% or 80%, of the cells when
determined as described in Example 17, and binds the same epitope
as at least one reference antibody comprising the VH and VL regions
selected from the group consisting of: [0367] a) a VH region
comprising the sequence of SEQ ID NO:22 and a VL region comprising
the sequence of SEQ ID NO:26 (025); [0368] b) a VH region
comprising the sequence of SEQ ID NO:29 and a VL region comprising
the sequence of SEQ ID NO:32 (091); [0369] c) a VH region
comprising the sequence of SEQ ID NO:35 and a VL region comprising
the sequence of SEQ ID NO:39 (129); and [0370] d) a VH region
comprising the sequence of SEQ ID NO:63 and, preferably, a VL
region comprising the sequence of SEQ ID NO:67 (153).
[0371] In an additional or alternative embodiment, the first
anti-HER2 antibody is internalized by tumor cells expressing HER2,
such as AU565 cells, to a higher degree than trastuzumab and
pertuzumab, preferably more than twice or three times the amount of
internalized trastuzumab, preferably when determined according to
Example 18, and binds to the same epitope as an antibody comprising
VH and VL regions selected from the group consisting of: [0372] a)
a VH region comprising the sequence of SEQ ID NO:46 and a VL region
comprising the sequence of SEQ ID NO:49 (127); [0373] b) a VH
region comprising the sequence of SEQ ID NO:49 and a VL region
comprising the sequence of SEQ ID NO:53 (159); [0374] c) a VH
region comprising the sequence of SEQ ID NO:56 and a VL region
comprising the sequence of SEQ ID NO:60 (098); [0375] d) a VH
region comprising the sequence of SEQ ID NO:63 and a VL region
comprising the sequence of SEQ ID NO:67 (153); and [0376] e) a VH
region comprising the sequence of SEQ ID NO:70 and a VL region
comprising the sequence of SEQ ID NO:74 (132).
[0377] Preferably, the antibody binds to the same epitope as an
antibody comprising VH and VL regions selected from [0378] a) a VH
region comprising the sequence of SEQ ID NO:46 and a VL region
comprising the sequence of SEQ ID NO:49 (127) and [0379] b) a VH
region comprising the sequence of SEQ ID NO:56 and a VL region
comprising the sequence of SEQ ID NO:60 (098).
[0380] In a further embodiment, the antibody binds to Domain II or
IV of HER2, preferably wherein the antibody does not significantly
promote proliferation of HER2 expressing cells, and is more
efficiently internalized, or is internalized to a higher degree,
than trastuzumab or pertuzumab into HER2-expressing tumor cells,
preferably when determined as described in the Examples, e.g.
examples 16 and 19, respectively.
[0381] In a further embodiment the antibody enhanced HER2
downmodulation more than trastuzumab, e.g. the antibody enhanced
HER2 downmodulation by more 30%, such as more than 40% or more than
50% when determined as described in Example 22, preferably wherein
the antibody binds to the same epitope as an antibody of
cross-block group 3 of the present invention, e.g. an antibody
binding to the same epitope as an antibody comprising VH and VL
regions selected from the group consisting of: [0382] a) a VH
region comprising the sequence of SEQ ID NO:56 and a VL region
comprising the sequence of SEQ ID NO:60 (098); [0383] b) a VH
region comprising the sequence of SEQ ID NO:63 and a VL region
comprising the sequence of SEQ ID NO:67 (153).
[0384] In another or alternative embodiment the antibody decreased
tumour growth and improved survival in vivo more than trastuzumab,
when determined as described in Example 25, preferably wherein the
antibody binds to the same epitope as an antibody of cross-block 1
or cross-block 2 of the present invention, e.g. an antibody binding
to the same epitope as an antibody comprising VH and VL regions
selected from the group consisting of: [0385] a) a VH region
comprising the sequence of SEQ ID NO:1 and a VL region comprising
the sequence of SEQ ID NO:5 (169); [0386] b) a VH region comprising
the sequence of SEQ ID NO:15 and a VL region comprising the
sequence of SEQ ID NO:19 (084); and [0387] c) a VH region
comprising the sequence of SEQ ID NO:29 and a VL region comprising
the sequence of SEQ ID NO:32 (091).
[0388] In another or alternative embodiment the antibody decreased
tumour growth and improved survival in vivo more than trastuzumab,
when determined as described in Example 26, preferably wherein the
antibody binds to the same epitope as an antibody of cross-block 2
or cross-block 3 of the present invention, e.g. an antibody binding
to the same epitope as an antibody comprising VH and VL regions
selected from the group consisting of: [0389] a) a VH region
comprising the sequence of SEQ ID NO:22 and a VL region comprising
the sequence of SEQ ID NO:26 (025); [0390] b) a VH region
comprising the sequence of SEQ ID NO:29 and a VL region comprising
the sequence of SEQ ID NO:32 (091); [0391] c) a VH region
comprising the sequence of SEQ ID NO:35 and a VL region comprising
the sequence of SEQ ID NO:39 (129); and [0392] d) a VH region
comprising the sequence of SEQ ID NO:63 and a VL region comprising
the sequence of SEQ ID NO:67 (153).
[0393] More particularly, wherein the antibody binds to the same
epitope as an antibody comprising VH and VL regions selected from
the group consisting of: [0394] a) a VH region comprising the
sequence of SEQ ID NO:22 and a VL region comprising the sequence of
SEQ ID NO:26 (025); and [0395] b) a VH region comprising the
sequence of SEQ ID NO:29 and a VL region comprising the sequence of
SEQ ID NO:32 (091).
[0396] In one embodiment, the conjugated antibody kills at least
60%, preferably at least 70% AU565 cells or A431 cells, when
determined as described in Example 18, and cross-blocks at least
one antibody selected from [0397] a) an antibody comprising a VH
region comprising the sequence of SEQ ID NO:1 and a VL region
comprising the sequence of SEQ ID NO:5 (005) [0398] b) an antibody
comprising a VH region comprising the sequence of SEQ ID NO:22 and
a VL region comprising the sequence of SEQ ID NO:26 (060) [0399] c)
an antibody comprising a VH region comprising the sequence of SEQ
ID NO:15 and a VL region comprising the sequence of SEQ ID NO:19
(059), and [0400] d) an antibody comprising a VH region comprising
the sequence of SEQ ID NO:36 and a VL region comprising the
sequence of SEQ ID NO:40 (111).
[0401] In separate and specific embodiments, the antibody of the
preceding embodiment fully cross-blocks, preferably bind to the
same epitope as, antibody 005, 060, 059, 111, or a combination
thereof.
[0402] In one embodiment, the antibody of the preceding embodiment
kills at least 80% of A431 cells when determined as described in
Example 18, and cross-blocks at least one antibody selected from
[0403] a) an antibody comprising a VH region comprising the
sequence of SEQ ID NO:1 and a VL region comprising the sequence of
SEQ ID NO:5 (005), and [0404] b) an antibody comprising a VH region
comprising the sequence of SEQ ID NO:22 and a VL region comprising
the sequence of SEQ ID NO:26 (060).
[0405] In separate and specific embodiments, the antibody of the
preceding embodiment fully cross-blocks, preferably bind to the
same epitope as, antibody 005, 060, or a combination thereof.
[0406] In an additional or alternative embodiment, the antibody is
internalized by tumor cells expressing HER2, such as AU565 cells,
more than trastuzumab is, preferably more than twice or three times
the amount of internalized trastuzumab, preferably when determined
according to Example 19, and cross-blocks at least one antibody
selected from the group consisting of: [0407] a) an antibody
comprising a VH region comprising the sequence of SEQ ID NO:1 and a
VL region comprising the sequence of SEQ ID NO:5 (005) [0408] b) an
antibody comprising a VH region comprising the sequence of SEQ ID
NO:8 and a VL region comprising the sequence of SEQ ID NO:11 (006)
[0409] c) an antibody comprising a VH region comprising the
sequence of SEQ ID NO:15 and a VL region comprising the sequence of
SEQ ID NO:19 (059) [0410] d) an antibody comprising a VH region
comprising the sequence of SEQ ID NO:22 and a VL region comprising
the sequence of SEQ ID NO:26 (060) [0411] e) an antibody comprising
a VH region comprising the sequence of SEQ ID NO:29 and a VL region
comprising the sequence of SEQ ID NO:33 (106) [0412] f) an antibody
comprising a VH region comprising the sequence of SEQ ID NO:36 and
a VL region comprising the sequence of SEQ ID NO:40 (111).
[0413] In separate and specific embodiments, the antibody of the
preceding embodiment fully cross-blocks, preferably bind to the
same epitope as, antibody 005, 006, 059, 060, 106, 111, or a
combination thereof.
Bispecific Antibodies
[0414] In one embodiment, the antibody is a bispecific antibody,
comprising (i) a first antigen-binding region of a HER2 antibody as
defined herein, e.g. an antibody of cross-block 1, 2, 3 or 4, and
(ii) a second antibody comprising an antigen-binding region of an
antibody which binds to CD3.
First Antigen-Binding Region
[0415] In one embodiment the first antigen-binding region comprises
a VH region comprising a CDR3 sequence of an antibody of
cross-block 1, 2, 3 or 4 as defined herein, such as SEQ ID NO: 4,
25, 66 or 168 (169, 025, 153, or 005). In a particular embodiment,
the first antigen-binding region comprises a VH region comprising a
CDR3 sequence of SEQ ID NO: 4 (169).
[0416] In one embodiment the first antigen-binding region comprises
a VH region comprising CDR1, CDR2 and CDR3 sequences of an antibody
of cross-block 1, 2, 3 or 4 as defined herein, such as CDR1, CDR2,
and CDR3 sequences SEQ ID NOs: 2, 3 and 4 (169), or CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs:23, 24 and 25 (025), or CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs: 64, 65 and 66 (153), or CDR1, CDR2
CDR3 sequence of SEQ ID NOs: 166, 167 and 168 (005). In a
particular embodiment, the first antigen-binding region comprises a
VH region comprising CDR1, CDR2 and CDR3 sequences of CDR1, CDR2,
and CDR3 sequences SEQ ID NOs: 2, 3 and 4 (169).
[0417] In a further or alternative embodiment the first
antigen-binding region comprises a VH region comprising a CDR3
sequence of an antibody of cross-block 1, 2, 3 or 4 as defined
herein, such as CDR3 sequence an antibody of cross-block 1 of SEQ
ID NO: 11 (050), or SEQ ID NO: 18 (084); or a CDR3 sequence of an
antibody of cross-block 2 of SEQ ID NO: 31 (091), or SEQ ID NO: 38
(129), or a CDR3 sequence of an antibody of cross-block 3 of SEQ ID
NO: 45 (127), or SEQ ID NO:52 (159), or SEQ ID NO:59 (098), or SEQ
ID NO:73 (132), or a CDR3 sequence of an antibody of cross-block 4
of SEQ ID NO:175 (006), SEQ ID NO: 182 (059), SEQ ID NO:189 (060),
SEQ ID NO:196 (106), or SEQ ID NO:203 (111).
[0418] In one embodiment the first antigen-binding region comprises
a VH region comprising CDR1, CDR2 and CDR3 sequences of an antibody
of cross-block 1, 2 or 3 as defined herein, such as CDR1, CDR2, and
CDR3 sequences SEQ ID NOs: 2, 3 and 4 (169), or CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:23, 24 and 25 (025), or CDR1, CDR2 and CDR3
sequences of SEQ ID NOs: 64, 65 and 66 (153), or CDR1, CDR2 CDR3
sequence of SEQ ID NOs: 166, 167 and 168 (005).
[0419] In one embodiment the first antigen-binding region comprises
a VH region comprising CDR1, CDR2 and CDR3 sequences of an antibody
of cross-block 1, 2, 3 or 4 as defined herein, and a VL region
comprising CDR1, CDR2 and CDR3 sequences of an antibody of
cross-block 1, 2, 3 or 4 as defined herein.
[0420] In a further or alternative embodiment the first
antigen-binding region comprises a VH region comprising CDR1, CDR2
and CDR3 sequences of an antibody of cross-block 1, 2, 3 or 4 as
defined herein, such as CDR1, CDR2, and CDR3 sequences of an
antibody of cross-block 1 of SEQ ID NOs: 9, 10 and 11 (050), or SEQ
ID NOs: 16, 17 and 18 (084); or CDR1, CDR2, and CDR3 sequences of
an antibody of cross-block 2 of SEQ ID NOs: 30, 163 and 31 (091),
or SEQ ID NOs: 36, 37 and 38 (129), or CDR1, CDR2, and CDR3
sequences of an antibody of cross-block 3 SEQ ID NOs: 43, 44 and 45
(127), or SEQ ID NOs:50, 51 and 52 (159), or SEQ ID NOs:57, 58 and
59 (098), or SEQ ID NOs:71, 72 and 73 (132), or CDR1, CDR2 and CDR3
sequences of an antibody of cross-block 4 such as SEQ ID NOS: 173,
174, and 175 (006), SEQ ID NOS: 180, 181, and 182 (059), SEQ ID
NOS:187, 188, and 189 (060), SEQ ID NOS:194, 195, and 196 (106), or
SEQ ID NOS:201, 202, and 203 (111).
[0421] In one embodiment the first antigen-binding region comprises
a VH region and a VL region selected from the group consisting of:
[0422] a) a VH region comprising the CDR1, CDR2, and CDR3 sequences
of SEQ ID NOs: 2, 3 and 4; and a VL region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID: 6, DAS and SEQ ID NO:7,
respectively (169); [0423] b) a VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID NOs: 23, 24 and 25; and a VL
region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:
27, AAS and SEQ ID NO:28, respectively (025); [0424] c) a VH region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:64, 65
and 66; and a VL region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NO: 68, DAS and SEQ ID NO:69 (153); and [0425]
d) a VH region comprising the CDR1, CDR2 and CDR3 sequences of SEQ
ID NOs:166, 167 and 168; and a VL region comprising the CDR1, CDR2
and CDR3 sequences of SEQ ID NO: 170, GAS and SEQ ID NO:171
(005).
[0426] In a particular embodiment, the VH region comprises the
CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 2, 3 and 4 the VL
region comprises the CDR1, CDR2 and CDR3 sequences of SEQ ID: 6,
DAS and SEQ ID NO:7, respectively (169).
[0427] In a further or alternative embodiment the first
antigen-binding region comprises a VH region and a VL region
selected from the group consisting of: [0428] a) a VH region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:9, 127
and 11, such as the CDR1, CDR2 and CDR3 sequences of SEQ ID NOS: 9,
10 and 11 (050); optionally where the VH region is derived from an
IgHV3-23-1 germline; [0429] b) a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:128, 129 and 130, such the
CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:16, 17 and 18,
respectively (084), optionally where the VH region is derived from
an IgHV1-69-04 germline; and [0430] c) a VH region comprising the
CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:137, 138 and 139, such
the CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:30, 163, and 31,
respectively (091), optionally where the VH region is derived from
an IgHV4-34-01 germline; and [0431] d) a VH region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:140, 141 and 142, such
as the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 36, 37 and 38
(129), respectively, optionally where the VH region is derived from
an IgHV3-30-01 germline. [0432] e) a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:146, 147 and 148, such as the
CDR1, CDR2 and CDR3 sequences of SEQ ID NOS: 43, 44 and 45 (127);
optionally where the VH region is derived from an IgHV5-51-01
germline; [0433] f) a VH region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NOs:149, 51 and 52, such as the CDR1, CDR2 and
CDR3 sequences of SEQ ID NOs:50, 51 and 52, respectively (159),
optionally where the VH region is derived from an IgHV5-51-01
germline; [0434] g) a VH region comprising the CDR1, CDR2, and CDR3
sequences of SEQ ID NOs:143, 144 and 145, such as the CDR1, CDR2,
and CDR3 sequences of SEQ ID NOs: 57, 58 and 59 (098),
respectively, optionally where the VH region is derived from an
IgHV3-23-01 germline; [0435] h) a VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID NOs:71, 150 and 151, such as the
CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 71, 72 and 73 (132),
respectively, optionally where the VH region is derived from an
IgHV1-18-01 germline; [0436] i) a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:221, 222 and 223, such as the
CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:187, 188 and 189,
respectively (060), optionally where the VH region is derived from
an IgHV5-51-1 germline; [0437] j) A VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID NOs:194, 195 and 196,
respectively (106), optionally where the VH region is derived from
an IgHV5-51-1 germline; [0438] k) a VH region comprising the CDR1,
CDR2 and CDR3 sequences of SEQ ID NOs:224, 225 and 226, such the
CDR1, CDR2 and CDR3 sequences of SEQ ID NOs:173, 174, and 175,
respectively (006), optionally where the VH region is derived from
an IgHV3-23-1 germline; [0439] l) a VH region comprising the CDR1,
CDR2, and CDR3 sequences of SEQ ID NOs:227, 228, and 229, such as
the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 180, 181 and 182
(059), respectively, optionally where the VH region is derived from
an IgHV1-18-1 germline; and [0440] m) a VH region comprising the
CDR1, CDR2, and CDR3 sequences of SEQ ID NOs:230, 202 and 231, such
as the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 201, 202 and
203 (111), respectively, optionally where the VH region is derived
from an IgHV1-69-4 germline.
Second Antigen-Binding Region
[0441] In any one of the preceding embodiments, the second
antigen-binding region can be derived from a CD3 antibody.
[0442] In one embodiment, the second antigen-binding region is
derived from a CD3 antibody comprising the VH CDR3 sequence of SEQ
ID NO: 244 (huCLB-T3/4).
[0443] In a further embodiment, the second antigen-binding region
is derived from a CD3 antibody comprising the VL CDR3 sequence of
SEQ ID NO: 246 (huCLB-T3/4).
[0444] In further embodiment, the second antigen-binding region is
derived from a CD3 antibody is an antibody comprising a VH region
selected from the group consisting of: [0445] a) a VH region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NOS:242, 243
and 244, respectively (huCLB-T3/4); [0446] b) a VH region
comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID NO:234 (YTH
12.5); [0447] c) a VH region comprising the CDR1, CDR2 and CDR3
sequences of SEQ ID NO:238 (huOKT3-C114S-gLC); and [0448] d) a VH
region comprising the CDR1, CDR2 and CDR3 sequences of SEQ ID
NO:236 (HUM291).
[0449] In a further embodiment, the second antigen-binding region
is derived from a CD3 antibody comprising a VH region comprising
the VH CDR1, CDR2 and CDR3 sequences of SEQ ID NO:234 and a VL
region comprising the VLCDR1, CDR2 and CDR3 sequences of SEQ ID
NO:235 (YTH12.5).
[0450] In a specific embodiment, the second antigen-binding region
is derived from a CD3 antibody comprising a VH region comprising
the sequence of SEQ ID NO: 234 (YTH12.5) and VL region comprising
the sequence of SEQ ID NO:235 (YTH12.5).
[0451] In one embodiment, the second antigen-binding region is
derived from a CD3 antibody comprising a VH region comprising the
VH CDR1, CDR2 and CDR3 sequences of SEQ ID NOS:242, 243 and 244,
respectively, and, optionally, a VL region comprising the VL CDR1,
CDR2 and CDR3 sequences of SEQ ID NOS:245, DTS and 246,
respectively (huCLB-T3/4).
[0452] In a specific embodiment, the second antigen-binding region
is derived from a CD3 antibody comprising a VH region comprising
the sequence of SEQ ID NO: 240 (huCLB-T3/4) and, optionally, VL
region comprising the sequence of SEQ ID NO:241 (huCLB-T3/4).
[0453] In one embodiment, the second antigen-binding region is
derived from a CD3 antibody comprising a VH region comprising the
VH CDR1, CDR2 and CDR3 sequences of SEQ ID NO:238 and a VL region
comprising the VL CDR1, CDR2 and CDR3 sequences of SEQ ID NO:239
(huOKT3-C114S-gLC).
[0454] In a specific embodiment, the second antigen-binding region
is derived from a CD3 antibody comprising a VH region comprising
the sequence of SEQ ID NO: 238 and VL region comprising the
sequence of SEQ ID NO:239 (huOKT3-C114S-gLC).
[0455] In one embodiment, the second antigen-binding region is
derived from a CD3 antibody comprising a VH region comprising the
VH CDR1, CDR2 and CDR3 sequences of SEQ ID NO:236 and a VL region
comprising the VL CDR1, CDR2 and CDR3 sequences of SEQ ID NO:237
(HUM291).
[0456] In a specific embodiment, the second antigen-binding region
is derived from a CD3 antibody comprising a VH region comprising
the sequence of SEQ ID NO:236 and VL region comprising the sequence
of SEQ ID NO:237 (HUM291).
Specific Combinations of Bispecific Antibodies
[0457] One embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising a CDR3 sequence of a CD3 antibody
according to SEQ ID NO: 244 (huCLB-T3/4), and a first
antigen-binding region comprising a VH region comprising a CDR3
sequence of a HER2 antibody of cross-block 1, 2, 3, or 4 as defined
herein, such as SEQ ID NOs: 4, 25, 66, or 168 (169, 025, 153, or
005).
[0458] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising a CDR3 sequence of a CD3 antibody
according to SEQ ID NO: 244 (huCLB-T3/4) and a VL region comprising
a CDR3 sequence of a CD3 antibody according to SEQ ID NO: 246
(huCLB-T3/4), and a first antigen-binding region comprising a VH
region comprising a CDR3 sequence of a HER2 antibody of cross-block
1, 2, 3, or 4 as defined herein, such as SEQ ID NOs: 4, 25, 66, or
168 (169, 025, 153, or 005) and a VL region comprising a CDR3
sequence of a HER2 antibody of cross-block 1, 2, 3, or 4 as defined
herein, such as SEQ ID NOs: 7, 28, 69, or 171 (169, 025, 153, or
005).
[0459] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising CDR1, CDR2, and CDR3 sequences of
a CD3 antibody according to SEQ ID NOs: 242, 243, and 244
(huCLB-T3/4), and a first antigen-binding region comprises a VH
region comprising CDR1, CDR2, and CDR3 sequences of a HER2 antibody
of cross-block 1, 2, 3, or 4 as defined herein, such as SEQ ID NOs:
2, 3, and 4 (169), SEQ ID NOs: 23, 24, and 25 (025), SEQ ID NOs:
64, 65, and 66 (153), or SEQ ID NOs: 166, 167, and 168 (005).
[0460] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising CDR1, CDR2, and CDR3 sequences of
a CD3 antibody according to SEQ ID NOs: 242, 243, and 244
(huCLB-T3/4) and a VL region comprising CDR1, CDR2, and CDR3
sequences of a CD3 antibody according to SEQ ID NOs: 245, DTS, and
246 (huCLB-T3/4), and a first antigen-binding region comprising a
VH region comprising CDR1, CDR2, and CDR3 sequences of a HER2
antibody of cross-block 1, 2, 3, or 4 as defined herein and a VL
region comprising CDR1, CDR2, and CDR3 sequences of a HER2 antibody
of cross-block 1, 2, 3, or 4 as defined herein, such as SEQ ID NOs:
2, 3, 4, 6, DAS, and 7 (169), SEQ ID NOs: 23, 24, 25, 27, AAS, and
28 (025), SEQ ID NOs: 64, 65, 66, 68, DAS, and 69 (153), or SEQ ID
NOs: 166, 167, 168, 170, GAS, and 171 (005).
[0461] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region of a CD3 antibody according to SEQ ID NO:
240 (huCLB-T3/4), and a first antigen-binding region comprising a
VH region of a HER2 antibody of cross-block 1, 2, 3, or 4 as
defined herein, such as SEQ ID NOs: 1, 22, 63, or 165 (169, 025,
153, or 005).
[0462] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region and a VL region of a CD3 antibody according
to SEQ ID NOs: 240 and 241 (huCLB-T3/4), and a first
antigen-binding region comprising a VH region and a VL region of a
HER2 antibody of cross-block 1, 2, 3, or 4 as defined herein, such
as SEQ ID NOs: 1 and 5 (169), 22 and 26 (025), 63 and 67 (153), or
165 and 169 (005).
[0463] One embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising a VH CDR3 sequence of a CD3
antibody according to SEQ ID NO: 234 (YTH12.5), and a first
antigen-binding region comprising a VH region of a HER2 antibody of
cross-block 1, 2, 3, or 4 as defined herein, such as SEQ ID NOs: 4,
25, 66, or 168 (169, 025, 153, or 005).
[0464] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising a CDR3 sequence of a CD3 antibody
according to SEQ ID NO: 234 (YTH12.5) and a VL region comprising a
CDR3 sequence of a CD3 antibody according to SEQ ID NO: 235
(YTH12.5), and a first antigen-binding region comprising a VH
region comprising a CDR3 sequence of a HER2 antibody of cross-block
1, 2, 3, or 4 as defined herein, such as SEQ ID NOs: 4, 25, 66, or
168 (169, 025, 153, or 005) and a VL region comprising a CDR3
sequence of a HER2 antibody of cross-block 1, 2, 3, or 4 as defined
herein, such as SEQ ID NOs: 7, 28, 69, or 171 (169, 025, 153, or
005).
[0465] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising a VH CDR1, CDR2, and CDR3
sequence according to SEQ ID NO: 234 (YTH12.5), and a first
antigen-binding region of a HER2 antibody of cross-block 1, 2, 3,
or 4 as defined herein, such as SEQ ID NOs: 2, 3, and 4 (169), SEQ
ID NOs: 23, 24, and 25 (025), SEQ ID NOs: 64, 65, and 66 (153), or
SEQ ID NOs: 166, 167, and 168 (005).
[0466] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising CDR1, CDR2, and CDR3 sequences of
a CD3 antibody according to SEQ ID NO: 234 (YTH12.5) and a VL
region comprising CDR1, CDR2, and CDR3 sequences of a CD3 antibody
according to SEQ ID NO: 235 (YTH12.5), and a first antigen-binding
region comprising a VH region comprising CDR1, CDR2, and CDR3
sequences of a HER2 antibody of cross-block 1, 2, 3, or 4 as
defined herein and a VL region comprising CDR1, CDR2, and CDR3
sequences of a HER2 antibody of cross-block 1, 2, 3, or 4 as
defined herein, such as SEQ ID NOs: 2, 3, 4, 6, DAS, and 7 (169),
SEQ ID NOs: 23, 24, 25, 27, AAS, and 28 (025), SEQ ID NOs: 64, 65,
66, 68, DAS, and 69 (153), or SEQ ID NOs: 166, 167, 168, 170, GAS,
and 171 (005).
[0467] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region of a CD3 antibody according to SEQ ID NO:
234 (YTH12.5), and a first antigen-binding region of a HER2
antibody of cross-block 1, 2, 3, or 4, such as SEQ ID NOs: 1, 22,
63, or 165 (169, 025, 153, or 005).
[0468] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region and a VL region of a CD3 antibody according
to SEQ ID NOs: 234 and 235 (YTH12.5), and a first antigen-binding
region comprising a VH region and a VL region of a HER2 antibody of
cross-block 1, 2, 3, or 4 as defined herein, such as SEQ ID NOs: 1
and 5 (169), 22 and 26 (025), 63 and 67 (153), or 165 and 169
(005).
[0469] One embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising a VH CDR3 sequence of a CD3
antibody according to SEQ ID NO: 236 (HUM291), and a first
antigen-binding region comprising a VH region of a HER2 antibody of
cross-block 1, 2, 3, or 4 as defined herein, such as SEQ ID NOs: 4,
25, 66, or 168 (169, 025, 153, or 005).
[0470] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising a CDR3 sequence of a CD3 antibody
according to SEQ ID NO: 236 (HUM291) and a VL region comprising a
CDR3 sequence of a CD3 antibody according to SEQ ID NO: 237
(HUM291), and a first antigen-binding region comprising a VH region
comprising a CDR3 sequence of a HER2 antibody of cross-block 1, 2,
3, or 4 as defined herein, such as SEQ ID NOs: 4, 25, 66, or 168
(169, 025, 153, or 005) and a VL region comprising a CDR3 sequence
of a HER2 antibody of cross-block 1, 2, 3, or 4 as defined herein,
such as SEQ ID NOs: 7, 28, 69, or 171 (169, 025, 153, or 005).
[0471] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising a VH CDR1, CDR2, and CDR3
sequence according to SEQ ID NO: 236 (HUM291), and a first
antigen-binding region of a HER2 antibody of cross-block 1, 2, 3,
or 4 as defined herein, such as SEQ ID NOs: 2, 3, and 4 (169), SEQ
ID NOs: 23, 24, and 25 (025), SEQ ID NOs: 64, 65, and 66 (153), or
SEQ ID NOs: 166, 167, and 168 (005).
[0472] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising CDR1, CDR2, and CDR3 sequences of
a CD3 antibody according to SEQ ID NO: 236 (HUM291) and a VL region
comprising CDR1, CDR2, and CDR3 sequences of a CD3 antibody
according to SEQ ID NO: 237 (HUM2915), and a first antigen-binding
region comprising a VH region comprising CDR1, CDR2, and CDR3
sequences of a HER2 antibody of cross-block 1, 2, 3, or 4 as
defined herein and a VL region comprising CDR1, CDR2, and CDR3
sequences of a HER2 antibody of cross-block 1, 2, 3, or 4 as
defined herein, such as SEQ ID NOs: 2, 3, 4, 6, DAS, and 7 (169),
SEQ ID NOs: 23, 24, 25, 27, AAS, and 28 (025), SEQ ID NOs: 64, 65,
66, 68, DAS, and 69 (153), or SEQ ID NOs: 166, 167, 168, 170, GAS,
and 171 (005).
[0473] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region of a CD3 antibody according to SEQ ID NO:
236 (HUM291), and a first antigen-binding region of a HER2 antibody
of cross-block 1, 2, 3, or 4, such as SEQ ID NOs: 1, 22, 63, or 165
(169, 025, 153, or 005).
[0474] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region and a VL region of a CD3 antibody according
to SEQ ID NOs: 236 and 237 (HUM291), and a first antigen-binding
region comprising a VH region and a VL region of a HER2 antibody of
cross-block 1, 2, 3, or 4 as defined herein, such as SEQ ID NOs: 1
and 5 (169), 22 and 26 (025), 63 and 67 (153), or 165 and 169
(005).
[0475] One embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising a VH CDR3 sequence of a CD3
antibody according to SEQ ID NO: 238 (huOKT3-C114S-gLC), and a
first antigen-binding region comprising a VH region of a HER2
antibody of cross-block 1, 2, 3, or 4 as defined herein, such as
SEQ ID NOs: 4, 25, 66, or 168 (169, 025, 153, or 005).
[0476] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising a CDR3 sequence of a CD3 antibody
according to SEQ ID NO: 238 (huOKT3-C114S-gLC) and a VL region
comprising a CDR3 sequence of a CD3 antibody according to SEQ ID
NO: 239 (huOKT3-C114S-gLC), and a first antigen-binding region
comprising a VH region comprising a CDR3 sequence of a HER2
antibody of cross-block 1, 2, 3, or 4 as defined herein, such as
SEQ ID NOs: 4, 25, 66, or 168 (169, 025, 153, or 005) and a VL
region comprising a CDR3 sequence of a HER2 antibody of cross-block
1, 2, 3, or 4 as defined herein, such as SEQ ID NOs: 7, 28, 69, or
171 (169, 025, 153, or 005).
[0477] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising a VH CDR1, CDR2, and CDR3
sequence according to SEQ ID NO: 238 (huOKT3-C114S-gLC), and a
first antigen-binding region of a HER2 antibody of cross-block 1,
2, 3, or 4 as defined herein, such as SEQ ID NOs: 2, 3, and 4
(169), SEQ ID NOs: 23, 24, and 25 (025), SEQ ID NOs: 64, 65, and 66
(153), or SEQ ID NOs: 166, 167, and 168 (005).
[0478] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region comprising CDR1, CDR2, and CDR3 sequences of
a CD3 antibody according to SEQ ID NO: 238 (huOKT3-C114S-gLC) and a
VL region comprising CDR1, CDR2, and CDR3 sequences of a CD3
antibody according to SEQ ID NO: 239 (huOKT3-C114S-gLC), and a
first antigen-binding region comprising a VH region comprising
CDR1, CDR2, and CDR3 sequences of a HER2 antibody of cross-block 1,
2, 3, or 4 as defined herein and a VL region comprising CDR1, CDR2,
and CDR3 sequences of a HER2 antibody of cross-block 1, 2, 3, or 4
as defined herein, such as SEQ ID NOs: 2, 3, 4, 6, DAS, and 7
(169), SEQ ID NOs: 23, 24, 25, 27, AAS, and 28 (025), SEQ ID NOs:
64, 65, 66, 68, DAS, and 69 (153), or SEQ ID NOs: 166, 167, 168,
170, GAS, and 171 (005).
[0479] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region of a CD3 antibody according to SEQ ID NO:
238 (huOKT3-C114S-gLC), and a first antigen-binding region of a
HER2 antibody of cross-block 1, 2, 3, or 4, such as SEQ ID NOs: 1,
22, 63, or 165 (169, 025, 153, or 005).
[0480] Another embodiment of the present invention relates to a
bispecific antibody having a second antigen-binding region
comprising a VH region and a VL region of a CD3 antibody according
to SEQ ID NOs: 238 and 239 (huOKT3-C114S-gLC), and a first
antigen-binding region comprising a VH region and a VL region of a
HER2 antibody of cross-block 1, 2, 3, or 4 as defined herein, such
as SEQ ID NOs: 1 and 5 (169), 22 and 26 (025), 63 and 67 (153), or
165 and 169 (005).
[0481] In an additional or alternative embodiment the bispecific
antibody is a HER2.times.CD3 bispecific antibody induce T cell
mediated cytotoxicity of AU565 as described in Example 21, and
binds the same epitopes as at least one of the bispecific
antibodies selected from the group consisting of
huCLB-T3/4.times.HER2-169, huCLB-T3/4.times.HER2 153, and
huCLB-T3/4.times.HER2 005 described in Example 21.
[0482] In a further embodiment, the first and second
antigen-binding regions of the bispecific antibody according to the
invention comprise human antibody VH sequences and, optionally,
human antibody VL sequences.
[0483] In a further embodiment, the first and second
antigen-binding regions of the bispecific antibody according to the
invention the first and second antigen-binding regions are from
heavy-chain antibodies.
[0484] In a further embodiment, the first and second
antigen-binding regions of the bispecific antibody according to the
invention the first and second antigen-binding regions comprise a
first and second light chain.
[0485] In a further embodiment, the first and second
antigen-binding regions of the bispecific antibody according to the
invention wherein said first and second light chains are
different.
Fc Regions
[0486] In one aspect of the present invention, the bispecific
HER2.times.CD3 antibody according to the present invention further
comprises a first Fc region and a second Fc region which may be
comprised in a first and a second Fab-arm which respectively
further comprise the first and second antigen-binding regions
described above (or vice versa).
[0487] In another aspect of the present invention, the bispecific
HER2.times.CD3 antibody comprises a first and a second Fab-arm
comprising a first and a second antigen-binding region,
respectively. Typically, the first and second antigen-binding
region is the HER2 binding domain and the CD3 binding domain,
respectively. The bispecific HER2.times.CD3 antibody further
comprises a first and a second Fc region, typically comprising a
first and a second heavy chain polypeptide, respectively.
[0488] In the one aspect of the present invention, the bispecific
HER2.times.CD3 antibody comprises the first Fab-arm comprising the
first antigen-binding region and the first Fc region, and the
second Fab-arm comprising the second antigen-binding region and the
second Fc region.
[0489] In another aspect of the present invention, the bispecific
HER2.times.CD3 antibody comprises the second Fab-arm comprising the
second antigen-binding region and the first Fc region, and the
first Fab-arm comprising the first antigen-binding region and the
second Fc region.
[0490] The first and second Fc-regions may each be of any isotype,
including, but not limited to, IgG1, IgG2, IgG3 and IgG4, and may
comprise one or more mutations or modifications. In one embodiment,
each of the first and second Fc regions is of the IgG4 isotype or
derived therefrom, optionally with one or more mutations or
modifications. In one embodiment, each of the first and second Fc
regions is of the IgG1 isotype or derived therefrom, optionally
with one or more mutations or modifications. In another embodiment,
one of the Fc regions is of the IgG1 isotype and the other of the
IgG4 isotype, or is derived from such respective isotype,
optionally with one or more mutations or modifications.
[0491] In one embodiment, one or both Fc-regions are
effector-function-deficient. For example, the Fc-region(s) may be
of an IgG4 isotype, or a non-IgG4 type, e.g. IgG1, IgG2 or IgG3,
which has been mutated such that the ability to mediate effector
functions, such as ADCC, has been reduced or even eliminated. Such
mutations have e.g. been described in Dall'Acqua W F et al., J
Immunol. 177(2):1129-1138 (2006) and Hezareh M, J Virol.;
75(24):12161-12168 (2001). Other exemplary modifications are
described in the Examples, e.g., in Example 27.
[0492] In one embodiment, one or both Fc-regions comprise an IgG1
wildtype sequence (SEQ ID NO:247, see Example 21).
[0493] In one embodiment, one or both of the Fc regions comprise a
mutation removing the acceptor site for Asn-linked glycosylation or
is otherwise manipulated to change the glycosylation properties.
For example, in an IgG1 Fc-region, an N297Q mutation can be used to
remove an Asn-linked glycosylation site. Accordingly, in a specific
embodiment, one or both Fc-regions comprise an IgG1 wildtype
sequence with an N297Q mutation (SEQ ID NO:250, see Example
21).
[0494] In a further embodiment, one or both of the Fc regions are
glyco-engineered to reduce fucose and thus enhance ADCC, e.g. by
addition of compounds to the culture media during antibody
production as described in US2009317869 or as described in van
Berkel et al. (2010) Biotechnol. Bioeng. 105:350 or by using FUT8
knockout cells, e.g. as described in Yamane-Ohnuki et al (2004)
Biotechnol. Bioeng 87:614. ADCC may alternatively be optimized
using the method described by Uma{umlaut over (n)}a et al. (1999)
Nature Biotech 17:176. In a further embodiment, one or both of the
Fc-regions have been engineered to enhance complement activation,
e.g. as described in Natsume et al. (2009) Cancer Sci.
100:2411.
[0495] In one embodiment of the invention, the first or second
antigen-binding regions or a part thereof, e.g. one or more CDRs,
are of a species in the family Camelidae, see WO2010001251, or a
species of cartilaginous fish, such as the nurse shark. In one
embodiment, the first and second antigen-binding regions or heavy
chains are from heavy-chain antibodies.
[0496] In one embodiment, the first and/or second Fc-region is
conjugated to a drug, a prodrug or a toxin or contains an acceptor
group for the same. Such acceptor group may e.g. be an unnatural
amino acid.
[0497] In one aspect, the bispecific antibody of the invention
comprises a first Fc-region comprising a first CH3 region, and a
second Fc-region comprising a second CH3 region, wherein the
sequences of the first and second CH3 regions are different and are
such that the heterodimeric interaction between said first and
second CH3 regions is stronger than each of the homodimeric
interactions of said first and second CH3 regions. More details on
these interactions and how they can be achieved are provided in
PCT/EP2011/056388, published as WO 2011131746 (Genmab), which is
hereby incorporated by reference in its entirety.
[0498] As described further herein and in the Examples, a stable
bispecific HER2.times.CD3 molecule can be obtained at high yield
using a particular method on the basis of one homodimeric starting
HER2 antibody and one homodimeric starting CD3 antibody containing
only a few, fairly conservative, asymmetrical mutations in the CH3
regions. Asymmetrical mutations mean that the sequences of said
first and second CH3 regions contain amino acid substitutions at
non-identical positions.
[0499] In one embodiment, the first Fc-region has an amino acid
substitution at a position selected from the group consisting of:
366, 368, 370, 399, 405, 407 and 409, and the second Fc-region has
an amino acid substitution at a position selected from the group
consisting of: 366, 368, 370, 399, 405, 407 and 409, and wherein
the first and second Fc-regions are not substituted in the same
positions.
[0500] In one embodiment, the first Fc-region has an amino acid
substitution at position 366, and said second Fc-region has an
amino acid substitution at a position selected from the group
consisting of: 368, 370, 399, 405, 407 and 409. In one embodiment
the amino acid at position 366 is selected from Ala, Asp, Glu, His,
Asn, Val, or Gln.
[0501] In one embodiment, the first Fc-region has an amino acid
substitution at position 368, and said second Fc-region has an
amino acid substitution at a position selected from the group
consisting of: 366, 370, 399, 405, 407 and 409.
[0502] In one embodiment, the first Fc-region has an amino acid
substitution at position 370, and said second Fc-region has an
amino acid substitution at a position selected from the group
consisting of: 366, 368, 399, 405, 407 and 409.
[0503] In one embodiment, the first Fc-region has an amino acid
substitution at position 399, and said second Fc-region has an
amino acid substitution at a position selected from the group
consisting of: 366, 368, 370, 405, 407 and 409.
[0504] In one embodiment, the first Fc-region has an amino acid
substitution at position 405, and said second Fc-region has an
amino acid substitution at a position selected from the group
consisting of: 366, 368, 370, 399, 407 and 409.
[0505] In one embodiment, the first Fc-region has an amino acid
substitution at position 407, and said second Fc-region has an
amino acid substitution at a position selected from the group
consisting of: 366, 368, 370, 399, 405, and 409.
[0506] In one embodiment, the first Fc-region has an amino acid
substitution at position 409, and said second Fc-region has an
amino acid substitution at a position selected from the group
consisting of: 366, 368, 370, 399, 405, and 407.
[0507] Accordingly, in one embodiment, the sequences of said first
and second CH3 regions contain asymmetrical mutations, i.e.
mutations at different positions in the two CH3 regions, e.g. a
mutation at position 405 in one of the CH3 regions and a mutation
at position 409 in the other CH3 region.
[0508] In one embodiment, the first Fc-region has an amino acid
other than Lys, Leu or Met, e.g. Gly, Ala, Val, Ile, Ser, Thr, Phe,
Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, at position
409 and said second Fc-region has an amino-acid substitution at a
position selected from the group consisting of: 366, 368, 370, 399,
405 and 407. In one such embodiment, said first Fc-region has an
amino acid other than Lys, Leu or Met, e.g. Gly, Ala, Val, Ile,
Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys,
at position 409 and said second Fc-region has an amino acid other
than Phe, e.g. Gly, Ala, Val, Ile, Ser, Thr, Lys, Arg, His, Asp,
Asn, Glu, Gln, Pro, Trp, Tyr, Cys, Lys, or Leu, at position 405. In
a further embodiment hereof, said first Fc-region has an amino acid
other than Lys, Leu or Met, e.g. Gly, Ala, Val, Ile, Ser, Thr, Phe,
Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, at position
409 and said second Fc-region has an amino acid other than Phe, Arg
or Gly, e.g. Leu, Ala, Val, Ile, Ser, Thr, Met, Lys, His, Asp, Asn,
Glu, Gln, Pro, Trp, Tyr, or Cys, at position 405.
[0509] In another embodiment, said first Fc-region comprises a Phe
at position 405 and an amino acid other than Lys, Leu or Met, e.g.
Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln,
Pro, Trp, Tyr, or Cys, at position 409 and said second Fc-region
comprises an amino acid other than Phe, e.g. Gly, Ala, Val, Ile,
Ser, Thr, Lys, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, Leu,
Met, or Cys, at position 405 and a Lys at position 409. In a
further embodiment hereof, said first Fc-region comprises a Phe at
position 405 and an amino acid other than Lys, Leu or Met, e.g.
Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln,
Pro, Trp, Tyr, or Cys, at position 409 and said second Fc-region
comprises an amino acid other than Phe, Arg or Gly, e.g. Leu, Ala,
Val, Ile, Ser, Thr, Met, Lys, His, Asp, Asn, Glu, Gln, Pro, Trp,
Tyr, or Cys, at position 405 and a Lys at position 409.
[0510] In another embodiment, said first Fc-region comprises a Phe
at position 405 and an amino acid other than Lys, Leu or Met, e.g.
Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln,
Pro, Trp, Tyr, or Cys, at position 409 and said second Fc-region
comprises a Leu at position 405 and a Lys at position 409. In a
further embodiment hereof, said first Fc-region comprises a Phe at
position 405 and an Arg at position 409 and said second Fc-region
comprises an amino acid other than Phe, Arg or Gly, e.g. Leu, Ala,
Val, Ile, Ser, Thr, Lys, Met, His, Asp, Asn, Glu, Gln, Pro, Trp,
Tyr, or Cys, at position 405 and a Lys at position 409. In another
embodiment, said first Fc-region comprises Phe at position 405 and
an Arg at position 409 and said second Fc-region comprises a Leu at
position 405 and a Lys at position 409.
[0511] In a further embodiment, said first Fc-region comprises an
amino acid other than Lys, Leu or Met, e.g. Gly, Ala, Val, Ile,
Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys,
at position 409 and said second Fc-region comprises a Lys at
position 409, a Thr at position 370 and a Leu at position 405. In a
further embodiment, said first Fc-region comprises an Arg at
position 409 and said second Fc-region comprises a Lys at position
409, a Thr at position 370 and a Leu at position 405.
[0512] In an even further embodiment, said first Fc-region
comprises a Lys at position 370, a Phe at position 405 and an Arg
at position 409 and said second Fc-region comprises a Lys at
position 409, a Thr at position 370 and a Leu at position 405.
[0513] In another embodiment, said first Fc-region comprises an
amino acid other than Lys, Leu or Met, e.g. Gly, Ala, Val, Ile,
Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys,
at position 409 and said second Fc-region comprises a Lys at
position 409 and: a) an Ile at position 350 and a Leu at position
405, or b) a Thr at position 370 and a Leu at position 405.
[0514] In another embodiment, said first Fc-region comprises an Arg
at position 409 and said second HER2 antibody comprises a Lys at
position 409 and: a) an Ile at position 350 and a Leu at position
405, or b) a Thr at position 370 and a Leu at position 405.
[0515] In another embodiment, said first Fc-region comprises a Thr
at position 350, a Lys at position 370, a Phe at position 405 and
an Arg at position 409 and said second HER2 antibody comprises a
Lys at position 409 and: a) an Ile at position 350 and a Leu at
position 405, or b) a Thr at position 370 and a Leu at position
405.
[0516] In another embodiment, said first Fc-region comprises a Thr
at position 350, a Lys at position 370, a Phe at position 405 and
an Arg at position 409 and said second Fc-region comprises an Ile
at position 350, a Thr at position 370, a Leu at position 405 and a
Lys at position 409.
[0517] In another embodiment, said first Fc-region has an amino
acid other than Lys, Leu or Met, e.g. Gly, Ala, Val, Ile, Ser, Thr,
Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, at
position 409 and said second Fc-region has an amino acid other than
Tyr, Asp, Glu, Phe, Lys, Gln, Arg, Ser or Thr, e.g. Leu, Met, Gly,
Ala, Val, Ile, His, Asn, Pro, Trp, or Cys, at position 407. In
another embodiment, said first Fc-region has an amino acid other
than Lys, Leu or Met, e.g. Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg,
His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, at position 409 and
said second Fc-region has an Ala, Gly, His, Ile, Leu, Met, Asn, Val
or Trp at position 407.
[0518] In another embodiment, said first Fc-region has an amino
acid other than Lys, Leu or Met, e.g. Gly, Ala, Val, Ile, Ser, Thr,
Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, at
position 409 and said second Fc-region has a Gly, Leu, Met, Asn or
Trp at position 407.
[0519] In another embodiment, said first Fc-region has a Tyr at
position 407 and an amino acid other than Lys, Leu or Met, e.g.
Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln,
Pro, Trp, Tyr, or Cys, at position 409 and said second Fc-region
has an amino acid other than Tyr, Asp, Glu, Phe, Lys, Gln, Arg, Ser
or Thr, e.g. Leu, Met, Gly, Ala, Val, Ile, His, Asn, Pro, Trp, or
Cys, at position 407 and a Lys at position 409.
[0520] In another embodiment, said first Fc-region has a Tyr at
position 407 and an amino acid other than Lys, Leu or Met, e.g.
Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln,
Pro, Trp, Tyr, or Cys, at position 409 and said second Fc-region
has an Ala, Gly, His, Ile, Leu, Met, Asn, Val or Trp at position
407 and a Lys at position 409.
[0521] In another embodiment, said first Fc-region has a Tyr at
position 407 and an amino acid other than Lys, Leu or Met, e.g.
Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln,
Pro, Trp, Tyr, or Cys, at position 409 and said second Fc-region
has a Gly, Leu, Met, Asn or Trp at position 407 and a Lys at
position 409.
[0522] In another embodiment, said first Fc-region has a Tyr at
position 407 and an Arg at position 409 and said second Fc-region
has an amino acid other than Tyr, Asp, Glu, Phe, Lys, Gln, Arg, Ser
or Thr, e.g. Leu, Met, Gly, Ala, Val, Ile, His, Asn, Pro, Trp, or
Cys, at position 407 and a Lys at position 409.
[0523] In another embodiment, said first Fc-region has a Tyr at
position 407 and an Arg at position 409 and said second Fc-region
has an Ala, Gly, His, Ile, Leu, Met, Asn, Val or Trp at position
407 and a Lys at position 409.
[0524] In another embodiment, said first Fc-region has a Tyr at
position 407 and an Arg at position 409 and said second Fc-region
has a Gly, Leu, Met, Asn or Trp at position 407 and a Lys at
position 409.
[0525] In one embodiment, the first Fc-region has an amino acid
other than Lys, Leu or Met, e.g. Gly, Ala, Val, Ile, Ser, Thr, Phe,
Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, at position
409, and the second Fc-region has
(i) an amino acid other than Phe, Leu and Met, e.g. Gly, Ala, Val,
Ile, Ser, Thr, Lys, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or
Cys, at position 368, or (ii) a Trp at position 370, or (iii) an
amino acid other than Asp, Cys, Pro, Glu or Gln, e.g. Phe, Leu,
Met, Gly, Ala, Val, Ile, Ser, Thr, Lys, Arg, His, Asn, Trp, Tyr, or
Cys, at position 399 or (iv) an amino acid other than Lys, Arg,
Ser, Thr, or Trp, e.g. Phe, Leu, Met, Ala, Val, Gly, Ile, Asn, His,
Asp, Glu, Gln, Pro, Tyr, or Cys, at position 366.
[0526] In one embodiment, the first Fc-region has an Arg, Ala, His
or Gly at position 409, and the second homodimeric protein has
(i) a Lys, Gln, Ala, Asp, Glu, Gly, His, Ile, Asn, Arg, Ser, Thr,
Val, or Trp at position 368, or (ii) a Trp at position 370, or
(iii) an Ala, Gly, Ile, Leu, Met, Asn, Ser, Thr, Trp, Phe, His,
Lys, Arg or Tyr at position 399, or (iv) an Ala, Asp, Glu, His,
Asn, Val, Gln, Phe, Gly, Ile, Leu, Met, or Tyr at position 366.
[0527] In one embodiment, the first Fc-region has an Arg at
position 409, and the second homodimeric protein has
(i) an Asp, Glu, Gly, Asn, Arg, Ser, Thr, Val, or Trp at position
368, or (ii) a Trp at position 370, or (iii) a Phe, His, Lys, Arg
or Tyr at position 399, or (iv) an Ala, Asp, Glu, His, Asn, Val,
Gln at position 366.
[0528] In addition to the above-specified amino-acid substitutions,
said first and second homodimeric protein may contain further
amino-acid substitutions, deletion or insertions relative to
wild-type Fc sequences.
[0529] In a further embodiment, said first and second Fab-arms (or
heavy-chain constant domains) comprising the first and second Fc
regions comprise, except for the specified mutations, a sequence
independently selected from the following:
TABLE-US-00002 (IgGinn(a)): (SEQ ID NO: 256)
GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK
(IgGinn(f)): (SEQ ID NO: 257)
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK, and
(IgGinn(ax)): (SEQ ID NO: 258)
GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEGLHNHYTQKS LSLSPGK.
[0530] In one embodiment, neither said first nor said second
Fc-region comprises a Cys-Pro-Ser-Cys sequence in the (core) hinge
region.
[0531] In a further embodiment, both said first and said second
Fc-region comprise a Cys-Pro-Pro-Cys sequence in the (core) hinge
region.
[0532] In separate and specific embodiments, one or both Fab arms
comprise a heavy-chain constant region sequence independently
selected from SEQ ID NO: 247, 248, 249, 250, 251, 252, 253, 254,
and 255 (see Example 21).
[0533] In one particular example, the CD3 antibody is an antibody
with a VH region comprising the sequence of SEQ ID NO:234 (VH
YTH12.5) and VL region comprising the sequence of SEQ ID NO:235 (VL
YTH12.5). Another example is a CD3 antibody with a VH region
comprising the sequence of SEQ ID NO:240 (VH huCLB-T3/4) and VL
region comprising the sequence of SEQ ID NO:241 (VL
huCLB-T3/4).
[0534] In one embodiment, the bispecific antibody comprises (i) a
first Fab-arm comprising an Fc region and VH and VL sequences,
wherein the VH region comprises the amino acid sequence of SEQ ID
NO:63, and the VL region comprises the amino acid sequence of SEQ
ID NO:67 (153), optionally wherein the first Fab-arm comprises an
IgG1,.kappa. Fc region having Arg at position 409, or Gln at
position 297, or Arg at position 409 and Gln at position 297; and
(ii) a second Fab-arm having an Fc region and VH and VL sequences,
wherein the VH region comprises the amino acid sequence of SEQ ID
NO:171 and the VL region comprises the amino acid sequence of SEQ
ID NO:172 (YTH12.5), optionally wherein the second Fab-arm
comprises an IgG1,.kappa. Fc region having an Gln at position 297,
or Leu at position 405, or Gln at position 297 and Leu at position
405.
[0535] In one embodiment, the bispecific antibody comprises (i) a
first Fab-arm having an Fc region and VH and VL sequences, wherein
the VH region comprises the amino acid sequence of SEQ ID NO:1, and
the VL region comprises the amino acid sequence of SEQ ID NO:5
(169), optionally wherein the first Fab-arm comprises an
IgG1,.kappa. Fc region having Arg at position 409; and (ii) a
second Fab-arm having an Fc region and VH and VL sequences, wherein
the VH region comprises the amino acid sequence of SEQ ID NO:171
and the VL region comprises the amino acid sequence of SEQ ID
NO:172 (YTH12.5), optionally wherein the second Fab-arm comprises
an IgG1,.kappa. Fc region having an Gln at position 297, or Leu at
position 405, or Gln at position 297 and Leu at position 405.
[0536] In one embodiment, the bispecific antibody comprises (i) a
first Fab-arm having an Fc region and VH and VL sequences, wherein
the VH region comprises the amino acid sequence of SEQ ID NO:63,
and the VL region comprises the amino acid sequence of SEQ ID NO:67
(153), optionally wherein the first Fab-arm comprises an
IgG1,.kappa. Fc region having Arg at position 409, or Gln at
position 297, or Arg at position 409 and Gln at position 297; and
(ii) a second Fab-arm having an Fc region and VH and VL sequences,
wherein the VH region comprises the amino acid sequence of SEQ ID
NO:173 and the VL region comprises the amino acid sequence of SEQ
ID NO:174 (huCLB-T3/4), optionally wherein the second Fab-arm
comprises an IgG1,.kappa. Fc region having an Gln at position 297,
or Leu at position 405, or Gln at position 297 and Leu at position
405.
[0537] In one embodiment, the bispecific antibody comprises (i) a
first Fab-arm having an Fc region and VH and VL sequences, wherein
the VH region comprises the amino acid sequence of SEQ ID NO:1, and
the VL region comprises the amino acid sequence of SEQ ID NO:5
(169), optionally wherein the first Fab-arm comprises an
IgG1,.kappa. Fc region having Arg at position 409; and (ii) a
second Fab-arm having an Fc region and VH and VL sequences, wherein
the VH region comprises the amino acid sequence of SEQ ID NO:173
and the VL region comprises the amino acid sequence of SEQ ID
NO:174 (huCLB-T3/4), optionally wherein the second Fab-arm
comprises an IgG1,.kappa. Fc region having an Gln at position 297,
or Leu at position 405, or Gln at position 297 and Leu at position
405.
[0538] In any of the above embodiments, the first and/or second
Fab-arm may further comprise CH1 and/or CL sequences.
[0539] In one embodiment the bispecific antibody is selected from
the group consisting of:
IgG1-HER2-153-K409R.times.IgG1-YTH12.5-F405L,
IgG1-HER2-153-K409R.times.IgG1-YTH12.5-N297Q-F405L,
IgG1-HER2-153-K409R.times.IgG1-hu-CLB-T3/4-F405L,
IgG1-HER2-153-K409R.times.IgG1-hu-CLB-T3/4-N297Q-F405L,
IgG1-HER2-153-N297Q-K409R.times.IgG1-YTH12.5-F405L,
IgG1-HER2-153-N297Q-K409R.times.IgG1-YTH12.5-N297Q-F405L,
IgG1-HER2-153-N297Q-K409R.times.IgG1-hu-CLB-T3/4-F405L,
IgG1-HER2-153-N297Q-K409R.times.IgG1-hu-CLB-T3/4-N297Q-F405L,
IgG1-HER2-169-K409R.times.IgG1-hu-CLB-T3/4-F405L,
IgG1-HER2-169-K409R.times.IgG1-hu-CLB-T3/4-N297Q-F405L,
IgG1-HER2-169-K409R.times.IgG1-YTH12.5-F405L and
IgG1-HER2-169-K409R.times.IgG1-YTH12.5-N297Q-F405L, wherein ITL
means IgG1,.kappa. having Ile at position 350, Thr at position 370,
and Leu at position 405, K409R means IgG1,.kappa. having an Arg at
position 409, and F405L means IgG1,.kappa. having a Leu at position
405, N297Q means a Gln at position 297, and wherein the bold
numbers refer to antibodies described herein with the VH and VL
regions comprising the sequences described in Table 1 and Example
21.
[0540] In an additional embodiment, the bispecific antibody induces
dose-dependent killing of AU565, NIH-3T3, A431 and A549 cells when
determined as described in Example 29, and binds the same epitopes
as the bispecific antibody IgG1-HER2-169.times.IgG1-CLBT3/4.
Bispecific Antibody Formats
[0541] The present invention provides bispecific HER2.times.CD3
antibodies which efficiently promote T cell-mediated killing of
HER2-expressing tumor cells. Depending on the desired functional
properties for a particular use, particular antigen-binding regions
can be selected from the set of antibodies or antigen-binding
regions provided by the present invention or from those antibodies
or antigen-binding regions sharing, e.g., an epitope or
cross-blocking region with the antibodies or antigen-binding
regions provided by the present invention. Many different formats
and uses of bispecific antibodies are known in the art, and were
recently been reviewed by Chames and Baty (2009) Curr Opin Drug
Disc Dev 12: 276.
[0542] Exemplary bispecific antibody molecules of the invention
comprise (i) a single antibody that has two arms comprising
different antigen-binding regions, one with a specificity to a HER2
epitope and one with a specificity to CD3, (ii) a single antibody
that has one antigen-binding region or arm specific to a HER2
epitope and a second antigen-binding region or arm specific to a
CD3 epitope, (iii) a single chain antibody that has a first
specificity to a HER2 epitope and a second specificity to a CD3
epitope, e.g., via two scFvs linked in tandem by an extra peptide
linker; (iv) a dual-variable-domain antibody (DVD-Ig), where each
light chain and heavy chain contains two variable domains in tandem
through a short peptide linkage (Wu et al., Generation and
Characterization of a Dual Variable Domain Immunoglobulin
(DVD-Ig.TM.) Molecule, In: Antibody Engineering, Springer Berlin
Heidelberg (2010)); (v) a chemically-linked bispecific (Fab').sub.2
fragment; (vi) a Tandab, which is a fusion of two single chain
diabodies resulting in a tetravalent bispecific antibody that has
two binding sites for each of the target antigens; (vii) a
flexibody, which is a combination of scFvs with a diabody resulting
in a multivalent molecule; (viii) a so called "dock and lock"
molecule, based on the "dimerization and docking domain" in Protein
Kinase A, which, when applied to Fabs, can yield a trivalent
bispecific binding protein consisting of two identical Fab
fragments linked to a different Fab fragment; (ix) a so-called
Scorpion molecule, comprising, e.g., two scFvs fused to both
termini of a human Fab-arm; and (x) a diabody.
[0543] In one embodiment, the bispecific antibody of the present
invention is a diabody, a cross-body, or a bispecific antibody
obtained via a controlled Fab arm exchange as those described in
the present invention.
[0544] Examples of different classes of bispecific antibodies
include but are not limited to [0545] IgG-like molecules with
complementary CH3 domains to force heterodimerisation [0546]
recombinant IgG-like dual targeting molecules, wherein the two
sides of the molecule each contain the Fab fragment or part of the
Fab fragment of at least two different antibodies; [0547] IgG
fusion molecules, wherein full length IgG antibodies are fused to
extra Fab fragment or parts of Fab fragment; [0548] Fc fusion
molecules, wherein single chain Fv molecules or stabilized
diabodies are fused to heavy-chain constant-domains, Fc-regions or
parts thereof; [0549] Fab fusion molecules, wherein different
Fab-fragments are fused together; [0550] ScFv- and diabody-based
and heavy chain antibodies (e.g., domain antibodies, nanobodies)
wherein different single chain Fv molecules or different diabodies
or different heavy-chain antibodies (e.g. domain antibodies,
nanobodies) are fused to each other or to another protein or
carrier molecule.
[0551] Examples of IgG-like molecules with complementary CH3
domains molecules include but are not limited to the
Triomab/Quadroma (Trion Pharma/Fresenius Biotech), the
Knobs-into-Holes (Genentech), CrossMAbs (Roche) and the
electrostatically-matched (Amgen), the LUZ-Y (Genentech), the
Strand Exchange Engineered Domain body (SEEDbody)(EMD Serono), the
Biclonic (Merus) and the DuoBody (Genmab A/S).
[0552] Examples of recombinant IgG-like dual targeting molecules
include but are not limited to Dual Targeting (DT)-Ig
(GSK/Domantis), Two-in-one Antibody (Genentech), Cross-linked Mabs
(Karmanos Cancer Center), mAb.sup.2 (F-Star) and CovX-body
(CovX/Pfizer).
[0553] Examples of IgG fusion molecules include but are not limited
to Dual Variable Domain (DVD)-Ig (Abbott), IgG-like Bispecific
(InnClone/Eli Lilly), Ts2Ab (MedImmune/AZ) and BsAb (Zymogenetics),
HERCULES (Biogen Idec) and TvAb (Roche).
[0554] Examples of Fc fusion molecules include but are not limited
to ScFv/Fc Fusions (Academic Institution), SCORPION (Emergent
BioSolutions/Trubion, Zymogenetics/BMS), Dual Affinity Retargeting
Technology (Fc-DART) (MacroGenics) and Dual(ScFv).sub.2-Fab
(National Research Center for Antibody Medicine--China).
[0555] Examples of Fab fusion bispecific antibodies include but are
not limited to F(ab).sub.2 (Medarex/AMGEN), Dual-Action or Bis-Fab
(Genentech), Dock-and-Lock (DNL) (ImmunoMedics), Bivalent
Bispecific (Biotecnol) and Fab-Fv (UCB-Celltech). Examples of
ScFv-, diabody-based and domain antibodies include but are not
limited to Bispecific T Cell Engager (BITE) (Micromet, Tandem
Diabody (Tandab) (Affimed), Dual Affinity Retargeting Technology
(DART) (MacroGenics), Single-chain Diabody (Academic), TCR-like
Antibodies (AIT, ReceptorLogics), Human Serum Albumin ScFv Fusion
(Merrimack) and COMBODY (Epigen Biotech), dual targeting nanobodies
(Ablynx), dual targeting heavy chain only domain antibodies.
Methods of Preparing Bispecific Antibodies
[0556] Methods of preparing bispecific antibodies of the present
invention include those described in WO 2008119353 (Genmab), WO
2011131746 (Genmab) and reported by van der Neut-Kolfschoten et al.
(Science. 2007 Sep. 14; 317(5844):1554-7). Examples of other
platforms useful for preparing bispecific antibodies include but
are not limited to BITE (Micromet), DART (MacroGenics), Fcab and
Mab.sup.e (F-star), Fc-engineered IgG1 (Xencor) or DuoBody (based
on Fab arm exchange, Genmab, this application, described below and
in, e.g., Example 20).
[0557] Traditional methods such as the hybrid hybridoma and
chemical conjugation methods (Marvin and Zhu (2005) Acta Pharmacol
Sin 26:649) can also be used. Co-expression in a host cell of two
antibodies, consisting of different heavy and light chains, leads
to a mixture of possible antibody products in addition to the
desired bispecific antibody, which can then be isolated by, e.g.,
affinity chromatography or similar methods.
[0558] Strategies favoring the formation of a functional
bispecific, product, upon co-expression of different antibody
constructs can also be used, e.g., the method described by
Lindhofer et al. (1995 J Immunol 155:219). Fusion of rat and mouse
hydridomas producing different antibodies leads to a limited number
of heterodimeric proteins because of preferential
species-restricted heavy/light chain pairing. Another strategy to
promote formation of heterodimers over homodimers is a
"knob-into-hole" strategy in which a protuberance is introduced on
a first heavy-chain polypeptide and a corresponding cavity in a
second heavy-chain polypeptide, such that the protuberance can be
positioned in the cavity at the interface of these two heavy chains
so as to promote heterodimer formation and hinder homodimer
formation. "Protuberances" are constructed by replacing small
amino-acid side-chains from the interface of the first polypeptide
with larger side chains. Compensatory "cavities" of identical or
similar size to the protuberances are created in the interface of
the second polypeptide by replacing large amino-acid side-chains
with smaller ones (U.S. Pat. No. 5,731,168). EP1870459 (Chugai) and
WO 2009089004 (Amgen) describe other strategies for favoring
heterodimer formation upon co-expression of different antibody
domains in a host cell. In these methods, one or more residues that
make up the CH3-CH3 interface in both CH3 domains are replaced with
a charged amino acid such that homodimer formation is
electrostatically unfavorable and heterodimerization is
electrostatically favorable. WO2007110205 (Merck) describe yet
another strategy, wherein differences between IgA and IgG CH3
domains are exploited to promote heterodimerization.
[0559] Another in vitro method for producing bispecific antibodies
has been described in WO 2008119353 (Genmab), wherein a bispecific
antibody is formed by "Fab-arm" or "half-molecule" exchange
(swapping of a heavy chain and attached light chain) between two
monospecific IgG4- or IgG4-like antibodies upon incubation under
reducing conditions. The resulting product is a bispecific antibody
having two Fab arms which may comprise different sequences.
[0560] A preferred method for preparing bispecific HER2.times.CD3
antibodies of the present invention includes the method described
in WO 2011131746 (Genmab) comprising the following steps: [0561] a)
providing a first antibody comprising an Fc region, said Fc region
comprising a first CH3 region; [0562] b) providing a second
antibody comprising a second Fc region, said Fc region comprising a
second CH3 region, wherein the first antibody is a HER2 antibody
and the second antibody is a CD3 antibody, or vice versa; [0563]
wherein the sequences of said first and second CH3 regions are
different and are such that the heterodimeric interaction between
said first and second CH3 regions is stronger than each of the
homodimeric interactions of said first and second CH3 regions;
[0564] c) incubating said first antibody together with said second
antibody under reducing conditions; and [0565] d) obtaining said
bispecific HER2.times.CD3 antibody.
[0566] Without being limited to theory, in step c), the heavy-chain
disulfide bonds in the hinge regions of the parent antibodies are
reduced and the resulting cysteines are then able to form inter
heavy-chain disulfide bond with cysteine residues of another parent
antibody molecule (originally with a different specificity). In one
embodiment of this method, the reducing conditions in step c)
comprise the addition of a reducing agent, e.g. a reducing agent
selected from the group consisting of: 2-mercaptoethylamine
(2-MEA), dithiothreitol (DTT), dithioerythritol (DTE), glutathione,
tris(2-carboxyethyl)phosphine (TCEP), L-cysteine and
beta-mercapto-ethanol, preferably a reducing agent selected from
the group consisting of: 2-mercaptoethylamine, dithiothreitol and
tris(2-carboxyethyl)phosphine. In a further embodiment, step c)
comprises restoring the conditions to become non-reducing or less
reducing, for example by removal of a reducing agent, e.g. by
desalting.
[0567] Typically, in this method, the first and second antibodes
are a HER2 and CD3 antibody binding to epitopes of HER2 and CD3,
respectively, and/or comprising different antigen-binding sequences
of HER2 and CD3, respectively.
[0568] For this method any of the HER2 and CD3 antibodes described
above may be used including first and second HER2 and CD3
antibodies, respectively, comprising a first and/or second Fc
regions. Examples of such first and second Fc regions, including
combination of such first and second Fc regions may include any of
those described above. In a particular embodiment the first and
second HER2 and CD3 antibodies, respectively, may be chosen so as
to obtain a bispecific antibody as described herein.
[0569] In one embodiment of this method, said first and/or second
antibodies are full-length antibodies.
[0570] The Fc regions of the first and second antibodies may be of
any isotype, including, but not limited to, IgG1, IgG2, IgG3 or
IgG4. In one embodiment of this method, the Fc regions of both said
first and said second antibodies are of the IgG1 isotype. In
another embodiment, one of the Fc regions of said antibodies is of
the IgG1 isotype and the other of the IgG4 isotype. In the latter
embodiment, the resulting bispecific antibody comprises an Fc
region of an IgG1 and an Fc region of IgG4 and may thus have
interesting intermediate properties with respect to activation of
effector functions. A similar product can be obtained if said first
and/or said second antibody comprises a mutation removing the
acceptor site for Asn-linked glycosylation or is otherwise
manipulated to change the glycosylation properties.
[0571] In a further embodiment of this method, one or both of the
antibodies is glyco-engineered to reduce fucose and thus enhance
ADCC, e.g. by addition of compounds to the culture media during
antibody production as described in US2009317869 or as described in
van Berkel et al. (2010) Biotechnol. Bioeng. 105:350 or by using
FUT8 knockout cells, e.g. as described in Yamane-Ohnuki et al
(2004) Biotechnol. Bioeng 87:614. ADCC may alternatively be
optimized using the method described by Uma{umlaut over (n)}a et
al. (1999) Nature Biotech 17:176. In a further embodiment, one or
both of the antibodies have been engineered to enhance complement
activation, e.g. as described in Natsume et al. (2009) Cancer Sci.
100:2411.
[0572] In a further embodiment of this method, one or both of the
antibodies have been engineered to reduce or increase the binding
to the neonatal Fc receptor (FcRn) in order to manipulate the serum
half-life of the heterodimeric protein. In a further embodiment,
one of the antibody starting proteins has been engineered to not
bind Protein A, thus allowing to separate the heterodimeric protein
from said homodimeric starting protein by passing the product over
a protein A column.
[0573] In a particular embodiment of this method, the antibody or a
part thereof, e.g. one or more CDRs, is of a species in the family
Camelidae, see WO2010001251, or a species of cartilaginous fish,
such as the nurse shark, or is a heavy-chain or domain
antibody.
[0574] In one embodiment, the first and/or second HER2 antibody is
conjugated to a drug, a prodrug or a toxin or contains an acceptor
group for the same. Such acceptor group may e.g. be an unnatural
amino acid.
[0575] As described above, the sequences of the first and second
CH3 regions of the homodimeric starting antibodies are different
and are such that the heterodimeric interaction between said first
and second CH3 regions is stronger than each of the homodimeric
interactions of said first and second CH3 regions. More details on
these interactions and how they can be achieved are provided in
PCT/EP2011/056388, published as WO 2011131746 (Genmab), which is
hereby incorporated by reference in its entirety.
[0576] In particular, a stable bispecific HER2.times.CD3 molecule
can be obtained at high yield using the above method of the
invention on the basis of two homodimeric starting antibodies which
bind HER2 and CD3, respectively, and contain only a few, fairly
conservative, asymmetrical mutations in the CH3 regions.
Asymmetrical mutations mean that the sequences of said first and
second CH3 regions contain amino acid substitutions at
non-identical positions.
[0577] In one embodiment of this method, the first antibody has an
amino acid substitution at a position selected from the group
consisting of: 366, 368, 370, 399, 405, 407 and 409, and the second
antibody has an amino acid substitution at a position selected from
the group consisting of: 366, 368, 370, 399, 405, 407 and 409, and
wherein the first and second antibodies are not substituted in the
same positions.
[0578] In one embodiment of this method, the first antibody has an
amino acid substitution at position 366, and said second antibody
has an amino acid substitution at a position selected from the
group consisting of: 368, 370, 399, 405, 407 and 409. In one
embodiment the amino acid at position 366 is selected from Ala,
Asp, Glu, His, Asn, Val, or Gln.
[0579] In one embodiment of this method, the first antibody protein
has an amino acid substitution at position 368, and said second
antibody has an amino acid substitution at a position selected from
the group consisting of: 366, 370, 399, 405, 407 and 409.
[0580] In one embodiment of this method, the first antibody has an
amino acid substitution at position 370, and said second antibody
has an amino acid substitution at a position selected from the
group consisting of: 366, 368, 399, 405, 407 and 409.
[0581] In one embodiment of this method, the first antibody has an
amino acid substitution at position 399, and said second antibody
has an amino acid substitution at a position selected from the
group consisting of: 366, 368, 370, 405, 407 and 409.
[0582] In one embodiment of this method, the first antibody has an
amino acid substitution at position 405, and said second antibody
has an amino acid substitution at a position selected from the
group consisting of: 366, 368, 370, 399, 407 and 409.
[0583] In one embodiment of this method, the first antibody has an
amino acid substitution at position 407, and said second antibody
has an amino acid substitution at a position selected from the
group consisting of: 366, 368, 370, 399, 405, and 409.
[0584] In one embodiment of this method, the first antibody has an
amino acid substitution at position 409, and said second antibody
has an amino acid substitution at a position selected from the
group consisting of: 366, 368, 370, 399, 405, and 407.
[0585] Accordingly, in one embodiment of this method, the sequences
of said first and second CH3 regions contain asymmetrical
mutations, i.e. mutations at different positions in the two CH3
regions, e.g. a mutation at position 405 in one of the CH3 regions
and a mutation at position 409 in the other CH3 region.
[0586] In one embodiment of this method, the first antibody has an
amino acid other than Lys, Leu or Met at position 409 and said
second antibody has an amino-acid substitution at a position
selected from the group consisting of: 366, 368, 370, 399, 405 and
407. In one such embodiment, said first antibody has an amino acid
other than Lys, Leu or Met at position 409 and said second antibody
has an amino acid other than Phe at position 405. In a further
embodiment hereof, said first antibody has an amino acid other than
Lys, Leu or Met at position 409 and said second antibody has an
amino acid other than Phe, Arg or Gly at position 405.
[0587] In another embodiment of this method, said first antibody
comprises a Phe at position 405 and an amino acid other than Lys,
Leu or Met at position 409 and said second antibody comprises an
amino acid other than Phe at position 405 and a Lys at position
409. In a further embodiment hereof, said first antibody comprises
a Phe at position 405 and an amino acid other than Lys, Leu or Met
at position 409 and said second antibody comprises an amino acid
other than Phe, Arg or Gly at position 405 and a Lys at position
409.
[0588] In another embodiment of this method, said first antibody
comprises a Phe at position 405 and an amino acid other than Lys,
Leu or Met at position 409 and said second antibody comprises a Leu
at position 405 and a Lys at position 409. In a further embodiment
hereof, said first antibody comprises a Phe at position 405 and an
Arg at position 409 and said second antibody comprises an amino
acid other than Phe, Arg or Gly at position 405 and a Lys at
position 409. In another embodiment, said first antibody comprises
Phe at position 405 and an Arg at position 409 and said second
antibody comprises a Leu at position 405 and a Lys at position
409.
[0589] In a further embodiment of this method, said first antibody
comprises an amino acid other than Lys, Leu or Met at position 409
and said second homodimeric protein comprises a Lys at position
409, a Thr at position 370 and a Leu at position 405. In a further
embodiment, said first homodimeric protein comprises an Arg at
position 409 and said second homodimeric protein comprises a Lys at
position 409, a Thr at position 370 and a Leu at position 405.
[0590] In an even further embodiment of this method, said first
antibody comprises a Lys at position 370, a Phe at position 405 and
an Arg at position 409 and said second antibody comprises a Lys at
position 409, a Thr at position 370 and a Leu at position 405.
[0591] In another embodiment of this method, said first antibody
comprises an amino acid other than Lys, Leu or Met at position 409
and said second antibody comprises a Lys at position 409 and: a) an
Ile at position 350 and a Leu at position 405, or b) a Thr at
position 370 and a Leu at position 405.
[0592] In another embodiment of this method, said first antibody
comprises an Arg at position 409 and said second antibody comprises
a Lys at position 409 and: a) an Ile at position 350 and a Leu at
position 405, or b) a Thr at position 370 and a Leu at position
405.
[0593] In another embodiment of this method, said first antibody
comprises a Thr at position 350, a Lys at position 370, a Phe at
position 405 and an Arg at position 409 and said second antibody
comprises a Lys at position 409 and: a) an Ile at position 350 and
a Leu at position 405, or b) a Thr at position 370 and a Leu at
position 405.
[0594] In another embodiment of this method, said first antibody
comprises a Thr at position 350, a Lys at position 370, a Phe at
position 405 and an Arg at position 409 and said second comprises
an Ile at position 350, a Thr at position 370, a Leu at position
405 and a Lys at position 409.
[0595] In another embodiment of this method, said first antibody
has an amino acid other than Lys, Leu or Met at position 409 and
said second antibody has an amino acid other than Tyr, Asp, Glu,
Phe, Lys, Gln, Arg, Ser or Thr at position 407. In another
embodiment, said first antibody has an amino acid other than Lys,
Leu or Met at position 409 and said second antibody has an Ala,
Gly, His, Ile, Leu, Met, Asn, Val or Trp at position 407.
[0596] In another embodiment of this method, said first antibody
has an amino acid other than Lys, Leu or Met at position 409 and
said second antibody has a Gly, Leu, Met, Asn or Trp at position
407.
[0597] In another embodiment of this method, said first antibody
has a Tyr at position 407 and an amino acid other than Lys, Leu or
Met at position 409 and said second antibody has an amino acid
other than Tyr, Asp, Glu, Phe, Lys, Gln, Arg, Ser or Thr at
position 407 and a Lys at position 409.
[0598] In another embodiment of this method, said first antibody
has a Tyr at position 407 and an amino acid other than Lys, Leu or
Met at position 409 and said second antibody has an Ala, Gly, His,
Ile, Leu, Met, Asn, Val or Trp at position 407 and a Lys at
position 409.
[0599] In another embodiment of this method, said first antibody
has a Tyr at position 407 and an amino acid other than Lys, Leu or
Met at position 409 and said second antibody has a Gly, Leu, Met,
Asn or Trp at position 407 and a Lys at position 409.
[0600] In another embodiment of this method, said first antibody
has a Tyr at position 407 and an Arg at position 409 and said
second antibody has an amino acid other than Tyr, Asp, Glu, Phe,
Lys, Gln, Arg, Ser or Thr at position 407 and a Lys at position
409.
[0601] In another embodiment of this method, said first antibody
has a Tyr at position 407 and an Arg at position 409 and said
second antibody has an Ala, Gly, His, Ile, Leu, Met, Asn, Val or
Trp at position 407 and a Lys at position 409.
[0602] In another embodiment of this method, said first antibody
has a Tyr at position 407 and an Arg at position 409 and said
second antibody has a Gly, Leu, Met, Asn or Trp at position 407 and
a Lys at position 409.
[0603] In one embodiment of this method, the first antibody has an
amino acid other than Lys, Leu or Met at position 409, and the
second antibody has
(i) an amino acid other than Phe, Leu and Met at position 368, or
(ii) a Trp at position 370, or (iii) an amino acid other than Asp,
Cys, Pro, Glu or Gln at position 399, or (iv) an amino acid other
than Lys, Arg, Ser, Thr, or Trp at position 366.
[0604] In one embodiment of this method, the first homodimeric
protein has an Arg, Ala, His or Gly at position 409, and the second
homodimeric protein has
(i) a Lys, Gln, Ala, Asp, Glu, Gly, His, Ile, Asn, Arg, Ser, Thr,
Val, or Trp at position 368, or (ii) a Trp at position 370, or
(iii) an Ala, Gly, Ile, Leu, Met, Asn, Ser, Thr, Trp, Phe, His,
Lys, Arg or Tyr at position 399, or (iv) an Ala, Asp, Glu, His,
Asn, Val, Gln, Phe, Gly, Ile, Leu, Met, or Tyr at position 366.
[0605] In one embodiment of this method, the first homodimeric
protein has an Arg at position 409, and the second homodimeric
protein has
(i) an Asp, Glu, Gly, Asn, Arg, Ser, Thr, Val, or Trp at position
368, or (ii) a Trp at position 370, or (iii) a Phe, His, Lys, Arg
or Tyr at position 399, or (iv) an Ala, Asp, Glu, His, Asn, Val,
Gln at position 366.
[0606] In addition to the above-specified amino-acid substitutions,
said first and second homodimeric protein may contain further
amino-acid substitutions, deletion or insertions relative to
wild-type Fc sequences.
[0607] In a further embodiment, said first and second CH3 regions,
except for the specified mutations, comprise the sequences of
IgG1m(a) (SEQ ID NO:256), IgG1m(f) (SEQ ID NO:257), or IgG1m(ax)
(SEQ ID NO:258).
[0608] Thus, in one embodiment, neither said first nor said second
antibody comprises a Cys-Pro-Ser-Cys sequence in the (core) hinge
region.
[0609] In a further embodiment, both said first and said second
antibody comprise a Cys-Pro-Pro-Cys sequence in the (core) hinge
region.
[0610] The bispecific antibodies of the invention may also be
obtained by co-expression of constructs encoding the first and
second polypeptides in a single cell. Thus, in a further aspect,
the invention relates to a method for producing a bispecific
antibody, said method comprising the following steps:
[0611] a) providing a first nucleic-acid construct encoding a first
polypeptide comprising a first Fc region and a first
antigen-binding region of a first antibody heavy chain, said first
Fc region comprising a first CH3 region,
[0612] b) providing a second nucleic-acid construct encoding a
second polypeptide comprising a second Fc region and a second
antigen-binding region of a second antibody heavy chain, said
second Fc region comprising a first CH3 region,
[0613] wherein the sequences of said first and second CH3 regions
are different and are such that the heterodimeric interaction
between said first and second CH3 regions is stronger than each of
the homodimeric interactions of said first and second CH3 regions,
and
[0614] wherein said first homodimeric protein has an amino acid
other than Lys, Leu or Met at position 409 and said second
homodimeric protein has an amino-acid substitution at a position
selected from the group consisting of: 366, 368, 370, 399, 405 and
407,
[0615] optionally wherein said first and second nucleic acid
constructs encode light chain sequences of said first and second
antibodies
[0616] c) co-expressing said first and second nucleic-acid
constructs in a host cell, and
[0617] d) obtaining said heterodimeric protein from the cell
culture.
[0618] Thus, the present invention also relates to a recombinant
eukaryotic or prokaryotic host cell which produces a bispecific
antibody of the present invention.
[0619] In one embodiment of the present invention, the bispecific
antibody is obtained by any of the methods according to the present
invention.
[0620] Suitable expression vectors, including promoters, enhancers,
etc., and suitable host cells for the production of antibodies are
well-known in the art. Examples of host cells include yeast,
bacterial and mammalian cells, such as CHO or HEK cells.
[0621] In one embodiment of this method, said first CH3 region has
an amino acid other than Lys, Leu or Met at position 409 and said
second CH3 region has an amino acid other than Phe at position
405.
[0622] In another embodiment of this method, said first CH3 region
has an amino acid other than Lys, Leu or Met at position 409 and
said second CH3 region has an amino acid other than Phe at position
405, such as other than Phe, Arg or Gly at position 405; or said
first CH3 region has an amino acid other than Lys, Leu or Met at
position 409 and said second CH3 region has an amino acid other
than Tyr, Asp, Glu, Phe, Lys, Gln, Arg, Ser or Thr at position
407.
[0623] In some embodiments, said first and second polypeptides are
full-length heavy chains of two antibodies that bind different
epitopes (i.e. said first and second nucleic-acid constructs encode
full-length heavy chains of two antibodies that bind different
epitopes), and thus the heterodimeric protein is a bispecific
antibody. This bispecific antibody can be a heavy-chain antibody,
or said host cell may further express one or more nucleic-acid
constructs encoding a light-chain. If only one light-chain
construct is co-expressed with the heavy chain constructs, then a
functional bispecific antibody is only formed if the light chain
sequence is such that it can form a functional antigen-binding
domain with each of the heavy chains. If two or more different
light-chain constructs are co-expressed with the heavy chain,
multiple products will be formed.
[0624] In further embodiments, the co-expression method according
to the invention comprises any of the further features described
under the in vitro method above. In a further aspect, the invention
relates to an expression vector comprising the first and second
nucleic-acid constructs specified herein above. In a further
embodiment, the expression vector further comprises a nucleotide
sequence encoding the constant region of a light chain, a heavy
chain or both light and heavy chains of an antibody, e.g. a human
antibody.
[0625] An expression vector in the context of the present invention
may be any suitable vector, including chromosomal, non-chromosomal,
and synthetic nucleic acid vectors (a nucleic acid sequence
comprising a suitable set of expression control elements). Examples
of such vectors include derivatives of SV40, bacterial plasmids,
phage DNA, baculovirus, yeast plasmids, vectors derived from
combinations of plasmids and phage DNA, and viral nucleic acid (RNA
or DNA) vectors. In one embodiment, a HER2 antibody-encoding
nucleic acid is comprised in a naked DNA or RNA vector, including,
for example, a linear expression element (as described in for
instance Sykes and Johnston, Nat Biotech 17, 355-59 (1997)), a
compacted nucleic acid vector (as described in for instance U.S.
Pat. No. 6,077,835 and/or WO 00/70087), a plasmid vector such as
pBR322, pUC 19/18, or pUC 118/119, a "midge" minimally-sized
nucleic acid vector (as described in for instance Schakowski et
al., Mol Ther 3, 793-800 (2001)), or as a precipitated nucleic acid
vector construct, such as a CaP04-precipitated construct (as
described in for instance WO 00/46147, Benvenisty and Reshef, PNAS
USA 83, 9551-55 (1986), Wigler et al., Cell 14, 725 (1978), and
Coraro and Pearson, Somatic Cell Genetics 7, 603 (1981)). Such
nucleic acid vectors and the usage thereof are well known in the
art (see for instance U.S. Pat. No. 5,589,466 and U.S. Pat. No.
5,973,972).
[0626] Exemplary expression vectors for the antibodies of the
invention are also described in Examples 2 and 3.
[0627] In one embodiment, the vector is suitable for expression of
the HER2 antibody in a bacterial cell. Examples of such vectors
include expression vectors such as BlueScript (Stratagene), pIN
vectors (Van Heeke & Schuster, J Biol Chem 264, 5503-5509
(1989), pET vectors (Novagen, Madison Wis.) and the like).
[0628] An expression vector may also or alternatively be a vector
suitable for expression in a yeast system. Any vector suitable for
expression in a yeast system may be employed. Suitable vectors
include, for example, vectors comprising constitutive or inducible
promoters such as alpha factor, alcohol oxidase and PGH (reviewed
in: F. Ausubel et al., ed. Current Protocols in Molecular Biology,
Greene Publishing and Wiley InterScience New York (1987), and Grant
et al., Methods in Enzymol 153, 516-544 (1987)).
[0629] An expression vector may also or alternatively be a vector
suitable for expression in mammalian cells, e.g. a vector
comprising glutamine synthetase as a selectable marker, such as the
vectors described in Bebbington (1992) Biotechnology (NY)
10:169-175.
[0630] A nucleic acid and/or vector may also comprises a nucleic
acid sequence encoding a secretion/localization sequence, which can
target a polypeptide, such as a nascent polypeptide chain, to the
periplasmic space or into cell culture media. Such sequences are
known in the art, and include secretion leader or signal
peptides.
[0631] The expression vector may comprise or be associated with any
suitable promoter, enhancer, and other expression-facilitating
elements. Examples of such elements include strong expression
promoters (e. g., human CMV IE promoter/enhancer as well as RSV,
SV40, SL3-3, MMTV, and HIV LTR promoters), effective poly (A)
termination sequences, an origin of replication for plasmid product
in E. coli, an antibiotic resistance gene as selectable marker,
and/or a convenient cloning site (e.g., a polylinker). Nucleic
acids may also comprise an inducible promoter as opposed to a
constitutive promoter such as CMV IE.
[0632] In one embodiment, the HER2 antibody-encoding expression
vector may be positioned in and/or delivered to the host cell or
host animal via a viral vector.
[0633] In an even further aspect, the invention relates to a host
cell comprising the first and second nucleic-acid constructs
specified herein above.
[0634] Thus the present invention also relates to a recombinant
eukaryotic or prokaryotic host cell which produces a bispecific
antibody of the present invention, such as a transfectoma.
[0635] The first HER2 antibody may be expressed in a recombinant
eukaryotic or prokaryotic host cell, such as a transfectoma,
[0636] Examples of host cells include yeast, bacterial, and
mammalian cells, such as CHO or HEK cells. For example, in one
embodiment, the host cell may comprise a first and second nucleic
acid construct stably integrated into the cellular genome. In
another embodiment, the present invention provides a cell
comprising a non-integrated nucleic acid, such as a plasmid,
cosmid, phagemid, or linear expression element, which comprises a
first and second nucleic acid construct as specified above.
[0637] In an even further aspect, the invention relates to a
transgenic non-human animal or plant comprising nucleic acids
encoding one or two sets of a human heavy chain and a human light
chain, wherein the animal or plant produces an bispecific antibody
of the invention of the invention.
[0638] In a further aspect, the invention relates to a hybridoma
which produces an antibody of the invention as defined herein. In
an even further aspect, the invention relates to a transgenic
non-human animal or plant comprising nucleic acids encoding one or
two sets of a human heavy chain and a human light chain, wherein
the animal or plant produces an bispecific antibody of the
invention of the invention.
[0639] In a further aspect, the invention relates to a method for
producing a HER2.times.CD3 antibody of the invention, said method
comprising the steps of
a) culturing a host cell of the invention as described herein
above, and b) purifying the antibody of the invention from the
culture media.
[0640] Preparation of HER2 and CD3 antibodies Depending on the
method for production of a bispecific antibody according to the
present invention, it may be relevant to first produce bivalent,
monospecifc antibodies. This may for example be relevant if the
bispecific antibody is produced as described above which methods
are based on the mixing of two bivalent monospecific antibodies
under reducing conditions.
[0641] Monoclonal antibodies, such as the HER2 antibody, for use in
the present invention, for example to provide an antigen-binding
region sharing an epitope or cross-blocking region with an antibody
of cross-block groups 1, 2, 3 or 4 may be produced, e.g., by the
hybridoma method first described by Kohler et al., Nature 256, 495
(1975), or may be produced by recombinant DNA methods. Monoclonal
antibodies may also be isolated from phage antibody libraries using
the techniques described in, for example, Clackson et al., Nature
352, 624-628 (1991) and Marks et al., J. Mol. Biol. 222, 581-597
(1991). Monoclonal antibodies may be obtained from any suitable
source. Thus, for example, monoclonal antibodies may be obtained
from hybridomas prepared from murine splenic B cells obtained from
mice immunized with an antigen of interest, for instance in form of
cells expressing the antigen on the surface, or a nucleic acid
encoding an antigen of interest. Monoclonal antibodies may also be
obtained from hybridomas derived from antibody-expressing cells of
immunized humans or non-human mammals such as rats, dogs, primates,
etc.
[0642] In one embodiment, the antibody is a human antibody. Human
monoclonal antibodies directed against HER2 or CD3 may be generated
using transgenic or transchromosomal mice carrying parts of the
human immune system rather than the mouse system. Such transgenic
and transchromosomic mice include mice referred to herein as
HuMAb.RTM. mice and KM mice, respectively, and are collectively
referred to herein as "transgenic mice".
[0643] The HuMAb.RTM. mouse contains a human immunoglobulin gene
miniloci that encodes unrearranged human heavy (.mu. and .gamma.)
and .kappa. light chain immunoglobulin sequences, together with
targeted mutations that inactivate the endogenous .mu. and .kappa.
chain loci (Lonberg, N. et al., Nature 368, 856-859 (1994)).
Accordingly, the mice exhibit reduced expression of mouse IgM or K
and in response to immunization, the introduced human heavy and
light chain transgenes, undergo class switching and somatic
mutation to generate high affinity human IgG,.kappa. monoclonal
antibodies (Lonberg, N. et al. (1994), supra; reviewed in Lonberg,
N. Handbook of Experimental Pharmacology 113, 49-101 (1994),
Lonberg, N. and Huszar, D., Intern. Rev. Immunol. Vol. 13 65-93
(1995) and Harding, F. and Lonberg, N. Ann. N.Y. Acad. Sci 764
536-546 (1995)). The preparation of HuMAb mice is described in
detail in Taylor, L. et al., Nucleic Acids Research 20, 6287-6295
(1992), Chen, J. et al., International Immunology 5, 647-656
(1993), Tuaillon et al., J. Immunol. 152, 2912-2920 (1994), Taylor,
L. et al., International Immunology 6, 579-591 (1994), Fishwild, D.
et al., Nature Biotechnology 14, 845-851 (1996). See also U.S. Pat.
No. 5,545,806, U.S. Pat. No. 5,569,825, U.S. Pat. No. 5,625,126,
U.S. Pat. No. 5,633,425, U.S. Pat. No. 5,789,650, U.S. Pat. No.
5,877,397, U.S. Pat. No. 5,661,016, U.S. Pat. No. 5,814,318, U.S.
Pat. No. 5,874,299, U.S. Pat. No. 5,770,429, U.S. Pat. No.
5,545,807, WO 98/24884, WO 94/25585, WO 93/1227, WO 92/22645, WO
92/03918 and WO 01/09187.
[0644] The HCo7, HCo12, HCo17 and HCo20 mice have a JKD disruption
in their endogenous light chain (kappa) genes (as described in Chen
et al., EMBO J. 12, 821-830 (1993)), a CMD disruption in their
endogenous heavy chain genes (as described in Example 1 of WO
01/14424), and a KCo5 human kappa light chain transgene (as
described in Fishwild et al., Nature Biotechnology 14, 845-851
(1996)). Additionally, the Hco7 mice have a HCo7 human heavy chain
transgene (as described in U.S. Pat. No. 5,770,429), the HCo12 mice
have a HCo12 human heavy chain transgene (as described in Example 2
of WO 01/14424), the HCo17 mice have a HCo17 human heavy chain
transgene (as described in Example 2 of WO 01/09187) and the HCo20
mice have a HCo20 human heavy chain transgene. The resulting mice
express human immunoglobulin heavy and kappa light chain transgenes
in a background homozygous for disruption of the endogenous mouse
heavy and kappa light chain loci.
[0645] In the KM mouse strain, the endogenous mouse kappa light
chain gene has been homozygously disrupted as described in Chen et
al., EMBO J. 12, 811-820 (1993) and the endogenous mouse heavy
chain gene has been homozygously disrupted as described in Example
1 of WO 01/09187. This mouse strain carries a human kappa light
chain transgene, KCo5, as described in Fishwild et al., Nature
Biotechnology 14, 845-851 (1996). This mouse strain also carries a
human heavy chain transchromosome composed of chromosome 14
fragment hCF (SC20) as described in WO 02/43478. HCo12-Balb/C mice
can be generated by crossing HCo12 to KCo5[J/K](Balb) as described
in WO/2009/097006.
[0646] Splenocytes from these transgenic mice may be used to
generate hybridomas that secrete human monoclonal antibodies
according to well known techniques.
[0647] Further, HER2 antigen-binding regions may be obtained from
human antibodies or antibodies from other species identified
through display-type technologies, including, without limitation,
phage display, retroviral display, ribosomal display, and other
techniques, using techniques well known in the art and the
resulting molecules may be subjected to additional maturation, such
as affinity maturation, as such techniques are well known in the
art (see for instance Hoogenboom et al., J. Mol. Biol. 227, 381
(1991) (phage display), Vaughan et al., Nature Biotech 14, 309
(1996) (phage display), Hanes and Plucthau, PNAS USA 94, 4937-4942
(1997) (ribosomal display), Parmley and Smith, Gene 73, 305-318
(1988) (phage display), Scott TIBS 17, 241-245 (1992), Cwirla et
al., PNAS USA 87, 6378-6382 (1990), Russel et al., Nucl. Acids
Research 21, 1081-1085 (1993), Hogenboom et al., Immunol. Reviews
130, 43-68 (1992), Chiswell and McCafferty TIBTECH 10, 80-84
(1992), and U.S. Pat. No. 5,733,743). If display technologies are
utilized to produce antibodies that are not human, such antibodies
may be humanized.
[0648] The bispecific antibody of the invention can be of any
isotype. The choice of isotype typically will be guided by the
desired effector functions, such as ADCC induction. Exemplary
isotypes are IgG1, IgG2, IgG3, and IgG4. Either of the human light
chain constant regions, kappa or lambda, may be used. The effector
function of the antibodies of the present invention may be changed
by isotype switching to, e.g., an IgG1, IgG2, IgG3, IgG4, IgD, IgA,
IgE, or IgM antibody for various therapeutic uses. In one
embodiment, both Fc-regions of an antibody of the present invention
are of the IgG1 isotype, for instance an IgG1,.kappa.. In one
embodiment, the two Fc-regions of a bispecific antibody are of the
IgG1 and IgG4 isotypes, respectively. Optionally, the Fc-region may
be modified in the hinge and/or CH3 region as described elsewhere
herein.
[0649] In one embodiment, the bispecific antibody of the invention
is a full-length antibody, preferably an IgG1 antibody, in
particular an IgG1,.kappa. antibody or a variant thereof. In
another embodiment, the bispecific antibody of the invention
comprises an antibody fragment or a single-chain antibody. Antibody
fragments may e.g. be obtained by fragmentation using conventional
techniques, and the fragments screened for utility in the same
manner as described herein for whole antibodies. For example,
F(ab').sub.2 fragments may be generated by treating an antibody
with pepsin. The resulting F(ab').sub.2 fragment may be treated to
reduce disulfide bridges with a reducing agent, such as
dithiothreitol, to produce Fab' fragments. Fab fragments may be
obtained by treating an antibody with papain. A F(ab').sub.2
fragment may also be produced by binding Fab' fragments via a
thioether bond or a disulfide bond. Antibody fragments may also be
generated by expression of nucleic acids encoding such fragments in
recombinant cells (see for instance Evans et al., J. Immunol. Meth.
184, 123-38 (1995)). For example, a chimeric gene encoding a
portion of an F(ab').sub.2 fragment could include DNA sequences
encoding the C.sub.H1 domain and hinge region of the H chain,
followed by a translational stop codon to yield such a truncated
antibody fragment molecule.
[0650] Bispecific HER2.times.CD3 antibodies of the invention may
also be prepared from single chain antibodies. Single chain
antibodies are peptides in which the heavy and light chain Fv
regions are connected. In one embodiment, the bispecific antibody
of the present invention comprises a single-chain Fv (scFv) wherein
the heavy and light chains in the Fv of a HER2 antibody of the
present invention are joined with a flexible peptide linker
(typically of about 10, 12, 15 or more amino acid residues) in a
single peptide chain. Methods of producing such antibodies are
described in for instance U.S. Pat. No. 4,946,778, Pluckthun in The
Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and
Moore eds. Springer-Verlag, New York, pp. 269-315 (1994), Bird et
al., Science 242, 423-426 (1988), Huston et al., PNAS USA 85,
5879-5883 (1988) and McCafferty et al., Nature 348, 552-554 (1990).
A bispecific antibody can then be formed from two V.sub.H and
V.sub.L from a single-chain HER2 antibody and a single-chain CD3
antibody, or a polyvalent antibody formed from more than two
V.sub.H and V.sub.L chains.
[0651] In one embodiment, one or both Fc-regions of the HER2 and
CD3 mAbs for producing a bispecific antibody of the invention are
effector-function-deficient. In one embodiment, the
effector-function-deficient antibody is a human stabilized IgG4
antibody, which has been modified to prevent Fab-arm exchange (van
der Neut Kolfschoten et al. (2007) Science 317(5844):1554-7).
Examples of suitable human stabilized IgG4 antibodies are
antibodies, wherein arginine at position 409 in a heavy chain
constant region of human IgG4, which is indicated in the EU index
described in Kabat et al., is substituted with lysine, threonine,
methionine, or leucine, preferably lysine (described in
WO2006033386 (Kirin)) and/or wherein the hinge region has been
modified to comprise a Cys-Pro-Pro-Cys sequence.
[0652] In one embodiment, the stabilized IgG4 antibody is an IgG4
antibody comprising a heavy chain and a light chain, wherein said
heavy chain comprises a human IgG4 constant region having a residue
selected from the group consisting of: Lys, Ala, Thr, Met and Leu
at the position corresponding to 409 and/or a residue selected from
the group consisting of: Ala, Val, Gly, Ile and Leu at the position
corresponding to 405, and wherein said antibody optionally
comprises one or more further substitutions, deletions and/or
insertions, but does not comprise a Cys-Pro-Pro-Cys sequence in the
hinge region. Preferably, said antibody comprises a Lys or Ala
residue at the position corresponding to 409 or the CH3 region of
the antibody has been replaced by the CH3 region of human IgG1, of
human IgG2 or of human IgG3. See also WO2008145142 (Genmab) and WO
211131746 (Genmab).
[0653] In an even further embodiment, the stabilized IgG4 antibody
is an IgG4 antibody comprising a heavy chain and a light chain,
wherein said heavy chain comprises a human IgG4 constant region
having a residue selected from the group consisting of: Lys, Ala,
Thr, Met and Leu at the position corresponding to 409 and/or a
residue selected from the group consisting of: Ala, Val, Gly, Ile
and Leu at the position corresponding to 405, and wherein said
antibody optionally comprises one or more further substitutions,
deletions and/or insertions and wherein said antibody comprises a
Cys-Pro-Pro-Cys sequence in the hinge region. Preferably, said
antibody comprises a Lys or Ala residue at the position
corresponding to 409 or the CH3 region of the antibody has been
replaced by the CH3 region of human IgG1, of human IgG2 or of human
IgG3.
[0654] In a further embodiment, the effector-function-deficient
antibody is an antibody of a non-IgG4 type, e.g. IgG1, IgG2 or IgG3
which has been mutated such that the ability to mediate effector
functions, such as ADCC, has been reduced or even eliminated. Such
mutations have e.g. been described in Dall'Acqua W F et al., J
Immunol. 177(2):1129-1138 (2006) and Hezareh M, J Virol.;
75(24):12161-12168 (2001).
Conjugates
[0655] In a further aspect, the present invention provides a
bispecific HER2.times.CD3 antibody linked or conjugated to one or
more therapeutic moieties, such as a cytotoxin, a chemotherapeutic
drug, a cytokine, an immunosuppressant, and/or a radioisotope. Such
conjugates are referred to herein as "immunoconjugates" or "drug
conjugates". Immunoconjugates which include one or more cytotoxins
are referred to as "immunotoxins".
Compositions
[0656] In a further main aspect, the invention relates to a
pharmaceutical composition comprising:
[0657] a bispecific HER2.times.CD3 antibody as defined herein,
and
[0658] a pharmaceutically-acceptable carrier.
[0659] The pharmaceutical composition of the present invention may
contain one bispecific antibody of the present invention or a
combination of different bispecific antibodies of the present
invention.
[0660] The pharmaceutical compositions may be formulated in
accordance with conventional techniques such as those disclosed in
Remington: The Science and Practice of Pharmacy, 19th Edition,
Gennaro, Ed., Mack Publishing Co., Easton, Pa., 1995. A
pharmaceutical composition of the present invention may e.g.
include diluents, fillers, salts, buffers, detergents (e. g., a
nonionic detergent, such as Tween-20 or Tween-80), stabilizers (e.
g., sugars or protein-free amino acids), preservatives, tissue
fixatives, solubilizers, and/or other materials suitable for
inclusion in a pharmaceutical composition.
[0661] Pharmaceutically acceptable carriers include any and all
suitable solvents, dispersion media, coatings, antibacterial and
antifungal agents, isotonicity agents, antioxidants and absorption
delaying agents, and the like that are physiologically compatible
with a bispecific antibody of the present invention. Examples of
suitable aqueous and nonaqueous carriers which may be employed in
the pharmaceutical compositions of the present invention include
water, saline, phosphate buffered saline, ethanol, dextrose,
polyols (such as glycerol, propylene glycol, polyethylene glycol,
and the like), and suitable mixtures thereof, vegetable oils,
carboxymethyl cellulose colloidal solutions, tragacanth gum and
injectable organic esters, such as ethyl oleate, and/or various
buffers. Pharmaceutically acceptable carriers include sterile
aqueous solutions or dispersions and sterile powders for the
extemporaneous preparation of sterile injectable solutions or
dispersion. Proper fluidity may be maintained, for example, by the
use of coating materials, such as lecithin, by the maintenance of
the required particle size in the case of dispersions, and by the
use of surfactants.
[0662] Pharmaceutical bispecific antibodies of the present
invention may also comprise pharmaceutically acceptable
antioxidants for instance (1) water soluble antioxidants, such as
ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium
metabisulfite, sodium sulfite and the like; (2) oil-soluble
antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole,
butylated hydroxytoluene, lecithin, propyl gallate,
alpha-tocopherol, and the like; and (3) metal chelating agents,
such as citric acid, ethylenediamine tetraacetic acid (EDTA),
sorbitol, tartaric acid, phosphoric acid, and the like.
[0663] Pharmaceutical bispecific antibodies of the present
invention may also comprise isotonicity agents, such as sugars,
polyalcohols, such as mannitol, sorbitol, glycerol or sodium
chloride in the compositions.
[0664] The pharmaceutical bispecific antibodies of the present
invention may also contain one or more adjuvants appropriate for
the chosen route of administration such as preservatives, wetting
agents, emulsifying agents, dispersing agents, preservatives or
buffers, which may enhance the shelf life or effectiveness of the
pharmaceutical composition. The bispecific antibodies of the
present invention may be prepared with carriers that will protect
the bispecific antibody against rapid release, such as a controlled
release formulation, including implants, transdermal patches, and
microencapsulated delivery systems. Such carriers may include
gelatin, glyceryl monostearate, glyceryl distearate, biodegradable,
biocompatible polymers such as ethylene vinyl acetate,
polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and
polylactic acid alone or with a wax, or other materials well known
in the art. Methods for the preparation of such formulations are
generally known to those skilled in the art.
[0665] Sterile injectable solutions may be prepared by
incorporating the active compound in the required amount in an
appropriate solvent with one or a combination of ingredients e.g.
as enumerated above, as required, followed by sterilization
microfiltration. Generally, dispersions are prepared by
incorporating the active compound into a sterile vehicle that
contains a basic dispersion medium and the required other
ingredients e.g. from those enumerated above. In the case of
sterile powders for the preparation of sterile injectable
solutions, examples of methods of preparation are vacuum drying and
freeze-drying (lyophilization) that yield a powder of the active
ingredient plus any additional desired ingredient from a previously
sterile-filtered solution thereof.
[0666] The actual dosage levels of the active ingredients in the
pharmaceutical compositions may be varied so as to obtain an amount
of the active ingredient which is effective to achieve the desired
therapeutic response for a particular patient, composition, and
mode of administration, without being toxic to the patient. The
selected dosage level will depend upon a variety of pharmacokinetic
factors including the activity of the particular compositions of
the present invention employed, or the amide thereof, the route of
administration, the time of administration, the rate of excretion
of the particular compound being employed, the duration of the
treatment, other drugs, compounds and/or materials used in
combination with the particular compositions employed, the age,
sex, weight, condition, general health and prior medical history of
the patient being treated, and like factors well known in the
medical arts.
[0667] The pharmaceutical composition may be administered by any
suitable route and mode. In one embodiment, a pharmaceutical
composition of the present invention is administered parenterally.
"Administered parenterally" as used herein means modes of
administration other than enteral and topical administration,
usually by injection, and include epidermal, intravenous,
intramuscular, intraarterial, intrathecal, intracapsular,
intraorbital, intracardiac, intradermal, intraperitoneal,
intratendinous, transtracheal, subcutaneous, subcuticular,
intraarticular, subcapsular, subarachnoid, intraspinal,
intracranial, intrathoracic, epidural and intrasternal injection
and infusion.
[0668] In one embodiment that pharmaceutical composition is
administered by intravenous or subcutaneous injection or
infusion.
Uses
[0669] In a further main aspect, the invention relates to a
bispecific HER2.times.CD3 antibody of the invention for use as a
medicament.
[0670] The bispecific antibodies of the invention may be used for a
number of purposes. In particular, the antibodies of the invention
may be used for the treatment of various forms of cancer, including
metastatic cancer and refractory cancer.
[0671] In one embodiment, the bispecific antibodies of the
invention are used for the treatment of breast cancer, including
primary, metastatic, and refractory breast cancer.
[0672] In one embodiment, the bispecific antibodies of the
invention are used for the treatment of a form of cancer selected
from the group consisting of prostate cancer, non-small cell lung
cancer, bladder cancer, ovarian cancer, gastric cancer, colorectal
cancer, esophageal cancer, squamous cell carcinoma of the head
& neck, cervical cancer, pancreatic cancer, testis cancer,
malignant melanoma and a soft-tissue cancer (e.g. synovial
sarcoma).
[0673] Similarly, the invention relates to a method for killing a
tumor cell expressing HER2, comprising administration, to an
individual in need thereof, of an effective amount of an antibody
of the invention, such as an antibody drug-conjugate (ADC).
[0674] The present invention also relates to a method for
inhibiting growth and/or proliferation of one or more tumor cells
expressing HER2, comprising administration, to an indicidual in
need thereof, of a bispecific antibody of the present
invention.
[0675] The present invention alto relates to a method for treating
cancer, comprising [0676] a) selecting a subject suffering from a
cancer comprising rumor cells co-expressing HER2, and [0677] b)
administering to the subject the bispecific antibody of the present
invention or a pharmaceutical composition of the present
invention.
[0678] In one embodiment, said tumor cell is involved in a form of
cancer selected from the group consisting of: breast cancer,
prostate cancer, non-small cell lung cancer, bladder cancer,
ovarian cancer, gastric cancer, colorectal cancer, esophageal
cancer and squamous cell carcinoma of the head & neck, cervical
cancer, pancreatic cancer, testis cancer, malignant melanoma, and a
soft-tissue cancer (e.g., synovial sarcoma).
[0679] In one embodiment, the tumor cell is one that co-expresses
HER2, and is a tumor cell involved in breast cancer, colorectal
cancer, endometrial/cervical cancer, lung cancer, malignant
melanoma, ovarian cancer, pancreatic cancer, prostate cancer,
testis cancer, a soft-tissue tumor (e.g., synovial sarcoma), or
bladder cancer.
[0680] In one aspect, the invention relates to a method for
treating cancer in a subject, comprising selecting a subject
suffering from a cancer comprising tumor cells expressing HER2, and
administering to the subject a bispecific antibody of the
invention. In one embodiment, the subject suffers from a cancer
selected from the group consisting of breast cancer, colorectal
cancer, endometrial/cervical cancer, lung cancer, malignant
melanoma, ovarian cancer, pancreatic cancer, prostate cancer,
testis cancer, a soft-tissue tumor (e.g., synovial sarcoma), or
bladder cancer.
[0681] Also, the invention relates to the use of a bispecific
antibody that binds to human HER2 and human CD3 for the preparation
of a medicament for the treatment of cancer, such as one of the
specific cancer indications mentioned above.
[0682] The invention further relates to a bispecific antibody for
use in the treatment of cancer, such as one of the cancer
indications mentioned above.
[0683] In a further embodiment of the methods of treatment of the
present invention, the efficacy of the treatment is being monitored
during the therapy, e.g. at predefined points in time, by
determining tumor burden or HER2 expression levels on the relevant
tumor cells.
[0684] Dosage regimens in the above methods of treatment and uses
are adjusted to provide the optimum desired response (e.g., a
therapeutic response). For example, a single bolus may be
administered, several divided doses may be administered over time
or the dose may be proportionally reduced or increased as indicated
by the exigencies of the therapeutic situation. Parenteral
compositions may be formulated in dosage unit form for ease of
administration and uniformity of dosage.
[0685] The efficient dosages and the dosage regimens for the
bispecific antibodies depend on the disease or condition to be
treated and may be determined by the persons skilled in the art. An
exemplary, non-limiting range for a therapeutically effective
amount of a compound of the present invention is about 0.001-10
mg/kg, such as about 0.001-5 mg/kg, for example about 0.001-2
mg/kg, such as about 0.001-1 mg/kg, for instance about 0.001, about
0.01, about 0.1, about 1 or about 10 mg/kg.
[0686] A physician or veterinarian having ordinary skill in the art
may readily determine and prescribe the effective amount of the
pharmaceutical composition required. For example, the physician or
veterinarian could start doses of the bispecific antibody employed
in the pharmaceutical composition at levels lower than that
required in order to achieve the desired therapeutic effect and
gradually increase the dosage until the desired effect is achieved.
In general, a suitable daily dose of a bispecific antibody of the
present invention will be that amount of the compound which is the
lowest dose effective to produce a therapeutic effect.
Administration may e.g. be parenteral, such as intravenous,
intramuscular or subcutaneous. In one embodiment, the bispecific
antibodies may be administered by infusion in a weekly dosage of
calculated by mg/m.sup.2. Such dosages can, for example, be based
on the mg/kg dosages provided above according to the following:
dose (mg/kg).times.70: 1.8. Such administration may be repeated,
e.g., 1 to 8 times, such as 3 to 5 times. The administration may be
performed by continuous infusion over a period of from 2 to 24
hours, such as of from 2 to 12 hours. In one embodiment, the
bispecific antibodies may be administered by slow continuous
infusion over a long period, such as more than 24 hours, in order
to reduce toxic side effects.
[0687] In one embodiment the bispecific antibodies may be
administered in a weekly dosage of calculated as a fixed dose for
up to 8 times, such as from 4 to 6 times when given once a week.
Such regimen may be repeated one or more times as necessary, for
example, after 6 months or 12 months. Such fixed dosages can, for
example, be based on the mg/kg dosages provided above, with a body
weight estimate of 70 kg. The dosage may be determined or adjusted
by measuring the amount of bispecific antibody of the present
invention in the blood upon administration by for instance taking
out a biological sample and using anti-idiotypic antibodies which
target the HER2 antigen binding region of the bispecific antibodies
of the present invention.
[0688] In one embodiment, the bispecific antibodies may be
administered by maintenance therapy, such as, e.g., once a week for
a period of 6 months or more.
[0689] A bispecific antibody may also be administered
prophylactically in order to reduce the risk of developing cancer,
delay the onset of the occurrence of an event in cancer
progression, and/or reduce the risk of recurrence when a cancer is
in remission.
[0690] The bispecific antibodies of the invention may also be
administered in combination therapy, i.e., combined with other
therapeutic agents relevant for the disease or condition to be
treated. Accordingly, in one embodiment, the antibody-containing
medicament is for combination with one or more further therapeutic
agent, such as a cytotoxic, chemotherapeutic or anti-angiogenic
agent.
[0691] Such combined administration may be simultaneous, separate
or sequential. For simultaneous administration the agents may be
administered as one composition or as separate compositions, as
appropriate. The present invention thus also provides methods for
treating a disorder involving cells expressing HER2 as described
above, which methods comprise administration of a bispecific
antibody of the present invention combined with one or more
additional therapeutic agents as described below.
[0692] In one embodiment, the present invention provides a method
for treating a disorder involving cells expressing HER2 in a
subject, which method comprises administration of a therapeutically
effective amount of a bispecific antibody of the present invention,
and optionally at least one additional therapeutic agent, or an
antibody binding to a different HER2 epitope than said antibody, to
a subject in need thereof.
[0693] In one embodiment, the present invention provides a method
for treating or preventing cancer, which method comprises
administration of a therapeutically effective amount of a
bispecific antibody of the present invention and at least one
additional therapeutic agent to a subject in need thereof.
[0694] In one embodiment, such an additional therapeutic agent may
be selected from an antimetabolite, such as methotrexate,
6-mercaptopurine, 6-thioguanine, cytarabine, fludarabine,
5-fluorouracil, decarbazine, hydroxyurea, asparaginase, gemcitabine
or cladribine.
[0695] In another embodiment, such an additional therapeutic agent
may be selected from an alkylating agent, such as mechlorethamine,
thioepa, chlorambucil, melphalan, carmustine (BSNU), lomustine
(CCNU), cyclophosphamide, busulfan, dibromomannitol,
streptozotocin, dacarbazine (DTIC), procarbazine, mitomycin C,
cisplatin and other platinum derivatives, such as carboplatin.
[0696] In another embodiment, such an additional therapeutic agent
may be selected from an anti-mitotic agent, such as taxanes, for
instance docetaxel, and paclitaxel, and vinca alkaloids, for
instance vindesine, vincristine, vinblastine, and vinorelbine.
[0697] In another embodiment, such an additional therapeutic agent
may be selected from a topoisomerase inhibitor, such as topotecan
or irinotecan, or a cytostatic drug, such as etoposide and
teniposide.
[0698] In another embodiment, such an additional therapeutic agent
may be selected from a growth factor inhibitor, such as an
inhibitor of ErbB1 (EGFR) (such as an EGFR antibody, e.g.
zalutumumab, cetuximab, panitumumab or nimotuzumab or other EGFR
inhibitors, such as gefitinib or erlotinib), another inhibitor of
ErbB2 (HER2/neu) (such as a HER2 antibody, e.g. trastuzumab,
trastuzumab-DM1 or pertuzumab) or an inhibitor of both EGFR and
HER2, such as lapatinib).
[0699] In another embodiment, such an additional therapeutic agent
may be selected from a tyrosine kinase inhibitor, such as imatinib
(Glivec, Gleevec STI571) or lapatinib, PTK787/ZK222584.
[0700] In another embodiment, the present invention provides a
method for treating a disorder involving cells expressing HER2 in a
subject, which method comprises administration of a therapeutically
effective amount of a bispecific antibody of the present invention
and at least one inhibitor of angiogenesis, neovascularization,
and/or other vascularization to a subject in need thereof
[0701] Examples of such angiogenesis inhibitors are urokinase
inhibitors, matrix metalloprotease inhibitors (such as marimastat,
neovastat, BAY 12-9566, AG 3340, BMS-275291 and similar agents),
inhibitors of endothelial cell migration and proliferation (such as
TNP-470, squalamine, 2-methoxyestradiol, combretastatins,
endostatin, angiostatin, penicillamine, SCH66336 (Schering-Plough
Corp, Madison, N.J.), R115777 (Janssen Pharmaceutica, Inc,
Titusville, N.J.) and similar agents), antagonists of angiogenic
growth factors (such as such as ZD6474, SU6668, antibodies against
angiogenic agents and/or their receptors (such as VEGF (e.g.
bevacizumab), bFGF, and angiopoietin-1), thalidomide, thalidomide
analogs (such as CC-5013), Sugen 5416, SU5402, antiangiogenic
ribozyme (such as angiozyme), interferon .alpha. (such as
interferon .alpha.2a), suramin and similar agents), VEGF-R kinase
inhibitors and other anti-angiogenic tyrosine kinase inhibitors
(such as SU011248), inhibitors of endothelial-specific
integrin/survival signaling (such as vitaxin and similar agents),
copper antagonists/chelators (such as tetrathiomolybdate, captopril
and similar agents), carboxyamido-triazole (CAI), ABT-627, CM101,
interleukin-12 (IL-12), IM862, PNU145156E as well as nucleotide
molecules inhibiting angiogenesis (such as antisense-VEGF-cDNA,
cDNA coding for angiostatin, cDNA coding for p53 and cDNA coding
for deficient VEGF receptor-2).
[0702] Other examples of such inhibitors of angiogenesis,
neovascularization, and/or other vascularization are
anti-angiogenic heparin derivatives (e.g., heperinase III),
temozolomide, NK4, macrophage migration inhibitory factor,
cyclooxygenase-2 inhibitors, inhibitors of hypoxia-inducible factor
1, anti-angiogenic soy isoflavones, oltipraz, fumagillin and
analogs thereof, somatostatin analogues, pentosan polysulfate,
tecogalan sodium, dalteparin, tumstatin, thrombospondin, NM-3,
combrestatin, canstatin, avastatin, antibodies against other
targets, such as anti-alpha-v/beta-3 integrin and anti-kininostatin
antibodies.
[0703] In one embodiment, a therapeutic agent for use in
combination with a bispecific antibody for treating the disorders
as described above may be an anti-cancer immunogen, such as a
cancer antigen/tumor-associated antigen (e.g., epithelial cell
adhesion molecule (EpCAM/TACSTD1), mucin 1 (MUC1), carcinoembryonic
antigen (CEA), tumor-associated glycoprotein 72 (TAG-72), gp100,
Melan-A, MART-1, KDR, RCAS1, MDA7, cancer-associated viral vaccines
(e.g., human papillomavirus vaccines) or tumor-derived heat shock
proteins,
[0704] In one embodiment, a therapeutic agent for use in
combination with a bispecific antibody for treating the disorders
as described above may be an anti-cancer cytokine, chemokine, or
combination thereof. Examples of suitable cytokines and growth
factors include IFN.gamma., IL-2, IL-4, IL-6, IL-7, IL-10, IL-12,
IL-13, IL-15, IL-18, IL-23, IL-24, IL-27, IL-28a, IL-28b, IL-29,
KGF, IFN.alpha. (e.g., INF.alpha.2b), IFN.beta., GM-CSF, CD40L,
Flt3 ligand, stem cell factor, ancestim, and TNF.alpha.. Suitable
chemokines may include Glu-Leu-Arg (ELR)-negative chemokines such
as IP-10, MCP-3, MIG, and SDF-1a from the human CXC and C-C
chemokine families. Suitable cytokines include cytokine
derivatives, cytokine variants, cytokine fragments, and cytokine
fusion proteins.
[0705] In one embodiment, a therapeutic agent for use in
combination with a bispecific antibody for treating the disorders
as described above may be a cell cycle control/apoptosis regulator
(or "regulating agent"). A cell cycle control/apoptosis regulator
may include molecules that target and modulate cell cycle
control/apoptosis regulators such as (i) cdc-25 (such as NSC
663284), (ii) cyclin-dependent kinases that overstimulate the cell
cycle (such as flavopiridol (L868275, HMR1275),
7-hydroxystaurosporine (UCN-01, KW-2401), and roscovitine
(R-roscovitine, CYC202)), and (iii) telomerase modulators (such as
BIBR1532, SOT-095, GRN163 and compositions described in for
instance U.S. Pat. No. 6,440,735 and U.S. Pat. No. 6,713,055).
Non-limiting examples of molecules that interfere with apoptotic
pathways include TNF-related apoptosis-inducing ligand
(TRAIL)/apoptosis-2 ligand (Apo-2L), antibodies that activate TRAIL
receptors, IFNs, and anti-sense Bcl-2.
[0706] In one embodiment, a therapeutic agent for use in
combination with a bispecific antibody for treating the disorders
as described above may be a hormonal regulating agent, such as
agents useful for anti-androgen and anti-estrogen therapy. Examples
of such hormonal regulating agents are tamoxifen, idoxifene,
fulvestrant, droloxifene, toremifene, raloxifene,
diethylstilbestrol, ethinyl estradiol/estinyl, an antiandrogene
(such as flutaminde/eulexin), a progestin (such as such as
hydroxyprogesterone caproate, medroxy-progesterone/provera,
megestrol acepate/megace), an adrenocorticosteroid (such as
hydrocortisone, prednisone), luteinizing hormone-releasing hormone
(and analogs thereof and other LHRH agonists such as buserelin and
goserelin), an aromatase inhibitor (such as anastrazole/arimidex,
aminoglutethimide/cytraden, exemestane) or a hormone inhibitor
(such as octreotide/sandostatin).
[0707] In one embodiment, a therapeutic agent for use in
combination with a bispecific antibody for treating the disorders
as described above may be an anti-anergic agent, such asmolecules
that block the activity of CTLA-4, e.g. ipilimumab.
[0708] In one embodiment, a therapeutic agent for use in
combination with a bispecific antibody for treating the disorders
as described above may be an anti-cancer nucleic acid or an
anti-cancer inhibitory RNA molecule.
[0709] Examples of other anti-cancer agents, which may be relevant
as therapeutic agents for use in combination with a bispecific
antibody according to the invention for treating the disorders as
described above are differentiation inducing agents, retinoic acid
analogues (such as all trans retinoic acid, 13-cis retinoic acid
and similar agents), vitamin D analogues (such as seocalcitol and
similar agents), inhibitors of ErbB3, ErbB4, IGF-IR, insulin
receptor, PDGFRa, PDGFRbeta, Flk2, Flt4, FGFR1, FGFR2, FGFR3,
FGFR4, TRKA, TRKC, RON (such as an anti-RON antibody), Sea, Tie,
Tie2, Eph, Ret, Ros, Alk, LTK, PTK7 and similar agents.
[0710] Examples of other anti-cancer agents, which may be relevant
as therapeutic agents for use in combination with a bispecific
antibody according to the invention for treating the disorders as
described above are estramustine and epirubicin.
[0711] Examples of other anti-cancer agents, which may be relevant
as therapeutic agents for use in combination with a bispecific
antibody according to the invention for treating the disorders as
described above are a HSP90 inhibitor like 17-allyl amino
geld-anamycin, antibodies directed against a tumor antigen such as
PSA, CA125, KSA, integrins, e.g. integrin .beta.1, or inhibitors of
VCAM. Examples of other anti-cancer agents, which may be relevant
as therapeutic agents for use in combination with a bispecific
antibody for treating the disorders as described above are
calcineurin-inhibitors (such as valspodar, PSC 833 and other MDR-1
or p-glycoprotein inhibitors), TOR-inhibitors (such as sirolimus,
everolimus and rapamcyin), and inhibitors of "lymphocyte homing"
mechanisms (such as FTY720), and agents with effects on cell
signaling such as adhesion molecule inhibitors (for instance
anti-LFA).
[0712] In one embodiment, the bispecific antibody of the invention
is for use in combination with one or more other therapeutic
antibodies, such as ofatumumab, zanolimumab, daratumumab,
ranibizumab, nimotuzumab, panitumumab, hu806, daclizumab (Zenapax),
basiliximab (Simulect), infliximab (Remicade), adalimumab (Humira),
natalizumab (Tysabri), omalizumab (Xolair), efalizumab (Raptiva)
and/or rituximab.
[0713] In another embodiment, two or more different antibodies of
the invention as described herein are used in combination for the
treatment of disease. Particularly interesting combinations include
two or more non-blocking antibodies. Such combination therapy may
lead to binding of an increased number of antibody molecules per
cell, which may give increase efficacy, e.g. via activation of
complement-mediated lysis.
[0714] In addition to the above, other embodiments of combination
therapies of the invention include the following:
[0715] For the treatment of breast cancer, a bispecific antibody or
a therapeutic conjugate thereof, in combination with methotrexate,
paclitaxel, doxorubicin, carboplatin, cyclophosphamide,
daunorubicin, epirubicin, 5-fluorouracil, gemcitabine, ixabepilone,
mutamycin, mitoxantrone, vinorelbine, docetaxel, thiotepa,
vincristine, capecitabine, an EGFR antibody (e.g. zalutumumab,
cetuximab, panitumumab or nimotuzumab) or other EGFR inhibitor
(such as gefitinib or erlotinib), another HER2 antibody or
-conjugate (such as, e.g., trastuzumab, trastuzumab-DM1 or
pertuzumab), an inhibitor of both EGFR and HER2 (such as
lapatinib), and/or in combination with a HER3 inhibitor.
[0716] For the treatment of non-small-cell lung cancer, a
bispecific antibody of the invention in combination with EGFR
inhibitors, such as an EGFR antibody, e.g. zalutumumab, cetuximab,
panitumumab or nimotuzumab or other EGFR inhibitors (such as
gefitinib or erlotinib), or in combination with an another HER2
agent (such as a HER2 antibody, e.g. trastuzumab, trastuzumab-DM1
or pertuzumab) or in combination with an inhibitor of both EGFR and
HER2, such as lapatinib, or in combination with a HER3
inhibitor.
[0717] For the treatment of colorectal cancer, a bispecific
antibody of the invention in combination with one or more compounds
selected from: gemcitabine, bevacizumab, FOLFOX, FOLFIRI, XELOX,
IFL, oxaliplatin, irinotecan, 5-FU/LV, Capecitabine, UFT, EGFR
targeting agents, such as cetuximab, panitumumab, zalutumumab; VEGF
inhibitors, or tyrosine kinase inhibitors such as sunitinib.
[0718] For the treatment of prostate cancer, a bispecific antibody
in combination with one or more compounds selected from:
hormonal/antihormonal therapies; such as antiandrogens, Luteinizing
hormone releasing hormone (LHRH) agonists, and chemotherapeutics
such as taxanes, mitoxantrone, estramustine, 5FU, vinblastine, and
ixabepilone.
Radiotherapy--Surgery
[0719] In one embodiment, the present invention provides a method
for treating a disorder involving cells expressing HER2 in a
subject, which method comprises administration of a therapeutically
effective amount of a bispecific antibody, such as a HER2.times.CD3
antibody of the present invention, and radiotherapy to a subject in
need thereof.
[0720] In one embodiment, the present invention provides a method
for treating or preventing cancer, which method comprises
administration of a therapeutically effective amount of a
bispecific antibody, such as a HER2.times.CD3 antibody of the
present invention, and radiotherapy to a subject in need
thereof.
[0721] In one embodiment, the present invention provides the use of
a bispecific antibody of the present invention, for the preparation
of a pharmaceutical composition for treating cancer to be
administered in combination with radiotherapy.
[0722] Radiotherapy may comprise radiation or associated
administration of radiopharmaceuticals to a patient is provided.
The source of radiation may be either external or internal to the
patient being treated (radiation treatment may, for example, be in
the form of external beam radiation therapy (EBRT) or brachytherapy
(BT)). Radioactive elements that may be used in practicing such
methods include, e.g., radium, cesium-137, iridium-192,
americium-241, gold-198, cobalt-57, copper-67, technetium-99,
iodide-123, iodide-131, and indium-111.
[0723] In a further embodiment, the present invention provides a
method for treating or preventing cancer, which method comprises
administration to a subject in need thereof of a therapeutically
effective amount of a bispecific antibody of the present invention,
in combination with surgery.
Diagnostic Uses
[0724] The bispecific antibodies of the invention may also be used
for diagnostic purposes. Thus, in a further aspect, the invention
relates to a diagnostic composition comprising a bispecific
HER2.times.CD3 antibody as defined herein, and to its use. In one
embodiment, the present invention provides a kit for diagnosis of
cancer comprising a container comprising a bispecific
HER2.times.CD3 antibody, and one or more reagents for detecting
binding of the antibody to HER2. Reagents may include, for example,
fluorescent tags, enzymatic tags, or other detectable tags. The
reagents may also include secondary or tertiary antibodies or
reagents for enzymatic reactions, wherein the enzymatic reactions
produce a product that may be visualized.
[0725] The present invention is further illustrated by the
following examples, which should not be construed as limiting the
scope of the invention.
EXAMPLES
Example 1
Expression Constructs for HER2 and HER2 Variants
[0726] Fully codon-optimized constructs for expression of full
length HER2 (1255 aa, Swissprot P04626), the extracellular domain
(ECD) of HER2 (Her2-ECDHis, aa 1-653 with a C-terminal His6 tag),
the naturally occurring HER2 splice variant (Her2-delex16,
resulting from exon 16 deletion and lacking aa 633-648) and a
truncated form of the HER2 receptor (Her2-stumpy, aa 648-1256),
were generated. The construct contained suitable restriction sites
for cloning and an optimal Kozak sequence (Kozak, M., Gene 1999;
234(2):187-208.). The constructs were cloned in the mammalian
expression vector pEE13.4 (Lonza Biologics; Bebbington, C. R., et
al., Biotechnology (N Y) 1992; 10(2):169-75) and fully sequenced to
confirm the correctness of the construct.
Example 2
Expression Constructs for Pertuzumab, C1 and F5
[0727] Fully codon-optimized constructs for expression of the heavy
chain (HC) and the light chain (LC) of the IgG1 antibodies
pertuzumab, C1 and F5 in HEK cells, were generated. The variable
regions encoded by these constructs are identical to those
described in U.S. Pat. No. 6,949,245 for pertuzumab heavy chain and
light chain and U.S. Pat. No. 7,244,826 for C1 and F5 heavy and
light chain. For C1 and F5, the mammalian expression vectors p33G1f
and p33K or p33L (pcDNA3.3 (Invitrogen)) containing the fully codon
optimized constant region for the human IgG1 heavy chain (allotype
f), the human kappa light chain or the human lambda light chain,
respectively, were used. For pertuzumab, the mammalian expression
vectors pG1f (pEE12.4 (Lonza Biologics) and pKappa (pEE6.4 (Lonza
Biologics), containing the fully codon-optimized constant region
for the human IgG1 heavy chain (allotype f) and the human kappa
light chain, respectively, were used.
[0728] Trastuzumab (Herceptin.RTM.) can be produced in the same
manner, using the heavy and light chain sequences described in,
e.g., U.S. Pat. No. 7,632,924.
[0729] The sequence disclosures of U.S. Pat. Nos. 6,949,245;
7,244,826 and 7,632,924 are hereby incorporated by reference in
their entirities.
Example 3
Transient Expression in HEK-293 or CHO Cells
[0730] Freestyle.TM. 293-F (a HEK-293 subclone adapted to
suspension growth and chemically defined Freestyle medium,
(HEK-293F)) cells were obtained from Invitrogen and transfected
with the appropriate plasmid DNA, using 293fectin (Invitrogen)
according to the manufacturer's instructions. In the case of
antibody expression, the appropriate heavy chain and light chain
expression vectors were co-expressed.
[0731] pEE13.4Her2, pEE13.4Her2-delex16 and pEE13.4Her2-stumpy were
transiently transfected in the Freestyle.TM. CHO-S (Invitrogen)
cell line using Freestyle MAX transfection reagent (Invitrogen).
Expression of HER2 and Her2-delex16 was tested by means of FACS
analysis as described below.
Example 4
Stable Polyclonal Pool Expression in NS0
[0732] pEE13.4Her2, pEE13.4Her2-delex16 and pEE13.4Her2-stumpy were
stably transfected in NS0 cells by nucleofection (Amaxa). A pool of
stably transfected cells was established after selection on
glutamine dependent growth, based on the integrated glutamine
synthetase selection marker (Barnes, L. M., et al., Cytotechnology
2000; 32(2):109-123).
Example 5
Purification of His-Tagged HER2
[0733] Her2ECDHis was expressed in HEK-293F cells. The His-tag in
Her2ECDHis enabled purification with immobilized metal affinity
chromatography, since the His-tagged protein binds strongly to the
resin beads, while other proteins present in the culture
supernatant do not bind strongly.
[0734] In this process, a chelator fixed onto the chromatographic
resin was charged with Co.sup.2+ cations. Her2ECDHis containing
supernatant was incubated with the resin in batch mode (i.e.
solution). After incubation, the beads were retrieved from the
supernatant and packed into a column. The column was washed in
order to remove weakly bound proteins. The strongly bound
Her2ECDHis proteins were then eluted with a buffer containing
imidazole, which competes with the binding of His to Co.sup.2+. The
eluent was removed from the protein by buffer exchange on a
desalting column.
Example 6
Immunization Procedure of Transgenic Mice
[0735] Antibodies 001, 019, 021, 025, 027, 032, 033, 035, 036, 049,
050, 051, 054, 055, 084, 091, 094, 098, 100, 105, 123 and 124 were
derived from the following immunization: three female HCo12 mice,
one male and two female HCo12-Balb/C mice, one male HCo17 mouse and
one male HCo20 mouse (Medarex, San Jose, Calif., USA) were
immunized alternating with 5.times.10.sup.6 NS0 cells stably
transfected with Her2ECD intraperitoneal (IP) and 20 .mu.g
Her2ECDHis protein coupled to the hapten Keyhole Limpet Hemocyanin
(KLH) subcutaneous (SC) at the tail base, with an interval of
fourteen days. A maximum of eight immunizations was performed per
mouse (four IP and four SC immunizations). The first immunization
with cells was done in complete Freunds' adjuvant (CFA; Difco
Laboratories, Detroit, Mich., USA). For all other immunizations,
cells were injected IP in PBS and KLH coupled Her2ECDHis was
injected SC using incomplete Freunds' adjuvant (IFA; Difco
Laboratories, Detroit, Mich., USA).
[0736] Antibodies 125, 127, 129, 132, 152, 153 and 159 were derived
from the following immunization: one male and two female
HCo12-Balb/C mice, one female HCo20 mouse, and one female HCo12
mouse (Medarex) were immunized alternating with 5.times.10.sup.6
NS0 cells stably transfected with Her2delex16 IP and 20 .mu.g
Her2ECDHis protein coupled to the hapten Keyhole Limpet Hemocyanin
(KLH) SC at the tail base, with an interval of fourteen days. A
maximum of eight immunizations was performed per mouse (four IP and
four SC immunizations). The first immunization with cells was done
in complete Freunds' adjuvant (CFA; Difco Laboratories, Detroit,
Mich., USA). For all other immunizations, cells were injected IP in
PBS and KLH coupled Her2ECD was injected SC using incomplete
Freunds' adjuvant (IFA; Difco Laboratories, Detroit, Mich.,
USA).
[0737] Antibody 143, 160, 161, 162, 166 and 169 were derived from
the following immunization: one female and one male Hco12 mouse,
one female Hco12-Balb/C mouse, one male HCo17 mouse and one male
HCo20 mouse (Medarex) were immunized alternating with 20 .mu.g
Her2ECDHis protein coupled to the hapten Keyhole Limpet Hemocyanin
(KLH), alternating IP and SC at the tail base with an interval of
fourteen days. A maximum of eight immunizations was performed per
mouse (four IP and four SC immunizations). The first immunization
was done IP in complete Freunds' adjuvant (CFA; Difco Laboratories,
Detroit, Mich., USA). The other immunizations were injected using
incomplete Freunds' adjuvant (IFA; Difco Laboratories, Detroit,
Mich., USA).
[0738] Antibodies 005, 006, 041, 044, 059, 060, 067, 072, 093, 106
and 111 were derived from the following immunization procedure: two
female HCo12 mice, one female and one male HCo12-Balb/C mouse, one
female and one male HCo17 mouse, and two male HCo20 mice (Medarex,
San Jose, Calif., USA) were immunized every fortnight, alternating
between 5.times.10.sup.6 NS0 cells stably transfected with
Her2ECDHis intraperitoneal (IP) and 20 .mu.g Her2ECDHis protein
coupled to the hapten Keyhole Limpet Hemocyanin (KLH) subcutaneous
(SC) at the tail base. A maximum of eight immunizations was
performed per mouse (four IP and four SC immunizations). The first
immunization with cells was done in complete Freunds' adjuvant
(CFA; Difco Laboratories, Detroit, Mich., USA). For all other
immunizations, cells were injected IP in PBS and KLH coupled
Her2ECD was injected SC using incomplete Freunds' adjuvant (IFA;
Difco Laboratories, Detroit, Mich., USA).
[0739] Antibody 150 was derived from immunization of one female
HCo17 mouse (Medarex) alternating with 5.times.10.sup.6 NS0 cells
stably transfected with Her2delex16 IP and 20 .mu.g Her2ECDHis
protein coupled to the hapten Keyhole Limpet Hemocyanin (KLH) SC at
the tail base, with an interval of fourteen days. A maximum of
eight immunizations was performed (four IP and four SC
immunizations). The first immunization with cells was done in
complete Freunds' adjuvant (CFA; Difco Laboratories, Detroit,
Mich., USA). For all other immunizations, cells were injected IP in
PBS and KLH coupled Her2ECD was injected SC using incomplete
Freunds' adjuvant (IFA; Difco Laboratories, Detroit, Mich.,
USA).
[0740] Antibody 163 was derived from immunization of one male HCo20
mouse (Medarex) with 20 .mu.g Her2ECDHis protein coupled to the
hapten Keyhole Limpet Hemocyanin (KLH), alternating IP and SC at
the tailbase with an interval of fourteen days. A maximum of eight
immunizations was performed (four IP and four SC immunizations).
The first immunization was done IP in complete Freunds' adjuvant
(CFA; Difco Laboratories, Detroit, Mich., USA). The other
immunizations were injected using incomplete Freunds' adjuvant
(IFA; Difco Laboratories, Detroit, Mich., USA).
[0741] Mice with at least two sequential titers against
TC1014-Her2, TC1014-Her2delex16 or TC1014-Her2stumpy in the antigen
specific FMAT screening assay (as described in Example 7), were
considered positive and fused.
Example 7
Homogeneous Antigen Specific Screening Assay
[0742] The presence of HER2 antibodies in sera of immunized mice or
HuMab (human monoclonal antibody) hybridoma or transfectoma culture
supernatant was determined by homogeneous antigen specific
screening assays (four quadrant) using Fluorometric Micro volume
Assay Technology (FMAT; Applied Biosystems, Foster City, Calif.,
USA). For this, a combination of 4 cell based assays was used.
Binding to TC1014-Her2 (CHO-S cells transiently expressing the HER2
receptor; produced as described above), TC1014-Her2delex16 (CHO-S
cells transiently expressing the extracellular domain of Her2-delex
(a 16 amino acid deletion mutant of the HER2 receptor; produced as
described above) and TC1014-Her2stumpy (CHO-S cells transiently
expressing the extracellular stumpy domain of the HER2 receptor;
produced as described above) as well as CHO-S wild type cells
(negative control cells which do not express HER2) was determined.
Samples were added to the cells to allow binding to HER2.
Subsequently, binding of HuMab was detected using a fluorescent
conjugate (Goat anti-Human IgG-Cy5; Jackson ImmunoResearch).
TH1014-Pertuzumab (produced in HEK-293F cells) was used as a
positive control and HuMab.RTM.-mouse pooled serum and HuMab-KLH
were used as negative controls. The samples were scanned using an
Applied Biosystems 8200 Cellular Detection System (8200 CDS) and
`counts.times.fluorescence` was used as read-out. Samples were
stated positive when counts were higher than 50 and
counts.times.fluorescence were at least three times higher than the
negative control.
Example 8
HuMab Hybridoma Generation
[0743] HuMab mice with sufficient antigen-specific titer
development (defined as above) were sacrificed and the spleen and
lymph nodes flanking the abdominal aorta and vena cava were
collected. Fusion of splenocytes and lymph node cells to a mouse
myeloma cell line was done by electrofusion using a CEEF 50
Electrofusion System (Cyto Pulse Sciences, Glen Burnie, Md., USA),
essentially according to the manufacturer's instructions. Next, the
primary wells were sub cloned using the ClonePix system (Genetix,
Hampshire, UK). To this end specific primary well hybridoma's were
seeded in semisolid medium made from 40% CloneMedia (Genetix,
Hampshire, UK) and 60% HyQ 2.times. complete media (Hyclone,
Waltham, USA). The sub clones were retested in the antigen-specific
binding assay as described in Example 7 and IgG levels were
measured using an Octet (Fortebio, Menlo Park, USA) in order to
select the most specific and best producing clone per primary well
for further expansion. Further expansion and culturing of the
resulting HuMab hybridomas were done based upon standard protocols
(e.g. as described in Coligan J. E., Bierer, B. E., Margulies, D.
H., Shevach, E. M. and Strober, W., eds. Current Protocols in
Immunology, John Wiley & Sons, Inc., 2006). Clones derived by
this process were designated PC1014.
Example 9
Mass Spectrometry of Purified Antibodies
[0744] Small aliquots of 0.8 mL antibody containing supernatant
from 6-well or Hyperflask stage were purified using PhyTip columns
containing Protein G resin (PhyNexus Inc., San Jose, USA) on a
Sciclone ALH 3000 workstation (Caliper Lifesciences, Hopkinton,
USA). The PhyTip columns were used according to manufacturer's
instructions, although buffers were replaced by: Binding Buffer PBS
(B. Braun, Medical B. V., Oss, Netherlands) and Elution Buffer 0.1M
Glycine-HCl pH 2.7 (Fluka Riedel-de Haen, Buchs, Germany). After
purification, samples were neutralized with 2M Tris-HCl, pH 9.0
(Sigma-Aldrich, Zwijndrecht, Netherlands). Alternatively, in some
cases larger volumes of culture supernatant were purified using
MabSelect SuRe columns (GE Health Care).
[0745] After purification, the samples were placed in a 384-well
plate (Waters, 100 .mu.l square well plate, part#186002631).
Samples were deglycosylated overnight at 37.degree. C. with
N-glycosidase F (Roche cat no 11365177001. DTT (15 mg/mL) was added
(1 .mu.L/well) and incubated for 1 h at 37.degree. C. Samples (5 or
6 .mu.L) were desalted on an Acquity UPLC.TM. (Waters, Milford,
USA) with a BEH300 C18, 1.7 .mu.m, 2.1.times.50 mm column at
60.degree. C. MQ water and LC-MS grade acetonitrile (Biosolve, cat
no 01204101, Valkenswaard, The Netherlands) with both 0.1% formic
acid (Fluke, cat no 56302, Buchs, Germany), were used as Eluens A
and B, respectively. Time-of-flight electrospray ionization mass
spectra were recorded on-line on a micrOTOF.TM. mass spectrometer
(Bruker, Bremen, Germany) operating in the positive ion mode. Prior
to analysis, a 900-3000 m/z scale was calibrated with ES tuning mix
(Agilent Technologies, Santa Clara, USA). Mass spectra were
deconvoluted with DataAnalysis.TM. software v. 3.4 (Bruker) using
the Maximal Entropy algorithm searching for molecular weights
between 5 and 80 kDa.
[0746] After deconvolution, the resulting heavy and light chain
masses for all samples were compared in order to find duplicate
antibodies. This was sometimes due to the presence of an extra
light chain, but in the comparison of the heavy chains, the
possible presence of C-terminal lysine variants was also taken into
account. This resulted in a list of unique antibodies, i.e., a
unique combination of specific heavy and light chains. In case
duplicate antibodies were found, one unique antibody was selected
based on results from other tests.
Example 10
Sequence Analysis of the HER2 Antibody Variable Domains and Cloning
in Expression Vectors
[0747] Total RNA of the HER2 HuMabs was prepared from
5.times.10.sup.6 hybridoma cells and 5'-RACE-Complementary DNA
(cDNA) was prepared from 100 ng total RNA, using the SMART RACE
cDNA Amplification kit (Clontech), according to the manufacturer's
instructions. VH and VL coding regions were amplified by PCR and
cloned directly, in frame, in the pG1f and pKappa expression
vectors, by ligation independent cloning (Aslanidis, C. and P. J.
de Jong, Nucleic Acids Res 1990; 18(20): 6069-74). The appropriate
heacy chain and light chain vectors were transiently co-expressed
in Freestyle.TM. 293-F cells using 293fectin. Clones derived by
this process were designated TH1014 (TH stands for transient HEK
cells). For each antibody, 16 VL clones and 8 VH clones were
sequenced. Clones with predicted heavy and light chain mass in
agreement with the mass of the hybridoma derived material of the
same antibody (as determined by mass spectrometry) were selected
for further study and expression.
[0748] The resulting sequences are shown in FIGS. 1 and 2 and in
the Sequence Listing. Selected sequences are also described in more
detail below. CDR sequences were defined according to IMGT (Lefranc
M P. et al., Nucleic Acids Research, 27, 209-212, 1999 and Brochet
X. Nucl. Acids Res. 36, W503-508 (2008)). Table 1, Table 2 and
Table 3 give an overview of antibody sequence information or
germline sequences, and Table 4 shows consensus sequences.
TABLE-US-00003 TABLE 1A and 1B Heavy chain variable region (VH),
light chain variable region (VL) and CDR sequences of HuMabs 169,
050, 084, 025, 091, 129, 127, 159, 098, 153, and 132 (Table 1A) and
HuMabs 005, 006, 059, 060, 106, and 111 (Table 1B). 1A: SEQ ID No:
1 VH 169 QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGISW
VRQAPGQGLEWMGWLSAYSGNTIYAQKLQGRVTMT
TDTSTTTAYMELRSLRSDDTAVYYCARDRIVVRPDYF DYWGQGTLVTVSS SEQ ID No: 2 VH
169, CDR1 GYTFTNYG SEQ ID No: 3 VH 169, CDR2 LSAYSGNT SEQ ID No: 4
VH 169, CDR3 ARDRIVVRPDYFDY SEQ ID No: 5 VL 169
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQ
QKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTI
SSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK SEQ ID No: 6 VL 169, CDR1 QSVSSY
VL 169, CDR2 DAS SEQ ID No: 7 VL 169, CDR3 QQRSNWPRT SEQ ID No: 8
VH 050 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAM NW
VRQAPGKGLEWVSAISGRGGTTYYADSVKGRFTISR
DNSKNTLYLQMSSLRAEDTAVYYCAKARANWDYFDY WGQGTLVTVSS SEQ ID No: 9 VH
050, CDR1 GFTFSSYA SEQ ID No: 10 VH 050, CDR2 ISGRGGTT SEQ ID No:
11 VH 050, CDR3 AKARANWDYFDY SEQ ID No: 12 VL 050
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWY
QHKPGKAPKLLIYAASILQSGVPSRFSGSGSGTDFTL
TISSLQPEDFATYYCQQANSFPITFGQGTRLEIK SEQ ID No: 13 VL 050, CDR1
QGISSW VL 050, CDR2 AAS SEQ ID No: 14 VL 050, CDR3 QQANSFPIT SEQ ID
No: 15 VH 084 QVQLVQSGAEVKKPGSSVKVSCKASGGTFRTYAINW
VRQAPGQGLEWMGRINTVLGIVNHAQKFQGRVTITA
DKSTNTAYMELNSLRSEDTAVYYCAREKGVDYYYGIE VWGQGTTVTVSS SEQ ID No: 16 VH
084, CDR1 GGTFRTYA SEQ ID No: 17 VH 084, CDR2 INTVLGIV SEQ ID No:
18 VH 084, CDR3 AREKGVDYYYGIEV SEQ ID No: 19 VL 084
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWY
QHKPGKAPKLLIYVASTLQSGVPSRFSGSGSGTDFTL
TISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK SEQ ID No: 20 VL 084, CDR1
QGISSW VL 084, CDR2 VAS SEQ ID No: 21 VL 084, CDR3 QQANSFPLT SEQ ID
No: 22 VH 025 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWN
WIRQPPGKGLEWIGEIHHSGSTNYNPSLKSRVTISVD
TSKNQFSLKLSSVTAADTAVYYCARGYYDSGVYYFDY WAQGTLVTVSS SEQ ID No: 23 VH
025, CDR1 GGSFSDYY SEQ ID No: 24 VH 025, CDR2 IHHSGST SEQ ID No: 25
VH 025, CDR3 ARGYYDSGVYYFDY SEQ ID No: 26 VL 025
DIQMTQSPSSLSASVGDRVTITCRASQGISRWLAWY
QQKPEKAPKSLIYAASSLRSGVPSRFSGSGSGTDFTL
TISSLQPEDFATYYCQQYNSYPITFGQGTRLEIK SEQ ID No: 27 VL 025, CDR1
QGISRW VL 025, CDR2 AAS SEQ ID No: 28 VL 025, CDR3 QQYNSYPIT SEQ ID
No: 29 VH 091 QVQLQQWGAGLLKPSETLSLTCAVSGGSFSGYYWT
WIRQPPGKGLEWIGEIYHSGDTNYNPSLKSRVTISVD
TSKNQFSLKLYSVTAADTAVYYCARLYFGSGIYYLDY WGQGTLVTVSS SEQ ID No: 30 VH
091, CDR1 GGSFSGYY SEQ ID No: 163 VH 091, CDR2 IYHSGDT SEQ ID No:
31 VH 091, CDR3 ARLYFGSGIYYLDY SEQ ID No: 32 VL 091
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLVWY
QQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTL
TISSLQPEDFATYYCQQYNSFPPTFGQGTKVEIK SEQ ID No: 33 VL 091, CDR1
QGISSW VL 091, CDR2 AAS SEQ ID No: 34 VL 091, CDR3 QQYNSFPPT SEQ ID
No: 35 VH 129 QVQLVESGGGVVQPGRSLRLSCAASGFTFSTFAIHW
VRQAPGKGLEWVAVISYDGGHKFYADSVKGRFTISR DNSKNTLYLQM
NSLRAEDTAMYYCARGLGVWGAFD YWGQGTLVTVSS SEQ ID No: 36 VH 129, CDR1
GFTFSTFA SEQ ID No: 37 VH 129, CDR2 ISYDGGHK SEQ ID No: 38 VH 129,
CDR3 ARGLGVWGAFDY SEQ ID No: 39 VL 129
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQ
QKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTI
SSLEPEDFAVYYCQQRSNWWTFGQGTKVEIK SEQ ID No: 40 VL 129, CDR1 QSVSSY
VL 129, CDR2 DAS SEQ ID No: 41 VL 129, CDR3 QQRSNWWT SEQ ID No: 42
VH 127 EVQLVQSGAEVKKPGESLTISCKGSGYSFSIYWIGW
VRQMPGKGLEWMGIIFPGDSDIRYSPSFQGQVTISA
DKSISTAYLQWSSLKASDTAMYYCARQPGDWSPRH WYFDLWGRGTLVTVSS SEQ ID No: 43
VH 127, CDR1 GYSFSIYW SEQ ID No: 44 VH 127, CDR2 IFPGDSDI SEQ ID
No: 45 VH 127, CDR3 ARQPGDWSPRHWYFDL SEQ ID No: 46 VL 127
VIWMTQSPSLLSASTGDRVTISCRMSQGISSYLAWY
QQKPGKAPELLIYAASTLQSGVPSRFSGSGSGTDFTL
TISYLQSEDFATYYCQQYYSFPLTFGGGTKVEIK SEQ ID No: 47 VL 127, CDR1
QGISSY VL 127, CDR2 AAS SEQ ID No: 48 VL 127, CDR3 QQYYSFPLT SEQ ID
No: 49 VH 159 EVQLVQSGAEVKKPGESLKISCKGSGYNFTSYWIGW
VRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISA
DKSISTAYLQWSSLKASDTAMYYCARWGTYYDILTG YFNWFDPWGQGTLVTVSS SEQ ID No:
50 VH 159, CDR1 GYNFTSYW SEQ ID No: 51 VH 159, CDR2 IYPGDSDT SEQ ID
No: 52 VH 159, CDR3 ARWGTYYDILTGYFN SEQ ID No: 53 VL 159
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWY
QQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTL
TISSLQPEDFATYYCQQYYIYPWTFGQGTKVEIK SEQ ID No: 54 VL 159, CDR1
QGISSW VL 159, CDR2 AAS SEQ ID No: 55 VL 159, CDR3 QQYYIYPWT SEQ ID
No: 56 VH 098 EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSW
VRQAPGKGLEWVSAISGSAYSTYYADSVKGRFTISR
DNSKNTLWLQMNSLRAEDTAVYYCAKAHYHGSGSYY TLFDYWGQGTLVTVSS SEQ ID No: 57
VH 098, CDR1 GFTFSNYG SEQ ID No: 58 VH 098, CDR2 ISGSAYST SEQ ID
No: 59 VH 098, CDR3 AKAHYHGSGSYYTLFDY SEQ ID No: 60 VL 098
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWY
QQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTL
TISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK SEQ ID No: 61 VL 098, CDR1
QGISSW VL 098, CDR2 AAS SEQ ID No: 62 VL 098, CDR3 QQYNSYPYT SEQ ID
No: 63 VH 153 QVQLVESGGGVVQPGRSLRLSCAASGFTFSDYVIHW
VRQAPGKGLEWVTVISYDGSNKYYADSVKGRFTISR DNSKNTLYLQM
NSLSAEDTAMYYCARGGITGTTGVF DYWGQGTLVTVSS SEQ ID No: 64 VH 153, CDR1
GFTFSDYV SEQ ID No: 65 VH 153, CDR2 ISYDGSNK SEQ ID No: 66 VH 153,
CDR3 ARGGITGTTGVFDY SEQ ID No: 67 VL 153
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWY
QQKPEKAPKSLIYDASSLQSGVPSRFSGSGYGTDFSL
TISSLQPEDFAIYYCQQYKSYPITFGQGTRLEIK SEQ ID No: 68 VL 153, CDR1
QGISSW VL 153, CDR2 DAS SEQ ID No: 69 VL 153, CDR3 QQYKSYPIT SEQ ID
No: 70 VH 132 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISW
VRQAPGQGLEWMGWISAYNGNSNYVQKFQGRVTM
TTDTTTSTAYMELRSLTSDDTAVYYCAREYSYDSGTY FYYGMDVWGQGTTVTVSS SEQ ID No:
71 VH 132, CDR1 GYTFTSYG SEQ ID No: 72 VH 132, CDR2 ISAYNGNS SEQ ID
No: 73 VH 132, CDR3 AREYSYDSGTYFYYGMDV SEQ ID No: 74 VL 132
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQ
QKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTI
SSLEPEDFAVYYCQQRSNWPMYTFGQGTKLEIK SEQ ID No: 75 VL 132, CDR1 QSVSSY
VL 132, CDR2 DAS SEQ ID No: 76 VL 132, CDR3 QQRSNWPMYT 1B) SEQ ID
No: 165 VH 005 EVQLVQSGAEVKKPGESLKISCKASGYSFHFYWIGW
VRQMPGKGLEWMGSIYPGDSDTRYRPSFQGQVTISA
DKSISTAYLQWTSLKASDTAIYYCARQRGDYYYFYGM DVWGQGTTVTVSS SEQ ID No: 166
VH 005, CDR1 GYSFHFYW SEQ ID No: 167 VH 005, CDR2 IYPGDSDT SEQ ID
No: 168 VH 005, CDR3 ARQRGDYYYFYGMDV
SEQ ID No: 169 VL 005 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWY
QQKPGQVPRLLIYGASSRATGIPDRFSGSGSGTDFTL
TISRLEPEDFAVYYCQQYGSS-LTFGGGTKVEIK SEQ ID No: 170 VL 005, CDR1
QSVSSSY VL 005, CDR2 GAS SEQ ID No: 171 VL 005, CDR3 QQYGSSLT SEQ
ID No: 172 VH 006 EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYALIWV
RQAPGKGLEWVSIIRGGAGSTYYADSVKGRFTISRD
NSKNTLYLQMNSLRAEDTAVYYCAKARIWGPLFDYW GQGTLVTVSS SEQ ID No: 173 VH
006, CDR1 GFTFSNYA SEQ ID No: 174 VH 006, CDR2 IRGGAGST SEQ ID No:
175 VH 006, CDR3 AKARIWGPLFDY SEQ ID No: 176 VL 006
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQ
QKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTI
SSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIK SEQ ID No: 177 VL 006, CDR1
QSVSSY VL 006, CDR2 DAS SEQ ID No: 178 VL 006, CDR3 QQRSNWPPLT SEQ
ID No: 179 VH 059 QVQLVQSGAEVKKPGASVRVPCKASGYTFTRYGISW
VRQAPGQGLEWMGWISAYNGKTYYAQKLQGRVTMT
TDTSTSTAYMELRSLRSDDTAVYYCARSPLLWFEELY FDYWGQGTLVTVSS SEQ ID No: 180
VH 059, CDR1 GYTFTRYG SEQ ID No: 181 VH 059, CDR2 ISAYNGKT SEQ ID
No: 182 VH 059, CDR3 ARSPLLWFEELYFDY SEQ ID No: 183 VL 059
EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWY
QQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTL
TISRLEPEDFAVYYCQQYGTSLFTFGPGTKVDIK SEQ ID No: 184 VL 059, CDR1
QSVSSTY VL 059, CDR2 GAS SEQ ID No: 185 VL 059, CDR3 QQYGTSLFT SEQ
ID No: 186 VH 060 EVQLVQSGAEVKKPGESLKISCKGSGYRFTSYWIGW
VRQMPGKGLEWMGSIYPGDSYTRNSPSFQGQVTISA
DKSIATAYLQWNSLKASDTAMYYCARHAGDFYYFDG LDVWGQGTTVTVSS SEQ ID No: 187
VH 060, CDR1 GYRFTTSYW SEQ ID No: 188 VH 060, CDR2 IYPGDSYT SEQ ID
No: 189 VH 060, CDR3 ARHAGDFYYFDGLDV SEQ ID No: 190 VL 060
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWY
QQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTL
TISRLEPEDFAVYYCQQYGSSPPITFGQGTRLEIK SEQ ID No: 191 VL 060, CDR1
QSVSSSY VL 060, CDR2 GAS SEQ ID No: 192 VL 060, CDR3 QQYGSSPPIT SEQ
ID No: 193 VH 106 EVQLVQSGAEVKKPGESLKISCKGSGYSFTRYWIGW
VRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISA
DKSISTAYLQWSSLKASDTAMYYCARLTGDRGFDYY SGMDVWGQGTTVTVSS SEQ ID No:
194 VH 106, CDR1 GYSFTRYW SEQ ID No: 195 VH 106, CDR2 IYPGDSDT SEQ
ID No: 196 VH 106, CDR3 ARLTGDRGFDYYSGMDV SEQ ID No: 197 VL 106
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWY
QQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTL
TISRLEPEDFAVYYCQQYGSS-FTFGPGTKVDIK SEQ ID No: 198 VL 106, CDR1
QSVSSSY VL 106, CDR2 GAS SEQ ID No: 199 VL 106, CDR3 QQYGSSFT SEQ
ID No: 200 VH 111 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISW
VRQAPGPGLEWMGRIIPILGIANYAQKFQGRVTITAD
KSTNTAYMELSSLRSEDTAVYYCARDQEYSSNWYYW GQGTLVTVSS SEQ ID No: 201 VH
111, CDR1 GGTFSSYG SEQ ID No: 202 VH 111, CDR2 IIPILGIA SEQ ID No:
203 VH 111, CDR3 ARDQEYSSNWYY SEQ ID No: 204 VL 111
EIVLTQSPGTLSLSPGERATLSCRASQSVRSSYLAWY
QQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTL
TISRLEPEDFAVYYCQLYGSSPTFGPGTKVDIK SEQ ID No: 205 VL 111, CDR1
QSVRSSY VL 111, CDR2 GAS SEQ ID No: 206 VL 111, CDR3 QLYGSSPT
TABLE-US-00004 TABLE 2 Mouse origin and heavy and light chain
sequence homologies of selected HuMabs. HuMab: Mouse: Strain:
Germline VH: Germline VL: 169 361494 HCo20 IgHV1-18-01 IgKV3-11-01
050 350633 HCo12 IgHV3-23-01 IgKV1-12-01 084 350615 HCo12-BalbC
IgHV1-69-04 IgKV1-12-01 025 350631 HCo12 IgHV4-34-01 IgKV1D-16-01
091 350630 HCo12 IgHV4-34-01 IgKV1D-16-01 129 359783 HCo12-BalbC
IgHV3-30-3-01 IgKV3-11-01 127 359783 HCo12-BalbC IgHV5-51-01
IgKV1D-8-01 159 363503 HCo12 IgHV5-51-01 IgKV1D-16-01 098 350659
HCo17 IgHV3-23-01 IgKV1D-16-01 153 359785 HCo12-BalbC IgHV3-30-3-01
IgKV1D-16-01 132 361487 HCo20 IgHV1-18-01 IgKV3-11-01 005 350611
HCo12-BalbC IgHV5-51-1 IgKV3-20-01 006 350611 HCo12-BalbC
IgHV3-23-1 IgKV3-11-01 059 350654 HCo17 IgHV1-18-1 IgKV3-20-01 060
350654 HCo17 IgHV5-51-1 IgKV3-20-01 106 350660 HCo17 IgHV5-51-1
IgKV3-20-01 111 350660 HCo17 IgHV1-69-4 IgKV3-20-01
TABLE-US-00005 TABLE 3A and 3B Heavy chain variable region (VH),
light chain variable region (VL) sequences of HuMabs 049, 051, 055,
123, 161, 124, 001, 143, 019, 021, 027, 032, 035, 036, 054, 094
(3A) and HuMabs 041, 150, 067, 072, 163, 093, and 044 (3B). The
respective CDRs correspond to those underlined in Figures 1 and 2,
for VH and VL sequences, respectively. 3A: SEQ ID No: 77 VH 049
EVQLLESGGDLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPG
KGLEWVSAISGRGGTTYYADSVKGRFTISRDNSKSTLCLQMNS
LRAEDTAVYYCAKARANWDYFDYWGQGTLVTVSS SEQ ID No: 78 VL 049
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQHKPGK
APKLLIYAASILQSGVPSRFSGSGSGTDFTLTISSLRPEDFATYY CQQANSFPITFGQGTRLEIK
SEQ ID No: 79 VH 051 EVQLLESGGDLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPG
KGLEWVSAISGRGGTTYYADSVKGRFTISRDNSKSTLCLQMNS
LRAEDTAVYYCAKARANWDYFDYWGQGTLVTVSS SEQ ID No: 80 VL 051
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQHKPGK
APKLLIYAASILQSGVPSRFSGSGSGTDFTLTISSLRPEDFATYY CQQANSFPITFGQGTRLEIK
SEQ ID No: 81 VH 055 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPG
KGLEWVSAISGRGGTTYYADSVKGRFTISRDNSKSTLCLQMNS
LRAEDTAVYYCAKARANWDYFDYWGQGTLVTVSS SEQ ID No: 82 VL 055
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQHKPGK
APKLLIYAASILQSGVPSRFSGSGSGTDFTLTISSLRPEDFATYY CQQANSFPITFGQGTRLEIK
SEQ ID No: 83 VH 123 QVQLVQSGAEVKKPGASVKVSCKAAGYTFTNYGISWVRQAPG
QALEWMGWITTYSSNTIYAQKLQGRVTMTTDTSTSTAYMELRS
LRSDDTAVYYCARDRVVVRPDYFDYWGQGTLVTVSS SEQ ID No: 84 VL 123
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAP
RLLIYDTSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQ QRSHWPRTFGQGTKVEIK
SEQ ID No: 85 VH 161 QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGISWVRQAPG
QGLEWMGWLSAYSGNTIYAQKLQGRVTMTTDTSTTTAYMELR
SLRSDDTAVYYCARDRIVVRPDYFDYWGQGTLVTVSS SEQ ID No: 86 VL 161
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAP
RLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQ QRSNWPRTFGQGTKVEIK
SEQ ID No: 87 VH 124 QVQLVQSGAEVKKPGASVKVSCKAAGYTFTNYGISWVRQAPG
QGLEWMGWIITYNGNTIYAQRFQDRVTMTTDTSTSTAYM ELRS
LRSDDTAVYYCARDRIIVRPDYFDYWGQGTLVTVSS SEQ ID No: 88 VL 124
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAP
RLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQ QRSNWPRTFGQGTKVEIK
SEQ ID No: 89 VH 001 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWNWIRQPPG
KGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVT
AADTAVYYCARGNYGSGYYYFDLWGRGTQVTVSS SEQ ID No: 90 VL 001
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEK
APKSLIFAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYISFPITFGQGTRLEIK
SEQ ID No: 91 VH 143 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWNWIRQPPG
KGLEWIGEIHHSGSANYNPSLMSRVTISVDTSKNQFSLQLSSV
TAADTAVYYCARGYYGSGYYYFDYWGQGTLVTVSS SEQ ID No: 92 VL 143
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEK
APKSLIYAASRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSYPITFGQGTRLEIK
SEQ ID No: 93 VH 019 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPG
KGLEWIGEIHHVGSTNYNPSLKSRVTISVDTSKSQFSLKLSSVT
AADTAVYYCARGYYDSGVYYFDYWAQGTLVTVSS SEQ ID No: 94 VL 019
DIQMTQSPSSLSASVGDRVTITCRASQGISRWLAWYQQKPEK
APKSLIYAASSLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSYPITFGQGTRLEIK
SEQ ID No: 95 VH 021 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPG
KGLEWIGEIHHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVT
AADTAVYYCARGYYASGVYYFDYWGQGTLVTVSS SEQ ID No: 96 VL 021
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEK
APKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSYPITFGQGTRLEIK
SEQ ID No: 97 VH 027 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYFWNWIRQPPG
KGLEWIGEIHHSGSTNYNPSLKSRVTISVDTSKNQFSLNLSSVT
AADTAVYYCARGLIGSGYYYFDYWDQGTLVTVSS SEQ ID No: 98 VL 027
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEK
APKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSYPITFGQGTRLEIK
SEQ ID No: 99 VH 032 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPG
KGLEWIGEINHSGDTNYNPSLTSRVTISVDTSKNQFSLKLSSVT
AADTAVYYCARLFYGSGIYYFDYWGQGTLVTVSS SEQ ID No: 100 VL 032
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEK
APKSLIYATFRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSFPPTFGQGTKVEIK
SEQ ID No: 101 VH 035 QVQLQQWGAGLLKPSETLSLTCAIYGGSFSGYYWSWIRQPPG
KGLEWIGEINHSGDTNYNPSLTSRVTISVDTSKNQFSLKLSSVT
AADTAVYYCARLFYGSGIYYFDYWGQGTLVTVSS SEQ ID No: 102 VL 035
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEK
APKSLIYATFRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSFPPTFGQGTKVEIK
SEQ ID No: 103 VH 036 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWSWIRQPPG
KGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVT
AADTAVYYCARLYYGSGTYYFDYWGQGTLVTVSS SEQ ID No: 104 VL 036
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLTWYQQKPEKA
PKSLIYAASRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQYNSFPPTFGQGTKVEIK
SEQ ID No: 105 VH 054 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPG
KGLEWIGEIHHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVT
AADTAVYYCARLWYGSGSYYFDYWGQGTLVTVSS SEQ ID No: 106 VL 054
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEK
APKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSFPPTFGGGTKVEIK
SEQ ID No: 107 VH 094 QVQLQQWGAGLLKPSETLSLTCAVSGGSFSGYYWTWIRQPPG
KGLEWIGEIYHSGDTNYNPSLKSRVTISVDTSKNQFSLKLYSVT
AADTAVYYCARLYFGSGIYYLDYWGQGTLVTVSS SEQ ID No: 108 VL 094
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLVWYQQKPEK
APKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSFPPTFGQGTKVEIK
SEQ ID No: 109 VH 105 EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPG
KGLEWVSAISGSAYSTYYADSVKGRFTISRDNSKNTLWLQMNS
LRAEDTAVYYCAKAHYHGSGSYYTLFDYWGQGTLVTVSS SEQ ID No: 110 VL 105
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEK
APKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSYPYTFGQGTKLEIK
SEQ ID No: 111 VH 100 EVQLLESGGGLVQPGGSLRLSCAASGFTFNNYGMNWVRQAPG
KGLEWVSAISGTGYSTYYADSVKGRFTISRDNSKNTLYLQMNS
LRAEDTAVYYCAKAHYFGSGSYYTLFDYWGQGTLVTVSS SEQ ID No: 112 VL 100
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEK
APKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSYPYTFGQGTKLEIK
SEQ ID No: 113 VH 125 EVQLLESGGGLVQPGGSLRLSCAASGFTFTDYAMNWVRQAPG
KGLEWVSTISGSGYATYYADSVKGRFTISRDNSKTTLYLQMNS
LRAEDTAVYYCAKGHTLGSGSYYTLFDYWGQGTLVTVSS SEQ ID No: 114 VL 125
DIQMTQSPSSLSASVGDRVTITCRASQGINSWLAWYQQKPEK
APKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSYPYTFGQGTKLEIK
SEQ ID No: 115 VH 162 EVQLWESGGGSVQPGGSLRLSCAASGFTFSSYGMSWVRQAP
GKLEWVSGISGSGYSTYYADSVKGRFTISRDNSKNTLYLQMN
SLRAEDTAVYYCAKGYYHGSGSYYTSFDYWGQGTLVTVSS SEQ ID No: 116 VL 162
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEK
APKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSYPLTFGGGTKVEIK
SEQ ID No: 117 VH 033 QVQLVESGGGVVQTGRSLRLSCAASGFTFSSHAMHWVRQAPG
KGLEWVAAISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNS
LRAEDTAVYYCARGDYISSSGVFDYWGQGTLVTVSS SEQ ID No: 118 VL 033
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEK
APKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSYPITFGQGTRLEIK
SEQ ID No: 119 VH 160 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSHAMHWVRQAPG
KGLEWVAAISYDGSNKYYADSVKGRFTISRDNSKNTMYLQMN
SLRAEDTAMCYCARGSITGSTGVFDYWGQGTLVTVSS SEQ ID No: 120 VL 160
DIQMTQSPSSLSASVGDRVTITCRASQDISSWLAWYQQKPEK
APKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSYPITFGQGTRLEIK
SEQ ID No: 121 VH 166 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPG
KGLEWVAVISYDGSNEYYADSVKGRFTISRDNSKNTLYLQMNS
LRAEDTAVYYCARGSIIGSTGVFDYWGQGTLVTVSS SEQ ID No: 122 VL 166
DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEK
APKSLIYDASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSYPITFGQGTRLEIK
SEQ ID No: 123 VH 152 QVQVVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPG
KGLEWVAVISYDGSYKYYADSVKGRFTISRDNSKNTLYLQMNS
LRAEDTAVYYCARGSITGSTGVFDYWGQGTLVTVSS SEQ ID No: 124 VL 152
DIQMTQSPSSLSASVGDRVTITCRASQGINSWLAWYQQKPEK
APKSLIYDASSLQSGVPSRFSGSGSGTDFTLTISSLQPENFATYY CQQYNSYPITFGQGTRLEIK
SEQ ID No: 125 VH 167 QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAIHWVRQAPG
KGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNS
LRAEDTAVYYCARGSITGSTGVFDYWGQGTLVTVSS SEQ ID No: 126 VL 167
DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEK
APKSLIYDASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQYNSYPITFGQGTRLEIK
3B: SEQ ID No: 207 VH 041
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPG
KGLEWMGSIYPGDSHTRYRPSFQGQVTISADKSISTAYLQWSS LKASDTAMYYCARQKGDFYYFFG
LDVWGQGTAITVSS SEQ ID No: 208 VL 041
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQ
APRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYY CQQYGSSLTFGGGTKVEIK
SEQ ID No: 209 VH 150 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPG
KGLEWMGSIYPGDSHTRYRPSFQGQVTISADKSISTAYLQWSS
LKASDTAMYYCARQAGDYYYYNGMDVWGQGTTVTVSS SEQ ID No: 210 VL 150
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLTWYQQKPGQ
APRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYY CQQYGSSLTFGGGTKVEIK
SEQ ID No: 211 VH 067 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPG
KGLEWMGIIYPGDSDTRYSPSFQGQVTISVDKSISTAYLQWSS LKASDTAMYYCARQKGDYYYHYG
LDVWGQGTTVTVSS SEQ ID No: 212 VL 067
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQ
APRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYY CQQYGSSPRLTFGGGTKVEIK
SEQ ID No: 213 VH 072 EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPG
KGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSS
LKASDTAMYYCARQKGDYYYFNGLDVWGQGTTVTVSS SEQ ID No: 214 VL 072
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQ
APRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYY CQQYGSSPRLTFGGGTKVEIK
SEQ ID No: 215 VH 163 EVQLVQSGAEVKKPGESLKISCQGSGYRFISYWIGWVRQMPG
KGLEWMGRIYPGDSDTRYSPSFQGQVTISVDKSISTAYLQWSS
LKASDTAMYYCARQRGDYYYFNGLDVWGQGTTVTVSS SEQ ID No: 216 VL 163
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQ
APRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYY
CQQYGSSLTFGGGTKVEIK SEQ ID No: 217 VH 093
EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPG
KGLEWMGRIYPGDSDTRYSPSFQGQVTISADKSITTAYLQWSS
LRASDTAMYYCARQRGDYYYFFGLDIWGQGTTVTVSL SEQ ID No: 218 VL 093
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQ
APRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYY CQQYGSSLTFGGGTKVEIK
SEQ ID No: 219 VH 044 EVQLVQSGAEVKKPGESLKISCKGSGYRFSSYWIGWVRQMPG
KGLEWMGSIFPGDSDTRYSPSFQGQVTISADKSITTAYLQWSS
LKASDTAMYYCARQAGDYYYYNGMDVWGQGTTVTVSS SEQ ID No: 220 VL 044
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQ
APRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYY
CQQYGSSLTFGGGTKVEIK
TABLE-US-00006 TABLE 4 Consensus CDRs based on sequence alignments
shown in Figures 1 and 2. SEQ ID No: 9 IgHV3-23-1 VH GFTFSSYA
050-049-051- CDR1 055 SEQ ID No: 127 IgHV3-23-1 VH ISGX1GGX2T
Wherein X1 = R or S, and 050-049-051- CDR2 X2 = T or S; preferably,
055 wherein X1 = R and X2 = T SEQ ID No: 11 IgHV3-23-1 VH
AKARANWDYFDY 050-049-051- CDR3 055 SEQ ID No: 128 IgHV1-69-04 VH
GGTFX1X2YA Wherein X1 = R or S, and 084 CDR1 X2 = T or S;
preferably, wherein X1 = R and X2 = T SEQ ID No: 129 IgHV1-69-04 VH
IX1X2X3LGIX4 Wherein X1 = N or I, X2 = T or 084 CDR2 P, X3 = V or
I, and X4 = V or A, preferably, wherein X1 = N, X2 = T, X3 = V, and
X4 = V SEQ ID No: 130 IgHV1-69-04 VH AREKGVDYYYG Wherein X1 = I or
M, X2 = E or 084 CDR3 X1X2 D; preferably, wherein X1 = I, X2 = E
SEQ ID No: 131 IgHV1-18-1 VH GYTFTXYG Wherein X = N or S,
preferably 169-123-161- CDR1 N 124 SEQ ID No: 132 IgHV1-18-1 VH
IX1X2YX3GNT Wherein X1 = S, T, or I; X2 = A 169-123-161- CDR2 or T;
X3 = S or N; preferably, 124 wherein X1 = S, X2 = A, and X3 = S SEQ
ID No: 133 IgHV1-18-1 VH ARDRX1X2VRP Wherein X1 = I or V, X2 = V or
169-123-161- CDR3 DYFDY I; preferably, wherein X1 = I 124 and X2 =
V SEQ ID No: 134 IgHV4-34-01 VH GGSFSX1YX2 Wherein X1 = D or G and
025-001-143- CDR1 X2 = Y or F; preferably, 019-021-027 wherein X1 =
D and X2 = Y SEQ ID No: 135 IgHV4-34-01 VH IX1HX2GSX3 Wherein X1 =
H or N, X2 = S or 025-001-143- CDR2 V, and X3 = T or A; preferably,
019-021-027 wherein X1 = H, X2 = S, and X3 = T SEQ ID No: 136
IgHV4-34-01 VH ARGX1X2X3SG Wherein X1 = Y, N or L; X2 = Y
025-001-143- CDR3 X4YYFDX5 or I, X3 = D, G or A; X4 = V or
019-021-027 Y; and X5 = Y or L; preferably, wherein X1 = Y, X2 = Y,
X3 = D, X4 = V, and X5 = Y SEQ ID No: 137 IgHV4-34-01 VH GGSFSX1YY
Wherein X1 = G or D, 091-032-035- CDR1 preferably G 036-054-094 SEQ
ID No: 138 IgHV4-34-01 VH IX1HSGX2T Wherein X1 = Y, N or H; and
091-032-035- CDR2 X2 = D or S; preferably, 036-054-094 wherein X1 =
Y and X2 = D SEQ ID No: 139 IgHV4-34-01 VH ARLX1X2GSGX Wherein X1 =
Y, F or W; X2 = F 091-032-035- CDR3 3YYX4DY or Y; X3 = I, T or S;
and X4 = L 036-054-094 or F; preferably, wherein X1 = Y, X2 = F, X3
= I, and X4 = L SEQ ID No: 140 IgHV3-30-01 VH GFTFSX1X2A Wherein X1
= T or F, X2 = F or 129 CDR1 Y; preferably, wherein X1 = T and X2 =
F SEQ ID No: 141 IgHV3-30-01 VH ISYDGX1X2K Wherein X1 = G or S, X2
= H or 129 CDR2 N; preferably, wherein X1 = G and X2 = H SEQ ID No:
142 IgHV3-30-01 VH ARGLGVWGX1F Wherein X1 = A or Y, 129 CDR3 DY
preferably A SEQ ID No: 143 IgHV3-23-01 VH GFTFX1X2YX3 Wherein X1 =
S, N or T; X2 = N, 098-105-100- CDR1 D or S; and X3 = G or A;
125-162 preferably, wherein X1=S, X2 = N and X3 = G SEQ ID No: 144
IgHV3-23-01 VH ISGX1X2X3X4T Wherein X1 = S or T, X2 = A or
098-105-100- CDR2 G, X3 = Y or G, X4 = S or A; 125-162 preferably,
wherein X1=S, X2 = A, X3 = Y, X4 = S SEQ ID No: 145 IgHV3-23-01 VH
AKX1X2X3X4G Wherein X1 = A or G; X2 = H or 098-105-100- CDR3
SGSYYTX5FDY Y; X3 = Y or T; X4 = H, F or L; 125-162 X5 = L or S;
preferably, wherein X1 = A; X2 = H; X3 = Y; X4 = H; X5 = L SEQ ID
No: 146 IgHV5-51-01 VH GYSFX1X2YW Wherein X1 = S or T, X2 = I or
127 CDR1 S; preferably, wherein X1 = S, X2 = I SEQ ID No: 147
IgHV5-51-01 VH IX1PGDSDX2 Wherein X1 = F or Y, X2 = I or 127 CDR2
T; preferably, wherein X1 = F, X2 = I SEQ ID No: 148 IgHV5-51-01 VH
ARQPGDWSPR 127 CDR3 HWYFDL SEQ ID No: 149 IgHV5-51-01 VH GYXFTSYW
Wherein X = N or S, preferably 159 CDR1 N SEQ ID No: 51 IgHV5-51-01
VH IYPGDSDT 159 CDR2 SEQ ID No:52 IgHV5-51-01 VH ARWGTYYDILT 159
CDR3 GYFN SEQ ID No:71 IgHV1-18-01 VH GYTFTSYG 132 CDR1 SEQ ID No:
150 IgHV1-18-01 VH ISAYNGNX Wherein X = S or T, preferably 132 CDR2
S SEQ ID No: 151 IgHV1-18-01 VH AREYSYDSGTY 132 CDR3 FYYGMDV SEQ ID
No: 152 IgHV3-30- VH GFTFSX1X2X3 Wherein X1 = D or S, X2 = Y or
153-033-160- 03-01 CDR1 H, X3 = V or A; preferably, 166-152-167
wherein X1 = D, X2 = Y, X3 = V SEQ ID No: 153 IgHV3-30- VH
ISYDGSX1X2 Wherein X1 = N or Y, X2 = K or 153-033-160- 03-01 CDR2
E, preferably wherein X1 = N 166-152-167 and X2 = K SEQ ID No: 154
IgHV3-30- VH ARGX1X2X3X4 Wherein X1 = G, D or S; X2 = I
153-033-160- 03-01 CDR3 X5X6GX7FDY or Y; X3 = T or I; X4 = G or S;
166-152-167 X5 = T or S; X6 = T or S; X7 = Y or V; preferably,
wherein X1 = G; X2 = I; X3 = T; X4 = G; X5 = T; X6 = T; and X7 = V
SEQ ID No: 13 IgKV1-12-01 VL QGISSW 050-084-049- CDR1 051-055
050-084-049- IgKV1-12-01 VL XAS Wherein X = A or V 051-055 CDR2 SEQ
ID No:155 IgKV1-12-01 VL QQANSFPXT Wherein X = I or L 050-084-049-
CDR3 051-055 SEQ ID No: 6 IgKV3-11-01 VL QSVSSY 169-124-161- CDR1
123 169-124-161- IgKV3-11-01 VL DXS Wherein X = A or T, preferably
123 CDR2 A SEQ ID No: 156 IgKV3-11-01 VL QQRSXWPRT Wherein X = N or
H, preferably 169-124-161- CDR3 N 123 SEQ ID No: 157 IgKV1D-16- VL
QGISXW Wherein X = R or S, preferably 025-001-019- 01 CDR1 R
143-021-027 025-001-019- IgKV1D-16- VL AAS 143-021-027 01 CDR2 SEQ
ID No: 164 IgKV1D-16- VL QQYNSXPIT Wherein X = Y or F, preferably
025-001-019- 01 CDR3 Y 143-021-027 SEQ ID No: 33 IgKV1D-16- VL
QGISSW 091-032-035- 01 CDR1 036-054-094 091-032-035- IgKV1D-16- VL
AX1X2 Wherein X1 = A or T, and 036-054-094 01 CDR2 X2 = S or F;
preferably, wherein X1 = A and X2 = S SEQ ID No: 158 IgKV1D-16- VL
QQYNSFPPT 091-032-035- 01 CDR3 036-054-094 SEQ ID No: 159
IgKV1D-16- VL QGIXSW Wherein X = S or N, preferably 098-100-105- 01
CDR1 S 125-162 098-100-105- IgKV1D-16- VL AAS 125-162 01 CDR2 SEQ
ID No: 160 IgKV1D-16- VL QQYNSYPXT Wherein X = Y or L, preferably
098-100-105- 01 CDR3 Y 125-162 SEQ ID No: 161 IgKV1D-16- VL
QGIX1X2W Wherein X1 = S or N; X2 = S or 153-152-166- 01 CDR1 N;
preferably, wherein 167-160-033 X1 = X2 = S 153-152-166- IgKV1D-16-
VL XAS Wherein X = D or A, preferably 167-160-033 01 CDR2 D SEQ ID
No: 162 IgKV1D-16- VL QQYXSYPIT Wherein X = K or N, preferably
153-152-166- 01 CDR3 K 167-160-033 SEQ ID No: 221 IgHV5-51-1 VH
GYX1FX2X3YW wherein X1 = S or R; X2 = S, T, 005-060-106- CDR1 H, or
I; and X3 = S, R, or F; 041-150-067- preferably, wherein X2 = H or
072-163-093- T 044 SEQ ID No: 222 IgHV5-51-1 VH IX1PGDSX2T wherein
X1 = Y or F; X2 = D, Y, 005-060-106- CDR2 or H 041-150-067-
preferably, wherein X2 = D or 072-163-093- Y 044 SEQ ID No: 223
IgHV5-51-1 VH ARX1X2X3X4X wherein X1 = Q, H, or L; X2 = R,
005-060-106- CDR3 5X6X7X8YX9X10 A, T, or K; X3 = G; X4 = D;
041-150-067- GX11DX12 X5 = R or none; X6 = G or 072-163-093- none;
X7 = Y or F; X8 = Y or D; 044 X9 = Y, F, or H; X10 = Y, D, S, F, or
N; X11 = M or L; and X12 = V or I; preferably, wherein X1 = Q, X2 =
R or A; X5 = X6 = none; X7 = Y or F; X8 = Y; X9 = F; X10 = Y; and
X12 = V SEQ ID No: 224 IgHV3-23-1 VH GFTFSXYA wherein X = N or S,
preferably 006 CDR1 N SEQ ID No: 225 IgHV3-23-1 VH IX1GX2X3GST
wherein X1 = R or S; X2 = G or 006 CDR2 S; and X3 = A or G,
preferably wherein X1 = R; X2 = G; and X3 = A SEQ ID No: 226
IgHV3-23-1 VH AKRIWGPXFDY wherein X = L or Y, preferably 006 CDR3 L
SEQ ID No: 227 IgHV1-18-1 VH GYTFTXYG wherein X = R or S,
preferably 059 CDR1 R SEQ ID No: 228 IgHV1-18-1 VH ISAYNGXT wherein
X = K or N, preferably 059 CDR2 K SEQ ID No: 229 IgHV1-18-1 VH
ARSPLLWFEELY
059 CDR3 FDY SEQ ID No: 230 IgHV1-69-4 VH GGTFSSYX wherein X = G or
A, preferably 111 CDR1 G SEQ ID No: 202 IgHV1-69-4 VH IIPILGIA 111
CDR2 SEQ ID No: 231 IgHV1-69-4 VH ARDQEYSSX1X wherein X1 = N or Y;
X2 = W or 111 CDR3 2X3 F; and X3 = Y or D, preferably wherein X1 =
N; X2 = W; and X3 = Y SEQ ID No: 232 IgKV3-20-01 VL QSVX1SX2Y
wherein X1 = S or R and X2 = S 005-059-060- CDR1 or T 106-111-041-
150-067-072- 163-093-044 005-059-060- IgKV3-20-01 VL GAS
106-111-041- CDR2 150-067-072- 163-093-044 SEQ ID No: 233
IgKV3-20-01 VL QX1YGX2SX3X wherein X1 = Q or L; X2 = S or
005-059-060- CDR3 4X5T T; X3 = P or none; X4 = P, L, R,
106-111-041- or none; and X5 = L, F, I, or 150-067-072- none;
163-093-044 preferably, wherein X4 = P, L, or none SEQ ID No: 177
IgKV3-11-01 VL QSVSSY 006 CDR1 006 IgKV3-11-01 VL DAS CDR2 SEQ ID
No: 178 IgKV3-11-01 VL QQRSNWPPLT 006 CDR3
Example 11
Purification of Antibodies
[0749] Culture supernatant was filtered over 0.2 .mu.m dead-end
filters, loaded on 5 mL MabSelect SuRe columns (GE Health Care) and
eluted with 0.1 M sodium citrate-NaOH, pH 3. The eluate was
immediately neutralized with 2M Tris-HCl, pH 9 and dialyzed
overnight to 12.6 mM NaH2PO4, 140 mM NaCl, pH 7.4 (B. Braun).
Alternatively, subsequent to purification, the eluate was loaded on
a HiPrep Desalting column and the antibody was exchanged into 12.6
mM NaH2PO4, 140 mM NaCl, pH 7.4 (B. Braun) buffer. After dialysis
or exchange of buffer, samples were sterile filtered over 0.2 .mu.m
dead-end filters. Purity was determined by SDS-PAGE and
concentration was measured by nephelometry and absorbance at 280
nm. Purified antibodies were stored at 4.degree. C. Mass
spectrometry was performed to identify the molecular mass of the
antibody heavy and light chains expressed by the hybridomas as
described in Example 9.
Example 12
Binding of HER2 Clones to Tumor Cells Expressing Membrane-Bound
HER2 Measured by Means of FACS Analysis
[0750] The binding of HER2 antibodies to AU565 cells (purchased at
ATCC, CRL-2351) and A431 cells (purchased at ATCC, CRL-1555), was
tested using flow cytometry (FACS Canto II, BD Biosciences). Qifi
analysis (Dako, Glostrup, Denmark) revealed that AU565 cells
expressed on average 1,000,000 copies of HER2 protein per cell,
whereas A431 cells expressed on average 15,000 copies per cell.
Binding of HER2 antibodies was detected using a Phycoerythrin
(PE)-conjugated goat-anti-human IgG antibody (Jackson). Trastuzumab
(clinical-grade Herceptin.RTM.) was used as positive control
antibody, and an isotype control antibody was used as negative
control antibody. EC.sub.50 values were determined by means of
non-linear regression (sigmoidal dose-response with variable slope)
using GraphPad Prism V4.03 software (GraphPad Software, San Diego,
Calif., USA).
[0751] All tested HER2 antibodies bound to HER2 expressed on both
AU565 and A431 cells in a dose-dependent manner. For antibodies of
cross-block groups 1, 2 and 3, the EC.sub.50 values for binding
varied between 0.336-2.290 .mu.g/mL for AU565 cells and 0.068-1.135
.mu.g/mL for A431 cells (FIG. 3A-D). For antibodies of cross-block
group 4, the EC.sub.50 values for binding varied between
0.304-2.678 .mu.g/mL for AU565 cells and 0.106-1.982 .mu.g/mL for
A431 cells (FIG. 3E and F). Especially on A431 cells, large
differences in EC.sub.50 values were observed between the tested
antibodies. However, antibody 098 had the best (i.e., lowest)
EC.sub.50 value on both types of cells. Also some differences in
maximum binding levels were observed between different antibodies,
on both AU565 and A431 cells. Of the tested cross-block groups 1-3
antibodies, antibody 098 also had the highest maximum binding level
on AU565 cells, whereas antibody 025 had the highest maximum
binding level on A431 cells. For antibodies of cross-block group 4,
antibodies 005 and 006 demonstrated higher maximum binding levels
on A431 as compared to other HER2 antibodies.
Example 13
Binding of HER2 Antibodies to Membrane-Bound HER2 Expressed on
Rhesus Epithelial Cells Measured by Means of FACS Analysis
[0752] To determine cross-reactivity with Rhesus HER2, the binding
of HER2 antibodies to HER2-positive Rhesus epithelial cells (4MBr-5
purchased at ATCC) was tested using flow cytometry (FACS Canto II,
BD Biosciences). A Phycoerythrin-conjugated goat-anti-human IgG
antibody (Jackson) was used as a secondary conjugate. An isotype
control antibody was used as negative control antibody.
[0753] All tested HER2 antibodies were cross-reactive with Rhesus
monkey HER2 (FIG. 4A and B). At both tested concentrations (1
.mu.g/mL and 10 .mu.g/mL), the HER2 antibodies were able to bind
specifically to Rhesus monkey HER2. Antibody 127 demonstrated poor
binding at 1 .mu.g/mL concentration, but showed good binding at 10
.mu.g/mL concentration. Antibody 098 had the highest binding level
at both antibody concentrations. No binding was observed with the
isotype control antibody.
Example 14
Competition of HER2 Antibodies for Binding to Soluble Her2ECDHis
Measured in Sandwich-ELISA
[0754] The optimal coating concentrations of the tested HER2
antibodies and optimal Her2ECDHis concentration were determined in
the following manner: ELISA wells were coated overnight at
4.degree. C. with HER2 HuMabs serially diluted in PBS (0.125-8
.mu.g/mL in 2-fold dilutions). Next, the ELISA wells were washed
with PBST (PBS supplemented with 0.05% Tween-20 [Sigma-Aldrich,
Zwijndrecht, The Netherlands]) and blocked for one hour at room
temperature (RT) with PBSTC (PBST supplemented 2% [v/v] chicken
serum [Gibco, Paisley, Scotland]). The ELISA wells were then washed
with PBST and incubated for one hour at RT with Her2ECDHis serially
diluted in PBSTC (0.25-2 .mu.g/mL in 2-fold dilutions). Unbound
Her2ECDHis was washed away with PBST, and bound Her2ECDHis was
incubated for one hour at RT with 0.25 .mu.g/mL biotinylated
rabbit-anti-6xhis-biot (Abcam, Cambridge, UK). The plate was
thereafter washed with PBST and incubated for one hour with 0.1
.mu.g/mL Streptavidin-poly-HRP (Sanquin, Amsterdam, The
Netherlands) diluted in PBST. After washing, the reaction was
visualized through a 15 minutes incubation with 2,2'-azino-bis
(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS: one ABTS tablet
diluted in 50 mL ABTS buffer (Roche Diagnostics, Almere, The
Netherlands)) at RT protected from light. The colorization was
stopped by adding an equal volume of oxalic acid (Sigma-Aldrich,
Zwijndrecht, The Netherlands). Fluorescence at 405 nm was measured
on a microtiter plate reader (Biotek Instruments, Winooski, USA).
The antibody concentrations that resulted in sub-optimal binding of
each antibody were determined and used for the following
cross-block experiments.
[0755] Each HER2 antibody was coated to the ELISA wells at the
sub-optimal dose that was determined as described above. After
blocking of the ELISA wells, the wells were incubated with the
predetermined concentration of 1 .mu.g/mL biotinylated Her2ECDHis
in the presence or absence of an excess of a second (competitor)
HER2 antibody. The ELISA was then performed as described above.
Residual binding of Her2ECDHis to the coated antibody was expressed
as a percentage relative to the binding observed in the absence of
competitor antibody. Percentage competition was then determined as
100 minus the percentage of inhibition. 75% competition was
considered as complete cross-block, whereas 25-74% competition was
considered as partial cross-block, and 0-24% competition was
considered non-blocking.
Cross-Block Groups 1, 2 and 3:
[0756] As shown in Table 5A, all HER2 antibodies of these groups
were found to be able to block binding to Her2ECDHis, at least
partially, for themselves. After dividing the antibodies into 3
major cross-block groups, all antibodies were tested for
competition with at least one representative antibody from each
group.
[0757] The first group comprised trastuzumab and antibodies 169,
050 and 084, which blocked each other for binding to Her2ECDHis,
but did not cross-block antibodies from other groups.
[0758] The second group comprised pertuzumab and antibodies 025,
091 and 129, which blocked each other for binding to Her2ECDHis,
except for antibodies 129 and 091 which both cross-blocked
pertuzumab and 025, but not each other. None of the antibodies of
group 2 blocked antibodies from other groups.
[0759] A third group comprised antibodies C1, F5, 127, 098, 132,
153 and 159, which did not cross-block any antibody from the other
groups. Within this group 3, some variation was observed. Antibody
127 was the only antibody that was able to cross-block all other
antibodies in this group for binding to Her2ECDHis; antibody 159
cross-blocked all other antibodies within this group, except 132;
clone 098 cross-blocked all antibodies of group 3, except 132 and
153; antibody 153 cross-blocked 127, 132 and 159 for binding to
Her2ECDHis, but not 098, C1 or F5; clone 132 cross-blocked 127, 132
and 153. When added as competitor antibodies, F5 and C1 only
demonstrated cross-blocking of each other. However, the reverse
reaction also revealed competition with antibodies 127, 098 and
159, but not 153 and 132. Possibly, these differences may have
resulted from lower affinities of antibodies C1 and F5 for
Her2ECDHis.
[0760] Values higher than 100% can be explained by avidity effects
and the formation of antibody-Her2ECDHis complexes containing two
non-competing antibodies.
Cross-Block Group 4:
[0761] As shown in Table 5, all HER2 antibodies of this group
competed for binding to Her2ECDHis, at least partially, with
themselves. Trastuzumab (clinical grade Herceptin.RTM.) and
pertuzumab (TH1014-pert, transiently produced in HEK-293 cells)
could only compete with themselves, and not with any of the other
listed HER2 antibodies of cross-block group 4. C1 and F5 (both
transiently produced in HEK-293 cells) competed with each other for
binding to Her2ECDHis, but did not compete with other HER2
antibodies of cross-block group 4.
[0762] Antibodies 005, 006, 059, 060, 106 and 111 all competed with
each other for binding to Her2ECDHis, but did not cross-block with
trastuzumab, pertuzumab, C1 or F5. Clones 005, 059, 060 and 106
only blocked 006 when 006 was the competitor antibody. In the
reverse reaction where 006 was immobilized, no blocking was found
with 005, 059, 060 or 106. This was possibly a result of the higher
apparent affinity of clone 006 compared to 005, 059, 060, 106 and
111, shown in FIGS. 3A and 3B. Values higher than 100% can be
explained by avidity effects and the formation of
antibody-Her2ECDHis complexes containing two non-blocking
antibodies.
TABLE-US-00007 TABLE 5 Competition and cross-blocking of HER2
antibodies for binding to Her2ECDHis ##STR00001## ##STR00002##
[0763] Depicted values are mean percentages of binding relative to
the binding observed in the absence of competitor antibody, of two
independent experiments. Competition experiments with HEK produced
TH1014-C1 and TH1014-F5 were performed once. Trastuzumab (clinical
grade Herceptin.RTM.) and HEK-produced pertuzumab (TH1014-pert)
were also tested.
Example 15
Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
[0764] SK-BR-3 cells (purchased at ATCC, HTB-30) were harvested
(5.times.10.sup.6 cells), washed (twice in PBS, 1500 rpm, 5 min)
and collected in 1 mL RPMI 1640 medium supplemented with 10% cosmic
calf serum (CCS) (HyClone, Logan, Utah, USA), to which 200 .mu.Ci
.sup.51Cr (Chromium-51; Amersham Biosciences Europe GmbH,
Roosendaal, The Netherlands) was added. The mixture was incubated
in a shaking water bath for 1.5 hours at 37.degree. C. After
washing of the cells (twice in PBS, 1500 rpm, 5 min), the cells
were resuspended in RPMI 1640 medium supplemented with 10% CCS,
counted by trypan blue exclusion and diluted to a concentration of
1.times.10.sup.5 cells/mL.
[0765] Meanwhile, peripheral blood mononuclear cells (PBMCs) were
isolated from fresh buffy coats (Sanquin, Amsterdam, The
Netherlands) using standard Ficoll density centrifugation according
to the manufacturer's instructions (lymphocyte separation medium;
Lonza, Verviers, France). After resuspension of cells in RPMI 1640
medium supplemented with 10% CCS, cells were counted by trypan blue
exclusion and concentrated to 1.times.10.sup.7 cells/mL.
[0766] Trastuzumab was produced in CHO cells resulting in an
(increased) non-core fucosylation grade of 12.4%, whereas the other
HER2 antibodies were produced in HEK cells, resulting on average in
4% non-core fucosylation.
[0767] For the ADCC experiment, 50 .mu.L .sup.51Cr-labeled SK-BR-3
cells (5.000 cells) were pre-incubated with 15 .mu.g/mL HER2
antibody (IgG1,.kappa.) in a total volume of 100 .mu.L RPMI medium
supplemented with 10% CCS in a 96-well microtiter plate. After 15
min at RT, 50 .mu.L PBMCs (500,000 cells) were added, resulting in
an effector to target ratio of 100:1. The maximum amount of cell
lysis was determined by incubating 50 .mu.L .sup.51Cr-labeled
SK-BR-3 cells (5,000 cells) with 100 .mu.L 5% Triton-X100. The
amount of spontaneous lysis was determined by incubating 5000
.sup.51Cr-labeled SK-BR-3 cells in 150 .mu.L medium, without any
antibody or effector cells. The level of antibody-independent cell
lysis was determined by incubating 5,000 SK-BR-3 cells with 500,000
PBMCs without antibody. Subsequently, the cells were incubated 4 hr
at 37.degree. C., 5% CO.sub.2. To determine the amount of cell
lysis, the cells were centrifuged (1,200 rpm, 3 min) and 75 .mu.L
of supernatant was transferred to micronic tubes, after which the
released .sup.51Cr was counted using a gamma counter. The measured
counts per minute (cpm) were used to calculate the percentage of
antibody-mediated lysis as follows:
(cpm sample-cpm Ab-independent lysis)/(cpm maxlysis-cpm spontaneous
lysis).times.100%
[0768] HER2 antibodies from cross-block groups 1 and 2 induced
efficient lysis of SK-BR-3 cells through ADCC (FIG. 5A). From group
3, antibody 153 was the only antibody that induced efficient ADCC,
antibody 132 induced about 10% ADCC, and clones 098, 159 and 127
did not induce ADCC. See FIG. 5. All HER2 antibodies from
cross-block group 4 induced efficient lysis of SK-BR-3 cells
through ADCC (FIG. 5B). The average percentage lysis by the
different antibodies of cross-block group 4 varied between 15% and
28%, in constrast to trastuzumab (Herceptin.RTM.), which showed on
average 41% lysis. Without being bound by theory, the higher
percentage lysis by trastuzumab possibly resulted from an increased
non-core fucosylation grade (12.4%) due to its CHO production,
compared to .about.4% non-core fucosylation on the other
HEK-produced HER2 antibodies, or by recognizing an epitope that
induces less internalization of the HER2 receptor-antibody
complexes.
Example 16
Inhibition of Ligand-Independent Proliferation of AU565 Cells
[0769] HER2 antibodies were tested for their ability to inhibit
proliferation of AU565 cells in vitro. Due to the high HER2
expression levels on AU565 cells (.about.1,000,000 copies per cell
as described in Example 12), HER2 is constitutively active in these
cells and thus not dependent on ligand-induced
heterodimerization.
[0770] In a 96-well tissue culture plate (Greiner bio-one,
Frickenhausen, Germany), 9,000 AU565 cells were seeded per well in
the presence of 10 fag/mL HER2 antibody in serum-free cell culture
medium. As a control, cells were seeded in serum-free medium
without antibody. After 3 days, the amount of viable cells was
quantified with Alamarblue (BioSource International, San Francisco,
US) according to the manufacturer's instructions. Fluorescence was
monitored using the EnVision 2101 Multilabel reader (PerkinElmer,
Turku, Finland) with standard Alamarblue settings. The Alamarblue
signal of antibody-treated cells was plotted as a percentage
relative to untreated cells. Dunnett's test was applied for
statistical analysis.
[0771] The percentage proliferation of AU565 cells after HER2
antibody treatment was compared to untreated cells, which was set
to 100%. Of the tested Group 1 antibodies, trastuzumab, 050 and 169
demonstrated significant inhibition of AU565 cell proliferation
(P<0.05), whereas 084 had no effect. None of the tested
antibodies from group 2 (Pertuzumab, 025, 092 and 129) was able to
inhibit AU565 cell proliferation. The tested antibodies from group
3 (098 and 153) did not inhibit AU565 proliferation. In contrast,
both antibodies induced enhanced proliferation of AU565 cells
compared to untreated cells (098 more than 153). See FIG. 6. For
trastuzumab and pertuzumab, this was in accordance with the results
described by Juntilla et al. (Cancer Cell 2009; 15(5):353-355).
[0772] From cross-block group 4, TH1014-F5 significantly enhanced
proliferation of AU565 cells indicating that this is an agonistic
antibody, whereas none of the other antibodies of cross-block group
4 tested (005, 060 and pertuzumab) had a substantial effect on
AU565 proliferation (data not shown). Enhancing proliferation can
be an advantage in some therapeutic applications of ADC-conjugates,
e.g., where the cytotoxic action of the drug relies on, or is
enhanced by, cell proliferation.
Example 17
Inhibition of Ligand-Induced Proliferation of MCF-7 Cells
[0773] Since HER2 is an orphan receptor, its signaling is mainly
dependent on activation of other ErbB-family members such as EGFR
and Her3. Upon ligand binding, these two receptors can bind to and
activate the HER2 receptor, resulting in e.g. proliferation.
Various publications describe that pertuzumab efficiently inhibits
Heregulin-.beta.1-induced proliferation (Franklin MC. Cancer Cell
2004/Landgraf R. BCR 2007). For trastuzumab, it has been described
that it has little effect on Heregulin-.beta.1-induced HER2/HER3
heterodimerization and proliferation (Larsen SS., et al., Breast
Cancer Res Treat 2000; 58:41-56; Agus D B., et al., Cancer Cell
2002; 2:127-137; Wehrman et al. (2006), supra).
[0774] To investigate the ability of the present human HER2
antibodies to interfere with Heregulin-.beta.1-induced HER2/HER3
heterodimers, a Heregulin-.beta.1-induced proliferation assay was
performed. Therefore, MCF7 cells (purchased at ATCC, HTB-22)
expressing .about.20.000 HER2 molecules per cell, were seeded in a
96-wells tissue culture plate (Greiner bio-one) (2.500 cells/well)
in complete cell culture medium. After 4 hours, the cell culture
medium was replaced with starvation medium containing 1% Cosmic
Calf Serum (CCS) and 10 .mu.g/mL HER2 antibody. Next,
Heregulin-.beta.1 (PeproTech, Princeton Business Park, US) diluted
in 1% CCS containing starvation medium was added to the wells to a
final concentration of 1.5 ng/mL. After 4 days incubation, the
amount of viable cells was quantified with Alamarblue (BioSource
International) according to the manufacturer's instructions.
Fluorescence was monitored using the EnVision 2101 Multilabel
reader (PerkinElmer) with standard Alamarblue settings. The
Alamarblue signal of HER2 antibody-treated ligand-induced cells was
plotted as a percentage signal compared to ligand-induced cells
incubated without HER2 antibody. Dunnett's test was applied for
statistical analysis.
[0775] The percentage of viable MCF7 cells stimulated with
Heregulin-.beta.1 and treated with the indicated HER2 antibody,
relative to the viable cells after stimulation with
Heregulin-.beta.1 in the absence of HER2 antibody, was calculated.
There was no MCF-7 proliferation in absence of both
Heregulin-.beta.1 and antibody. Antibodies 025, 091, 129, 153 and
pertuzumab (TH1014-pert) demonstrated significant inhibition of
Heregulin-.beta.1-induced MCF-7 proliferation (P<0.05). Also
trastuzumab showed some inhibition of Heregulin-.beta.1-induced
proliferation of MCF-7 cells, although not as efficient as the
other tested HER2 antibodies. It has been reported that domain IV
of HER2 is involved in the stabilization of EGFR/HER2 heterodimers,
but without details on its contribution to HER2/HER3 heterodimers
(Wehrman et al., supra). Antibodies 050, 084, 169 and 098 had no
statistically significant effect on Heregulin-.beta.1-induced
proliferation of MCF-7 cells. See FIG. 7. Without being limited to
theory, this suggests that these antibodies do not inhibit
ligand-induced HER2/HER3 heterodimerization.
Example 18
Anti-Kappa-ETA' Assay
[0776] To investigate the suitability of HER2 antibodies for an
antibody-drug conjugate approach, a generic in vitro cell-based
killing assay using kappa-directed pseudomonas-exotoxin A
(anti-kappa-ETA') was developed. The assay makes use of a high
affinity anti-kappa domain antibody conjugated to a truncated form
of the pseudomonas-exotoxin A. Upon internalization, the
anti-kappa-ETA' domain antibody undergoes proteolysis and
disulfide-bond reduction, separating the catalytic from the binding
domain. The catalytic domain is transported from the Golgi to the
endoplasmic reticulum via the KDEL retention motif, and
subsequently translocated to the cytosol where it inhibits protein
synthesis and induces apoptosis (ref. Kreitman R J. BioDrugs 2009;
23(1):1-13). In this assay, to identify HER2 antibodies that enable
internalization and killing through the toxin, HER2 antibodies are
preconjugated with the anti-kappa-ETA' before incubation with
HER2-positive cells.
[0777] First, the optimal concentration of anti-kappa-ETA' was
determined for each cell line, i.e. the maximally tolerated dose
that does not lead to induction of non-specific cell death. AU565
cells (7,500 cells/well) and A431 cells (2500 cells/well) were
seeded in normal cell culture medium in 96-wells tissue culture
plate (Greiner bio-one) and allowed to adhere for at least 4 hours.
Next, cells were incubated with 100, 10, 1, 0.1, 0.01, 0.001 and 0
.mu.g/mL anti-kappa-ETA' dilutions in normal cell culture medium.
After 3 days, the amount of viable cells was quantified with
Alamarblue (BioSource International, San Francisco, US) according
to the manufacturer's instruction. Fluorescence was monitored using
the EnVision 2101 Multilabel reader (PerkinElmer, Turku, Finland)
with standard Alamarblue settings. The highest concentration
anti-kappa-ETA' that did not kill the cells by itself was used for
following experiments (0.5 .mu.g/mL for AU565 and 1 .mu.g/mL for
A431).
[0778] Next, antibody-mediated internalization and killing by the
toxin was tested for different HER2 antibodies. Cells were seeded
as described above. Dilution-series of HER2 antibodies were
pre-incubated for 30 minutes with the predetermined concentration
anti-kappa-ETA' before adding them to the cells. After 3 days of
incubation, the amount of viable cells was quantified as described
above. The Alamarblue signal of cells treated with anti-kappa-ETA'
conjugated antibodies was plotted compared to cells treated with
antibody alone. 23.4 .mu.g/mL Staurosporin was used as positive
control for cell killing. An isotype control antibody was used as
negative control.
Cross-Block Groups 1, 2 and 3:
[0779] As shown in FIG. 8A/B and Table 6A, all
anti-kappa-ETA'-conjugated HER2 antibodies were able to kill AU565
cells in a dose-dependent manner. All tested
anti-kappa-ETA'-conjugated HER2 antibodies demonstrated better
killing of AU565 cells (70.3-49.9%) compared to both
anti-kappa-ETA'-conjugated trastuzumab (31.9%) and
anti-kappa-ETA'-conjugated pertuzumab (TH1014-pert) (47.51%). and
the EC.sub.50 values were increased. 12.12-46.49 ng/mL compared to
78.49 ng/mL for anti-kappa-ETA'-conjugated trastuzumab and 117.8
ng/mL for anti-kappa-ETA'-conjugated pertuzumab. Antibody 159 had
the highest percentage of cell-kill, and 098 the lowest
EC.sub.50.
[0780] As shown in FIGS. 8C,D and Table 7A, antibodies 025, 091,
098, 129 and 153 were able to induce effective killing of A431
cells (.gtoreq.75%). The highest percentage of cell-kill, and
lowest EC.sub.50 was shown by antibody 098. When conjugated to
anti-kappa-ETA', trastuzumab and isotype control antibody did not
induce killing of A431 cells. Antibodies 169, 084 and pertuzumab
induced percentages of cell kill of no more than about 50%. No cell
kill was observed with non-conjugated HER2 antibodies.
Cross-Block Group 4:
[0781] As shown in Table 6B, all anti-kappa-ETA'-conjugated HER2
antibodies of cross-block group 4 were able to kill AU565 cells in
a dose-dependent manner. (50-72% cell killing). Aantibodies 005 and
111 demonstrated more than three times improved EC.sub.50 values
(resp. 15.13 and 24.20 ng/mL) compared to trastuzumab (78.49
ng/mL). Non-conjugated HER2 antibodies of cross-block group 4 did
not induce killing of AU565 cells at the concentrations tested.
[0782] As shown in Table 7B, antibodies 005 and 060 were able to
induce effective killing of A431 cells (.gtoreq.85%) when
conjugated to anti-kappa-ETA' Antibodies 005 and 111 demonstrated
killing of A431 cells already at low antibody concentrations (10
ng/mL) with EC.sub.50 values of .about.10 ng/mL. No cell kill was
observed with non-conjugated HER2 antibodies of cross-block 4.
TABLE-US-00008 TABLE 6 Data shown are EC.sub.50 values and maximal
percentage cell kill of AU565 cells treated with
anti-kappa-ETA'-conjugated HER2 antibodies (A, cross-block groups
1, 2, and 3; b, cross-block group 4), measured in one
representative experiment. Cell-kill induced by Staurosporin was
set as 100% and MFI of untreated cells was set as 0%. antibody %
cells killed EC50 ng/mL A: PC1014-159 70.3 34.93 PC1014-127 69.0
34.46 PC1014-132 61.6 39.35 PC1014-129 60.8 30.85 PC1014-153 60.3
32.26 PC1014-025 60.0 16.71 PC1014-098 58.7 12.12 PC1014-084 58.1
26.97 PC1014-050 52.4 12.71 PC1014-091 50.6 46.49 PC1014-169 49.9
35.62 TH1014-pert 47.5 117.8 trastuzumab 31.9 78.49 isotype control
Ndet Ndet B: PC1014-111 72.0 24.2 PC1014-005 69.7 15.13 PC1014-059
67.0 67.65 PC1014-060 64.3 79.38 PC1014-106 59.1 107.9 PC1014-006
50.4 45.14 Trastuzumab 31.9 78.49 isotype control Ndet Ndet Ndet =
not detected.
TABLE-US-00009 TABLE 7 Data shown are EC.sub.50 values and maximal
percentage cell kill of A431 cells treated with
anti-kappa-ETA'-conjugated HER2 antibodies (A, cross-block groups
1, 2, and 3; b, cross-block group 4), measured in one
representative experiment. Cell kill induced by Staurosporin was
set as 100% and MFI of untreated cells was set as 0%. antibody %
cells killed EC50 ng/mL A: PC1014-025 86.7 ~9.77 PC1014-084 50.5 ND
PC1014-091 83.3 ~9.86 PC1014-098 87.2 1.65 PC1014-129 75.9 ~10.60
PC1014-153 82.4 ~10.11 PC1014-169 34.0 ND TH1014-pert 37.0 61.58
trastuzumab Ndet Ndet isotype control NDet NDet B: PC1014-005 88.5
~10.07 PC1014-060 85.0 ~10.03 Trastuzumab NDet NDet isotype control
NDet NDet "NDet" means not detected.
Example 19
Internalization of HER2 Antibodies Measured with an FMAT-Based
fab-CypHer5E Assay
[0783] To investigate whether the enhanced killing of AU565 cells
by the described HER2 antibodies compared to Trastuzumab
(Herceptin.RTM.) and pertuzumab in the kappa-toxin-ETA' assay
described in the previous Example correlated with enhanced
internalization of HER2 antibodies, a fab-CypHer5E-based
internalization assay was performed. CypHer5E is a pH-sensitive dye
which is non-fluorescent at basic pH (extracellular: culture
medium) and fluorescent at acidic pH (intracellular: lysosomes),
with an acid dissociation constant (pKa) of 7.3.
[0784] AU565 cells were seeded in 384-well tissue culture plates
(Greiner bio-one), at a density of 3,000 cells/well in normal cell
culture medium supplemented with 240 ng/mL fab-CypHer5E
(conjugation of Goat-fab-anti-Human IgG [Jackson] with CypHer5E [GE
Healthcare, Eindhoven, The Netherlands] was made according to
manufacturer's instructions). Next, HER2 antibodies were serially
diluted in normal cell culture medium, added to the cells and left
at room temperature for 9 hours. Mean fluorescent intensities (MFI)
of intracellular CypHer5E were measured using the 8200 FMAT
(Applied Biosystems, Nieuwerkerk A/D IJssel, The Netherlands) and
`counts.times.fluorescence` was used as read-out. An isotype
control antibody was used as negative control antibody. EC.sub.50
values and maximal MFI were determined by means of non-linear
regression (sigmoidal dose-response with variable slope) using
GraphPad Prism V4.03 software (GraphPad Software, San Diego,
Calif., USA).
Cross-Block Groups 1, 2 and 3:
[0785] The results are shown in Table 8A, depicting the EC.sub.50
and maximal MFI values for all tested HER2 antibodies of
cross-block groups 1, 2, and 3 in the CypHer5E internalization
assay with AU565 cells. The maximal MFI values indicate how many
HER2 receptors are internalized upon antibody binding. All HER2
antibodies showed higher maximal MFI values (137,904-38,801)
compared to trastuzumab (35,000) and pertuzumab (TH1014-pert)
(32,366), indicating that the tested HER2 antibodies induced
enhanced receptor internalization. Notably, antibodies that did not
compete for HER2 binding with trastuzumab (Herceptin.RTM.) or
TH1014-pert induced more receptor internalization compared to
antibodies that did compete with trastuzumab and TH1014-pert, with
the highest MFI achieved by antibodies 098 and 127. Without being
limited to theory, this might be inherent to an inability to
inhibit HER2 heterodimerization.
Cross-Block Group 4:
[0786] The results are shown in Table 8B, depicting the EC.sub.50
values and maximal MFI for all tested HER2 antibodies of
cross-block group 4 in the CypHer5E internalization assay with
AU565 cells. The maximal MFI values reflect how many HER2
antibodies were internalized upon binding. All tested human HER2
antibodies of cross-block group 4 showed higher maximal MFI values
(130.529-57.428) than trastuzumab (Herceptin.RTM.) (35.000) and
TH1014-pert (35.323), indicating that these antibodies induced
enhanced receptor internalization. The enhanced internalization of
TH1014-F5 may be a result from its agonistic activity and the
induction of HER2-HER2 dimerization (see Example 16).
TABLE-US-00010 TABLE 8 Cypher-5-based internalization assay of HER2
antibodies. Data shown are MFI and EC.sub.50 values of one
representative experiment of two experiments with AU565 cells
treated with fab-CypHer5E-labeled HER2 antibodies. Some EC.sub.50
values could not be calculated (ND). Cypher 5 EC.sub.50 Maximal
Antibody ng/mL MFI A: PC1014-025 30.05 63428 PC1014-091 32.99 50711
mAbs that compete with PC1014-129 7.15 60302 {close oversize
bracket} Herceptin TH1014-pert 530 32366 PC1014-169 ND 38801 mAbs
that compete with PC1014-084 30.51 71059 {close oversize bracket}
TH1014-pert trastuzumab 21.70 35000 PC1014-098 13.77 134575
PC1014-127 ~9.68 137904 mAbs that compete with PC1014-159 ND 92427
{close oversize bracket} TH1014-F5 TH1014-F5 22.65 113116
PC1014-132 11.42 112270 {close oversize bracket} Non-competing mAbs
PC1014-153 ~14.91 87531 B: PC1014-006 23.08 130829 PC1014-005 21.37
95117 PC1014-111 35.22 81680 PC1014-059 14.77 77123 PC1014-060
36.16 68184 PC1014-106 68.60 57428 TH1014-F5 22.65 113116
TH1014-pert ~1041 35323 Trastuzumab 21.70 35000
Example 20
Generation of Bispecific Antibodies by 2-MEA-Induced Fab-Arm
Exchange
[0787] An in vitro method for producing bispecific antibodies is
described in WO 2008119353 (Genmab) and reported by van der
Neut-Kolfschoten et al. (Science. 2007 Sep. 14; 317(5844):1554-7).
Herein, a bispecific antibody was formed by "Fab-arm" or
"half-molecule" exchange (swapping of a heavy chain and attached
light chain) between two monospecific IgG4- or IgG4-like antibodies
upon incubation under mildly reducing conditions. Without being
limited to theory, this Fab-arm exchange reaction was the result of
a disulfide-bond isomerization reaction wherein the inter
heavy-chain disulfide bonds in the hinge regions of monospecific
antibodies were reduced and the resulting free cysteines form a new
inter heavy-chain disulfide bond with cysteine residues of another
antibody molecule with a different specificity. The resulting
product was a bispecific antibody having two Fab arms with
different sequences.
[0788] The knowledge of this natural IgG4 Fab-arm exchange was
adapted to generate a method to produce stable IgG1-based
bispecific antibodies (WO 2011131746 (Genmab)). The bispecific
antibody product generated by this method described below will no
longer participate in IgG4 Fab-arm exchange. The basis for this
method was the use of complimentary CH3 domains, which promote the
formation of heterodimers under specific assay conditions. To
enable the production of bispecific antibodies by this method, IgG1
molecules carrying certain mutations in the CH3 domain were
generated: in one of the parental IgG1 antibody T350I, K370T and
F405L mutations (or minimally F405L) in the other parental IgG1
antibody the K409R mutation.
[0789] To generate bispecific antibodies, these two parental
antibodies, each antibody at a final concentration of 0.5 mg/mL
(equimolar concentration), were incubated with 25 mM
2-mercaptoethylamine-HCl (2-MEA) in a total volume of 100 .mu.L TE
at 37.degree. C. for 90 min. The reduction reaction is stopped when
the reducing agent 2-MEA is removed by using spin columns (Microcon
centrifugal filters, 30 k, Millipore) according to the
manufacturer's protocol.
Example 21
HER2.times.CD3 Bispecific Antibodies Tested in an In Vitro
Cytotoxicity Assay
[0790] CD3 is a protein complex that is associated with the T cell
receptor .alpha. and .beta. chain expressed on mature T cells.
Combination of a CD3 specific antibody Fab-arm with a tumor antigen
specific antibody Fab-arm in a bispecific antibody would result in
the specific targeting of T cells to tumor cells, leading to T cell
mediated tumor cell lysis. Likewise, CD3 positive T cells could be
targeted to other derailed cells in the body, to infected cells or
directly to pathogens.
[0791] Various HER2.times.CD3 bispecific antibodies were generated,
combining different HER2 and public domain CD3 antibody sequences.
Furthermore b12, a gp120 specific antibody (Barbas, CF. J Mol Biol.
1993 Apr. 5; 230(3):812-23.) was used as a negative control. Heavy
and light chain variable region sequences for the HER2-specific
Fab-arm for antibody 153 were SEQ ID NO:63 and 67, respectively,
and VH and VL sequences for the HER2-specific Fab-arm of antibody
169 were SEQ ID NO:1 and 5, respectively. The following heavy and
light chain variable region sequences for the CD3 specific Fab-arm
were used:
[0792] YTH12.5 (Routledge et al., Eur J Immunol. 1991,
21(11):2717-25, hereby incorporated by reference in its entirety,
including sequence disclosures)
TABLE-US-00011 SEQ ID NO: VH YTH12.5
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFPMAWVRQAP 234
GKGLEWVSTISTSGGRTYYRDSVKGRFTISRDNSKNTLYLQ
MNSLRAEDTAVYYCAKFRQYSGGFDYWGQGTLVTVSS SEQ ID NO: VL YTH12.5
DIQLTQPNSVSTSLGSTVKLSCTLSSGNIENNYVHWYQLYE 235
GRSPTTMIYDDDKRPDGVPDRFSGSIDRSSNSAFLTIHNVAI
EDEAIYFCHSYVSSFNVFGGGTKLTVL Sequences highlighted by bold represent
the CDR1 domains, sequences highlighted by underline represent the
CDR2 domains, and sequences highlighted by italic represent the
CDR3 domains.
[0793] HUM291 (humanized antibody visilizumab, sequences retrieved
from the NCBI protein database under GenBank accession No.:
AAC28464.1, hereby incorporated by reference in its entirety)
TABLE-US-00012 SEQ ID NO: VH HUM291
QVQLVQSGAEVKKPGASVKVSCKASGYTFISYTMHWVRQA 236
PGQGLEWMGYINPRSGYTHYNQKLKDKATLTADKSASTAYM
ELSSLRSEDTAVYYCARSAYYDYDGFAYWGQGTLVTVSS SEQ ID NO: VL HUM291
DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQKPG 237
KAPKRLIYDTSKLASGVPSRFSGSGSGTDFTLTISSLQPEDFA TYYCQQWSSNPPTFGGGTKVEIK
Sequences highlighted by bold represent the CDR1 domains, sequences
highlighted by underline represent the CDR2 domains, and sequences
highlighted by italic represent the CDR3 domains.
[0794] huOKT3-C114S-gLC (used in teplizumab, with an additional
C114S mutation in VH; Adair, J. et al. 1994. Hum Antibodies
Hybridomas 5:41-47, hereby incorporated by reference in its
entirety, including sequence disclosures).
TABLE-US-00013 SEQ ID NO: VH huOKT3-
QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVR 238 C114S-gLC
QAPGKGLEWIGYINPSRGYTNYNQKVKDRFTISRDNSKNT
AFLQMDSLRPEDTGVYFCARYYDDHYSLDYWGQGTPVTV SS SEQ ID NO: VL huOKT3-
DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTP 239 C114S-gLC
GKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQP
EDIATYYCQQWSSNPFTFGQGTKLQIT Sequences highlighted by bold represent
the CDR1 domains, sequences highlighted by underline represent the
CDR2 domains, and sequences highlighted by italic represent the
CDR3 domains.
[0795] huCLB-T3/4 is a humanized version of murine antibody
CLB-T3/4 (Parren et al., Res Immunol. 1991, 142(9):749-63, hereby
incorporated by reference in its entirety, including sequence
disclosures. Briefly, the CLB-T3/4 murine VH and VL sequences as
published in Parren et al. (1991) were aligned to the human VH and
VL repertoires using the IMGT's V-QUEST. The closest human
germlines that were found were IGHV3-21*01 for the VH gene and
IGKV3-11*01(+IGKJ4*02) for the VL gene. All amino acid residues in
the murine VH and VL sequences that differed were replaced by the
human equivalent, except for those within the CDR regions of
CLB-T3/4. As no related J-region was found for the VH sequence, the
common WGQGTLVTVSS sequence was used for the FR4 region of the
heavy chain. Both sequences were cloned into the relevant
expression vectors and expressed by cotransfection in HEK293F
cells.
TABLE-US-00014 SEQ ID NO: VH huCLB-T3/4
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMFWVRQ 240
APGKGLEWVATISRYSRYIYYPDSVKGRFTISRDNAKNSLY
LQMNSLRAEDTAVYYCARRPLYGSSPDYWGQGTLVTVSS SEQ ID NO: VL huCLB-T3/4
EIVLTQSPATLSLSPGERATLSCSASSSVTYVHWYQQKPG 241
QAPRLLIYDTSKLASGIPARFSGSGSGTDFTLTISSLEPEDF AVYYCFQGSGYPLTFGSGTKLEMR
SEQ ID NO: VH CDR1 GFTFSSYG 242 SEQ ID NO: VH CDR2 ISRYSRYI 243 SEQ
ID NO: VH CDR3 ARRPLYGSSPDY 244 SEQ ID NO: VL CDR1 SSVTY 245 VL
CDR2 DTS SEQ ID NO: VL CDR3 FQGSGYPLT 246
[0796] All antibodies were expressed as IgG1,.kappa. being modified
in their Fc regions as follows: IgG1-HER2-153-K409R,
IgG1-HER2-169-K409R, IgG1-b12-K409R, IgG1-hu-CLB-T3/4-F405L,
IgG1-YTH12.5-F405L, IgG1-HUM291-F405L and IgG1-huOKT3-F405L.
[0797] Also, for subsequent experiments, N297Q mutants of the same
antibodies were generated to make the Fc-domain of the antibodies
inert. An inert Fc-domain prevents the antibody to interact with
Fc-receptors present on monocytes, since it removes a glycosylation
site; glycosylation at this site is critical for IgG-Fcgamma
receptor interactions (Bolt S et al., Eur J Immunol 1993,
23:403-411). Alternatively to the N297Q mutation, residual Fc
activity was further removed by combining three sets of mutations
from the public domain in one antibody Fc domain. The mutations
L234F, L235E, P331S (Oganesyan, Acta Cryst. (2008). D64, 700-704),
D265A (Shields JBC (2001) 276(9) 6591-6604) and N297Q were
introduced in the K409R and F405L IgG1 backbone. The combinations
of these five mutations, designated LFLEDANQPS (SEQ ID NO:251) is
used in some of the examples as well. The following Fc sequences
for the different Fc-variants were used (mutations are highlighted
by underlined letters:
TABLE-US-00015 IgG1 heavy chain constant region-WT (SEQ ID NO: 247)
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV
TVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP
EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS
NKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTT
PPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK IgG1 heavy
chain constant region-F405L (SEQ ID NO: 248)
>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV
SNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFLLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK IgG1 heavy
chain constant region-K409R (SEQ ID NO: 249)
>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV
SNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK IgG1 heavy
chain constant region-N297Q (SEQ ID NO: 250)
>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKV
SNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK IgG1 heavy
chain constant region-LFLEDANQPS mut (SEQ ID NO: 251)
>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISR
TPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKV
SNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK IgG1 heavy
chain constant region-F405L N297Q (SEQ ID NO: 252)
>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKV
SNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFLLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK IgG1 heavy
chain constant region-K409R N297Q (SEQ ID NO: 253)
>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKV
SNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK IgG1 heavy
chain constant region-F405L LFLEDANQPS (SEQ ID NO: 254)
>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISR
TPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKV
SNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFLLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK IgG1 heavy
chain constant region-K409R LFLEDANQPS (SEQ ID NO: 255)
>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV
VTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISR
TPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRVVSVLTVLHQDWLNGKEYKCKV
SNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
[0798] The following heavy and light chain variable region
sequences for the b12, HIV gp120 specific Fab-arm were used
(sequence as described by: Barbas, CF. J Mol Biol. 1993 Apr. 5;
230(3):812-23.)
TABLE-US-00016 VH b12 (SEQ ID NO: 256)
>QVQLVQSGAEVKKPGASVKVSCQASGYRFSNFVIHWVRQAPGQRFEWMGWINPYNGNKEFSAKFQ
DRVTFTADTSANTAYMELRSLRSADTAVYYCARVGPYSWDDSPQDNYYMDVWGKGTTVIVSS VL
b12 (SEQ ID NO: 257)
>EIVLTQSPGTLSLSPGERATFSCRSSHSIRSRRVAWYQHKPGQAPRLVIHGVSNRASGISDRFSGSGS
GTDFTLTITRVEPEDFALYYCQVYGASSYTFGQGTKLERK
[0799] Bispecific antibodies from these HER2 and CD3 specific
antibodies were generated as described in Example 20.
[0800] Specificity for human CD3 was verified by binding of the
bispecific HER2.times.CD3 antibodies to Jurkat (CD3 expressing T
cell line) cells using flow cytometry. Bivalent binding of parental
IgG1 anti-CD3 antibodies was compared to binding by monospecific
parental antibodies. All generated bispecific batches showed good
binding to both Jurkat cells albeit with a lower affinity than
monospecific bivalent CD3 antibodies (FIG. 9A-D).
[0801] Simultaneous binding of the bispecific antibody
huCLB-T3/4-N297Q-F405L.times.HER2-169-N297Q-K409R was shown by
co-incubating two cell populations labeled with different
fluorescent dyes in the presence of bispecific antibodies or
control antibodies. HER2 positive AU565 cells were labeled with
CFSE (FITC/FL-1) and CD3 expressing Jurkat cells were labeled with
PKH26 (PE/FL-2), according to manufacturer's instructions. Both
cell types were then co-incubated for 30 min at 4.degree. C., in
the presence of bispecific HER2.times.CD3 antibodies. Samples were
analyzed by flow cytometry on FACS CantoII. A quadrant analysis was
performed to detect CSFE/PKH26 double-positive cells.
[0802] Only in the presence of bispecific antibody, a population of
double-positive cells (doublets) was observed, indicating that
these antibodies can bind two cell types simultaneously. Data are
summarized in FIG. 10A and representative examples of cells treated
with bispecific HER2.times.CD3 (169.times.CLB-T3/4) and a
monospecific control antibody are shown in FIG. 10B.
[0803] The HER2.times.CD3 antibodies were then tested in an in
vitro cytotoxicity assay using AU565 cells with either isolated T
cells alone or PBMCs as effector cells. AU565 cells were cultured
to near confluency. Cells were washed twice with PBS, and
trypsinized for 5 minutes at 37.degree. C. 12 mL culture medium was
added to inactivate trypsin and cells were spun down for 5 min, 800
rpm. Cells were resuspended in 10 mL culture medium and a single
cell suspension was made by passing the cells through a
cellstrainer. 100 .mu.L of a 5.times.10.sup.5 cells/mL suspension
was added to each well of a 96-well culture plate, and cells were
incubated at least 3 hrs at 37.degree. C., 5% CO2 to allow
adherence to the plate.
[0804] Peripheral blood mononuclear cells (PBMC) were isolated from
blood from healthy volunteers using Leucosep 30 mL tubes, according
to the manufacturer's protocol (Greiner Bio-one). T cells were
isolated from PBMC preparations by negative selection using the
Untouched Human T-cells Dynabead kit (Dynal). Isolated cells were
resuspended in culture medium to a final concentration op
7.times.10.sup.6 cells/mL.
[0805] Culture medium was removed from the adhered AU565 cells, and
replaced with 50 .mu.L/well 2.times. concentrated antibody-dilution
and 50 .mu.L/well 7.times.10.sup.6 T cells/mL (ratio
effector:target=7:1). Plates were incubated for 3 days at
37.degree. C., 5% CO.sub.2. Supernatants were removed and plates
were washed twice with PBS. To each well 150 .mu.L culture medium
and 15 .mu.L Alamar blue was added. Plates were incubate for 4
hours at 37.degree. C., 5% CO.sub.2, and absorbance was measured
(Envision, Perkin Elmer).
[0806] FIG. 11 shows that all bispecific HER2.times.CD3 antibodies
induced dose-dependent killing of AU565 cells in an in vitro
cytoxicity assay with isolated T cells. Killing was critically
dependent on the presence of a tumor-targeting Fab-arm (both clone
169 and 153), whereas control antibodies (CD3 monospecific
IgG1-YTH12.5, IgG1-huCLB-T3/4, IgG1-Hum291 and IgG1-OKT3 and
irrelevant antigen-specific IgG1-b12, and CD3.times.b12) did not
induce T cell cytotoxicity. Bispecific antibodies containing
HER2-169 were more potent than those containing HER2-153.
[0807] As shown in FIG. 17 of Example 27, the N297Q mutation and
therefore absence of Fc glycosylation of HER2.times.CD3 bispecific
antibody huCLB-T3/4.times.HER2-169 did not impact the potential to
induce dose dependent cytotoxicity of AU565 cells with PBMC.
Example 22
HER2 Downmodulation
[0808] To investigate if enhanced HER2 internalization induced by
Group 3 antibodies 098 and 153 and Group 4 antibody 005 also
results in enhanced receptor downmodulation, AU565 cells were
incubated with HER2 antibodies for 3 days, and analyzed for
presence of HER2. AU565 cells were seeded in a 24-wells tissue
culture plate (100.000 cells/well) in normal cell culture medium
and cultured for 3 days at 37.degree. C. in the presence of 10
.mu.g/mL HER2 antibody. After washing with PBS, cells were lysed by
incubating 30 min at room temperature with 25 .mu.L Surefire Lysis
buffer (Perkin Elmer, Turku, Finland). Total protein levels were
quantified using bicinchoninic acid (BCA) protein assay reagent
(Pierce) according to the manufacturer's protocol. HER2 protein
levels in the lysates were analyzed using a HER2-specific sandwich
ELISA. Rabbit-anti-human HER2 intracellular domain antibody (Cell
Signaling) was used to capture HER2 and biotinylated
goat-anti-human HER2 polyclonal antibody (R&D), followed by
streptavidin-poly-HRP, were used to detect bound HER2. The reaction
was visualized using 2,2'-azino-bis
3-ethylbenzothiazoline-6-sulfonic acid (ABTS: dilute one ABTS
tablet in 50 mL ABTS buffer [Roche Diagnostics, Almere, The
Netherlands]) and stopped with oxalic acid (Sigma-Aldrich,
Zwijndrecht, The Netherlands). Fluorescence at 405 nm was measured
on a microtiter plate reader (Biotek Instruments, Winooski, USA)
and the amount of HER2 was expressed as a percentage relative to
untreated cells.
[0809] The results shown in FIG. 12 and Table 10 demonstrate that
both tested Group 3 antibodies (098 and 153) induced more than 50%
HER2 downmodulation. In contrast, antibodies 025, 169 and
Trastuzumab (Herceptin.RTM.) barely induced downmodulation
(approximately 20% of untreated cells) while antibody 005 induced
moderate downmodulation (approximately 30% of untreated cells).
This was in line with enhanced internalization observed by
antibodies 098, 153, and 005.
TABLE-US-00017 TABLE 10 Antibody induced downmodulation of HER2
depicted as percentage HER2 compared to untreated cells antibody %
HER2 compared to untreated cells Herceptin 80 IgG1-1014-169 82
IgG1-1014-025 85 IgG1-1014-098 44 IgG1-1014-153 50 IgG1-1014-005 70
isotype control 108
Example 23
Colocalization of HER2 Antibodies with Lysosomal Marker LAMP1
Analyzed by Confocal Microscopy
[0810] The HER2 downmodulation assay as described in Example 21 and
the CypHer-5E based internalization assay as described in Example
19 indicated that HER2 antibodies from groups 3 and 4 were more
efficiently internalized and targeted towards lysosomes compared to
antibodies from Groups 1 and 2. To confirm the enhanced lysosomal
transport of antibodies from groups 3 and 4, AU565 cells were
cultured on glass coverslips and treated for 18 hours with the
indicated antibodies. Cells were fixed, permeabilized and stained
with FITC-conjugated goat anti-human IgG1 to visualize antibody and
mouse anti-human CD107a (LAMP1) followed by goat anti-mouse IgG-Cy5
to identify lysosomes.
[0811] However, in these experiments the confocal imaging was done
with settings that allowed discriminating between monospecific and
bispecific antibodies but not between different monospecific
antibodies, in fact, with these settings monospecific antibodies
could hardly be detected. To be able to compare between the
different monospecific antibodies, the confocal slides were
measured again with increased gain settings, to enhance
fluorescence intensity. All other steps of the procedure were the
same as described in Example 23.
[0812] The results are depicted in FIG. 13 and Table 11, and show
that the FITC pixel intensity overlapping with Cy5 for various
monospecific HER2 antibodies. From each slide three different
images were analyzed containing .about.1, 3 or >5 cells.
Significant variation was observed between the different images
within each slide. Still, it was evident that antibodies 005, 098
and 153 were more efficiently targeted towards lysosomal
compartments, compared to 025, pertuzumab, 169 and Trastuzumab
(Herceptin.RTM.). This correlated well with the enhanced
internalization and receptor degradation induced by these
antibodies.
TABLE-US-00018 TABLE 11 Mean FITC pixel intensities overlapping
with Cy5 depicted as arbitrary units FITC pixel intensity in
lysosomes antibody [arbitrary units] TH1014-005 0.619 TH1014-098
0.522 TH1014-153 0.409 TH1014-025 0.248 TH1014-pert 0.214
TH1014-169 0.255 Herceptin 0.236
Example 24
HER2 Extracellular Domain Shuffle Human-to-Chicken
[0813] To further define the HER2 binding regions recognized by
antibodies from the four different cross-competition groups
described in Example 14, a HER2 extracellular domain shuffle
experiment was performed. To this end, a small gene-synthesis
library with five constructs was generated, swapping the sequences
of domain I, II, III or IV of the extracellular domain of human
HER2 to the corresponding sequence of chicken HER2 (Gallus gallus
isoform B NCBI: NP.sub.--001038126.1): 1) fully human HER2 (Uniprot
PO4626) hereafter named hu-HER2, 2) hu-HER2 with chicken domain I
(replacing amino acids (aa) 1-203 of the human HER2 with the
corresponding chicken HER2 region) hereafter named hu-HER2-ch(I),
3) hu-HER2 with chicken domain II (replacing amino acids (aa)
204-330 of the human HER2 with the corresponding chicken HER2
region) hereafter named hu-HER2-ch(II), 4) hu-HER2 with chicken
domain III (replacing aa 331-507 of the human HER2 with the
corresponding chicken HER2 region) hereafter named hu-HER2-ch(III)
and 5) hu-HER2 with chicken domain IV (replacing aa 508-651 of the
human HER2 with the corresponding chicken HER2 region) hereafter
named hu-HER2-ch(IV). The human and chicken HER2 orthologs show 67%
homology in their extracellular domain with 62% homology in domain
I, 72% homology in domain II, 63% homology in domain III and 68%
homology in domain IV. The constructs were transiently transfected
in the Freestyle.TM. CHO-S (Invitrogen) cell line using Freestyle
MAX transfection reagent (Invitrogen) according to the instructions
of the manufacturer, and transfected cells were cultured for 20
hours. HER2 antibody binding to the transfected cells was analyzed
by means of flow cytometry: The transfected CHO-S cells were
harvested, washed with FACS buffer and incubated with 10 .mu.g/mL
HER2 antibody (30 minutes on ice). Binding of HER2 antibodies was
detected using a Phycoerythrin (PE)-conjugated goat-anti-human IgG
antibody (Jackson). To check if expression between different
batches was the same, cells were fixed and permeabilized using
Cytofix/Cytoperm solution (BD) according manufacturer's instruction
and stained with a rabbit-anti-human intracellular HER2 antibody
(DAKO) in combination with a secondary PE-conjugated
goat-anti-rabbit antibody (Jackson). An isotype control antibody
was used as negative control. Fluorescence was measured on a
FACSCanto-II (BD) and binding curves were made by means of
non-linear regression (sigmoidal dose-response with variable slope)
using GraphPad Prism V4.03 software (GraphPad Software, San Diego,
Calif., USA). Loss of binding was used as read out to identify
which HER2 domains were recognized by the different antibodies.
[0814] Exemplary binding curves for antibody 153 are shown in FIG.
14. All binding results are shown in Table 12. Group 1 HER2
antibodies 050, 084, 169 and Trastuzumab (Herceptin.RTM.) showed
loss of binding to Hu-HER2-ch(IV), but not to the proteins with one
of the remaining domains shuffled, demonstrating that the epitopes
of Group 1 mAbs reside in HER2 domain IV. Group 2 antibodies 025,
091, 129 and pertuzumab showed only loss of binding to
Hu-HER2-ch(II), indicating that the epitope resides in HER2 domain
II. Antibodies 098 and 153 were both defined to Group 3 in
cross-competition assays (not shown) but showed some variation in
the shuffle experiment. Antibody 098 clearly showed loss of binding
to Hu-HER2-ch(I) and a minor decrease in binding to Hu-HER2-ch(II),
while 153 showed only loss of binding to Hu-HER2-ch(II). These data
suggest that Group 3 mAbs 098 and 153 can also bind, at least
partially, to the HER2 domain II, with epitopes that possibly
extend into HER2 domain I, as is the case for 098. Antibodies 005,
006, 060 and 111 showed loss of binding upon substitution of HER2
domain III, which demonstrated that the epitope resides in HER2
domain III. Interestingly, antibodies 059 and 106 demonstrated loss
of binding to both hu-HER2-ch(III) and hu-HER2-ch(I), implying that
antibodies 059 and 106 recognize a conformational epitope within
these two domains.
TABLE-US-00019 TABLE 12 Summary of HER2 antibody binding to
different HER2ECD receptor constructs. HER2-domain shuffled
Antibody Group FL I II III IV Herceptin .RTM. 1 +++ +++ +++ +++ -
050 1 +++ +++ +++ +++ - 084 1 +++ +++ +++ +++ - 169 1 +++ +++ +++
+++ + Pertuzumab 2 +++ +++ + +++ +++ 025 2 +++ +++ - +++ +++ 091 2
+++ +++ - +++ +++ 129 2 +++ +++ - +++ +++ 153 3 +++ +++ - +++ +++
098 3 +++ - ++ +++ +++ 005 4 +++ +++ +++ - +++ 006 4 +++ +++ +++ -
+++ 059 4 +++ - +++ - +++ 060 4 +++ +++ +++ - +++ 106 4 +++ - +++ -
+++ 111 4 +++ +++ +++ - +++ FL; hu-HER2, I; hu-HER2-ch(I), II;
hu-HER2-ch(II), III; hu-HER2-ch(III), IV; hu-HER2-ch(IV). +++
indicates normal binding, ++ indicates reduced EC.sub.50 but the
similar maximal binding compared to binding observed to hu-HER2, +
indicates reduced EC.sub.50 and reduced maximal binding detected
compared to binding observed to hu-HER2, - indicates no
binding.
Example 25
In Vivo Efficacy of HER2 HuMabs 005, 091, 084 and 169 in NCI-N87
Human Gastric Carcinoma Xenografts in SCID Mice
[0815] The in vivo effect of HER2-HuMabs 091 (cross-competition
Group 2), 084 and 169 (both cross-competition Group 1), and 005
(cross-block Group 4) on tumor growth and survival in a NCI-N87
human gastric carcinoma xenograft model in female CB.17 severe
combined immunodeficiency (SCID) mice was determined.
10.times.10.sup.6 NCI-N87 tumor cells in 50% matrigel were injected
s.c. in female SCID mice, 10 mice per group. Eight days after tumor
inoculation, intravenous treatment with HER2-HuMabs 005, 091, 084,
and 169 or control antibody HuMab-HepC was started. In FIG. 15 (A)
and (C), this is indicated as day 1, day of treatment initiation.
The first dose was at 40 mg/kg, followed by 10 mg/kg on days 4, 8,
11, 15, 18, 22, and 25 after treatment initiation. Tumor volume was
determined at least 2 times per week. Volumes (mm.sup.3) were
calculated from caliper (PLEXX) measurements as
(width.sup.2.times.length)/2.
[0816] The results are depicted in FIG. 15A, 15B, 15C and 15D,
which show that the mice administered with HuMab 005, 084, 169 and
091 demonstrated slower tumor growth (A) and better survival (B)
than the mice that received negative control antibody HuMab-HepC.
All treatments were well-tolerated.
Example 26
Therapeutic Treatment of BT-474 Breast Tumor Xenografts in Balb/C
Nude Mice
[0817] The effect of therapeutic treatment of five different HER2
HuMabs on human subcutaneous BT-474 breast tumor xenografts in
Balb/C nude mice was determined. BT-474 tumor cells were injected
24 to 72 hours after a whole body irradiation with a .gamma.-source
(1.8 Gy, Co60, BioMep, France). 2.times.10.sup.7 BT-474 cells in
200 .mu.l of RPMI 1640 containing matrigel (50:50, v:v; BD
Biosciences) were injected subcutaneously into the right flank of
female Balb/C nude mice. Body weight and tumor volume of the mice
was recorded twice a week. Tumor volumes (mm.sup.3) were calculated
from caliper (PLEXX) measurements as:
(width.sup.2.times.length)/2.
[0818] Treatment with HER2 HuMabs was started when the tumors
reached a mean volume of 100-200 mm3. Tumor bearing mice were
randomized into groups of 8 mice. One group received twice weekly
intravenous (i.v.) injections of the control mAb HuMab-HepC. Four
other groups received twice weekly i.v. injections of HER2 HuMab
025, 129, 153 and 091, with a first dose of 20 mg/kg and following
9 doses of 5 mg/kg.
[0819] The results are depicted in FIG. 16A and 16B and show that
BT-474 tumor growth was partially inhibited with HuMab 129 and
HuMab 153 treatment (about 30 and 50% of inhibition compared to
HuMab-HepC control treatment). HuMab-025 and HuMab-091 strongly
inhibited the BT-474 tumor growth and the time to reach a tumor
volume of 800 mm.sup.3 was significantly delayed by these
antibodies. Survival was also improved in the HER2 HuMab receiving
mice.
Example 27
Removing Fc-Mediated T Cell Activation by Means of Fc Mutations
[0820] Monocytes, which are present in PBMCs, express Fc-receptors
which can interact with the Fc-domains in the IgG monospecific and
bispecific antibodies. In case monospecific CD3 antibodies are
used, it is known that such active Fc-domain can cause activation
of T-cells. Importantly, if purified T-cells are used as effector
cells this Fc-mediated effect is absent due to the absence of
monocytes.
[0821] In order to remove this activity, a strategy was set up to
create antibodies without such Fc-mediated activity.
Deglycosylation of antibodies, either post-translational via
N-glycanase or genetically via N297Q mutation has been described to
result in an inert antibody format (Tao M H et al., Immunol 1989,
143; 2595-2601). These Fc modified antibodies were generated to
determine the contribution of Fc-mediated activation of T cells. A
panel of (bispecific) antibodies with either a N297Q mutation in
the Fc-domain or chemically deglycosylated were compared to
antibodies with WT Fc regions in a cytotoxity assay with PBMCs (E:T
ratio 5:1). The cytotoxicity assay was performed as described in
Example 21, however human PBMC were used instead of purified
T-cells. Deglycosylation did not compromise the activity of the
HER2.times.CD3 bispecific antibodies in the cytotoxicity assay
whereas the Fc-mediated activity of monospecific huCLB-T3/4 was
strongly but not completely removed under the tested conditions
(FIG. 17).
[0822] To completely remove the residual Fc activity three sets of
mutations from the public domain were combined in one mutant. The
mutations L234F, L235E, P331S (Oganesyan Acta Cryst. (2008). D64,
700-704), D265A (Shields JBC (2001) 276(9) 6591-6604) and N297Q
were introduced in the K409R and F405L IgG1 backbone. This mutant,
designated LFLEDANQPS, did not show any residual Fc-mediated
activation of T cells in a cytotoxity assay (same protocol as
above) with PBMCs (FIG. 17).
Example 28
Effect of HER2 epitope on HER2.times.CD3 efficacy
[0823] The effect of the binding site on the tumor target (epitope)
was determined by generating three bispecific antibodies
recognizing different HER2 epitopes combined with a CD3 antibody
that was proven to be effective in a bispecific format (Examples 21
and 27). The HER2-clones 005, 153 and 169 are three
non-crossblocking antibodies recognizing a spatially segregated
part of HER2 as shown in Example 24. These three HER2-clones were
combined with CD3 antibody clone huCLB-T3/4, which recognizes human
CD3 as a bispecific molecule and tested in a cytotoxicity assay
with either human PBMCs or purified human T cells. The assay was
performed as described in example 21. An E:T ratio of 1:1 was used
for the T-cells assay, a 2:1 ratio was used for the PBMC assay.
[0824] As shown in FIG. 18, all three bispecific antibodies are
able to induce killing of AU565 target cells, albeit with different
efficacy. These data show an important effect of the location of
the target epitope on the cytotoxic potential of a HER2.times.CD3
bispecific antibody.
Example 29
Efficacy of T Cell Mediated Killing Depends on HER2 Expression
Levels
[0825] Cell lines with different HER2 expression levels were used
to study the effect of target density on the efficacy of bispecific
HER2.times.CD3 antibodies. Bispecific antibody
169.times.huCLB-T3/4-N297Q was tested in a cytotoxicity assay using
A549, A431, 3T3 and AU565 cells. HER2 expression was determined
using QIFIKIT.RTM. analysis, using the mouse anti-human HER2
(R&D Systems, Cat. MAB1129, Lot IBD0207061) and isotype control
antibody (BD, Cat. 555740 Lot 3280) at a concentration of 10
fag/mL. The expression levels are summarized in Table 13.
[0826] For the cytotoxity assay the different HER2 expressing cell
lines were co-cultured with freshly isolated human T cells with an
E:T ratio of 10:1, using the protocol described in Example 21.
[0827] The cytotoxic efficacy of 169.times.CLB-T3/4 was correlated
with the HER2 expression of the target cell line (FIG. 19). AU565
cells were killed at already very low concentrations of antibody
whereas the cells with lowest expression (A549) could hardly be
killed in this experimental set up.
TABLE-US-00020 TABLE 13 HER2 expression levels of cell lines used
in cytotoxity assay. HER2 expression (molecules Cell line per cell)
AU565 4 .times. 10e5 NIH-3T3 7 .times. 10e4 A431 1.4 .times.
10e4.sup. A549 1 .times. 10e4
Example 30
Characterization of HER2.times.CD3 Bispecific Antibody Induced T
Cell Activation
[0828] As shown in previous examples effective killing of various
HER2 expressing tumor cell lines was accomplished by using
bispecific HER2.times.CD3 antibodies. The expression of CD69, a
well characterized activation marker of cytotoxic T cells, was
monitored in T cells co-cultured with AU565 tumor cells in the
presence of bispecific HER2.times.CD3 antibody for 16 h at
37.degree. C. A dose dependent activation of the T cells as
measured by CD69 expression was observed (FIG. 20) which correlates
with the observed cytotoxicity data shown in Example 21.
[0829] In agreement with the cytotoxicity data shown in Example 27,
in vitro characterization of the T cell response revealed that also
in the absence of tumor cells, an Fc-mediated T cell activation
could be observed when PBMCs were used as effector cells (FIG. 21).
This effect was most prominent when a variant with an unmodified Fc
of DuoBody HER2 169.times.huCLBT3/4 was used and could be reduced
by introduction of the N297Q mutation. The Fc mediated activation
by monospecific CD3 antibodies could be further reduced by using an
LFLEDANQPS Fc-mutant (FIG. 21).
[0830] An in vitro cytotoxicity assay was performed as described in
Example 21. Th1/Th2 cytokine detection in the medium of the
different wells was performed by collecting supernatant samples of
a cytotoxicity assay to measure cytokine release. Undiluted samples
were analysed on FACS using the human Th1/Th2 Cytokine detection
kit (BD Biosciences, cat#551809), according to manufacturer's
instructions. Cytokine concentration of IL-2, IL-4, IL-6, IL-10,
IFN-.gamma. and TNF-.alpha. in the samples were calculated based on
standard curves of these cytokines. Data was analyzed using
Graphpad Prism 5.0 and Excel 2003 software. Three groups of
cytokines were analyzed (1) Pro-inflammatory cytokines TNF-.alpha.,
INF-.gamma. and IL-2 (2) Pro and anti-inflammatory cytokine IL6 and
(3) Anti-inflammatory cytokines IL4 and IL10. Cytokine profiles at
day 3 generated by T-cells or PBMCs in in vitro cytotoxicity assay
with DuoBody huCLB-T3/4.times.HER2-169 N297Q and all appropriate
controls are summarized in Table 14.
[0831] Cytokines are upregulated when tumor cells and T-cells were
incubated together with DuoBody huCLB-T3/4.times.HER2-169 N297Q in
contrast to the control antibodies and control treatments (medium
and T-cells only).
[0832] Incubation of tumor cells and PBMC with DuoBody
huCLB-T3/4.times.HER2-169 N297Q also resulted in upregulation of
the measured cytokines when compared to control antibody
IgG1-1014-169 N297Q and IgG1-Herceptin.RTM. and control situations
(medium and T-cells only). However, incubation of target cells and
PBMCs with control antibody DuoBody
huCLB-T3/4-N297Q.times.b12-N297Q and monospecific huCLB-T3/4-N297Q
also resulted in upregulation of most cytokines compared to control
situations (medium and T-cells only).
[0833] Cytokine expression was also followed over time. Cytokine
profiles at day 1, 2 and 3 generated by T-cells or PBMCs in in
vitro cytotoxicity assay with DuoBody.TM.
huCLB-T3/4-N297Q.times.HER2-169-N297Q are depicted in FIG. 22. In
general, the pro-inflammatory cytokines, TNF-.alpha., INF-.gamma.
and IL-2, were pronounced present in experiments were lower
antibody concentrations were used (3 ng/mL). In experiments where
antibody concentrations were increased with a factor 300, most
pro-inflammatory cytokines were present at lower concentrations.
IL-6, the cytokine with pro and anti-inflammatory activity, is
hardly secreted by T-cells, but highly secreted by PBMCs upon
incubation with tumor cells and DuoBody huCLB-T3/4.times.HER2-169
N297Q. Some cytokines are secreted at higher levels at day 1 and/or
day 2 and decrease at day 3, whereas others are secreted at lower
levels at day 1 and show increased expression at day 2 and or
3.
[0834] Additionally the release of GM-CSF as a measure for T cell
activation was measured. This cytokine is not consumed during the
activation of T cells and is therefore better suited for the
measurement of cytokines levels in long term experiments. To
investigate the observed cytokine release in the control samples as
described above Fc mutants were compared to WT antibodies. Hereto T
cells samples from co-cultures of PBMCs with AU565 tumor cells in
the presence of bispecific antibodies were analyzed in a GM-CSF
ELISA.
[0835] The following protocol was used: An ELISA plate was coated
with 100 .mu.L/well 2.0 .mu.g/mL coating antibody (anti-GM-CSF 9.1
Sanquin) in PBS and incubated 0/N at room temperature (RT). Plates
were then washed 3 times with PBS supplemented with 0.05% Tween
(PBST) using an Elisa-washer. Samples were diluted in PBST/0.2% BSA
and standard curve samples were prepared (Standard curve: first
point 1000 .mu.g/mL, two-fold dilution curve, 10 steps and 2 blanks
(Standard GM-CSF=rec GM-CSF Sandoz). 100 .mu.L/well of samples were
added to the plate and 10 .mu.L/well of monoclonal biotinylated
anti-GM-CSF (monoclonal anti-GM-CSF 16.3 Sanquin) (1 .mu.g/mL)
diluted in PBST/0.2% BSA and incubated for 2 h at RT on a shaker.
After washing 3 times with PBS-T 100 .mu.L/well Strep-poly-HRP
diluted in PBST/0.2% BSA (0.1 .mu.g/mL) was added and incubated for
20 minutes at room temperature on a shaker. For detection 1 tablet
of ABTS substrate was dissolved in 50 ml ABTS-buffer (Roche) and
100 .mu.L/well of the ABTS solution was added to well and incubated
for 15-30 mintues at RT in the dark. The reaction was stopped with
100 .mu.L/well 2% oxalic acid and incubated for 10 min in the dark.
Absorbance was read at 405 nm using an EL808-Elisa-reader.
[0836] DuoBody HER2 169.times.huCLB-T3/4 (both Fc variants, N297Q
and LFLEDANQPS) induced a dose-dependent activation of T cells as
shown by GM-CSF production (FIG. 23). The monospecific control
antibody IgG1-HER2-169-N297Q and the irrelevant antibody IgG1-b12
N297Q did not induce T cell activation as expected. As observed in
the TH1/TH2 cytokine profile assay monospecific IgG1-huCLB-T3/4
N297Q and DuoBody huCLB-T3/4.times.b12 N297Q did induce activation
of T cells. The (Fab').sub.2 control and the inactive Fc mutant
LFLEDANQPS of IgG1-CLB-T3/4 did not induce T cell activation
suggesting that Fc mediated activation of T cells by N297Q mutants
is occurring.
TABLE-US-00021 TABLE 14 Cytokine profile measured at day 3 of in
vitro cytotoxicity assay with A. T-cells or B. PBMCs (incubated
with 1000 ng/mL antibody). A Cytokines T-cells (conc. pg/mL)
INF.gamma. TNF.alpha. IL2 IL6 IL4 IL10 DuoBody 4268.0 1005.1 2371.3
45.3 32.6 2010.1 huCLB-T3/4-Q .times. HER2-169-Q DuoBody 0.5 0.3
9.3 0.1 0.1 1.7 huCLB-T3/4-Q .times. B12-Q IgG1-hCLB- 1.6 1.7 20.5
0.2 0.3 2.6 T3/4-Q IgG1-HER2- 4.8 0.7 5.1 0.3 0.2 0.5 169-Q T-cells
only 0.1 0.4 0.2 0.1 0.0 0.3 T-cell medium 3.8 1.0 7.9 0.2 0.1 0.3
B Cytokines PBMCs (conc. pg/mL) INF.gamma. TNF.alpha. IL2 IL6 IL4
IL10 DuoBody 4082.6 1073.3 585.6 4191.9 13.2 2018.2 huCLB-T3/4-Q
.times. HER2-169-Q * DuoBody 1760.2 115.0 10.1 569.4 1.4 592.4
huCLB-T3/4-Q .times. B12-Q * IgG1-hCLB- 1474.2 92.7 345.2 116.5 1.7
1295.4 T3/4-Q IgG1-HER2- 1.3 1.0 15.5 2.2 0.2 2.8 169-Q T-cells
only 0.4 0.7 0.3 0.2 0.4 0.4 T-cell medium 1.5 1.0 8.8 0.2 0.3 2.2
* Concentration antibody = 1000 ng/mL
Example 31
In Vivo Proof of Concept
[0837] The in vivo anti-tumor efficacy of bispecific HER2.times.CD3
antibody was evaluated, in a subcutaneous NCI-N87 xenograft model,
in which human T cells are co-inoculated in the form of
unstimulated PBMCs with the tumor cells, analogous to the model
described by Brischwein et al., (Mol. Immunol. 43 (2006),
1129-1143). Six to eleven weeks old female NOD-SCID
(NOD.CB17-Prkdcscid/NcrCrl) mice were used. PBMC from healthy
donors were isolated from a buffy coat as described in Example 21.
At day 0, a mixture containing 5.times.10.sup.6 cells of both PBMCs
(and NCI-N87 cells were inoculated subcutaneously in 200 .mu.L in
the right flank of each mouse (PBMCs from two donors were used in
parallel to rule out donor specific artefacts. Within one hour of
injection, the mice were sorted into five groups (n=7) and each
group was injected intraperitoneally (i.p.) with a single dose of
(bispecific) antibody. Treatment groups are shown in Table 15. All
antibody samples were supplemented with irrelevant mAb IgG1-b12 to
obtain a total antibody concentration of 4 mg/kg per sample.
[0838] Tumors were measured twice per week using caliper (PLEXX)
until an endpoint tumor volume of 1500 mm.sup.3, tumors showed
ulcerations or until the end of the study (day 50). FIG. 24A shows
that on day 42 tumor outgrowth is inhibited most optimal by
bispecific HER2.times.CD3 antibody effectively at a dose of 0.05
mg/kg.
[0839] In FIG. 24B, the percentage survival (with tumor sizes
smaller then 500 mm3) is shown in a Kaplan-Meier plot. Tumor
formation is significantly delayed (p<0.05, Log Rank
(Mantel-Cox)) in mice treated with HER2.times.CD3 antibodies (0.05
mg/kg) compared to control group treated with b12.times.CD3 control
antibody.
TABLE-US-00022 TABLE 15 Treatment groups and dosing. Group Antibody
Dose 1 DuoBody HER2 169 x 1 .mu.g (=0.05 mg/kg) CLB-T3/4-N297Q 2
DuoBody b12 x CLB-T3/4-N297Q 80 .mu.g (=4 mg/kg) 3 Neg control mAb
IgG1-b12 80 .mu.g (=4 mg/kg)
Example 32
Unraveling the Requirement of the T350I, K370T and F405L
Substitutions for Fab-Arm Exchange Engagement of Human IgG1
[0840] To further identify the determinants in the IgG1 CH3 domain
that are required for IgG1 to be engaged in Fab-arm exchange, IgG1
containing the triple mutation T350I-K370T-F405L (ITL) was compared
to the double mutants T350I-K370T (IT), T350I-F405L (IL) and
K370T-F405L (TL) were studied using antibodies 2F8 and 7D8,
respectively described in WO 02/100348 and WO 04/035607. Also the
single mutant F405L (L) was tested. 2-MEA was used as a reductant
to induce in vitro Fab-arm exchange (50 .mu.g of each antibody in
100 .mu.L PBS/25 mM 2-MEA for 90 min at 37.degree. C.). For the
single mutant F405L antibody, unpurified antibody from supernatant
of a transient transfection was used after buffer-exchange to PBS
using Amicon Ultra centrifugal devices (30 k, Millipore, cat. no.
UFC803096). To stop the reduction reaction, the reducing agent
2-MEA was removed by desalting the samples using spin columns. The
generation of bispecific antibodies was determined by bispecific
binding measured in an ELISA.
[0841] The triple (ITL), double mutations (IT, IL and TL) and
single mutation (L) were introduced in IgG1-2F8. These mutants were
combined with IgG4-7D8, containing a CPSC hinge (wild type) or a
stabilized hinge (IgG4-7D8-CPPC), for Fab-arm exchange using 25 mM
2-MEA for 90 min at 37.degree. C. FIGS. 25A-B show that the
IgG1-2F8-IL and -TL mutants showed Fab-arm exchange to the same
level as the triple mutant ITL, irrespective of the combined
IgG4-7D8 (CPSC or CPPC hinge). In contrast, no bispecific binding
was found for the combination with the IgG1-2F8-IT mutant. FIG. 25C
shows that also the IgG1-2F8-F405L mutant showed Fab-arm exchange,
irrespective of the combined IgG4-7D8 (CPSC or CPPC hinge). These
data indicate that the F405L mutation is sufficient to engage human
IgG1 for Fab-arm exchange under the conditions mentioned above.
Example 33
Determinants at the IgG1 409 Position for Engagement in
2-MEA-Induced Fab-Arm Exchange in Combination with IgG1-ITL
[0842] 2-MEA can induce Fab-arm exchange between human IgG1-ITL and
IgG4-CPPC. The CH3 interface residues of human IgG1 and IgG4 differ
at position 409 only: lysine (K) in IgG1 and arginine (R) in IgG4.
Therefore, it was tested whether substitution of lysine at position
409 by arginine or any other amino acid (K409X) could enable IgG1
to engage in 2-MEA-induced Fab-arm exchange with IgG1-ITL.
Combinations of 10 .mu.g human IgG1-2F8-ITL and 10 .mu.g
IgG1-7D8-K409X in 20 .mu.l PBS/25 mM 2-MEA (final concentration of
0.5 mg/mL for each antibody) were incubated for 90 min at
37.degree. C. Unpurified antibodies from supernatants of transient
transfections were used after buffer-exchange to PBS using Amicon
Ultra centrifugal devices (30 k, Millipore, cat. no. UFC803096).
After the Fab-arm exchange reaction, 20 .mu.L PBS was added to each
sample and the reducing agent was removed by desalting the samples
using spin desalting plate. Dilution series of the antibody samples
(total antibody concentration 0-20 .mu.g/mL in 3-fold dilutions)
were used in an ELISA to measure bispecific binding.
[0843] FIG. 26A shows the results of bispecific binding upon 2-MEA
induced Fab-arm exchange between IgG1-2F8-ITL.times.IgG1-7D8-K409X.
In FIG. 26B, the exchange is presented as bispecific binding
relative to a purified batch of bispecific antibody derived from a
2-MEA-induced Fab-arm-exchange between IgG1-2F8-ITL and
IgG4-7D8-CPPC, which was set to 100%. These data were also scored
as (-) no Fab-arm exchange, (+/-) low, (+) intermediate or (++)
high Fab-arm exchange, as presented in Table 1. No Fab-arm exchange
(-) was found when the 409 position in IgG1-7D8 was K (=wild type
IgG1), L or M. Fab-arm exchange was found to be intermediate (+)
when the 409 position in IgG1-7D8 was F, I, N or Y and high (++)
when the 409 position in IgG1-7D8 was A, D, E, G, H, Q, R, S, T, V
or W.
TABLE-US-00023 TABLE 16 2-MEA-induced Fab-arm exchange between
IgG1-2F8-ITL and IgG1-7D8-K409X mutants. The generation of
bispecific antibodies after 2-MEA-induced in vitro Fab-arm exchange
between IgG1-2F8-ITL and IgG1-7D8-K409X mutants was determined by a
sandwich ELISA. Fab-arm exchange IgG1-7D8-K409X x IgG1-2F8-ITL A ++
D ++ E ++ F + G ++ H ++ I + K - L - M - N + Q ++ R ++ S ++ T ++ V
++ W ++ Y + (-) no, (+/-) low, (+) intermediate, (++) high Fab-arm
exchange.
Example 34
Determinants at the IgG1 405 Position for Engagement in
2-MEA-Induced Fab-Arm-Exchange in Combination with IgG1-K409R
[0844] In Example 32 it is described that the F405L mutation is
sufficient to enable human IgG1 to engage in Fab-arm-exchange when
combined with IgG4-7D8. To further test the determinants at the
IgG1 405 position for engagement in 2-MEA-induced Fab-arm-exchange
in combination with human IgG1-K409R, all possible IgG1-2F8-F405X
mutants (with the exception of C and P) were combined with
IgG1-7D8-K409R. The procedure was performed with purified
antibodies as described in Example 32.
[0845] FIG. 27 shows the results of bispecific binding upon
2-MEA-induced Fab-arm-exchange between
IgG1-2F8-F405X.times.IgG1-7D8-K409R. These data were also scored as
(-) no Fab-arm exchange, (+/-) low, (+) intermediate or (++) high
Fab-arm exchange, as presented in Table 18. No Fab-arm exchange (-)
was found when the 405 position in IgG1-2F8 was F (=wild type
IgG1). Fab-arm exchange was found to be low (+/-) when the 405
position in IgG1-2F8 was G or R. Fab-arm exchange was found to be
high (++) when the 405 position in IgG1-2F8 was A, D, E, H, I, K,
L, M, N, Q, S, T, V, W or Y. These data indicate that particular
mutations at the IgG1 405 position allow IgG1 to engage in
2-MEA-induced Fab-arm-exchange when combined with IgG1-K409R.
TABLE-US-00024 TABLE 17 2-MEA-induced Fab-arm-exchange between
IgG1-2F8-F405X mutants and IgG1-7D8-K409R. The generation of
bispecific antibodies after 2-MEA-induced in vitro Fab-arm-exchange
between IgG1-2F8-F405X mutants and IgG1-7D8-K409R was determined by
a sandwich ELISA. Fab-arm-exchange IgG1-2F8-F405X x IgG1-7D8-K409R
A ++ D ++ E ++ F - G +/- H ++ I ++ K ++ L ++ M ++ N ++ Q ++ R +/- S
++ T ++ V ++ W ++ Y ++ (-) no, (+/-) low, (+) intermediate, (++)
high Fab-arm-exchange.
Example 35
Determinants at the IgG1 407 Position for Engagement in
2-MEA-Induced Fab-Arm-Exchange in Combination with IgG1-K409R
[0846] In the previous Example, it is described that certain single
mutations at position F405 are sufficient to enable human IgG1 to
engage in Fab-arm-exchange when combined with IgG1-K409R. To test
whether other determinants implicated in the Fc:Fc interface
positions in the CH3 domain could also mediate the Fab-arm-exchange
mechanism, mutagenesis of the IgG1 407 position was performed and
the mutants were tested for engagement in 2-MEA-induced
Fab-arm-exchange in combination with human IgG1-K409R. All possible
IgG1-2F8-Y407X mutants (with the exception of C and P) were
combined with IgG1-7D8-K409R. The procedure was performed with
purified antibodies.
[0847] FIG. 28 shows the results of bispecific binding upon
2-MEA-induced Fab-arm-exchange between
IgG1-2F8-Y407X.times.IgG1-7D8-K409R. These data were also scored as
(-) no Fab-arm exchange, (+/-) low, (+) intermediate or (++) high
Fab-arm exchange, as presented in Table 19. No Fab-arm exchange (-)
was found when the 407 position in IgG1-2F8 was Y (=wild type
IgG1), E, K, Q, or R. Fab-arm exchange was found to be low (+/-)
when the 407 position in IgG1-2F8 was D, F, I, S or T and
intermediate (+) when the 407 position in IgG1-2F8 was A, H, N or
V, and high (++) when the 407 position in IgG1-2F8 was G, L, M or
W. These data indicate that particular single mutations at the IgG1
407 position allow IgG1 to engage in 2-MEA-induced Fab-arm-exchange
when combined with IgG1-K409R.
TABLE-US-00025 TABLE 18 2-MEA-induced Fab-arm-exchange between
IgG1-2F8-Y407X mutants and IgG1-7D8-K409R. The generation of
bispecific antibodies after 2-MEA-induced in vitro Fab-arm exchange
between IgG1-2F8-Y407X mutants and IgG1-7D8-K409R was determined by
a sandwich ELISA. Fab-arm-exchange IgG1-2F8-Y407X x IgG1-7D8-K409R
A + D +/- E - F +/- G ++ H + I +/- K - L ++ M ++ N + Q - R - S +/-
T +/- V + W ++ Y - (-) no, (+/-) low, (+) intermediate, (++) high
Fab-arm-exchange.
Example 36
Determinants at the IgG1 368 Position for Engagement in
2-MEA-Induced Fab-Arm Exchange in Combination with IgG1-K409R
[0848] Examples 34 and 35 show that certain single mutations at
position F405 and Y407 are sufficient to enable human IgG1 to
engage in Fab-arm exchange when combined with IgG1-K409R. As
illustrated in this example further determinants implicated in the
Fc:Fc interface positions in the CH3 domain may also mediate the
Fab-arm exchange mechanism. To this effect mutagenesis of the IgG1
368 position was performed and the mutants were tested for
engagement in 2-MEA-induced Fab-arm-exchange in combination with
human IgG1-K409R. All possible IgG1-2F8-L368X mutants (with the
exception of C and P) were combined with IgG1-7D8-K409R. The
procedure was performed with purified antibodies.
[0849] FIG. 29 shows the results of bispecific binding upon
2-MEA-induced Fab-arm exchange between
IgG1-2F8-L368X.times.IgG1-7D8-K409R. These data were also scored as
(-) no Fab-arm exchange, (+/-) low, (+) intermediate or (++) high
Fab-arm exchange, as presented in Table 20. No Fab-arm exchange (-)
was found when the 368 position in IgG1-2F8 was L (=wild type
IgG1), F or M. Fab-arm exchange was found to be low (+/-) when the
368 position in IgG1-2F8 was Y. Fab-arm exchange was found to be
intermediate (+) when the 368 position in IgG1-2F8 was K and high
(++) when the 368 position in IgG1-2F8 was A, D, E, G, H, I, N, Q,
R, S, T, V, or W. These data indicate that particular mutations at
the IgG1 368 position allow IgG1 to engage in 2-MEA-induced Fab-arm
exchange when combined with IgG1-K409R.
TABLE-US-00026 TABLE 19 2-MEA-induced Fab-arm exchange between
IgG1-2F8-L368X mutants and IgG1-7D8-K409R. The generation of
bispecific antibodies after 2-MEA-induced in vitro Fab-arm exchange
between IgG1-2F8-L368X mutants and IgG1-7D8-K409R was determined by
a sandwich ELISA. Fab-arm exchange Fab-arm exchange IgG1-2F8-L368X
x IgG1-7D8-K409R A ++ D ++ E ++ F - G ++ H ++ I ++ K + L - M - N ++
Q ++ R ++ S ++ T ++ V ++ W ++ (-) no, (+/-) low, (+) intermediate
or (++) high Fab-arm exchange.
Example 37
Determinants at the IgG1 370 Position for Engagement in
2-MEA-Induced Fab-Arm Exchange in Combination with IgG1-K409R
[0850] The previous Examples show that certain single mutations at
positions F405, Y407 or L368 are sufficient to enable human IgG1 to
engage in Fab-arm exchange when combined with IgG1-K409R. As
illustrated in this example further determinants implicated in the
Fc:Fc interface positions in the CH3 domain may also mediate the
Fab-arm exchange mechanism. To this effect mutagenesis of the IgG1
370 position was performed and the mutants were tested for
engagement in 2-MEA-induced Fab-arm-exchange in combination with
human IgG1-K409R. All possible IgG1-2F8-K370X mutants (with the
exception of C and P) were combined with IgG1-7D8-K409R. The
procedure was performed with purified antibodies.
[0851] FIG. 30 shows the results of bispecific binding upon
2-MEA-induced Fab-arm exchange between
IgG1-2F8-K370X.times.IgG1-7D8-K409R. These data were also scored as
(-) no Fab-arm exchange, (+/-) low, (+) intermediate or (++) high
Fab-arm exchange, as presented in Table 21. No Fab-arm exchange (-)
was found when the 370 position in IgG1-2F8 was K (=wild type
IgG1), A, D, E, F, G, H, I, L, M, N, Q, R, S, T, V or Y. Only
substitution of K370 with W resulted in intermediate Fab-arm
exchange (+). These data indicate that only one mutation at the
IgG1 370 position (K370W) allows IgG1 to engage in 2-MEA-induced
Fab-arm exchange when combined with IgG1-K409R.
TABLE-US-00027 TABLE 20 2-MEA-induced Fab-arm exchange between
IgG1-2F8-K370X mutants and IgG1-7D8-K409R. The generation of
bispecific antibodies after 2-MEA-induced in vitro Fab-arm exchange
between IgG1-2F8-K370X mutants and IgG1-7D8-K409R was determined by
a sandwich ELISA. Fab-arm exchange IgG1-2F8-K370X x IgG1-7D8-K409R
A - D - E - F - G - H - I - K - L - M - N - Q - R - S - T - V - W +
Y - (-) no, (+/-) low, (+) intermediate or (++) high Fab-arm
exchange.
Example 38
Determinants at the IgG1 399 Position for Engagement in
2-MEA-Induced Fab-Arm Exchange in Combination with IgG1-K409R
[0852] The preceding Examples show that certain single mutations at
positions F405, Y407, L368 or K370 are sufficient to enable human
IgG1 to engage in Fab-arm exchange when combined with IgG1-K409R.
As illustrated in this example further determinants implicated in
the Fc:Fc interface positions in the CH3 domain may also mediate
the Fab-arm exchange mechanism. To this effect mutagenesis of the
IgG1 399 position was performed and the mutants were tested for
engagement in 2-MEA-induced Fab-arm-exchange in combination with
human IgG1-K409R. All possible IgG1-2F8-D399X mutants (with the
exception of C and P) were combined with IgG1-7D8-K409R. The
procedure was performed with purified antibodies as described in
Example 33.
[0853] FIG. 31 shows the results of bispecific binding upon
2-MEA-induced Fab-arm exchange between
IgG1-2F8-D399X.times.IgG1-7D8-K409R. These data were also scored as
(-) no, (+/-) low, (+) intermediate or (++) high Fab-arm exchange,
as presented in Table 10. No Fab-arm exchange (-) was found when
the 399 position in IgG1-2F8 was D (=wild type IgG1), E and Q.
Fab-arm exchange was found to be low (+/-) when the 399 position in
IgG1-2F8 was V, intermediate (+) when the 399 position in IgG1-2F8
was G, I, L, M, N, S, T or W. Fab-arm exchange was found to be high
(++) when the 399 position in IgG1-2F8 was A, F, H, K, R or Y.
These data indicate that particular mutations at the IgG1 399
position allow IgG1 to engage in 2-MEA-induced Fab-arm exchange
when combined with IgG1-K409R.
TABLE-US-00028 TABLE 21 2-MEA-induced Fab-arm exchange between
IgG1-2F8-D399X mutants and IgG1-7D8-K409R. The generation of
bispecific antibodies after 2-MEA-induced in vitro Fab-arm exchange
between IgG1-2F8-D399X mutants and IgG1-7D8-K409R was determined by
a sandwich ELISA. Fab-arm exchange IgG1-2F8-D399X x IgG1-7D8-K409R
A ++ D - E - F ++ G + H ++ I + K ++ L + M + N + Q - R ++ S + T + V
+/- W + Y ++ (-) no, (+/-) low, (+) intermediate or (++) high
Fab-arm exchange.
Example 39
Determinants at the IgG1 366 Position for Engagement in
2-MEA-Induced Fab-Arm Exchange in Combination with IgG1-K409R
[0854] Examples 32 to 38 show that certain single mutations at
positions F405, Y407, L368, K370 or D399 are sufficient to enable
human IgG1 to engage in Fab-arm exchange when combined with
IgG1-K409R. As illustrated in this example further determinants
implicated in the Fc:Fc interface positions in the CH3 domain may
also mediate the Fab-arm exchange mechanism. To this effect
mutagenesis of the IgG1 366 position was performed and the mutants
were tested for engagement in 2-MEA-induced Fab-arm-exchange in
combination with human IgG1-K409R. All possible IgG1-2F8-T366X
mutants (with the exception of C and P) were combined with
IgG1-7D8-K409R. The procedure was performed with purified
antibodies as described in Example 33.
[0855] FIG. 32 shows the results of bispecific binding upon
2-MEA-induced Fab-arm exchange between
IgG1-2F8-T366X.times.IgG1-7D8-K409R. These data were also scored as
(-) no, (+/-) low, (+) intermediate or (++) high Fab-arm exchange,
as presented in Table X. No Fab-arm exchange (-) was found when the
366 position in IgG1-2F8 was T (=wild type IgG1), K, R, S or W.
Fab-arm exchange was found to be low (+/-) when the 366 position in
IgG1-2F8 was F, G, I, L, M or Y, intermediate (+) when the 366
position in IgG1-2F8 was A, D, E, H, N, V or Q. These data indicate
that particular mutations at the IgG1 366 position allow IgG1 to
engage in 2-MEA-induced Fab-arm exchange when combined with
IgG1-K409R.
TABLE-US-00029 TABLE 22 2-MEA-induced Fab-arm exchange between
IgG1-2F8-T366X mutants and IgG1-7D8-K409R The generation of
bispecific antibodies after 2-MEA-induced in vitro Fab-arm exchange
between IgG1-2F8-T366X mutants and IgG1-7D8-K409R was determined by
a sandwich ELISA. Fab-arm exchange IgG1-2F8-T366X x IgG1-7D8-K409R
A + D + E + F +/- G +/- H + I +/- K - L +/- M +/- N + Q + R - S - T
- V + W - Y +/- (-) no, (+/-) low, (+) intermediate or (++) high
Fab-arm exchange.
Example 40
In Vivo Proof of Concept: Dose Titration
[0856] To further test the growth inhibitory effect of the
bispecific HER2.times.CD3 antibody, different antibody doses were
tested using the subcutaneous NCI-N87 xenograft model in NOD-SCID
mice with subcutaneous (s.c.) co-injection of unstimulated human
PBMCs (7 mice per group) as described in Example 31. This time, a
single dose of antibody was administered intravenously (i.v.) 1
hour after tumor inoculation. Treatment groups are shown in Table
23.
[0857] Control groups showed a donor-specific tumor growth
inhibition (alloreaction) in the absence of therapeutic antibody
with PBMCs from one of the two donors (data not shown). Therefore,
data received with PBMCs from that particular donor were excluded
from analysis.
TABLE-US-00030 TABLE 23 Treatment groups and dosing Group Antibody
Dose 1 DuoBody HER2 169 x 0.01 .mu.g (=0.0005 mg/kg) CLB-T3/4-N297Q
2 DuoBody HER2 169 x 0.1 .mu.g (=0.005 mg/kg) CLB-T3/4-N297Q 3
DuoBody HER2 169 x 1 .mu.g (=0.05 mg/kg) CLB-T3/4-N297Q 4 DuoBody
HER2 169 x 10 .mu.g (=0.5 mg/kg).sup. CLB-T3/4-N297Q 5 DuoBody b12
x 10 .mu.g (=0.5 mg/kg).sup. CLB-T3/4-N297Q 6 PBS
[0858] FIG. 33A shows that tumor growth was inhibited by 0.05 mg/kg
and 0.5 mg/kg HER2.times.CD3 N297Q.
[0859] FIG. 33B shows a Kaplan-Meier plot displaying the percentage
of mice with tumors <500 mm.sup.3. Tumor formation is delayed in
mice treated with 0.05 mg/kg and 0.5 mg/kg HER2.times.CD3-N297Q
bispecific antibody compared to control mice treated with PBS or
b12.times.CD3 control antibody.
Sequence CWU 1
1
2571121PRThomo sapiens 1Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser
Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln
Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Leu Ser Ala
Tyr Ser Gly Asn Thr Ile Tyr Ala Gln Lys Leu 50 55 60 Gln Gly Arg
Val Thr Met Thr Thr Asp Thr Ser Thr Thr Thr Ala Tyr 65 70 75 80 Met
Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90
95 Ala Arg Asp Arg Ile Val Val Arg Pro Asp Tyr Phe Asp Tyr Trp Gly
100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 28PRThomo
sapiens 2Gly Tyr Thr Phe Thr Asn Tyr Gly 1 5 38PRThomo sapiens 3Leu
Ser Ala Tyr Ser Gly Asn Thr 1 5 414PRThomo sapiens 4Ala Arg Asp Arg
Ile Val Val Arg Pro Asp Tyr Phe Asp Tyr 1 5 10 5107PRThomo sapiens
5Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1
5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser
Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg
Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro
Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu
Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr
Cys Gln Gln Arg Ser Asn Trp Pro Arg 85 90 95 Thr Phe Gly Gln Gly
Thr Lys Val Glu Ile Lys 100 105 66PRThomo sapiens 6Gln Ser Val Ser
Ser Tyr 1 5 79PRThomo sapiens 7Gln Gln Arg Ser Asn Trp Pro Arg Thr
1 5 8119PRThomo sapiens 8Glu Val Gln Leu Leu Glu Ser Gly Gly Gly
Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Asn Trp Val Arg
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser
Gly Arg Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80
Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Ala Lys Ala Arg Ala Asn Trp Asp Tyr Phe Asp Tyr Trp Gly Gln
Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 98PRThomo sapiens
9Gly Phe Thr Phe Ser Ser Tyr Ala 1 5 108PRThomo sapiens 10Ile Ser
Gly Arg Gly Gly Thr Thr 1 5 1112PRThomo sapiens 11Ala Lys Ala Arg
Ala Asn Trp Asp Tyr Phe Asp Tyr 1 5 10 12107PRThomo sapiens 12Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10
15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
20 25 30 Leu Ala Trp Tyr Gln His Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45 Tyr Ala Ala Ser Ile Leu Gln Ser Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys
Gln Gln Ala Asn Ser Phe Pro Ile 85 90 95 Thr Phe Gly Gln Gly Thr
Arg Leu Glu Ile Lys 100 105 136PRThomo sapiens 13Gln Gly Ile Ser
Ser Trp 1 5 149PRThomo sapiens 14Gln Gln Ala Asn Ser Phe Pro Ile
Thr 1 5 15121PRThomo sapiens 15Gln Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Gly Thr Phe Arg Thr Tyr 20 25 30 Ala Ile Asn Trp Val
Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile
Asn Thr Val Leu Gly Ile Val Asn His Ala Gln Lys Phe 50 55 60 Gln
Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Asn Thr Ala Tyr 65 70
75 80 Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95 Ala Arg Glu Lys Gly Val Asp Tyr Tyr Tyr Gly Ile Glu
Val Trp Gly 100 105 110 Gln Gly Thr Thr Val Thr Val Ser Ser 115 120
168PRThomo sapiens 16Gly Gly Thr Phe Arg Thr Tyr Ala 1 5 178PRThomo
sapiens 17Ile Asn Thr Val Leu Gly Ile Val 1 5 1814PRThomo sapiens
18Ala Arg Glu Lys Gly Val Asp Tyr Tyr Tyr Gly Ile Glu Val 1 5 10
19107PRThomo sapiens 19Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val
Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln His Lys
Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Val Ala Ser Thr
Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu
Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Leu 85 90
95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 206PRThomo
sapiens 20Gln Gly Ile Ser Ser Trp 1 5 219PRThomo sapiens 21Gln Gln
Ala Asn Ser Phe Pro Leu Thr 1 5 22120PRThomo sapiens 22Gln Val Gln
Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr
Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr 20 25
30 Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45 Gly Glu Ile His His Ser Gly Ser Thr Asn Tyr Asn Pro Ser
Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn
Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr
Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly Tyr Tyr Asp Ser Gly Val
Tyr Tyr Phe Asp Tyr Trp Ala Gln 100 105 110 Gly Thr Leu Val Thr Val
Ser Ser 115 120 238PRThomo sapiens 23Gly Gly Ser Phe Ser Asp Tyr
Tyr 1 5 247PRThomo sapiens 24Ile His His Ser Gly Ser Thr 1 5
2514PRThomo sapiens 25Ala Arg Gly Tyr Tyr Asp Ser Gly Val Tyr Tyr
Phe Asp Tyr 1 5 10 26107PRThomo sapiens 26Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr
Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Arg Trp 20 25 30 Leu Ala
Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45
Tyr Ala Ala Ser Ser Leu Arg Ser Gly Val Pro Ser Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln
Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser
Tyr Pro Ile 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105 276PRThomo sapiens 27Gln Gly Ile Ser Arg Trp 1 5 289PRThomo
sapiens 28Gln Gln Tyr Asn Ser Tyr Pro Ile Thr 1 5 29120PRThomo
sapiens 29Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro
Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Gly Ser
Phe Ser Gly Tyr 20 25 30 Tyr Trp Thr Trp Ile Arg Gln Pro Pro Gly
Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Tyr His Ser Gly Asp
Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser
Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Tyr Ser
Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Leu
Tyr Phe Gly Ser Gly Ile Tyr Tyr Leu Asp Tyr Trp Gly Gln 100 105 110
Gly Thr Leu Val Thr Val Ser Ser 115 120 308PRThomo sapiens 30Gly
Gly Ser Phe Ser Gly Tyr Tyr 1 5 3114PRThomo sapiens 31Ala Arg Leu
Tyr Phe Gly Ser Gly Ile Tyr Tyr Leu Asp Tyr 1 5 10 32107PRThomo
sapiens 32Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly
Ile Ser Ser Trp 20 25 30 Leu Val Trp Tyr Gln Gln Lys Pro Glu Lys
Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Phe Pro Pro 85 90 95 Thr Phe
Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 336PRThomo sapiens
33Gln Gly Ile Ser Ser Trp 1 5 349PRThomo sapiens 34Gln Gln Tyr Asn
Ser Phe Pro Pro Thr 1 5 35119PRThomo sapiens 35Gln Val Gln Leu Val
Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Phe 20 25 30 Ala
Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45 Ala Val Ile Ser Tyr Asp Gly Gly His Lys Phe Tyr Ala Asp Ser Val
50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
Met Tyr Tyr Cys 85 90 95 Ala Arg Gly Leu Gly Val Trp Gly Ala Phe
Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115
368PRThomo sapiens 36Gly Phe Thr Phe Ser Thr Phe Ala 1 5 378PRThomo
sapiens 37Ile Ser Tyr Asp Gly Gly His Lys 1 5 3812PRThomo sapiens
38Ala Arg Gly Leu Gly Val Trp Gly Ala Phe Asp Tyr 1 5 10
39106PRThomo sapiens 39Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu
Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala
Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn
Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu
Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Trp Thr 85 90
95 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 406PRThomo
sapiens 40Gln Ser Val Ser Ser Tyr 1 5 418PRThomo sapiens 41Gln Gln
Arg Ser Asn Trp Trp Thr 1 5 42123PRThomo sapiens 42Glu Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu
Thr Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Ile Tyr 20 25 30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35
40 45 Gly Ile Ile Phe Pro Gly Asp Ser Asp Ile Arg Tyr Ser Pro Ser
Phe 50 55 60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser
Thr Ala Tyr 65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr
Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Gln Pro Gly Asp Trp Ser Pro
Arg His Trp Tyr Phe Asp Leu 100 105 110 Trp Gly Arg Gly Thr Leu Val
Thr Val Ser Ser 115 120 438PRThomo sapiens 43Gly Tyr Ser Phe Ser
Ile Tyr Trp 1 5 448PRThomo sapiens 44Ile Phe Pro Gly Asp Ser Asp
Ile 1 5 4516PRThomo sapiens 45Ala Arg Gln Pro Gly Asp Trp Ser Pro
Arg His Trp Tyr Phe Asp Leu 1 5 10 15 46107PRThomo sapiens 46Val
Ile Trp Met Thr Gln Ser Pro Ser Leu Leu Ser Ala Ser Thr Gly 1 5 10
15 Asp Arg Val Thr Ile Ser Cys Arg Met Ser Gln Gly Ile Ser Ser Tyr
20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Glu Leu
Leu Ile 35 40 45 Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Tyr Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys
Gln Gln Tyr Tyr Ser Phe Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr
Lys Val Glu Ile Lys 100 105 476PRThomo sapiens 47Gln Gly Ile Ser
Ser Tyr 1 5 489PRThomo sapiens 48Gln Gln Tyr Tyr Ser Phe Pro Leu
Thr 1 5 49126PRThomo sapiens 49Glu Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys
Gly Ser Gly Tyr Asn Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val
Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile
Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln
Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70
75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr
Cys 85 90 95 Ala Arg Trp Gly Thr Tyr Tyr Asp Ile Leu Thr Gly Tyr
Phe Asn Trp 100 105 110 Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr
Val Ser Ser 115 120 125 508PRThomo sapiens 50Gly Tyr Asn Phe Thr
Ser Tyr Trp 1 5 518PRThomo sapiens 51Ile Tyr Pro Gly Asp Ser Asp
Thr 1 5 5215PRThomo sapiens 52Ala Arg Trp Gly Thr Tyr Tyr Asp Ile
Leu Thr Gly Tyr Phe Asn 1 5 10 15 53107PRThomo sapiens 53Asp Ile
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 20
25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu
Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
Gln Tyr Tyr Ile Tyr Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys
Val Glu Ile Lys 100
105 546PRThomo sapiens 54Gln Gly Ile Ser Ser Trp 1 5 559PRThomo
sapiens 55Gln Gln Tyr Tyr Ile Tyr Pro Trp Thr 1 5 56124PRThomo
sapiens 56Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
Phe Ser Asn Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Ala Tyr
Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ser Lys Asn Thr Leu Trp 65 70 75 80 Leu Gln Met Asn
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys
Ala His Tyr His Gly Ser Gly Ser Tyr Tyr Thr Leu Phe Asp 100 105 110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 578PRThomo
sapiens 57Gly Phe Thr Phe Ser Asn Tyr Gly 1 5 588PRThomo sapiens
58Ile Ser Gly Ser Ala Tyr Ser Thr 1 5 5917PRThomo sapiens 59Ala Lys
Ala His Tyr His Gly Ser Gly Ser Tyr Tyr Thr Leu Phe Asp 1 5 10 15
Tyr 60107PRThomo sapiens 60Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ala Ala Ser
Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr 85
90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
616PRThomo sapiens 61Gln Gly Ile Ser Ser Trp 1 5 629PRThomo sapiens
62Gln Gln Tyr Asn Ser Tyr Pro Tyr Thr 1 5 63121PRThomo sapiens
63Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1
5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp
Tyr 20 25 30 Val Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Thr Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Ser
Ala Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Ile
Thr Gly Thr Thr Gly Val Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr
Leu Val Thr Val Ser Ser 115 120 648PRThomo sapiens 64Gly Phe Thr
Phe Ser Asp Tyr Val 1 5 658PRThomo sapiens 65Ile Ser Tyr Asp Gly
Ser Asn Lys 1 5 6614PRThomo sapiens 66Ala Arg Gly Gly Ile Thr Gly
Thr Thr Gly Val Phe Asp Tyr 1 5 10 67107PRThomo sapiens 67Asp Ile
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 20
25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu
Ile 35 40 45 Tyr Asp Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60 Ser Gly Tyr Gly Thr Asp Phe Ser Leu Thr Ile
Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Ile Tyr Tyr Cys Gln
Gln Tyr Lys Ser Tyr Pro Ile 85 90 95 Thr Phe Gly Gln Gly Thr Arg
Leu Glu Ile Lys 100 105 686PRThomo sapiens 68Gln Gly Ile Ser Ser
Trp 1 5 699PRThomo sapiens 69Gln Gln Tyr Lys Ser Tyr Pro Ile Thr 1
5 70125PRThomo sapiens 70Gln Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser
Ala Tyr Asn Gly Asn Ser Asn Tyr Val Gln Lys Phe 50 55 60 Gln Gly
Arg Val Thr Met Thr Thr Asp Thr Thr Thr Ser Thr Ala Tyr 65 70 75 80
Met Glu Leu Arg Ser Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Ala Arg Glu Tyr Ser Tyr Asp Ser Gly Thr Tyr Phe Tyr Tyr Gly
Met 100 105 110 Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125 718PRThomo sapiens 71Gly Tyr Thr Phe Thr Ser Tyr Gly 1
5 728PRThomo sapiens 72Ile Ser Ala Tyr Asn Gly Asn Ser 1 5
7318PRThomo sapiens 73Ala Arg Glu Tyr Ser Tyr Asp Ser Gly Thr Tyr
Phe Tyr Tyr Gly Met 1 5 10 15 Asp Val 74108PRThomo sapiens 74Glu
Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10
15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu
Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Arg Ser Asn Trp Pro Met 85 90 95 Tyr Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 756PRThomo sapiens 75Gln Ser Val
Ser Ser Tyr 1 5 7610PRThomo sapiens 76Gln Gln Arg Ser Asn Trp Pro
Met Tyr Thr 1 5 10 77119PRThomo sapiens 77Glu Val Gln Leu Leu Glu
Ser Gly Gly Asp Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Ala Ile Ser Gly Arg Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu
Cys 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Ala Lys Ala Arg Ala Asn Trp Asp Tyr Phe Asp
Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115
78107PRThomo sapiens 78Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val
Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln His Lys
Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ile
Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Arg Pro 65 70 75 80 Glu
Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Ile 85 90
95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105 79119PRThomo
sapiens 79Glu Val Gln Leu Leu Glu Ser Gly Gly Asp Leu Val Gln Pro
Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Arg Gly Gly
Thr Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ser Lys Ser Thr Leu Cys 65 70 75 80 Leu Gln Met Asn
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys
Ala Arg Ala Asn Trp Asp Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110
Thr Leu Val Thr Val Ser Ser 115 80107PRThomo sapiens 80Asp Ile Gln
Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15 Asp
Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 20 25
30 Leu Ala Trp Tyr Gln His Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45 Tyr Ala Ala Ser Ile Leu Gln Ser Gly Val Pro Ser Arg Phe
Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Arg Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Ala Asn Ser Phe Pro Ile 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu
Glu Ile Lys 100 105 81119PRThomo sapiens 81Glu Val Gln Leu Leu Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met
Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Ala Ile Ser Gly Arg Gly Gly Thr Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu
Cys 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Ala Lys Ala Arg Ala Asn Trp Asp Tyr Phe Asp
Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115
82107PRThomo sapiens 82Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val
Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln His Lys
Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ile
Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Arg Pro 65 70 75 80 Glu
Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Ser Phe Pro Ile 85 90
95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105 83121PRThomo
sapiens 83Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ala Gly Tyr Thr
Phe Thr Asn Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly
Gln Ala Leu Glu Trp Met 35 40 45 Gly Trp Ile Thr Thr Tyr Ser Ser
Asn Thr Ile Tyr Ala Gln Lys Leu 50 55 60 Gln Gly Arg Val Thr Met
Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg
Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg
Asp Arg Val Val Val Arg Pro Asp Tyr Phe Asp Tyr Trp Gly 100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 84107PRThomo sapiens
84Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1
5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser
Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg
Leu Leu Ile 35 40 45 Tyr Asp Thr Ser Asn Arg Ala Thr Gly Ile Pro
Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu
Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr
Cys Gln Gln Arg Ser His Trp Pro Arg 85 90 95 Thr Phe Gly Gln Gly
Thr Lys Val Glu Ile Lys 100 105 85121PRThomo sapiens 85Gln Val Gln
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser
Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25
30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45 Gly Trp Leu Ser Ala Tyr Ser Gly Asn Thr Ile Tyr Ala Gln
Lys Leu 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr
Thr Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp
Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Arg Ile Val Val Arg
Pro Asp Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr
Val Ser Ser 115 120 86107PRThomo sapiens 86Glu Ile Val Leu Thr Gln
Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr
Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala
Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50
55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn
Trp Pro Arg 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 87121PRThomo sapiens 87Gln Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys
Ala Ala Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Ile Ser Trp Val
Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile
Ile Thr Tyr Asn Gly Asn Thr Ile Tyr Ala Gln Arg Phe 50 55 60 Gln
Asp Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 65 70
75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr
Cys 85 90 95 Ala Arg Asp Arg Ile Ile Val Arg Pro Asp Tyr Phe Asp
Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120
88107PRThomo sapiens 88Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu
Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala
Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn
Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu
Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Arg
85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
89120PRThomo sapiens 89Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu
Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Val Tyr
Gly Gly Ser Phe Ser Gly Tyr 20 25 30 Tyr Trp Asn Trp Ile Arg Gln
Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn His
Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val
Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys
Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90
95 Arg Gly Asn Tyr Gly Ser Gly Tyr Tyr Tyr Phe Asp Leu Trp Gly Arg
100 105 110 Gly Thr Gln Val Thr Val Ser Ser 115 120 90107PRThomo
sapiens 90Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly
Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys
Ala Pro Lys Ser Leu Ile 35 40 45 Phe Ala Ala Ser Ser Leu Gln Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Tyr Ile Ser Phe Pro Ile 85 90 95 Thr Phe
Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105 91120PRThomo sapiens
91Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 1
5 10 15 Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly
Tyr 20 25 30 Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu
Glu Trp Ile 35 40 45 Gly Glu Ile His His Ser Gly Ser Ala Asn Tyr
Asn Pro Ser Leu Met 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr
Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Gln Leu Ser Ser Val Thr Ala
Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly Tyr Tyr Gly
Ser Gly Tyr Tyr Tyr Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu
Val Thr Val Ser Ser 115 120 92107PRThomo sapiens 92Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg
Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35
40 45 Tyr Ala Ala Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser
Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr
Asn Ser Tyr Pro Ile 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu
Ile Lys 100 105 93120PRThomo sapiens 93Gln Val Gln Leu Gln Gln Trp
Gly Ala Gly Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr
Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr 20 25 30 Tyr Trp Asn
Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly
Glu Ile His His Val Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55
60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Ser Gln Phe Ser Leu
65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
Cys Ala 85 90 95 Arg Gly Tyr Tyr Asp Ser Gly Val Tyr Tyr Phe Asp
Tyr Trp Ala Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120
94107PRThomo sapiens 94Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Ser Arg Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys
Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ala Ala Ser Ser
Leu Arg Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu
Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Ile 85 90
95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105 95120PRThomo
sapiens 95Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro
Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser
Phe Ser Asp Tyr 20 25 30 Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly
Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile His His Ser Gly Ser
Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser
Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser
Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly
Tyr Tyr Ala Ser Gly Val Tyr Tyr Phe Asp Tyr Trp Gly Gln 100 105 110
Gly Thr Leu Val Thr Val Ser Ser 115 120 96107PRThomo sapiens 96Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10
15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser
Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys
Gln Gln Tyr Asn Ser Tyr Pro Ile 85 90 95 Thr Phe Gly Gln Gly Thr
Arg Leu Glu Ile Lys 100 105 97120PRThomo sapiens 97Gln Val Gln Leu
Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu
Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Asp Tyr 20 25 30
Phe Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35
40 45 Gly Glu Ile His His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu
Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln
Phe Ser Leu 65 70 75 80 Asn Leu Ser Ser Val Thr Ala Ala Asp Thr Ala
Val Tyr Tyr Cys Ala 85 90 95 Arg Gly Leu Ile Gly Ser Gly Tyr Tyr
Tyr Phe Asp Tyr Trp Asp Gln 100 105 110 Gly Thr Leu Val Thr Val Ser
Ser 115 120 98107PRThomo sapiens 98Asp Ile Gln Met Thr Gln Ser Pro
Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr
Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr
Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ala
Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65
70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr
Pro Ile 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100
105 99120PRThomo sapiens 99Gln Val Gln Leu Gln Gln Trp Gly Ala Gly
Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Val
Tyr Gly Gly Ser Phe Ser Gly Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg
Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn
His Ser Gly Asp Thr Asn Tyr Asn Pro Ser Leu Thr 50 55 60 Ser Arg
Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85
90 95 Arg Leu Phe Tyr Gly Ser Gly Ile Tyr Tyr Phe Asp Tyr Trp Gly
Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120
100107PRThomo sapiens 100Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ala Thr Phe
Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Phe Pro Pro 85
90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
101120PRThomo sapiens 101Gln Val Gln Leu Gln Gln Trp Gly Ala Gly
Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Ile
Tyr Gly Gly Ser Phe Ser Gly Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg
Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn
His Ser Gly Asp Thr Asn Tyr Asn Pro Ser Leu Thr 50 55 60 Ser Arg
Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85
90 95 Arg Leu Phe Tyr Gly Ser Gly Ile Tyr Tyr Phe Asp Tyr Trp Gly
Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120
102107PRThomo sapiens 102Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ala Thr Phe
Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Phe Pro Pro 85
90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
103120PRThomo sapiens 103Gln Val Gln Leu Gln Gln Trp Gly Ala Gly
Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Val
Tyr Gly Gly Ser Phe Ser Asp Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg
Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn
His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg
Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85
90 95 Arg Leu Tyr Tyr Gly Ser Gly Thr Tyr Tyr Phe Asp Tyr Trp Gly
Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120
104107PRThomo sapiens 104Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30 Leu Thr Trp Tyr Gln Gln
Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ala Ala Ser
Arg Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Phe Pro Pro 85
90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105
105120PRThomo sapiens 105Gln Val Gln Leu Gln Gln Trp Gly Ala Gly
Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Val
Tyr Gly Gly Ser Phe Ser Gly Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg
Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile His
His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg
Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85
90 95 Arg Leu Trp Tyr Gly Ser Gly Ser Tyr Tyr Phe Asp Tyr Trp Gly
Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120
106107PRThomo sapiens 106Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ala Ala Ser
Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Phe Pro Pro 85
90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105
107120PRThomo sapiens 107Gln Val Gln Leu Gln Gln Trp Gly Ala Gly
Leu Leu Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ala Val
Ser Gly Gly Ser Phe Ser Gly Tyr 20 25 30 Tyr Trp Thr Trp Ile Arg
Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Tyr
His Ser Gly Asp Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg
Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80
Lys Leu Tyr Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85
90 95 Arg Leu Tyr Phe Gly Ser Gly Ile Tyr Tyr Leu Asp Tyr Trp Gly
Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120
108107PRThomo sapiens 108Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Gly Ile Ser Ser Trp 20 25 30 Leu Val Trp Tyr Gln Gln
Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ala Ala Ser
Ser Leu Gln Ser Gly
Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe
Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr
Tyr Tyr Cys Gln Gln Tyr Asn Ser Phe Pro Pro 85 90 95 Thr Phe Gly
Gln Gly Thr Lys Val Glu Ile Lys 100 105 109124PRThomo sapiens
109Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
Asn Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Ala Tyr Ser Thr
Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg
Asp Asn Ser Lys Asn Thr Leu Trp 65 70 75 80 Leu Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Ala His
Tyr His Gly Ser Gly Ser Tyr Tyr Thr Leu Phe Asp 100 105 110 Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 110107PRThomo
sapiens 110Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly
Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys
Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr 85 90 95 Thr Phe
Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 111124PRThomo sapiens
111Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn
Asn Tyr 20 25 30 Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Thr Gly Tyr Ser Thr
Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg
Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Ala His
Tyr Phe Gly Ser Gly Ser Tyr Tyr Thr Leu Phe Asp 100 105 110 Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 112107PRThomo
sapiens 112Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly
Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys
Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr 85 90 95 Thr Phe
Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 113124PRThomo sapiens
113Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Thr
Asp Tyr 20 25 30 Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45 Ser Thr Ile Ser Gly Ser Gly Tyr Ala Thr
Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg
Asp Asn Ser Lys Thr Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Gly His
Thr Leu Gly Ser Gly Ser Tyr Tyr Thr Leu Phe Asp 100 105 110 Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 114107PRThomo
sapiens 114Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly
Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys
Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Tyr 85 90 95 Thr Phe
Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 115124PRThomo sapiens
115Glu Val Gln Leu Trp Glu Ser Gly Gly Gly Ser Val Gln Pro Gly Gly
1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Gly Ser Gly Tyr Ser Thr
Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg
Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Gly Tyr
Tyr His Gly Ser Gly Ser Tyr Tyr Thr Ser Phe Asp 100 105 110 Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 116107PRThomo
sapiens 116Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly
Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys
Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser
Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala
Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 85 90 95 Thr Phe
Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 117121PRThomo sapiens
117Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Thr Gly Arg
1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
Ser His 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45 Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys
Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg
Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu
Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp
Tyr Ile Ser Ser Ser Gly Val Phe Asp Tyr Trp Gly 100 105 110 Gln Gly
Thr Leu Val Thr Val Ser Ser 115 120 118107PRThomo sapiens 118Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10
15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp
20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser
Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys
Gln Gln Tyr Asn Ser Tyr Pro Ile 85 90 95 Thr Phe Gly Gln Gly Thr
Arg Leu Glu Ile Lys 100 105 119121PRThomo sapiens 119Gln Val Gln
Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser His 20 25
30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45 Ala Ala Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp
Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
Asn Thr Met Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
Thr Ala Met Cys Tyr Cys 85 90 95 Ala Arg Gly Ser Ile Thr Gly Ser
Thr Gly Val Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr
Val Ser Ser 115 120 120107PRThomo sapiens 120Asp Ile Gln Met Thr
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val
Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Ser Trp 20 25 30 Leu
Ala Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40
45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn
Ser Tyr Pro Ile 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile
Lys 100 105 121121PRThomo sapiens 121Gln Val Gln Leu Val Glu Ser
Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met His
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala
Val Ile Ser Tyr Asp Gly Ser Asn Glu Tyr Tyr Ala Asp Ser Val 50 55
60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Gly Ser Ile Ile Gly Ser Thr Gly Val Phe
Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115
120 122107PRThomo sapiens 122Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Gly Ile Ser Asn Trp 20 25 30 Leu Ala Trp Tyr Gln
Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Asp Ala
Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70
75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro
Ile 85 90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105
123121PRThomo sapiens 123Gln Val Gln Val Val Glu Ser Gly Gly Gly
Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met His Trp Val Arg
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser
Tyr Asp Gly Ser Tyr Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Ala Arg Gly Ser Ile Thr Gly Ser Thr Gly Val Phe Asp Tyr Trp
Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120
124107PRThomo sapiens 124Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Gly Ile Asn Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Asp Ala Ser
Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Glu Asn Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Ile 85
90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105
125121PRThomo sapiens 125Gln Val Gln Leu Val Glu Ser Gly Gly Gly
Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Ile His Trp Val Arg
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser
Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Ala Arg Gly Ser Ile Thr Gly Ser Thr Gly Val Phe Asp Tyr Trp
Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120
126107PRThomo sapiens 126Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Gly Ile Ser Asn Trp 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile 35 40 45 Tyr Asp Ala Ser
Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Ile 85
90 95 Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100 105
1278PRThomo sapiensMISC_FEATURE(4)..(4)wherein Xaa=Arg or Ser,
preferably Arg 127Ile Ser Gly Xaa Gly Gly Xaa Thr 1 5 1288PRThomo
sapiensMISC_FEATURE(5)..(5)wherein Xaa=Arg or Ser, preferably Arg
128Gly Gly Thr Phe Xaa Xaa Tyr Ala 1 5 1298PRThomo
sapiensMISC_FEATURE(2)..(2)wherein Xaa=Asn or Ile, preferably Asn
129Ile Xaa Xaa Xaa Leu Gly Ile Xaa 1 5 13013PRThomo
sapiensMISC_FEATURE(12)..(12)wherein Xaa=Ile or Met, preferably Ile
130Ala Arg Glu Lys Gly Val Asp Tyr Tyr Tyr Gly Xaa Xaa 1 5 10
1318PRThomo sapiensMISC_FEATURE(6)..(6)wherein Xaa=Asn or Ser,
preferably Ser 131Gly Tyr Thr Phe Thr Xaa Tyr Gly 1 5 1328PRThomo
sapiensMISC_FEATURE(2)..(2)wherein Xaa=Ser, Thr, or Ile, preferably
Ser 132Ile Xaa Xaa Tyr Xaa Gly Asn Thr 1 5
13314PRThomo sapiensMISC_FEATURE(5)..(5)wherein Xaa=Ile or Val,
preferably Ile 133Ala Arg Asp Arg Xaa Xaa Val Arg Pro Asp Tyr Phe
Asp Tyr 1 5 10 1348PRThomo sapiensMISC_FEATURE(6)..(6)wherein
Xaa=Asp or Gly, preferably Asp 134Gly Gly Ser Phe Ser Xaa Tyr Xaa 1
5 1357PRThomo sapiensMISC_FEATURE(2)..(2)wherein Xaa=His or Asn,
preferably His 135Ile Xaa His Xaa Gly Ser Xaa 1 5 13614PRThomo
sapiensMISC_FEATURE(4)..(4)wherein Xaa=Tyr, Asn or Leu, preferably
Tyr 136Ala Arg Gly Xaa Xaa Xaa Ser Gly Xaa Tyr Tyr Phe Asp Xaa 1 5
10 1378PRThomo sapiensMISC_FEATURE(6)..(6)wherein Xaa=Gly or Asp,
preferably Gly 137Gly Gly Ser Phe Ser Xaa Tyr Tyr 1 5 1387PRThomo
sapiensMISC_FEATURE(2)..(2)wherein Xaa=Tyr, Asn or His, preferably
Tyr 138Ile Xaa His Ser Gly Xaa Thr 1 5 13914PRThomo
sapiensMISC_FEATURE(4)..(4)wherein Xaa=Tyr, Phe or Trp, preferably
Tyr 139Ala Arg Leu Xaa Xaa Gly Ser Gly Xaa Tyr Tyr Xaa Asp Tyr 1 5
10 1408PRThomo sapiensMISC_FEATURE(6)..(6)wherein Xaa=Thr or Phe,
preferably Thr 140Gly Phe Thr Phe Ser Xaa Xaa Ala 1 5 1418PRThomo
sapiensMISC_FEATURE(6)..(6)wherein Xaa=Gly or Ser, preferably Gly
141Ile Ser Tyr Asp Gly Xaa Xaa Lys 1 5 14212PRThomo
sapiensMISC_FEATURE(9)..(9)wherein Xaa=Ala or Tyr, preferably Ala
142Ala Arg Gly Leu Gly Val Trp Gly Xaa Phe Asp Tyr 1 5 10
1438PRThomo sapiensMISC_FEATURE(5)..(5)wherein Xaa=Ser, Asn or Thr,
preferably Ser 143Gly Phe Thr Phe Xaa Xaa Tyr Xaa 1 5 1448PRThomo
sapiensMISC_FEATURE(4)..(4)wherein Xaa=Ser or Thr, preferably Ser
144Ile Ser Gly Xaa Xaa Xaa Xaa Thr 1 5 14517PRThomo
sapiensMISC_FEATURE(3)..(3)wherein Xaa=Ala or Gly, preferably Ala
145Ala Lys Xaa Xaa Xaa Xaa Gly Ser Gly Ser Tyr Tyr Thr Xaa Phe Asp
1 5 10 15 Tyr 1468PRThomo sapiensMISC_FEATURE(5)..(5)wherein
Xaa=Ser or Thr, preferably Ser 146Gly Tyr Ser Phe Xaa Xaa Tyr Trp 1
5 1478PRThomo sapiensMISC_FEATURE(2)..(2)wherein Xaa=Phe or Tyr,
preferably Phe 147Ile Xaa Pro Gly Asp Ser Asp Xaa 1 5 14816PRThomo
sapiens 148Ala Arg Gln Pro Gly Asp Trp Ser Pro Arg His Trp Tyr Phe
Asp Leu 1 5 10 15 1498PRThomo sapiensMISC_FEATURE(3)..(3)wherein
Xaa=Asn or Ser, preferably Asn 149Gly Tyr Xaa Phe Thr Ser Tyr Trp 1
5 1508PRThomo sapiensMISC_FEATURE(8)..(8)wherein Xaa=Ser or Thr,
preferably Ser 150Ile Ser Ala Tyr Asn Gly Asn Xaa 1 5 15118PRThomo
sapiens 151Ala Arg Glu Tyr Ser Tyr Asp Ser Gly Thr Tyr Phe Tyr Tyr
Gly Met 1 5 10 15 Asp Val 1528PRThomo
sapiensMISC_FEATURE(6)..(6)wherein Xaa=Asp or Ser, preferably Asp
152Gly Phe Thr Phe Ser Xaa Xaa Xaa 1 5 1538PRThomo
sapiensMISC_FEATURE(7)..(7)wherein Xaa=Asn or Tyr, preferably Asn
153Ile Ser Tyr Asp Gly Ser Xaa Xaa 1 5 15414PRThomo
sapiensMISC_FEATURE(4)..(4)wherein Xaa=Gly, Asp or Ser, preferably
Gly 154Ala Arg Gly Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Phe Asp Tyr 1 5
10 1559PRThomo sapiensMISC_FEATURE(8)..(8)wherein Xaa=Ile or Leu
155Gln Gln Ala Asn Ser Phe Pro Xaa Thr 1 5 1569PRThomo
sapiensMISC_FEATURE(5)..(5)wherein Xaa=Asn or His, preferably Asn
156Gln Gln Arg Ser Xaa Trp Pro Arg Thr 1 5 1576PRThomo
sapiensMISC_FEATURE(5)..(5)wherein Xaa=Arg or Ser, preferably Arg
157Gln Gly Ile Ser Xaa Trp 1 5 1589PRThomo sapiens 158Gln Gln Tyr
Asn Ser Phe Pro Pro Thr 1 5 1596PRThomo
sapiensMISC_FEATURE(4)..(4)wherein Xaa=Ser or Asn, preferably Ser
159Gln Gly Ile Xaa Ser Trp 1 5 1609PRThomo
sapiensMISC_FEATURE(8)..(8)wherein Xaa=Tyr or Leu, preferably Tyr
160Gln Gln Tyr Asn Ser Tyr Pro Xaa Thr 1 5 1616PRThomo
sapiensMISC_FEATURE(4)..(4)wherein Xaa=Ser or Asn, preferably Ser
161Gln Gly Ile Xaa Xaa Trp 1 5 1629PRThomo
sapiensMISC_FEATURE(4)..(4)wherein Xaa=Lys or Asn, preferably Lys
162Gln Gln Tyr Xaa Ser Tyr Pro Ile Thr 1 5 1637PRThomo sapiens
163Ile Tyr His Ser Gly Asp Thr 1 5 1649PRThomo
sapiensMISC_FEATURE(6)..(6)wherein Xaa=Tyr or Phe, preferably Tyr
164Gln Gln Tyr Asn Ser Xaa Pro Ile Thr 1 5 165122PRThomo sapiens
165Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe His
Phe Tyr 20 25 30 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly
Leu Glu Trp Met 35 40 45 Gly Ser Ile Tyr Pro Gly Asp Ser Asp Thr
Arg Tyr Arg Pro Ser Phe 50 55 60 Gln Gly Gln Val Thr Ile Ser Ala
Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 Leu Gln Trp Thr Ser Leu
Lys Ala Ser Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg Gln Arg
Gly Asp Tyr Tyr Tyr Phe Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln
Gly Thr Thr Val Thr Val Ser Ser 115 120 1668PRThomo sapiens 166Gly
Tyr Ser Phe His Phe Tyr Trp 1 5 1678PRThomo sapiens 167Ile Tyr Pro
Gly Asp Ser Asp Thr 1 5 16815PRThomo sapiens 168Ala Arg Gln Arg Gly
Asp Tyr Tyr Tyr Phe Tyr Gly Met Asp Val 1 5 10 15 169107PRThomo
sapiens 169Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser
Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly
Gln Val Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala
Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe
Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu 85 90 95 Thr Phe
Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 1707PRThomo sapiens
170Gln Ser Val Ser Ser Ser Tyr 1 5 1718PRThomo sapiens 171Gln Gln
Tyr Gly Ser Ser Leu Thr 1 5 172119PRThomo sapiens 172Glu Val Gln
Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25
30 Ala Leu Ile Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45 Ser Ile Ile Arg Gly Gly Ala Gly Ser Thr Tyr Tyr Ala Asp
Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Ala Arg Ile Trp Gly Pro
Leu Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser
Ser 115 1738PRThomo sapiens 173Gly Phe Thr Phe Ser Asn Tyr Ala 1 5
1748PRThomo sapiens 174Ile Arg Gly Gly Ala Gly Ser Thr 1 5
17512PRThomo sapiens 175Ala Lys Ala Arg Ile Trp Gly Pro Leu Phe Asp
Tyr 1 5 10 176108PRThomo sapiens 176Glu Ile Val Leu Thr Gln Ser Pro
Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser
Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr
Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp
Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65
70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp
Pro Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105 1776PRThomo sapiens 177Gln Ser Val Ser Ser Tyr 1 5
17810PRThomo sapiens 178Gln Gln Arg Ser Asn Trp Pro Pro Leu Thr 1 5
10 179122PRThomo sapiens 179Gln Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Arg Val Pro Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Arg Tyr 20 25 30 Gly Ile Ser Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser
Ala Tyr Asn Gly Lys Thr Tyr Tyr Ala Gln Lys Leu 50 55 60 Gln Gly
Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Ala Arg Ser Pro Leu Leu Trp Phe Glu Glu Leu Tyr Phe Asp Tyr
Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120
1808PRThomo sapiens 180Gly Tyr Thr Phe Thr Arg Tyr Gly 1 5
1818PRThomo sapiens 181Ile Ser Ala Tyr Asn Gly Lys Thr 1 5
18215PRThomo sapiens 182Ala Arg Ser Pro Leu Leu Trp Phe Glu Glu Leu
Tyr Phe Asp Tyr 1 5 10 15 183108PRThomo sapiens 183Glu Ile Val Leu
Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg
Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Thr 20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35
40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe
Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln
Tyr Gly Thr Ser Leu 85 90 95 Phe Thr Phe Gly Pro Gly Thr Lys Val
Asp Ile Lys 100 105 1847PRThomo sapiens 184Gln Ser Val Ser Ser Thr
Tyr 1 5 1859PRThomo sapiens 185Gln Gln Tyr Gly Thr Ser Leu Phe Thr
1 5 186122PRThomo sapiens 186Glu Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys
Gly Ser Gly Tyr Arg Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val
Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ser Ile
Tyr Pro Gly Asp Ser Tyr Thr Arg Asn Ser Pro Ser Phe 50 55 60 Gln
Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ala Thr Ala Tyr 65 70
75 80 Leu Gln Trp Asn Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr
Cys 85 90 95 Ala Arg His Ala Gly Asp Phe Tyr Tyr Phe Asp Gly Leu
Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115
120 1879PRThomo sapiens 187Gly Tyr Arg Phe Thr Thr Ser Tyr Trp 1 5
1888PRThomo sapiens 188Ile Tyr Pro Gly Asp Ser Tyr Thr 1 5
18915PRThomo sapiens 189Ala Arg His Ala Gly Asp Phe Tyr Tyr Phe Asp
Gly Leu Asp Val 1 5 10 15 190109PRThomo sapiens 190Glu Ile Val Leu
Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg
Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35
40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe
Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln
Tyr Gly Ser Ser Pro 85 90 95 Pro Ile Thr Phe Gly Gln Gly Thr Arg
Leu Glu Ile Lys 100 105 1917PRThomo sapiens 191Gln Ser Val Ser Ser
Ser Tyr 1 5 19210PRThomo sapiens 192Gln Gln Tyr Gly Ser Ser Pro Pro
Ile Thr 1 5 10 193124PRThomo sapiens 193Glu Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser
Cys Lys Gly Ser Gly Tyr Ser Phe Thr Arg Tyr 20 25 30 Trp Ile Gly
Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly
Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55
60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
Tyr Cys 85 90 95 Ala Arg Leu Thr Gly Asp Arg Gly Phe Asp Tyr Tyr
Ser Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val
Ser Ser 115 120 1948PRThomo sapiens 194Gly Tyr Ser Phe Thr Arg Tyr
Trp 1 5 1958PRThomo sapiens 195Ile Tyr Pro Gly Asp Ser Asp Thr 1 5
19617PRThomo sapiens 196Ala Arg Leu Thr Gly Asp Arg Gly Phe Asp Tyr
Tyr Ser Gly Met Asp 1 5 10 15 Val 197107PRThomo sapiens 197Glu Ile
Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20
25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu
Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp
Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Tyr Gly Ser Ser Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys
Val Asp Ile Lys 100 105 1987PRThomo sapiens 198Gln Ser Val Ser Ser
Ser Tyr 1 5 1998PRThomo sapiens 199Gln Gln Tyr Gly Ser Ser Phe Thr
1 5 200119PRThomo sapiens 200Gln Val Gln Leu Val Gln Ser Gly Ala
Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Gly Ile Ser Trp Val
Arg Gln Ala Pro Gly Pro Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile
Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln
Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Asn Thr Ala Tyr 65 70
75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95 Ala Arg Asp Gln Glu Tyr Ser Ser Asn Trp Tyr Tyr Trp
Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 2018PRThomo
sapiens 201Gly Gly Thr Phe Ser Ser Tyr Gly 1 5 2028PRThomo sapiens
202Ile Ile Pro Ile Leu Gly Ile Ala 1 5 20312PRThomo sapiens 203Ala
Arg Asp Gln Glu Tyr Ser Ser Asn Trp Tyr Tyr 1 5 10 204107PRThomo
sapiens 204Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser
Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser
Val Arg Ser Ser 20 25
30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg
Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln
Leu Tyr Gly Ser Ser Pro 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val
Asp Ile Lys 100 105 2057PRThomo sapiens 205Gln Ser Val Arg Ser Ser
Tyr 1 5 2068PRThomo sapiens 206Gln Leu Tyr Gly Ser Ser Pro Thr 1 5
207122PRThomo sapiens 207Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly
Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg
Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ser Ile Tyr
Pro Gly Asp Ser His Thr Arg Tyr Arg Pro Ser Phe 50 55 60 Gln Gly
Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85
90 95 Ala Arg Gln Lys Gly Asp Phe Tyr Tyr Phe Phe Gly Leu Asp Val
Trp 100 105 110 Gly Gln Gly Thr Ala Ile Thr Val Ser Ser 115 120
208107PRThomo sapiens 208Glu Ile Val Leu Thr Gln Ser Pro Gly Thr
Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln
Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala
Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu 85
90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105
209122PRThomo sapiens 209Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly
Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg
Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ser Ile Tyr
Pro Gly Asp Ser His Thr Arg Tyr Arg Pro Ser Phe 50 55 60 Gln Gly
Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85
90 95 Ala Arg Gln Ala Gly Asp Tyr Tyr Tyr Tyr Asn Gly Met Asp Val
Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120
210107PRThomo sapiens 210Glu Ile Val Leu Thr Gln Ser Pro Gly Thr
Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Thr Trp Tyr Gln
Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala
Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu 85
90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105
211122PRThomo sapiens 211Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly
Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg
Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Tyr
Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly
Gln Val Thr Ile Ser Val Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85
90 95 Ala Arg Gln Lys Gly Asp Tyr Tyr Tyr His Tyr Gly Leu Asp Val
Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120
212109PRThomo sapiens 212Glu Ile Val Leu Thr Gln Ser Pro Gly Thr
Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln
Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala
Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85
90 95 Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105
213122PRThomo sapiens 213Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly
Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg
Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Tyr
Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly
Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85
90 95 Ala Arg Gln Lys Gly Asp Tyr Tyr Tyr Phe Asn Gly Leu Asp Val
Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120
214109PRThomo sapiens 214Glu Ile Val Leu Thr Gln Ser Pro Gly Thr
Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln
Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala
Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85
90 95 Arg Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105
215122PRThomo sapiens 215Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Gln Gly
Ser Gly Tyr Arg Phe Ile Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg
Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Tyr
Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly
Gln Val Thr Ile Ser Val Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85
90 95 Ala Arg Gln Arg Gly Asp Tyr Tyr Tyr Phe Asn Gly Leu Asp Val
Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120
216107PRThomo sapiens 216Glu Ile Val Leu Thr Gln Ser Pro Gly Thr
Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln
Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala
Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu 85
90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105
217122PRThomo sapiens 217Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly
Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg
Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Tyr
Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly
Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Thr Thr Ala Tyr 65 70 75 80
Leu Gln Trp Ser Ser Leu Arg Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85
90 95 Ala Arg Gln Arg Gly Asp Tyr Tyr Tyr Phe Phe Gly Leu Asp Ile
Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Leu 115 120
218107PRThomo sapiens 218Glu Ile Val Leu Thr Gln Ser Pro Gly Thr
Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln
Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala
Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu 85
90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105
219122PRThomo sapiens 219Glu Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly
Ser Gly Tyr Arg Phe Ser Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg
Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ser Ile Phe
Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly
Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Thr Thr Ala Tyr 65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85
90 95 Ala Arg Gln Ala Gly Asp Tyr Tyr Tyr Tyr Asn Gly Met Asp Val
Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120
220107PRThomo sapiens 220Glu Ile Val Leu Thr Gln Ser Pro Gly Thr
Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln
Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala
Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Leu 85
90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105
2218PRThomo sapiensMISC_FEATURE(3)..(3)wherein Xaa=Ser or Arg
221Gly Tyr Xaa Phe Xaa Xaa Tyr Trp 1 5 2228PRThomo
sapiensMISC_FEATURE(2)..(2)wherein Xaa=Tyr or Phe 222Ile Xaa Pro
Gly Asp Ser Xaa Thr 1 5 22317PRThomo
sapiensMISC_FEATURE(3)..(3)wherein Xaa=Gln, His or leu, preferably
Gln 223Ala Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Xaa Xaa Gly Xaa
Asp 1 5 10 15 Xaa 2248PRThomo sapiensMISC_FEATURE(6)..(6)wherein
Xaa=Asn or Ser, preferably Asn 224Gly Phe Thr Phe Ser Xaa Tyr Ala 1
5 2258PRThomo sapiensMISC_FEATURE(2)..(2)wherein Xaa=Arg or Ser,
preferably Arg 225Ile Xaa Gly Xaa Xaa Gly Ser Thr 1 5 22611PRThomo
sapiensMISC_FEATURE(8)..(8)wherein Xaa=Leu or Tyr, preferably Leu
226Ala Lys Arg Ile Trp Gly Pro Xaa Phe Asp Tyr 1 5 10 2278PRThomo
sapiensMISC_FEATURE(6)..(6)wherein Xaa=Arg or Ser, preferably Arg
227Gly Tyr Thr Phe Thr Xaa Tyr Gly 1 5 2288PRThomo
sapiensMISC_FEATURE(7)..(7)wherein Xaa=Lys or Asn, preferably Lys
228Ile Ser Ala Tyr Asn Gly Xaa Thr 1 5 22915PRThomo sapiens 229Ala
Arg Ser Pro Leu Leu Trp Phe Glu Glu Leu Tyr Phe Asp Tyr 1 5 10 15
2308PRThomo sapiensMISC_FEATURE(8)..(8)wherein Xaa=Gly or Ala,
preferably Gly 230Gly Gly Thr Phe Ser Ser Tyr Xaa 1 5 23111PRThomo
sapiensMISC_FEATURE(9)..(9)wherein Xaa=Asn or Tyr, preferably Asn
231Ala Arg Asp Gln Glu Tyr Ser Ser Xaa Xaa Xaa 1 5 10 2327PRThomo
sapiensMISC_FEATURE(4)..(4)wherein Xaa=Ser or Arg 232Gln Ser Val
Xaa Ser Xaa Tyr 1 5 23310PRThomo sapiensMISC_FEATURE(2)..(2)wherein
Xaa=Gln or Leu 233Gln Xaa Tyr Gly Xaa Ser Xaa Xaa Xaa Thr 1 5 10
234119PRThomo sapiens 234Glu Val Gln Leu Leu Glu Ser Gly Gly Gly
Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Pro Met Ala Trp Val Arg
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Thr Ile Ser
Thr Ser Gly Gly Arg Thr Tyr Tyr Arg Asp Ser Val 50 55 60 Lys Gly
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Ala Lys Phe Arg Gln Tyr Ser Gly Gly Phe Asp Tyr Trp Gly Gln
Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 235110PRThomo
sapiens 235Asp Ile Gln Leu Thr Gln Pro Asn Ser Val Ser Thr Ser Leu
Gly Ser 1 5 10 15 Thr Val Lys Leu Ser Cys Thr Leu Ser Ser Gly Asn
Ile Glu Asn Asn 20 25 30 Tyr Val His Trp Tyr Gln Leu Tyr Glu Gly
Arg Ser Pro Thr Thr Met 35 40 45 Ile Tyr Asp Asp Asp Lys Arg Pro
Asp Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Ile Asp Arg Ser
Ser Asn Ser Ala Phe Leu Thr Ile His Asn 65 70 75 80 Val Ala Ile Glu
Asp Glu Ala Ile Tyr Phe Cys His Ser Tyr Val Ser 85 90 95 Ser Phe
Asn Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110
236120PRThomo sapiens 236Gln Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Ile Ser Tyr 20 25 30 Thr Met His Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Tyr Ile Asn
Pro Arg Ser Gly Tyr Thr His Tyr Asn Gln
Lys Leu 50 55 60 Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ala
Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Ala Tyr Tyr Asp Tyr
Asp Gly Phe Ala Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val
Ser Ser 115 120 237106PRThomo sapiens 237Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr
Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 20 25 30 Asn Trp
Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile Tyr 35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 50
55 60 Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
Glu 65 70 75 80 Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn
Pro Pro Thr 85 90 95 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100
105 238119PRThomo sapiens 238Gln Val Gln Leu Val Gln Ser Gly Gly
Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Arg Tyr 20 25 30 Thr Met His Trp Val
Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile
Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Val 50 55 60 Lys
Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Ala Phe 65 70
75 80 Leu Gln Met Asp Ser Leu Arg Pro Glu Asp Thr Gly Val Tyr Phe
Cys 85 90 95 Ala Arg Tyr Tyr Asp Asp His Tyr Ser Leu Asp Tyr Trp
Gly Gln Gly 100 105 110 Thr Pro Val Thr Val Ser Ser 115
239106PRThomo sapiens 239Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser
Ala Ser Ser Ser Val Ser Tyr Met 20 25 30 Asn Trp Tyr Gln Gln Thr
Pro Gly Lys Ala Pro Lys Arg Trp Ile Tyr 35 40 45 Asp Thr Ser Lys
Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 50 55 60 Gly Ser
Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu 65 70 75 80
Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Phe Thr 85
90 95 Phe Gly Gln Gly Thr Lys Leu Gln Ile Thr 100 105 240119PRThomo
sapiens 240Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro
Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
Phe Ser Ser Tyr 20 25 30 Gly Met Phe Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val 35 40 45 Ala Thr Ile Ser Arg Tyr Ser Arg
Tyr Ile Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn
Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg
Arg Pro Leu Tyr Gly Ser Ser Pro Asp Tyr Trp Gly Gln Gly 100 105 110
Thr Leu Val Thr Val Ser Ser 115 241106PRThomo sapiens 241Glu Ile
Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Ser Ala Ser Ser Ser Val Thr Tyr Val 20
25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
Tyr 35 40 45 Asp Thr Ser Lys Leu Ala Ser Gly Ile Pro Ala Arg Phe
Ser Gly Ser 50 55 60 Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Glu Pro Glu 65 70 75 80 Asp Phe Ala Val Tyr Tyr Cys Phe Gln
Gly Ser Gly Tyr Pro Leu Thr 85 90 95 Phe Gly Ser Gly Thr Lys Leu
Glu Met Arg 100 105 2428PRThomo sapiens 242Gly Phe Thr Phe Ser Ser
Tyr Gly 1 5 2438PRThomo sapiens 243Ile Ser Arg Tyr Ser Arg Tyr Ile
1 5 24412PRThomo sapiens 244Ala Arg Arg Pro Leu Tyr Gly Ser Ser Pro
Asp Tyr 1 5 10 2455PRThomo sapiens 245Ser Ser Val Thr Tyr 1 5
2469PRThomo sapiens 246Phe Gln Gly Ser Gly Tyr Pro Leu Thr 1 5
247330PRThomo sapiens 247Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser
Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85
90 95 Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro
Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp
Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu
Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210
215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu
Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val
Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln
Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330 248330PRThomo sapiens
248Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro
Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn
His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Pro
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130
135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys
Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 225 230 235 240 Met
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250
255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
Phe Leu 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala
Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser
Pro Gly Lys 325 330 249330PRThomo sapiens 249Ala Ser Thr Lys Gly
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe
Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40
45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
Lys Val Asp Lys 85 90 95 Arg Val Glu Pro Lys Ser Cys Asp Lys Thr
His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly
Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu
Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170
175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
Pro Pro Ser Arg Glu Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu
Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295
300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330
250330PRThomo sapiens 250Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser
Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85
90 95 Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro
Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp
Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu
Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Gln
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210
215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu
Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val
Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln
Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330 251330PRThomo sapiens
251Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro
Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn
His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Pro
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala
Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130
135 140 Val Val Val Ala Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Gln Ser Thr Tyr Arg Val Val
Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys
Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Ser
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 225 230 235 240 Met
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250
255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265
270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly
Lys 325 330 252330PRThomo sapiens 252Ala Ser Thr Lys Gly Pro Ser
Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly
Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55
60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
Asp Lys 85 90 95 Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile
Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser
His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu
Gln Tyr Gln Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185
190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Arg Glu Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Leu 275 280 285 Leu Tyr Ser
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310
315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330
253330PRThomo sapiens 253Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr
Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser
Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85
90 95 Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro
Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp
Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu
Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Gln
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210
215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu
Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val
Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Arg Leu Thr
Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln
Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330 254330PRThomo sapiens
254Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln
Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro
Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn
His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Pro
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala
Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130
135 140 Val Val Val Ala Val Ser His Glu Asp Pro Glu Val Lys Phe Asn
Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Gln Ser Thr Tyr Arg Val Val
Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys
Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Ser
Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu
Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 225 230 235 240 Met
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250
255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
Phe Leu 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala
Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser
Pro Gly Lys 325 330 255330PRThomo sapiens 255Ala Ser Thr Lys Gly
Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe
Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40
45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr
Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
Lys Val Asp Lys 85 90 95 Arg Val Glu Pro Lys Ser Cys Asp Lys Thr
His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Phe Glu Gly Gly
Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu
Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Ala
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170
175 Glu Gln Tyr Gln Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
Ser Asn 195 200 205 Lys Ala Leu Pro Ala Ser Ile Glu Lys Thr Ile Ser
Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
Pro Pro Ser Arg Glu Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys
Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu
Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295
300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330
256127PRThomo sapiens 256Gln Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Gln Ala
Ser Gly Tyr Arg Phe Ser Asn Phe 20 25 30 Val Ile His Trp Val Arg
Gln Ala Pro Gly Gln Arg Phe Glu Trp Met 35 40 45 Gly Trp Ile Asn
Pro Tyr Asn Gly Asn Lys Glu Phe Ser Ala Lys Phe 50 55 60 Gln Asp
Arg Val Thr Phe Thr Ala Asp Thr Ser Ala Asn Thr Ala Tyr 65 70 75 80
Met Glu Leu Arg Ser Leu Arg Ser Ala Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Ala Arg Val Gly Pro Tyr Ser Trp Asp Asp Ser Pro Gln Asp Asn
Tyr 100 105 110 Tyr Met Asp Val Trp Gly Lys Gly Thr Thr Val Ile Val
Ser Ser 115 120 125 257108PRThomo sapiens 257Glu Ile Val Leu Thr
Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala
Thr Phe Ser Cys Arg Ser Ser His Ser Ile Arg Ser Arg 20 25 30 Arg
Val Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Val 35 40
45 Ile His Gly Val Ser Asn Arg Ala Ser Gly Ile Ser Asp Arg Phe Ser
50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg
Val Glu 65 70 75 80 Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Val Tyr
Gly Ala Ser Ser 85 90 95 Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu
Arg Lys 100 105
* * * * *